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ABSTRACTS 
Dengue fever is one of the most important mosquito-borne diseases worldwide and 
is caused by infection with dengue virus (DENV). The disease is endemic in tropical 
and sub-tropical regions and has increased remarkably in the last few decades. At 
present, there is no antiviral or approved vaccine against the virus. Treatment of 
dengue patients is usually supportive, through oral or intravenous rehydration, or 
by blood transfusion for more severe dengue cases. Infection of DENV in humans 
and mosquitoes involves a complex interplay between the virus and host factors. 
This results in regulation of numerous intracellular processes, such as signal 
transduction and gene transcription which leads to progression of disease. To 
understand the mechanisms underlying the disease, the study of virus and host 
factors is therefore essential and could lead to the identification of human 
proteins modulating an essential step in the virus life cycle. Knowledge of these 
human proteins could lead to the discovery of potential new drug targets and 
disease control strategies in the future. 
Recent advances of high throughput screening technologies have provided 
researchers with molecular tools to carry out investigations on a large scale. 
Several studies have focused on determination of the host factors during DENV 
infection in human and mosquito cells. For instance, a genome-wide RNA 
interference (RNAi) screen has identified host factors that potentially play an 
important role in both DENV and West Nile virus replication (Krishnan et al. 2008). 
In the present study, a high-throughput yeast two-hybrid screen has been utilised 
in order to identify human factors interacting with DENV non-structural proteins. 
From the screen, 94 potential human interactors were identified. These include 
proteins involved in immune signalling regulation, potassium voltage-gated 
channels, transcriptional regulators, protein transporters and endoplasmic 
reticulum-associated proteins. Validation of fifteen of these human interactions 
revealed twelve of them strongly interacted with DENV proteins. Two proteins of 
particular interest were selected for further investigations of functional biological 
systems at the molecular level.  
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These proteins, including a nuclear-associated protein BANP and a voltage-gated 
potassium channel Kv1.3, both have been identified through interaction with the 
DENV NS2A. BANP is known to be involved in NF-B immune signalling pathway, 
whereas, Kv1.3 is known to play an important role in regulating passive flow of 
potassium ions upon changes in the cell transmembrane potential.  
 
This study also initiated a construction of an Aedes aegypti cDNA library for use 
with DENV proteins in Y2H screen. However, several issues were encountered 
during the study which made the library unsuitable for protein interaction 
analysis. In parallel, innate immune signalling was also optimised for downstream 
analysis. Overall, the work presented in this thesis, in particular the Y2H screen 
provides a number of human factors potentially targeted by DENV during infection. 
Nonetheless, more work is required to be done in order to validate these proteins 
and determine their functional properties, as well as testing them with infectious 
DENV to establish a biological significance. In the long term, data from this study 
will be useful for investigating potential human factors for development of 
antiviral strategies against dengue. 
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1 CHAPTER 1: INTRODUCTION 
1.1 Dengue disease 
1.1.1 Global distribution  
Dengue fever (DF) is the most common mosquito-borne viral disease which 
contributes to a global health concern (WHO 2012). The disease may progress into 
life threatening forms; dengue haemorrhagic fever (DHF) and dengue shock 
syndrome (DSS). Dengue is caused by infection with dengue virus (DENV), which is 
transmitted to humans by Aedes mosquitoes, particularly Aedes aegypti and Aedes 
albopictus (Gubler 1998). The disease is now endemic in more than 100 countries, 
particularly in South East Asia, Western Pacific, and the Americas (WHO 2011) 
(http://apps.searo.who.int/pds_docs/B4751.pdf) (Figure 1.1). The disease is 
estimated to cause 390 million infections per year (Bhatt et al. 2013). 
Epidemiological data across the countries show an increasing trend of dengue 
cases and an expansion of dengue geographical regions in recent years (Teixeira 
et al. 2013; Mia et al. 2013; Arima & Matsui 2011). 
DENV may have evolved from a sylvatic cycle involving non-human primates, 
approximately 500 years ago and was later introduced into human populations 
(Wang et al. 2000; Holmes & Twiddy 2003). As early as the 18th century, epidemics 
of dengue-like illness were reported in Asia, North America and Africa which was 
likely due to international sea-trade (Wilder-Smith & Gubler 2008; Gubler 2006). 
Epidemics were infrequent at that time with 10-40 year intervals due to the mode 
of transportation across the sea (Gubler 2002). In 1943, DENV was first isolated 
from the blood of an infected person by passage through mouse brain, during an 
epidemic in Japan (Hotta 1952).  
During World War II, there was a dramatic change in the epidemiology of dengue 
in South East Asia which resulted in an expansion of the geographical distribution 
of dengue and an increase in Aedes mosquito populations (Gubler 1997). Most 
countries in South East Asia have higher prevalence of dengue, which consequently 
led to the emergence of DHF (Gubler 1997). The first confirmed DHF were 
documented in the Philippines in 1953–1954, and spread through Thailand and 
Malaysia in 1958, followed by Singapore and Vietnam in the 1960s (Gubler 2002). 
Since then, major dengue outbreaks occurred at regular frequencies in the region 
 16 
 
which began to spread globally to the Western regions. After World War II, 
intensive vector control programs and collaborative efforts with the yellow fever 
disease were implemented in the Americas, including the use of 
dichlorodiphenyltrichloroethane (DDT), which successfully eradicated Aedes 
populations and reduced the spread of DENV (Gubler 2002).  
During the 1980-1990s however, rapid expansion of human settlements, 
deforestation of land for cultivation, and development of modern transportation 
have facilitated the movement of people across countries. As a consequence, 
there was a dramatic geographical expansion of epidemic DHF in Asia, involving 
India, Pakistan, Sri Lanka, the Maldives, and China (Gubler 1997). Since then, 
dengue has been re-introduced from Asia to the West Pacific and the Americas, a 
contributing factor was a decline in the vector control enforcements in the 
Americas (Gubler 2002; Gubler & Clark 1995). In 2010, 187,333 dengue cases have 
been documented in South East Asia countries including India, Philippines, 
Thailand, Indonesia and Myanmar (WHO 2011). The rate of dengue reported cases 
in this region has increased over the last decade with severe cases 18 times higher 
compared to the Americas (Shepard et al. 2013; WHO 2011).  
Several factors associated with human activities contributed to an increase in the 
number of dengue cases. The factors include uncontrolled urbanisation, 
international travel and increased human population (Arima et al. 2013; Gubler 
1998). The dynamic distribution of dengue has also been aided by environmental 
factors, such as temperature, rainfall and seasonal variations which greatly affect 
the mosquito population (Halstead 2008). Thus considerable efforts in managing 
the vector control and understanding DENV transmission strategies may greatly 
reduce the incidence of dengue in the future. 
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Figure 1.1: Global distribution of dengue countries (WHO, 2014).  
Highlighted in orange are countries reporting dengue cases in 2013. Two lines 
across the map denote the border line of dengue-infected regions. Data source: 
WHO.(http://gamapserver.who.int/mapLibrary/Files/Maps/Global_DengueTrans
mission_ITHRiskMap.png). 
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1.1.2 Importance of dengue  
Dengue is a disease of significant importance and has become an international 
public health concern. An estimated 500,000 DHF patients were hospitalised and 
a case-fatality rate of approximately 0.5-2.5% has been reported in South East 
Asia in 1985-2009 (WHO, 2011). In recent years, transmission of dengue has 
significantly increased in urban and semi-urban areas across the world (Messina et 
al. 2014). This is facilitated by the highly efficient Aedes mosquito vector 
transmitting the virus, resulting in a local spread within a community or to a 
different geographical region. Treatment of patients, environmental management 
of the mosquito vectors and disease prevention programs have imposed a massive 
economic burden for the governments and communities. For example, an 
estimation of the cost of dengue illness in America is $2.1 billion every year 
(Shepard et al. 2011), and US$950 million annually in twelve countries in South 
East Asia (Shepard et al. 2013). This indicates that dengue poses a significant 
impact on the health care system and greatly contributes to an economic burden 
in affected countries. 
DENV can subvert immune responses which contributes to its efficient capability 
to invade human hosts (Muñoz-Jordán 2010). Further, the existence of five DENV 
serotypes complicates treatment of dengue and hampers the development of an 
effective vaccine (Guzman et al. 2013). In dengue endemic areas, limited 
sensitivity of early dengue diagnostic tools and the cross-reactivity of antibodies 
to previous DENV infections may lead to improper care and increased the risk of 
death (Hunsperger et al. 2009). This is also worrisome because clinical features of 
mild DF resembles clinical symptoms of other viral infections which leads to 
misdiagnosis of dengue and can lead to mortality in dengue patients (Lahiri et al. 
2008). Taken together, dengue poses a significant threat and economic burden to 
many countries. Due to this reason, dengue has become a priority for collaborative 
scientific research and disease preventive programs under several international 
organisations including the World Health Organisation (WHO), United Nations 
Children’s Fund (UNICEF), the World Bank, United Nations Environment 
Programme (UNEP) and the Research and Training in Tropical Diseases (TDR) (WHO 
2011).   
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1.2 Dengue virus 
1.2.1 Structure and genome organisation 
DENV belongs to the genus Flavivirus of the family Flaviviridae and has five closely 
related serotypes; DENV-1, DENV-2, DENV-3, DENV-4 (Gubler 1998), and the most 
recently described DENV-5 (Mustafa et al. 2014; Normile 2013). Mature DENV is a 
spherical virion of approximately 50 nm in diameter (Zhang et al. 2003) (Figure 
1.2). DENV has a positive-sense single-stranded RNA genome of ~11 kb in length, 
which is flanked by highly structured 5′ and 3′ untranslated regions (UTRs) 
(Halstead 2007). Similar to other Flaviviruses, DENV RNA is capped at the 5’ end 
and lacks a poly(A) tail at the 3’ end.  
DENV genome encodes a single open reading frame (ORF) which is translated into 
a large polyprotein precursor consisting of three structural proteins; capsid (C), 
pre-membrane (prM), envelope (E), and seven non-structural (NS) proteins; NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, NS5 (Figure 1.3) (Lindenbach & Rice 2003). DENV 
has a nucleocapsid core containing the viral genome and multiple copies of C 
proteins, surrounded by an envelope derived from the host lipid bilayer (Kuhn et 
al. 2002). Fitting crystal structures into cryo-electron microscopy (cryo-EM) map 
revealed 180 copies of the E glycoproteins organised as 90 dimers in a herringbone 
pattern on the surface of the lipid bilayer (Kuhn et al. 2002). Similarly, 180 copies 
of membrane (M) protein are present on the surface, partly integrating with E 
proteins. Parts of the E and M proteins are anchored to the virus lipid bilayer 
exposing the α-helices on the virus envelope (Zhang et al. 2003). 
All four DENV serotypes share ~65% of their genome homology, with some genetic 
variations within a single serotype (Westaway and Blok, 1997). DENV serotypes 
differ from one another by 25-40% at the amino acid level. Each serotype is further 
separated into different genotypes that have a small divergence of ~3% (Westaway 
and Blok, 1997).  
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      (a)      (b) 
Figure 1.2: Dengue virion structures.  
(a) The virus was visualised by cryo-EM with X-ray structures fitted. The virus is 
spherical which consists of an icosahedral nucleocapsid core surrounded by a lipid 
bilayer envelope. E and M transmembrane proteins are partly embedded in the 
envelope where the E ectodomain spans to the outer membrane leaflet. (b) 
Surface rendering of the cryo-EM density map. Similar colours of E-M heterodimers 
are equivalent by icosahedral symmetry. Different colours of E-M heterodimers 
are quasi-equivalent in which the green demonstrates 5-fold axes of the 
icosahedral symmetry, blue 3-fold and red 2-fold. Symmetry axes are marked by 
a pentagon, small triangles and an oval, respectively. The large triangle indicates 
an asymmetric unit, which consists all parts of three E-M dimers. Figures (a) 
adapted from Zhang et al. (2003), (b) from (Zhang et al. 2013). 
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Figure 1.3: A schematic representation of DENV polyprotein.  
The viral genome encodes three structural proteins; capsid (C), pre-membrane 
(prM), envelope (E), and seven non-structural proteins; NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, NS5. C, prM and E are associated with the viral structure. NS1 is 
involved in RNA replication, NS2A participates in replication and assembly, NS2B 
serves as a cofactor for NS3 which is a serine protease, RNA helicase, 5’-RNA 
triphosphatase, and nucleoside triphosphatase. NS4A and NS4B participate in viral 
replication, and NS5 serves as a methyltransferase and RNA-dependent RNA 
polymerase.  
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1.2.2 Replication cycle 
DENV initiates an infection by entering the host cell through receptor-mediated 
endocytosis (Figure 1.4). Several host cell receptors have been described for DENV 
(Section 1.3.1). Upon entry, the viral E glycoproteins undergo trimerisation 
triggered by the acidic environment of the host cellular endosomal compartment 
(Modis et al. 2004; Allison et al. 1995). This results in fusion of the E glycoprotein 
to the endosomal membranes and uncoating of C protein that releases the viral 
genome into the cytoplasm. Following this process, translation of the viral 
proteins, genome replication and assembly of viral particles occur in the infected 
cell through manipulation of the host cell machinery. The single-stranded positive-
sense RNA genome is translated into a single polyprotein which is subsequently 
cleaved into individual proteins by the viral and host proteases (Kuhn et al. 2002).  
Replication of the viral genome occurs in endoplasmic reticulum (ER)-derived 
membrane where the positive-sense RNA is used to make a newly synthesised 
negative-strand RNA, which serves as a template for synthesis of more single-
stranded (ss) positive-strand RNA. The genomic RNA is subsequently enclosed in 
the C proteins, forming a nucleocapsid. The nucleocapsid core buds through the 
ER membrane, therefore acquiring an envelope that contains the major E 
glycoprotein, and the precursor membrane protein, prM. The immature viruses 
are transported through the Golgi network, and undergo proteolytic cleavage of 
prM to M protein by the host protease furin (Elshuber et al. 2003; Stadler et al. 
1997). Mature infectious viruses are then released from the infected cell by 
exocytosis and are capable of infecting other neighbouring cells. 
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Figure 1.4: A schematic diagram of DENV replication cycle.  
In short, the cycle begins upon internalisation of the virus through endocytosis, 
followed by synthesis of the viral RNA and protein translation mediated by the 
viral and host machinery. Upon maturation in the trans-Golgi network (TGN), the 
virus is released by exocytosis. Figure adapted from Mukhopadhyay et al. (2005). 
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1.2.3 Protein functions 
1.2.3.1 Envelope 
DENV E glycoprotein (~53 kDa) plays a vital role in viral attachment and membrane 
fusion for viral entry (Kuhn et al. 2002). Crystal structures revealed three distinct 
domains (I, II and III) of E ectodomain which are connected by hinges (Modis et al. 
2004; Modis et al. 2003). At low pH conditions in endosomes, conserved histidine 
residues within domain I and domain III become protonated, leading to E 
conformational changes and exposure of the fusion peptide (Nayak et al. 2009; 
Fritz et al. 2008). Fusion of the viral and endosomal membranes subsequently 
occurs, followed by the release of the viral genome into the cytoplasm. The E 
protein contains two N-glycosylation sites at Asn67 and Asn153 which participate 
in conformational changes during membrane fusion (Modis et al. 2005). Domain III 
has been shown to be involved in receptor binding (Crill & Roehrig 2001), thus it 
serves as a molecular target for antiviral strategy against dengue.  
1.2.3.2 Membrane 
M protein is the mature form of prM, consisting of 75 amino acids (~9 kDa). The 
protein is associated with E protein on the external surface of DENV. In the 
immature virion, prM forms prM-E heterocomplex (Kuhn et al. 2002). Some parts 
of the prM cover E protein preventing a premature fusion during travel in the 
acidic environment of Golgi network (Guirakhoo et al. 1992). During virus egress, 
the host furin cleaves prM, forming M-E heterodimers on the mature virus. This 
process is essential for maturation of virus and requires a reduced pH 
environment. It has been shown that alterations in intracellular pH produced non-
infectious virions (Yu et al. 2008). Similarly, a prM mutant failed to undergo 
cleavage, thus resulting in immature, non-infectious virions (Elshuber et al. 2003). 
M protein is capable of forming dimers and tetramers but the protein is found in 
its monomeric form entering the cellular secretory pathway (Wong et al. 2012). 
Apart from its structural association with E, prM/M is capable of eliciting a 
protective immune response in mice and has pro-apoptotic properties (Brabant et 
al. 2009; Catteau et al. 2003; Bray & Lai 1991). The protein has been shown to 
interact with several host proteins during virus entry and release (Brault et al. 
2011; Gao et al. 2010; Duan et al. 2008). 
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1.2.3.3 Capsid 
DENV C is a small (~12 kDa), dimeric protein which contains a highly hydrophobic 
region. C is responsible for encapsidation prior to virus maturation. It has been 
shown that the C protein interacts with the viral genetic material through the 
positively charged basic residues during virus assembly (Ma et al. 2004; Lindenbach 
& Rice 2003). This process is complex and is believed to involve NS proteins 
(Kummerer & Rice 2002). Although DENV C protein acts as a structural component 
of the virus particle, it has additional functions in the virus life cycle. Interaction 
between DENV and the host immune response may contribute to DENV-mediated 
apoptosis. For example, DENV C localised in the nucleus interacts with an 
apoptotic regulator and transcriptional repressor, human death-domain 
associated (Daxx) protein in order to induce Fas-mediated apoptosis in HepG2 cells 
(Netsawang et al. 2010).  
Furthermore, DENV C is found associated with lipid droplets (Carvalho et al. 2012; 
Samsa et al. 2009). A novel finding by Faustino et al. (2014) shows that C protein 
interacts with very low density lipoprotein surfaces in a potassium-dependent 
manner. Such an interaction produces lipoviroparticles, which are a novel way to 
release the newly synthesised virions to the extracellular surroundings (Faustino 
et al. 2014).  
1.2.3.4 NS1 
NS1 protein (~50 kDa) exists as a monomer and is secreted in mature form as a 
soluble hexadimer (Flamand et al. 1999). The protein forms a lipoprotein particle 
with an open-barrel protein shell and a lipid-rich central channel (Gutsche et al. 
2011). During viral infection, NS1 is found circulating in the bloodstream of virus-
infected patients beginning the onset of fever and its high concentration in the 
blood is associated with severity of dengue (Libraty et al. 2002; Alcon et al. 2002). 
Since NS1 is secreted, it plays a role as a molecular target for antibody 
recognition, therefore it is used as a molecular marker for diagnosis of dengue 
(Kassim et al. 2011; Singh et al. 2010).  
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Furthermore, NS1 has been found on cellular membranes associated with lipid 
rafts and within intracellular organelles of virus-infected cells (Welsch et al. 2009; 
Avirutnan et al. 2007). Binding of NS1 to the cellular surface induces complement 
activation, which contributes to vascular leakage which leads to DHF/DSS 
(Avirutnan et al. 2006). Increasing data support the involvement of NS1 in virus 
replication, although the specific functional role of NS1 is not fully understood 
(Lindenbach & Rice 1999; Mackenzie et al. 1996; Muylaert et al. 1996). NS1 
contains highly conserved cysteine (Cys) residues and two glycosylation sites at 
asparagine (Asn) residues; Asn130 and Asn207 (Wallis et al. 2004; Pryor & Wright 
1994). Recent data suggest mutation of these residues impaired RNA synthesis and 
reduced virus growth (Fan et al. 2014).  
NS1 interacts with ribosomal protein RPL18 in Huh-7 cells, which is shown to be 
important during DENV replication (Cervantes-Salazar et al. 2015). Further to this, 
NS1 has been reported to interact with vimentin and hnRNP C1/C2 in DENV-
infected cells (Kanlaya et al. 2010b; Noisakran et al. 2008). This interaction 
complex dissociates during vimentin disruption, which reduced dengue NS1 
expression and viral replication. Secreted NS1 has also been shown to interact 
with the complement component 1 (C1q) which suggests its important role in the 
human complement system and immune evasion during DENV infection (Silva et 
al. 2013).  
1.2.3.5 NS2A 
NS2A is a transmembrane protein (~22 kDa) and its function in DENV life cycle is 
not fully understood. NS2A is involved in virus replication where it can bind to the 
3’ UTR and components of the replication complex (Mackenzie et al. 1998). 
Studies on Flaviviruses show that NS2A has a functional role in virus assembly since 
mutation of NS2A disrupts this process (Leung et al. 2008; Kummerer & Rice 2002). 
This is supported by recent structural analysis and mutagenesis of the ER 
membrane-spanning region of DENV NS2A which affects the virus assembly and 
RNA synthesis (Xie et al. 2015; Xie et al. 2013). Another important role of NS2A is 
its capability to antagonize host immune responses and block dsRNA-activated 
protein kinase PKR (Tu et al. 2012; Liu et al. 2006; Muñoz-Jordan et al. 2003).  
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1.2.3.6 NS2B 
NS2B is small, hydrophobic protein (~14 kDa) about which very little is known. 
NS2B functions as a serine protease cofactor and acts as an activator by forming a 
heterodimeric complex with NS3 (Falgout et al. 1991). The protease component 
of NS2B/NS3 interacts with the host signal peptidase which catalyses proteolytic 
processing of DENV polyprotein (Falgout et al. 1991). This subsequently cleaves 
the NS region of NS2A/NS2B, NS2B/NS3, NS3/NS4A and NS4B/NS5 junctions (Yusof 
2000; Arias et al. 1993; Falgout et al. 1991). NS2B/NS3 protease complex has also 
been reported to inhibit type I interferon (IFN) response by inhibiting the 
phosphorylation of Interferon Regulatory Factor 3 (IRF3) (Rodriguez-Madoz et al. 
2010). 
1.2.3.7 NS3 
NS3 (~70 kDa) is a cytoplasmic protein which has multifunctional properties 
including RNA helicase, 5′-terminal RNA triphosphatase and serine protease. RNA 
helicase activity of NS3 has been associated with unwinding of the viral genome 
during RNA replication (Bartholomeusz & Wright 1993). The 5′-RNA triphosphatase 
activity in NS3 plays a role in 5’-capping of the RNA (Bartelma & Padmanabhan 
2002). A site-directed mutagenesis study by Shafee & AbuBakar (2003) suggests 
the possible involvement of the NS3 protease and NS2B/NS3 protease precursor in 
apoptosis during DENV-2 infection, although the specific mechanism of induction 
is unclear. Furthermore, West Nile virus (WNV) NS3 has the ability to cleave 
caspase-8 and caspase-3 which triggers the apoptotic pathway (Ramanathan et al. 
2006). Further, DENV-2 NS3 has been reported to interact with the host nuclear 
receptor binding protein (NRBP) that influences trafficking between the ER and 
trans-Golgi network, and involves in alteration of the cell membrane structures 
(Chua et al. 2004). 
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1.2.3.8 NS4A 
NS4A is a small protein (~16 kDa) and is highly hydrophobic. There is limited 
information about the specific role of this protein. NS4A is found in reticular 
structures and cytoplasmic foci derived from the ER which suggests its 
involvement in virus replication (Miller et al. 2007). NS4A has also been shown to 
play a role in membrane rearrangements during virus replication, and this is 
supported by recent structural analysis showing that NS4A is capable of inducing 
membrane undulation (Lin et al. 2014; Roosendaal et al. 2006). Furthermore, NS4A 
has been shown to be involved in autophagy which facilitates virus replication and 
prevents host cell death (McLean et al. 2011). Along with NS2A and NS4B, 
expression of NS4A in human cells inhibits IFN signalling indicating its functional 
role as IFN-antagonistic (Muñoz-Jordán 2010; Muñoz-Jordan et al. 2003). NS4A has 
also been shown to interact with polypyrimidine tract binding protein (PTB) by 
modulating the viral negative strand RNA synthesis (Jiang et al. 2009). Further 
examination has shown that silencing of PTB in DENV-infected cells decreases virus 
production.  
1.2.3.9 NS4B 
NS4B (~27 kDa) is a highly hydrophobic protein, which is found residing at the ER 
lumen side of the membrane (Miller et al. 2006). NS4B colocalizes with NS3 in the 
perinuclear region of infected human cells which suggests its involvement in viral 
replication (Umareddy et al. 2007). Although the precise role of NS4B is still 
unclear, the protein is thought to be involved in suppression of IFNs. In IFN-
induction experiments, NS4B has shown to be the strongest DENV IFN inhibitor 
compared to NS2A and NS4A (Muñoz-Jordan et al. 2003). Furthermore, NS4B is 
capable of interfering with signal transducer and activator of transcription 1 
(STAT1) phosphorylation, therefore blocking the IFN-induced signal transduction 
cascade (Ho et al. 2005). Recent evidence also suggests NS4B plays an important 
role in suppression of the human RNAi pathway. NS4B is capable of inhibiting RNase 
Dicer, a key enzyme of the antiviral RNAi pathway, which consequently promotes 
DENV replication (Kakumani et al. 2013). Conversely, deletion mutants of NS4B 
particular regions involving the transmembrane domains (TMDs); TMD3 and TMD5, 
has shown to activate the RNAi pathway and induce antiviral activity (Kakumani 
et al. 2013).  
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1.2.3.10 NS5 
NS5 is cytoplasmic and is the largest DENV protein (~103 kDa). This protein has a 
methyltransferase domain (MTase) at its N-terminus and an RNA-dependent RNA 
polymerase (RdRp) at its C-terminus (Kapoor et al. 1995). The N-terminal MTase 
domain is required for RNA capping while the C-terminal domain of RdRp is 
required for RNA replication (Egloff et al. 2002; Ackermann & Padmanabhan 2001). 
NS5 is therefore thought to contain the components of the RNA replicase complex 
in concert with NS3 helicase activity (Kapoor et al. 1995). Due to the functional 
enzymatic ability of NS5, the protein is a significant target for the development 
of anti-viral compounds. For example, the MTase activity of NS5 has been shown 
to be affected by ribavirin 5’-triphosphate in vitro, thus the drug has potential 
anti-dengue activity (Benarroch et al. 2004). NS5 is also characterised as an IFN-
antagonistic, because it has the ability to bind and degrade STAT2, therefore 
inhibiting the host immune responses (Ashour et al. 2009; Mazzon et al. 2009). 
 
1.3 Dengue virus-host factors 
 Cell surface receptors 
Interaction between DENV and its mosquito or human host factors occurs through 
many stages of the virus life cycle. The initial entry of the virus to the host cell 
requires binding of the viral E protein to receptors present on the cell surface. 
The precise mechanism of viral entry however, has not been completely 
elucidated due to the diverse tropism whereby virus infects the mosquito and 
human hosts through different cell surface receptors. In mammalian cells, the C-
type lectins, such as the dendritic-cell-specific ICAM3-grabbing non-integrin (DC-
SIGN), mannose receptors and C-type lectin domain family 5 member A (CLEC5A) 
have been described (Chen et al. 2008; Miller et al. 2008; Tassaneetrithep et al. 
2003). Crystal structures of DC-SIGN have shown that the carbohydrate recognition 
domain is capable of binding to the DENV E asparagine residue 67, which facilitates 
virus entry (Pokidysheva et al. 2006). CLEC5A however, lacks carbohydrate binding 
sites, its homodimeric structures on the cell surface have been suggested to 
mediate binding to DENV glycoprotein ligands (Watson et al. 2011). 
Glycosaminoglycans (GAGs) such as heparan sulphate, have been described as 
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putative DENV attachment factors (Chen et al. 1997). Site-directed mutagenesis 
analysis indicated that DENV interacts with GAGs through two lysine residues (K291 
and K295) located on domain III of E protein (Watterson et al. 2012). Heat-shock 
proteins (HSPs) present on surfaces of U937 and neuroblastoma cells, such as 
HSP90 and HSP70 have also been suggested as components of DENV receptor 
complex. Both HSPs act as chaperones in facilitating structural re-arrangement of 
DENV E protein during membrane fusion (Reyes-Del Valle et al. 2005). A major 
component of high density lipoprotein, apolipoprotein A-I (ApoA-I) has been shown 
capable to associate with DENV particles and promote virus infection (Li et al. 
2013). This occurs through interaction between DENV E protein and lipoprotein 
receptor, scavenger receptor class B type I (SR-BI), which resulted in increased 
virus infectivity.  
Recent progress has discovered two phosphatidylserine (PS) receptors; TIM-1 and 
AXL proteins, as potential DENV entry factors (Meertens et al. 2012). Both proteins 
play a vital role in PS-dependent phagocytic removal of apoptotic cells. 
Interaction of TIM-1 and AXL with PS on DENV surface has been shown to facilitate 
infection through a mechanism similar to engulfment of apoptotic cells (Meertens 
et al. 2012). This mechanism is supported by subsequent identification of another 
receptor, CD300a on the surface of human macrophages (Carnec et al. 2015). 
CD300a acts as a DENV attachment factor which is capable of recognising PS- and 
phosphatidylethanolamine-associated viral particles of the four DENV serotypes.  
In mosquito cells, a small number of host factors have been identified. These 
include prohibitin receptor (Kuadkitkan et al. 2010), tubulin or tubulin-like protein 
(Chee & AbuBakar 2004), and several proteins characterised by molecular weight 
sizes (Cao-Lormeau 2009; Mendoza et al. 2002). 
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 Screening of DENV host factors 
Viruses interact with the host cellular components to complete their life cycle and 
this requires manipulation of certain host cellular pathways to ensure virus 
survival (Fischl & Bartenschlager 2011). While viruses aim to survive in the host 
cells and synthesize more progeny virions, the host may initiate a cascade of 
events that leads to the elimination of the invading virus (Fernandez-Garcia et al. 
2009). The study of virus and host factors is therefore essential to assess gene 
expression and map the protein interaction networks, and provide understanding 
of the mechanisms underlying disease. Various high throughput screening 
technologies have been developed in order to identify the host cellular factors 
contributing to virus infection such as proteomics, microarray-based genomics, 
genome-wide RNAi screen and the yeast-two hybrid (Y2H) assay (Peng et al. 2009). 
Each screening technique has a certain level of strengths and weaknesses which 
may produce a unique distribution of interactions and the discovery of various 
interacting genes or proteins.  
 Proteomics and microarray studies  
Many studies utilise a proteomic approach to analyse the host response to DENV 
infection. This includes the use of two-dimensional gel electrophoresis (2DE) 
combined with mass spectrometry which identified many differentially expressed 
proteins in human and insect cells (Zhang et al. 2013; Higa et al. 2008; 
Pattanakitsakul et al. 2007). Using this technique, global changes of a cellular 
response in infected or treated samples could be analysed in a single run. These 
traditional proteomics approaches however have limited dynamic range and 
reproducibility due to the difficulty in resolving protein samples (Domon & 
Aebersold 2006). Highly acidic or basic proteins, low abundance, hydrophobic and 
high molecular weight proteins are known to resolve poorly by 2DE, which affects 
proteomic outcomes. Advanced proteomic approach based on non-gel based 
techniques and label-free liquid chromatography-mass spectrometry (LC-MS) has 
been further developed. The advantages of these techniques include the 
requirement of less protein samples and sample processing time, and production 
of higher peptide sequence coverage (Patel et al. 2009).  
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Analysis of Huh-7 cells infected with DENV-2 by label-free LC-MS technique 
revealed a decrease in the expression of enzymes involved in glycolytic pathway, 
citrate cycle, and pyruvate metabolism, also alterations in the expression of many 
proteins involved in mitochondrial function (Pando-Robles et al. 2014).  
Microarray uses complementary DNA sequences as probes for gene expression 
studies (Miller & Tang 2009). This technology allows simultaneous comparison of 
numerous genes by identification of genes associated with certain biological 
changes. Differential gene expression profiling in response to DENV infection by 
microarray has shown the involvement of host genes in NF-B immune response 
and the ubiquitin proteasome pathway (Hanley & Weaver 2010; Fink et al. 2007). 
Microarray technology however, is rather expensive, and data generated from this 
study requires substantial bioinformatic analysis. 
 Genome wide RNAi screen  
Genome-wide RNAi screen is a powerful method for high throughput analysis of 
sequence-specific knockdown of target genes. The gene silencing technique is 
highly efficient and able to simultaneously interrogate thousands of genes. A 
genome-wide RNAi screen in Drosophila melanogaster library led to the discovery 
of 116 DENV host factors; in which 82 have human homologs (Sessions et al. 2009). 
Of these, 42 are verified as human host factors including FLJ20254, TAZ, CNOT2, 
EXDL2, NPR2 and SEC61B, and knockdown of these proteins decreased DENV titres 
in HuH-7 cells. It has also been suggested that several proteins are exploited by 
DENV in both human and mosquito, probably because they play crucial roles for 
virus replication in both hosts (Sessions et al. 2009). Another RNAi screen by 
Krishnan et al. (2008) performed in HeLa cells has reported the identification of 
host cellular factors potentially important in WNV and DENV infection. Silencing 
at least 36% of WNV host proviral factors including SUMO-protein ligase UBE2I and 
vATPase has shown to decrease DENV infection. This study also highlights the 
ubiquitin-ligase CBLL1 in WNV internalisation and several protein components of 
the endoplasmic reticulum-associated protein degradation (ERAD) pathway that 
play a key role during WNV and DENV infection. A major drawback of using siRNA 
is the possibility of RNA sequences binding to more than one target which produces 
off-target effects (Jackson & Linsley 2010).  
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 Yeast-two hybrid screen  
The Y2H is a well-established technique used for detection and identification of 
protein-protein interaction. This assay employs the GAL4 system that encodes for 
two hybrid proteins; a DNA-binding domain and an activation domain. This system 
is capable of activating a downstream reporter gene when both DNA-binding and 
activation domains are in close proximity (Section 2.5). Several advantages and 
disadvantages of this technique are outlined in Table 1.1. 
Using the Y2H approach, analysis of protein-protein interactions has revealed 
potential DENV host factors. Khadka et al. (2011) has identified 105 proteins from 
a human liver cDNA library interacting with DENV-2, in which most proteins are 
related to the complement and coagulation system, centrosome and cytoskeleton. 
Of these, six proteins have been confirmed to interact with DENV including 
calreticulin (CALR), ATP-dependent RNA helicase (DDX3X), rab6-interacting 
protein 2 (ERC1), golgin-95 (GOLGA2), thyroid receptor-interacting protein 11 
(TRIP11) and SUMO-protein ligase (UBE2I) (Khadka et al. 2011). CALR in particular, 
may have a potential role in the viral RNA synthesis as the protein has been shown 
to co-localize with the viral NS3 and NS5 proteins, and the viral dsRNA in DENV-
infected cells (Khadka et al. 2011). Analysis of HCV-human protein-protein 
interactions by Dolan et al. (2013) identified 112 unique interactions representing 
94 human proteins. Interestingly, five proteins, CUL7, PCM1, RILPL2, RNASET2, 
and TCF7L2, were shown to be HCV and DENV shared targets, and required for 
both HCV and DENV replication. The remaining Y2H studies on DENV-human 
interactions are described in Chapter 3 of this thesis. 
There are fewer protein-protein interaction studies investigating DENV and its 
mosquito host. Mairiang et al. (2013) have revealed 102 interactions involving 93 
unique mosquito proteins, of which 58 have human orthologs. Several proteins had 
been previously encountered including the E3 ubiquitin ligase seven in absentia 
and seven in absentia homolog (SIAH2) (Le Breton et al. 2011), and the paramyosin 
and human cingulin like-1 (CGNL1) (Khadka et al. 2011). Further to this, 
carboxypeptidase B1 (CPB1) has been identified from Ae. aegypti midgut cDNA 
library interacting with DENV E protein (Tham et al. 2014). Binding of CBP1 to E 
which was demonstrated by a protein structural model is speculated to be involved 
in the viral encapsulation activity.
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Table 1.1: Advantages and disadvantages of yeast two-hybrid assay. 
Advantage Disadvantage 
Experiments are performed in yeast which enables 
analysis of protein-protein interaction in vivo.  
Lack of post-translational modifications in yeast. 
High throughput screening and can be performed 
using an automated robotic platform. 
Difficulty of transmembrane proteins to be expressed in the 
nucleus and activated transcription of the reporter gene. 
Easy to perform and scaling up yeast cultures, 
inexpensive and quick. 
Absence of optimal conditions for binding of proteins in the 
yeast nucleus.  
Simple readout by detecting the growth of yeast 
diploids on amino acid dropout medium. 
The expression and subcellular localisation of proteins may 
have been altered due to artificial expression.  
Able to identify transient and weak protein-protein 
interactions. 
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 Protein structure prediction  
Several studies have identified DENV host factors through protein structure 
prediction (Doolittle & Gomez 2011; Guo et al. 2010). Guo et al. (2010) have 
predicted a DENV-mosquito protein-protein interaction network using 
computational approach, annotating 4,214 Ae. aegypti proteins of which 714 are 
potential DENV host factors. These proteins are related to 
replication/transcription/translation (RTT), immunity, transport and metabolism. 
Further validation by RNAi gene silencing indicates five hypothetical proteins 
including AAEL012515, AEL001005, AAEL013989, AAEL005351 and AAEL013275, 
have shown a significant reduction of DENV titre in mosquito midguts. A similar 
structure prediction study predicted approximately 2,000 DENV-human 
interactions (reduced to 19 after data mining from literatures), while 18 
interactions were obtained for Ae. aegypti (Doolittle & Gomez 2011). Although 
the results are promising, the accuracy of interactions can be questioned due to 
the different structures of proteins in vivo, rather than in silico. 
1.4 Mosquito host 
1.4.1 Life cycle and behaviour 
DENV is transmitted to humans by Aedes (Stegomyia) mosquito vectors; 
particularly Ae. aegypti and Ae. albopictus. Other Aedes species are found in 
specific endemic areas such as Ae. polynesiensis in French Polynesia, Ae. 
scutellaris in the Pacific Islands and New Guinea, and Ae. niveus in Philippines. 
Aedes mosquitoes have four developmental stages: eggs, larvae, pupae and adults 
(Figure 1.5). Female Aedes mosquitoes lay eggs on the wet walls of water-filled 
containers or stagnant water. The eggs resist desiccation for several months and 
hatch into larvae when submerged in water. The larvae feed on particulate organic 
matter in the water and moult three times followed by metamorphosis into pupae. 
After 2-3 days, the pupae develop into adult mosquitoes and emerge from the 
pupae skin leaving the water. The entire mosquito life cycle lasts 8-10 days at 
ambient temperatures. 
Male mosquitoes feed on flower nectar, whereas female mosquitoes feed on 
human blood to develop their eggs. Human dengue transmission cycle begins when 
a female Aedes mosquito ingests the virus through blood feeding from a viraemic 
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human host. The infection first occurs in the mosquito midgut epithelial cells, 
spreads through the haemolymph to other organs such as the fat body and trachea, 
and finally disseminates to the mosquito salivary glands (Salazar et al. 2007; 
Linthicum et al. 1996). Once in the saliva, DENV can be transmitted to another 
host when the mosquito acquires a blood meal, thus spreading the disease. Female 
mosquitoes carrying the virus remain infectious for life.  
Aedes aegypti mosquitoes are domestic and prefer to rest in dark areas, frequently 
in bedrooms, bathrooms, and kitchens (Chadee 2013; Perich et al. 2000). They 
prefer vertical surfaces such as walls, furniture, hanging articles such as clothing, 
towels and curtains, and can be found on the ceiling and under furniture such as 
beds. Although they are mostly active during daylight hours, blood feeding and 
oviposition activities usually occur between 6-9 in the morning and at 4-6 in the 
afternoon (Chadee 2013).  
 
 
Figure 1.5: Mosquito life cycle.  
Aedes mosquitoes have four life stages: egg, larva, pupae and adult, where the 
first three stages are aquatic. The entire life cycle, from an egg to an adult, takes 
approximately 8-10 days. The figure was adapted from CDC Dengue Homepage as 
link below: 
http://www.cdc.gov/Dengue/entomologyEcology/m_lifecycle.html.  
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1.4.2 Routes of transmission 
While DENV is transmitted horizontally from an infected person to another through 
bites of infected mosquitoes, the virus can also be transmitted vertically from 
infected female mosquitoes to their offspring. Experimental evidence 
demonstrated the persistence of DENV in successive generations of mosquitoes 
following  intrathoracic inoculation with the virus (Joshi et al. 2002). In the wild, 
several studies have demonstrated the isolation of DENV from field-caught male 
Aedes mosquitoes indicating the occurrence of transovarial/vertical transmission 
(Espinosa et al. 2014; Arunachalam et al. 2008; Kow et al. 2001). Other studies on 
preimaginal stages of mosquitoes similarly detected the co-circulating DENV 
serotypes during an outbreak and during inter-epidemic periods (Martins et al. 
2012; Thongrungkiat et al. 2011; Le Goff et al. 2011). Since transovarial 
transmission in Aedes populations seems to peak at certain periods in nature, it 
has been proposed as an important strategy for the virus to persist during adverse 
climate conditions which are unfavourable for transmission to humans (Angel & 
Joshi 2008; Pherez 2007; Guo et al. 2007). The importance of vertical transmission 
in maintaining DENV in nature is also supported by mathematical models, however 
the role of transmission in maintenance of the virus in nature is not clearly 
described (Esteva & Vargas 2000). In contrast to this, the low rate of vertical 
transmission is believed to dilute down the virus with every generation which 
subsequently causes the virus to disappear (Adams & Boots 2010). Thus, it is 
believed that virus maintenance in nature is more likely contributed to by dengue 
asymptomatic cases within human populations (Adams & Boots 2010).  
Vertical transmission of dengue also occurs in humans where DENV is transmitted 
from an infected mother to the foetus. These cases however are rare and depend 
on the severity of disease and the stage of pregnancy during viral infection (Pouliot 
et al. 2010). Adverse outcomes have been suggested with symptomatic cases 
during the late stage of pregnancy including the risk of pre-term labour and low 
birth weight of infants (Friedman et al. 2014; Basurko et al. 2009). In a small 
number of cases, infection is associated with thrombocytopenia and even death 
in neonates (Chye et al. 1997; Thaithumyanon et al. 1994). There is also evidence 
that DENV can be transmitted through organ transplantation and blood transfusion 
(Tambyah et al. 2008; Tan et al. 2005). A recent case of blood transfusion 
contamination was encountered from a donor who had travelled to a dengue 
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endemic area and came down with dengue symptoms (Punzel et al. 2014), while 
other cases detected dengue from a high number of asymptomatic blood donors 
(Linnen et al. 2008; Mohammed et al. 2008). These scenarios imply a requirement 
of strict enforcements to forbid blood donations from donors four weeks after 
returning from disease endemic areas, and highlight the critical role of 
comprehensive screening prior to organs and blood transfusion.  
1.4.3 Vector competence and control strategies 
In addition to the use of biological and chemical control for dengue, other 
strategies including the use of genetically modified organisms have been 
established. One method was through the use of sterile insect technique (SIT), by 
releasing radiation-sterilised and chemosterilised male mosquitoes into the wild 
for mating with native females. Offspring produced from this mating are very few 
or non-viable, hence this technique can reduce mosquito populations (Dame et al. 
2009). This technique however has several drawbacks including that irradiation 
induced random dominant lethal mutations in males which may reduce their 
fitness, hence are non-competitive to the wild populations (Dame et al. 2009; 
Alphey et al. 2000). Aside from this technique, the Release of Insects carrying a 
Dominant Lethal gene (RIDL) has been a promising tool by introducing a genetically 
engineered late-acting lethal gene into mosquitoes (Phuc et al. 2007). Progeny 
developed from this technique contain the lethal gene and will die before turning 
into an adult. A similar technique was developed to generate mosquito progenies 
carrying genes that impose a tetracycline-repressible flightless-female phenotype 
(Wise de Valdez et al. 2011). This decreases the capability of female offspring to 
avoid predators and seek animal hosts for probing, hence reduces their chances 
of survival. 
Another efficient method involves inoculation of an insect parasitic bacterium, 
Wolbachia into mosquitoes which results in a reduction in their lifespan 
(McMeniman et al. 2009). Mosquitoes infected with Wolbachia will have high rates 
of cytoplasmic incompatibility, which kills the embryos produced by uninfected 
females after mating with infected males, thus preventing egg hatching 
(McMeniman et al. 2009). This has caused mosquito populations to decline, 
thereby reducing virus transmission.  
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1.5 Human host 
1.5.1 Clinical manifestation  
A person becomes infected when bitten by a DENV-infected mosquito. The onset 
of fever usually occurs after 4 to 12 days. During this period, dengue causes a 
highly infectious viremic phase that lasts 4-8 days (WHO 2011). Dengue illness 
ranges from asymptomatic and mild fever to the life-threatening forms; DHF and 
DSS. Both children and adults vary in clinical symptoms, depending on their age, 
immune status and genetic background. DF, also known as ‘break-bone fever’, is 
characterised by headache, retro orbital pain, severe muscle and joint pains, 
nausea, vomiting and maculopapular rash (WHO 2011). Patients with DHF/DSS may 
manifest a high fever, plasma leakage, thrombocytopenia or organ failure. 
Haemorrhagic signatures are bleeding into the skin, leakage of fluid into the 
interstitial space, elevated haematocrit and hypotension that result in shock and 
eventually death (WHO 2011).  
All four DENV serotypes result in similar clinical symptoms in humans. Infection 
with one serotype confers a lifelong immunity, however, a secondary infection 
with a different DENV serotype does not confer protection, which can lead to 
antibody-dependent enhancement (ADE) (Guzman et al. 2013; Halstead 1977). 
ADE is an explanatory hypothesis whereby the pre-existing circulating antibodies 
generated from a previous infection bind to the newly infecting virus and facilitate 
the viral entry into monocytes or macrophages through Fc receptor recognition 
(Guzman et al. 2013; Halstead 1977). These antibody-virus complexes are not 
neutralised, but enhance the infection resulting in high level of viraemia, which 
can lead to DHF/DSS (Flipse et al. 2013; Sasaki et al. 2013). 
1.5.2 Laboratory diagnostics 
Accurate diagnostic tests for detection of dengue are essential for early 
preventive measures to control the spread of disease. Clinical diagnostics for 
dengue are performed by isolation of the virus, detection of the viral nucleic acid 
or antigen, and virus-specific antibodies in the serum of infected patients 
(Mungrue 2014; Peeling et al. 2010). Earlier method of confirming dengue 
infection is through isolation of the virus in cell culture (Henchal et al. 1983), 
however this is time-consuming. Rapid detection of the viral nucleic acids with 
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higher sensitivity is achieved by reverse-transcriptase polymerase chain reaction 
(RT-PCR) during the viraemic phase of illness, thus are suitable for early detection 
of dengue (Yong et al. 2007; Lanciotti et al. 1992).  
Serological tests are less expensive and routinely performed in many laboratories 
after the fifth day of dengue illness (Mungrue 2014). IgM- and IgG-captured 
enzyme-linked immunosorbent assay (ELISA) have been successfully able to detect 
virus-specific antibodies from patient sera (Kuno et al. 1991). Detection of 
antibodies against the viral NS1 using commercial ELISA-based diagnostic kits is 
easy to perform but they are very expensive and have limited sensitivity 
particularly in dengue endemic regions (Hermann et al. 2014; Lima et al. 2010; 
Dussart et al. 2006). IgM assays are more useful for early detection of dengue, 
although the sensitivity and specificity varies with different commercial assays 
(Hunsperger et al. 2009). IgG assays correlate well with previously established 
hemagglutination assays but are limited in their ability to detect early infection. 
In this test, past or current dengue infections can be specifically identified through 
seroconversion of antibody titer between acute and convalescent sera of an 
individual (Peeling et al. 2010). Rapid NS1 IgM- and IgG-based diagnostic tests 
currently exist in various formats as a quick and easy method for use at point of 
care, including the dipstick ELISA, immunochromatographic card assay and antigen 
strips (Blacksell et al. 2011; Wu et al. 2000). Other diagnostic tests have been 
developed such as salivary IgA assays (Yap et al. 2011; Cuzzubbo et al. 1998), 
however all these tests have to be evaluated following WHO guidelines.  
1.5.3 Prevention and treatment 
Early diagnosis and optimal clinical management reduces the likelihood of severe 
dengue in patients. Due to the lack of commercially available antivirals or vaccines 
for dengue, treatment of patients is supportive. In the case of a mild or moderate 
illness, patients are usually treated with oral or intravenous rehydration (Gubler 
1998; WHO 1997). In severe dengue cases, particularly for patients with 
thrombocytopenia and active bleeding, intravenous fluid-replacement or 
prophylactic platelet transfusions are given in order to prevent haemorrhagic 
complications (Kaur & Kaur 2014).  
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Dengue can also be controlled by reducing the mosquito breeding sites and 
preventing exposure to the mosquito bites. Given that mosquito breeding sites are 
in close proximity to human settlements and domestic behaviour, controlling these 
breeding sites can be done through the use of effective chemical controls such as 
larvicides in water containers and insecticides (WHO 1997). The large usage of 
chemical agents however has led to development of insecticide-resistant Ae. 
aegypti which becomes an environmental and health concern (Rodríguez et al. 
2007). In contrast, the use of biological control agents, such as larvivorous fish 
and copepod crustaceans has shown to be environmentally safe and can effectively 
control Ae. aegypti populations (Nam et al. 2012; Nam et al. 2000). Self-protection 
methods including the application of skin repellent during outdoor activities, 
wearing protective clothing and using mosquito bed nets are recommended in 
order to prevent mosquito bites. An efficient environmental management and 
active surveillance play an important role in prevention and control strategies 
against dengue (Guzman et al. 2010; Gubler 1998).  
1.5.4 Vaccination strategies 
To date, there is a lack of vaccine commercially available for dengue. Although 
major efforts have been made to develop an effective vaccine, this has been 
hampered by difficulties in eliciting a protective immune response against the four 
DENV serotypes. In early attempts, several vaccines were developed through the 
production of purified inactivated virus and live-attenuated virus (LAV) (Robert 
Putnak et al. 2005; Innis & Eckels 2003; Eckels et al. 2003). These vaccines 
however, appeared to be reactogenic and were incapable of inducing a broad 
range protective immune response (Edelman 2007). In addition, the vaccines have 
been associated with higher adverse effect particularly among children. Several 
dengue vaccine candidates are currently at different stages of clinical studies. For 
example, the DENVax vaccine is developed based on previous DEN-2 PDK-53 
vaccine, with an additional mutation in NS3 gene for attenuation (Osorio et al. 
2011). The vaccine contains a mixture of the live-attenuated DENV-2 containing 
chimeric prM and E proteins of DENV-1, DENV-3, DENV-4 on the attenuated DENV-
2 backbone. Clinical trials in adults receiving this vaccine have recently shown an 
acceptable tolerability and immunogenicity (Osorio et al. 2014). This warrants 
further evaluation of this vaccine under the phase II clinical trials 
(https://clinicaltrials.gov/ct2/show/NCT02302066).  
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Among others, the most advanced vaccine candidate is the live-attenuated 
tetravalent chimeric yellow-fever dengue (CYD), developed by Sanofi Pasteur 
which is under evaluation in phase III clinical trials (Lang 2012; Guy et al. 2011). 
This vaccine is composed of the recombinant prM and E proteins of four DENV 
serotypes, each has been introduced into the yellow fever (YF) 17D virus backbone 
(Guy et al. 2011). Very recently, this vaccine has shown to be promising, which 
demonstrated a reduction in dengue among 35,000 children in Asian-Pacific and 
Latin American countries (Hadinegoro et al. 2015). 
 
1.5.5 Human innate immunity 
1.5.5.1 Innate immune responses against dengue virus 
The innate immune response plays an important role as the first defence 
mechanism against invading DENV. The initial cellular target upon infection is 
thought to be the interstitial dendritic cells followed by the lymphatic system and 
then distribution to monocytes and macrophages (Wong et al. 2012; Durbin et al. 
2008). Upon acidification of endosome and internalisation of DENV, pattern 
recognition receptors, such as the Toll-like receptors (TLRs) and intracellular 
molecules such as the DExE/H box RNA helicases are responsible for recognition 
of the viral RNA (reviewed by Green et al. 2014). TLR3 (TLR7/TLR8) recognizes 
the DENV RNA and triggers the phosphorylation of TIR-domain-containing adapter-
inducing interferon β (TRIF) (Figure 1.6) (Tsai et al. 2009). Interaction of TRIF with 
the TNF-receptor-associated factors (TRAF); TRAF3 and TRAF6, resulted in 
activation of two cascades: 1) TRAF3 interacts with TANK-binding kinase 1 (TBK1) 
and IkappaB kinase epsilon (IK) which activates the phosphorylation of 
interferon regulatory factor 3 (IRF3). Phosphorylated IRF3 translocates into the 
nucleus and induce the expression of type I IFNs. 2) TRAF6 recruits TAB2/3-TAK1 
and NF-B essential modulator protein (NEMO) to activate I/β, leading to 
translocation of NF-B transcription factors to the nucleus and activation of NF-
B targeted genes (Green et al. 2014).  
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Cytoplasmic helicases such as retinoic-acid-inducible gene I (RIG-I) and melanoma 
differentiation-associated gene 5 (MDA5) play an essential role in recognition of 
the viral RNA in the cytoplasm (Figure 1.6). RIG-I, MDA5 and TLR-3 have been 
reported to act synergistically inhibiting DENV replication in vitro (Nasirudeen et 
al. 2011). RIG-I recognizes short RNA ligands, whereas MDA5 recognizes long dsRNA 
and replication intermediates (Reikine et al. 2014). Upon recognition of these 
ligands, both RIG-I and MDA5 oligomerise, which subsequently activates the 
signalling partner mitochondrial antiviral signaling (MAVS) on the mitochondrial 
membranes. MAVS triggers an interaction with the ER protein stimulator of 
interferon genes (STING/MITA) and recruits TRAF3 and TRAF6 in order to activate 
the signaling cascades, hence the production of type I IFN (Liu et al. 2013).  
Secreted IFN binds to the cell surface IFN-/ receptor (IFNAR) and induces the 
Janus kinase-signal transducer and activator of transcription (JAK/STAT) signalling 
cascade (Green et al. 2014). This occurs through binding of the IFN on IFNAR which 
activates the adaptor molecules JAK1 and Tyk2 via tyrosine phosphorylation. This 
leads to the phosphorylation and dimerisation of STAT1 and STAT2, forming 
heterodimers that subsequently associate with IRF9. Association of these 
molecules generates an interferon-stimulated gene factor 3 (ISGF3) complex, 
which is translocated into the cell nucleus and binds to the interferon-stimulated 
response elements (ISREs) leading to the transcription of diverse IFN-stimulated 
genes (ISGs). This results in substantial production of pro-inflammatory cytokines 
and numerous effector proteins restricting virus infection, hence induction of an 
antiviral state (Fernandez-Garcia et al. 2009; Platanias 2005). 
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Figure 1.6: Host cellular innate immune responses during DENV infection.  
A: Recognition of the viral RNA in endosome by TLR3, B: Recognition of the viral 
RNA in the cytoplasm by RIG-I and MDA5, C: Activation of the RNAi pathway, D: 
hypertrophy of endoplasmic reticulum, E: lysosomal degradation by autophagy. 
Figure adapted from Green et al. (2014).    
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1.5.5.2 Other immune responses 
Humoral immunity usually develops ~6 days after an infection, in which antibodies 
target the E and prM proteins on the viral surface, as well as the secreted NS1 (Lai 
et al. 2008; Cardosa et al. 2002; Shu et al. 2000), resulting in either neutralisation 
or enhancement of dengue (Huang et al. 2006; Halstead 2003). It has been shown 
that the most potent neutralizing antibodies are strain-specific, which target the 
domain III of the E protein (Lisova et al. 2007; Oliphant et al. 2006). In the event 
of neutralisation, the antibodies are capable of preventing attachment of the virus 
to its receptor, thus inhibiting viral entry (Thompson et al. 2009). In contrast, the 
non-neutralizing antibodies are produced due to a secondary infection with a 
heterologous DENV serotype leading to ADE. It is believed that pre-existing 
antibodies bind to the virus particles and are engulfed by immune cells such as 
monocytes, macrophages and dendritic cells, through Fc receptors (Halstead 
1977). This results in replication of the virus in target cells generating a higher 
viral load and enhancement of infection (Chareonsirisuthigul et al. 2007). In 
patients suffering from DHF/DSS, a cytokine storm occurs with a significant 
increase in the levels of cytokines and immune mediators such as IFN-, IFN-, 
tumour necrosis factor- (TNF-) and interleukins (IL) which coincides with the 
severity of disease (Chakravarti & Kumaria 2006; Hober et al. 1993; Kurane et al. 
1991a).  
The precise role of the T cell response is debatable, either it contributes to the 
protection or enhancement of dengue (Malavige & Ogg 2013). It has been 
speculated that serotype-specific highly cross-reactive T cells may contribute to 
pathogenesis of dengue by producing high pro-inflammatory cytokines. However, 
this is difficult to define due to the lack of a suitable animal model for conducting 
such experiments. During a heterologous secondary infection, it is believed that 
the memory CD8+ T cells results in alteration of T cell function causing a marked 
increase in cytokines and immune modulators, which is a characteristic of 
DHF/DSS (Mathew & Rothman 2008). In contrast, a study by Yauch et al. (2009) 
using CD8+ T cell-depleted mice revealed that CD8+ T cells are important in 
defence mechanism against DENV (Yauch et al. 2009).  
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1.5.5.3 Subversion of host immune responses 
DENV is capable of manipulating the host cellular machinery and developing 
immune evasion strategies to establish an infection (Fischl & Bartenschlager 
2011). Recently published data suggests the virus is capable of antagonising 
cellular effects and blocking the host innate immune responses (Morrison et al. 
2012; Muñoz-Jordán 2010). These include the role of NS5 as a potent IFN 
antagonist where the protein is capable of blocking the JAK/STAT tyrosine kinase 
2 (Tyk2) phosphorylation (Ashour et al. 2009; Jones et al. 2005; Ho et al. 2005) 
(Figure 1.7). This causes an impairment of STAT2, followed by a subsequent 
degradation of STAT2. Further to this, DENV proteins NS2A, NS4A, and NS4B have 
been implicated in IFN inhibition (Rodriguez-Madoz et al. 2010; Muñoz-Jordán et 
al. 2005). Expression of these proteins in cell cultures has been shown to reduce 
STAT1 phosphorylation, which plays a key role in regulating type I IFN response 
pathway. Several reports show the inhibition of IFN production by NS2B/3 protease 
activity, in which the proteins directly cleaves STING, the downstream component 
of RIG-I/MDA5 (Angleró-Rodríguez et al. 2014; Rodriguez-Madoz et al. 2010).  
DENV is able to subvert autophagy by manipulating cellular autophagic machinery. 
Other viruses including hepatitis C virus, poliovirus and coronaviruses are also 
capable of modulating autophagy for replication (Reggiori et al. 2010; Dreux et 
al. 2009; Taylor & Kirkegaard 2007). Increased formation of autophagosomes and 
higher expression of autophagy-related proteins have been shown to correlate 
with enhanced DENV replication (Lee et al. 2008). These are supported by co-
localisation studies and detection of the virus translation/replication complex on 
immature autophagosomes (Panyasrivanit et al. 2009). Although the mechanism 
of DENV-induced autophagy is unclear, the role of ER stress response and 
suppression of the autophagic regulator, mammalian target of rapamycin (mTOR) 
have been suggested (Lee et al. 2008). DENV-induced autophagy has also been 
shown able to promote lipid metabolism for generation of energy which provides 
favourable conditions for virus replication (Heaton & Randall 2010).  
Virus infection often interferes with cellular homeostasis and leads to ER stress. 
In order to cope with the stress, DENV is capable of manipulating the unfolded 
protein response (UPR) through induction of X box binding protein 1 (XBP1) (Yu et 
al. 2006). XBP1 is a key transcription factor of UPR and has been shown to increase 
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synthesis of membrane phospholipid and ER volume for cell survival (Sriburi et al. 
2004). DENV NS proteins, such as NS2B/3 have been shown to activate XBP1, which 
resulted in prolong cell viability and thus, enhanced viral replication (Yu et al. 
2006).  
 
 
Figure 1.7: Subversion of antiviral responses during DENV infection.   
Subversion of antiviral responses is shown in boxes labelled A–H. (A) Maturity of 
viruses that affects the outcome of viral infection. (B) Suppression of IFN response 
resulted from virus infection that disrupts RIG-I/MDA5 and TLR signalling cascades. 
(C) Suppression of antiviral response resulted from cleavage of MITA/STING by 
DENV NS2B/3. (D) Inhibition of RNAi antiviral pathway by subgenomic Flavivirus 
RNA (sfRNA) and NS4B. (E) Autophagy induced by DENV which is capable of 
enhancing viral replication. (F) DENV-induced endoplasmic reticulum hypertrophy 
and manipulation of the unfolded protein response to compensate ER stress. (G) 
Inhibition of STAT1 phosphorylation and suppression of the JAK-STAT pathway by 
NS2A, NS4A, and NS4B. (H) STAT2 degradation by NS5 which results in inhibition 
of the JAK-STAT pathway and IFN response. Entry and release of the mature DENV 
virions are shown by red arrows. Figure adapted from Guzman & Harris 2014.  
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1.6 Hypotheses and aims of study 
Although DENV has been studied extensively, the molecular biology of the virus 
remains unclear. The hypothesis behind this research project was that a 
systematic analysis of virus-host protein-protein interaction would provide a 
greater understanding of the viral infection process. Identification of host factors 
interacting with the viral proteins indicates a putative physical association of 
DENV-host proteins during cellular processes which could reveal a specific 
mechanism or pathway contributing to the viral infection. Further, this interaction 
could be translated into a larger biological function, leading to the potential use 
of the identified proteins as candidates for diagnostics or drug discovery.  
The aims of this study were as following: 
1. To identify human host factors interacting with DENV-2 NS proteins through 
a yeast two-hybrid protein-protein interaction systematic analysis.  
2. To validate and confirm the protein interaction between DENV-2 NS 
proteins and the human interactors in mammalian system. 
3. To investigate the functional properties of the protein of interest and 
analyse its importance in DENV replication by siRNA gene silencing. 
4. To identify mosquito host factors interacting with DENV-2 NS proteins and 
optimize the downstream innate immune signalling assays. 
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2 CHAPTER 2: MATERIALS AND METHODS 
 Cell culture techniques 
 Cell lines 
 Mammalian cells 
Human embryonic kidney 293 (HEK293) and human lung adenocarcinoma epithelial 
cells (A549) were grown in Dulbecco's Modiﬁed Eagle's Medium (DMEM) (Gibco®) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Gibco®) and 
100 U/ml penicillin/100 μg/ml streptomycin (Pen/Strep) (Gibco®). Baby hamster 
kidney-21 (BHK-21) cells were grown in Glasgow Minimum Essential Medium 
(GMEM) (Gibco®) supplemented with 5% newborn calf serum (NBCS) (Gibco®), 10% 
tryptose phosphate broth (TPB) (Gibco®) and Pen/Strep. Each cell line was 
propagated in a culture flask (Nunc) under sterile conditions in a Class II Biosafety 
Cabinet and incubated at 37 °C in a humidified incubation chamber with 5% carbon 
dioxide. All cell lines are listed in Table 2.1. 
 Mosquito cells 
Aedes aegypti-derived Aag2 cells, Aedes albopictus-derived C6/36 and Aedes 
albopictus-derived U4.4 cells (Table 2.1) were maintained in L-15 (Leibovitz's) 
medium supplemented with 10% FBS, 10% TPB and 1% Pen/Strep. The cells were 
cultured under sterile conditions and incubated at 28 °C without carbon dioxide. 
Table 2.1: Cell lines used in this study. 
Cell name  Organism of origin Reference 
HEK293 Homo sapiens (Graham et al. 1977). Received from 
Edward Dornan, University of Glasgow 
A549 Homo sapiens (Giard et al. 1973) 
BHK-21 Mesocricetus auratus (Macpherson & Stoker 1962) 
Aag2 Aedes aegypti (Peleg 1968) 
C6/36 Aedes albopictus (Condreay & Brown 1986) 
U4.4 Aedes albopictus (Condreay & Brown 1986) 
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 Propagation of cells 
 Mammalian cells 
Cells were sub-cultured once they reached approximately 80% confluence and 
continuously propagated up to 30 passages before replacing them with fresh stocks 
from liquid nitrogen. Prior to harvesting, the medium was removed and the cell 
monolayer rinsed with 5 ml versene in PBS (E&O Laboratories Ltd.). After 
decanting the solution, 1x Trypsin (Sigma-Aldrich)/Versene was added and 
incubated at 37 °C to allow detachment of cells. The trypsinisation reaction was 
halted by adding 5 ml of medium and the cell suspension was spun down at 1,500 
rpm for 5 min. The cell pellet was re-suspended in fresh medium and the required 
volume was transferred to a new culture flask containing medium, followed by 
incubating at 37 °C for 4-5 days.  
 Mosquito cells 
To allow propagation of mosquito cells, medium was removed from a culture flask 
of 80% confluent cells and 5 ml fresh L-15 medium was added. The cells were 
detached by gently scraping them off from the surface of flask using a cell scraper 
and transferred into 15 ml Falcon tube (Corning). The cells were re-suspended 
followed by adding an appropriate volume of L-15 medium and subsequently 
transferred into a fresh culture flask prior to incubation at 28 °C. 
 Seeding of cells 
Cells were detached from the culture flasks as described in the above protocols 
(Section 2.1.2.1 and 2.1.2.2). After resuspension with medium, the total number 
of cells was counted using a haemocytometer under the microscope and the 
required number of cells (Table 2.2) was calculated as below: 
Number of cells/ ml  = Average count per square x dilution factor x 104 
 
An appropriate volume of pre-warmed growth medium was added to make up the 
required cell density and dispersed into 24-well plates (reduced by one-log when 
seeded in a 96-well plate) prior to incubation at their respective growth 
temperatures.  
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Table 2.2: Number of seeded cells used for experiments. 
Cell name  Number of seeded cells (cells/ ml) Growth conditions 
HEK293 1.4 x 105 37 °C 
A549 1.2 x 105 37 °C 
BHK-21 1.2 x 105 37 °C 
Aag2 1.7 x 105 28 °C 
C6/36 1.2 x 105 28 °C 
U4.4 1.2 x 105 28 °C 
 
 Cryopreservation of cells 
To preserve the mammalian and mosquito cells for long-term storage, the cells 
were harvested following their respective protocols above and re-suspended in 
medium containing 10% dimethyl sulfoxide (DMSO) (BDH). Prior to freezing, the 
cells were gently mixed to achieve a homogeneous suspension and divided into 1 
ml-aliquots in cryogenic storage vials (Greiner Bio-One). The vials were 
immediately placed in Mr. Frosty™ Freezing Container (Nalgene®) in the presence 
of isopropanol and kept at -80 °C overnight before storing them in liquid nitrogen 
the next day.  
 Recovery of frozen cells 
A cryovial containing frozen cells was removed from liquid nitrogen and the 
content was thawed by placing the vial at 37 °C in a water bath with gentle 
agitation. The vial content was quickly transferred into 25 cm2 culture flask 
containing 8 ml fresh medium prior to incubation at their respective growth 
temperature overnight. The culture medium was replaced with fresh medium the 
next day and the cells were incubated for 3-4 days before sub-culturing into a 
medium flask. All cell lines were reconstituted as mentioned above with the 
exception of HEK293 that required a complete removal of DMSO prior to growth. 
Once HEK293 cells were thawed, they were quickly transferred into a 15 ml tube 
containing 10 ml DMEM to dilute the DMSO and then immediately spun down at 
800 rpm for 1 min. The cell pellet was gently re-suspended in 5 ml fresh medium 
and transferred into a 25 cm2 culture flask followed by an incubation at 37 °C for 
2 days until further sub-culture was required.   
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 Nucleic acid techniques 
 RNA isolation 
Total RNA was extracted from cultured cells using TRIzol® reagent (Invitrogen) 
according to the manufacturer’s instruction. Briefly, the cells were washed with 
1x phosphate buffered saline (PBS) and spun at 1,500 rpm for 5 min. To lyse the 
cells, 1 ml TRIzol® reagent was added and incubated for 5 min at room 
temperature. Chloroform (0.2 ml) was added to the suspension, vortexed and spun 
for 15 min at 12,000 rpm at 4 °C. The colourless upper phase containing RNA was 
precipitated by adding 0.5 µl RNase free glycogen (10 mg/ ml) and 0.5 ml 
isopropanol. The mixture was incubated for 10 min at room temperature and spun 
at 12,000 rpm for 10 min at 4 °C. The RNA pellet was washed with 70% ethanol, 
spun at 10,500 rpm for 5 min at 4 °C and air-dried for 5 min. The RNA was re-
suspended in 20 µl nuclease free water and stored at -20 °C. All steps involving 
RNA procedures was performed in RNase free conditions.  
 RT-PCR 
To generate the first-strand cDNA, 1-5 μg total RNA, 1 μl oligo dT or random 
primers (50 μM), 1 μl dNTP mix (10 mM) (Invitrogen) and water (adjusted to make 
up 13 μl) was added into a nuclease-free PCR tube. The mixture was incubated at 
65 °C for 5 min in a thermal cycler followed by cooling on ice for 1 min. The 
reverse-transcriptase reaction was performed by adding 4 μl First-Strand buffer 
(5x), 1 μl DTT (0.1 M), 1 μl RNaseOUT™ Recombinant RNase Inhibitor (40 U/ μl), 1 
μl SuperScript™ II reverse transcriptase (200 U/ μl) (Invitrogen). An additional step 
when using random primers was done by incubating the mixture at 25 °C for 5 
min. The mixture was subsequently incubated at 50 °C for 1 hr in a thermal cycler 
and inactivated at 70 °C for 15 min. The resulting cDNA (2 μl) was used as a 
template for subsequent PCR amplification using the gene-specific primers. 
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 Polymerase chain reaction 
Standard PCR reactions were prepared in a master mix containing 10 μl 5x GoTaq® 
Flexi buffer, 4 μl MgCl2 (25 mM) (Promega), 1 μl dNTP mix (10 mM each), 1 μl 
Forward primer (10 μM), 1 μl Reverse primer (10 μM), 0.5 μl GoTaq® DNA 
Polymerase (5 U/ μl) (Promega) and nuclease-free water (to make the reaction up 
to 50 μl). The mixture was aliquoted into PCR tubes followed by addition of 10 ng 
template DNA. Amplification of the DNA was carried out in a thermal cycler 
GeneAmp® PCR System 9700 (Applied Biosystems). The PCR cycling parameters 
were as listed in Table 2.3. Amplified PCR fragments were visualised by agarose 
gel electrophoresis and stored in -20 °C.  
Table 2.3: Standard PCR parameters. 
Step Temperature PCR cycle Time 
Initial denaturation 95 °C   2 min 
Denaturation 95 °C  30 sec 
Annealing 50–65 °C 25-30 cycles 30 sec 
Extension 72 °C  1 min/ kb 
Final extension 72 °C  5 min 
 
 KOD PCR 
KOD PCR (Toyobo) was used for amplification of genes prior to cloning into 
appropriate vectors. The reaction kit contains high fidelity KOD DNA polymerase 
for efficient proof reading activity. KOD PCR reactions were prepared in 50 μl 
reaction containing 5 μl KOD Hot Start DNA Polymerase Buffer (10x), 3 μl MgSO4 
(25 mM), 5 μl dNTPs (2 mM each), 1.5 μl Forward primer (10 μM), 1.5 μl Reverse 
primer (10 μM), 1 μl KOD Hot Start DNA Polymerase (1 U/ μl), nuclease-free water 
and 10 ng DNA template. The KOD-PCR cycling conditions were listed in Table 2.4. 
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Table 2.4: KOD PCR parameters. 
Step Temperature PCR cycle Time 
Initial denaturation 95 °C   2 min 
Denaturation 95 °C  20 sec 
Annealing Lowest primer melting 
temperature 
20-30 cycles 10 sec 
Extension 70 °C  15 sec/kb 
 
 Agarose gel electrophoresis  
Agarose gels (0.8-1.2% depending on the size of DNA) were prepared by weighing 
agarose powder (Promega) to a desired percentage and adding the appropriate 
volume of 1x TAE (Tris-Acetate-EDTA) buffer (Severn Biotec, Ltd.). The agarose 
was dissolved by boiling in a microwave for 1-2 min, gently swirled and allowed to 
cool down for 5 min prior to addition of ethidium bromide (Promega) (final 
concentration 0.5-1 µg/ ml). The liquid agarose was immediately poured into a 
gel tray with the well comb in place and allowed to solidify for 20-30 min. DNA 
samples mixed with loading buffer were loaded into the wells of the gel and 
electrophoresed at 100 V until the dye front was approximately 75-80% of the way 
down the gel. The DNA bands were visualised and imaged under UV-
transilluminator Gel Doc™ 2000 Gel Documentation Systems (Bio-Rad). 
 Purification of DNA from PCR products 
PCR products were purified using the High Pure PCR Product Purification Kit 
(Roche) according to the manufacturer’s protocol with some modifications. 
Briefly, 500 µl Binding buffer was mixed with the PCR product and spun down 
through a spin column at 12,000 x g for 1 min. To wash the DNA, 500 µl Washing 
buffer was added and the column was spun at 12,000 x g for 1 min. This step was 
repeated by adding 200 µl Washing buffer and the spin column was spun again 
twice at 12,000 x g. Pre-heated Elution buffer (50 µl) was added to the spin column 
and incubated at 65 °C for 2 min followed by centrifugation at 12,000 x g for 2 
min. The purified DNA was stored at -20 °C.  
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 Purification of DNA from agarose gels 
DNA was extracted from agarose gels using illustra™ GFX™ PCR DNA and Gel Band 
Purification Kit (GE Healthcare) following the manufacturer’s instructions. In 
brief, the DNA fragment was excised from an agarose gel and dissolved in Capture 
buffer type 3 by incubating at 60 °C for 15–30 min. The mixture was transferred 
into GFX MicroSpin column, spun down at 12,000 x g for 1 min followed by washing 
of the DNA with 500 μl Wash buffer type 1. The column was spun again at 12,000 
x g for 1 min to remove excess buffer and the DNA was eluted using 50 μl Elution 
buffer type 6 (sterile nuclease-free water) prior to storage at -20 °C. 
 Quantitation of nucleic acids 
Measurement of DNA and RNA concentrations was carried out using a NanoDrop™ 
1000 spectrophotometer (Thermo Scientific) at UV wavelength 260-280 nm. The 
instrument was initialised by applying 2 μl deionised water on the optical surface. 
This was followed by a blank measurement using nuclease-free water or Tris-EDTA 
(TE) buffer (depending on which was used to dissolve the DNA/RNA). The nucleic 
acid concentration was measured by mixing the tube contents and loading 2 μl 
onto the optical surface. Pure preparations of DNA and RNA were indicated by 
optical density (OD) ratios OD260/OD280 of 1.8 to 2.0, respectively. 
 Transformation of plasmids 
Plasmid DNA (10-50 ng) was added to 50 µl Subcloning Efficiency™ DH5™ E. coli 
competent cells (Invitrogen) in a microcentrifuge tube. For propagation of the 
Gateway donor and destination vectors harbouring the ccdB gene, One Shot® ccdB 
Survival™ 2T1R E. coli competent cells (Invitrogen) were used. The cells were mixed 
gently and incubated on ice for 30 min. This was followed by a heat-shock at 42 
°C for 30 sec to allow the uptake of the DNA before placing the tube on ice again 
for 2 min. The bacterial cells were allowed to recover by the addition of 950 µl 
pre-warmed Luria Bertani (LB) broth (E&O Laboratories Ltd.) and incubation at 37 
°C for 1 hr with shaking at 225 rpm. The transformed cells (100 µl) were plated 
on LB agar plates containing the appropriate antibiotic (Table 2.6) and allowed to 
grow at 37 °C for 16-18 hr.  
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 Mini-scale plasmid purification 
Plasmids were purified in small-scale using ISOLATE Plasmid Mini Kit (Bioline) 
according to the manufacturer’s instructions. An overnight propagation of 
bacterial cultures were harvested and re-suspended in 250 µl of Buffer P1. To lyse 
the cells, 250 µl of Lysis buffer P2 was added and the content was incubated at 
room temperature for 5 min. The reaction was halted by adding 300 µl 
Neutralisation buffer P3 followed by centrifugation at 12,000 rpm for 5 min. The 
supernatant was applied into the spin column and spun at 12,000 rpm for 1 min. 
The DNA was washed with 600 µl Wash buffer PW2 supplemented with ethanol and 
spun at 12,000 rpm for 1 min. To remove excess residual ethanol, the spin column 
was spun again at 12,000 rpm for 2 min. Prior to elution of the DNA, 50 µl nuclease-
free water was added onto the membrane and allowed to incubate at room 
temperature for 1 min, followed by centrifugation at 12,000 rpm for 1 min. The 
DNA concentration was determined (as described in Section 2.2.8). 
 Large-scale plasmid purification 
 High-copy plasmids 
High-copy number plasmids were purified using Plasmid Maxi Kit (QIAGEN) 
following the manufacturer’s protocol with minor modifications. Briefly, the 
bacterial cells were harvested by centrifugation followed by re-suspension in 10 
ml Buffer P1. To lyse the cells, 10 ml Buffer P2 was added and the suspension was 
mixed by inverting the tube followed by incubation at room temperature for 5 
min. Next, Buffer P3 (10 ml) was added and the suspension was immediately mixed 
by inverting the tube resulting in white precipitation of materials. After an 
incubation on ice for 20 min, the precipitated materials were removed by 
filtration through a coffee filter (a modified protocol). The filtrate containing 
plasmid DNA was applied into a QIAGEN-tip 500 spin column equilibrated with 
Buffer QBT. The DNA was washed twice with 30 ml Buffer QC and eluted with 15 
ml Buffer QF into a 50 ml Falcon tube. Precipitation of the DNA was carried out 
by adding 10.5 ml isopropanol followed by centrifugation at 5,000 rpm at 4 °C for 
1 hr. The DNA pellet was washed in 70% ethanol, spun at 5,000 rpm at 4 °C for 1 
hr and air-dried for 5-10 min. The DNA was resolved in 100-150 µl nuclease free 
water or TE buffer prior to storage at -20 °C.  
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 Low-copy plasmids 
Low-copy number plasmids were purified as above (Section 2.2.11.1) with an 
additional DNA precipitation step after alkaline lysis to reduce the volume of 
lysate. Following cell lysis and removal of the precipitated cell debris through a 
coffee filter, the DNA in the supernatant was precipitated with 0.7 volumes 
isopropanol. This was followed by centrifugation at 9,500 rpm at 4 °C for 30 min 
and the DNA pellet was re-dissolved in 500 µl TE buffer (pH 8) and 4.5 ml Buffer 
QBT. The DNA was applied into the spin column QIAGEN-tip 500 and washed with 
Buffer QC twice. The remaining steps were performed as described for purification 
of high-copy plasmids above (Section 2.2.11.1).  
 Plasmid restriction digestion 
For analytical-scale enzymatic reactions, 1 μg plasmid DNA was digested in a total 
volume of 20 μl. A master mix containing nuclease-free water, 2 μl restriction 
enzyme buffer (10x) (New England Biolabs Inc.), 0.2 μl bovine serum albumin (BSA) 
(10 μg/ μl) and 0.2 μl of restriction enzyme (10 U/ μl) (New England Biolabs Inc.) 
was prepared followed by addition of the DNA. The reaction was mixed gently, 
briefly spun and allowed to incubate at 37 °C for 1-2 hr. The digestion reaction 
was halted by heat-inactivation at 65 °C for 20 min. For a large-scale restriction 
digestion in 40 μl reaction mix, 4-5 μg plasmid DNA was used along with 2 μl 
restriction enzyme and the reaction was incubated at 37 °C for 4-5 hr. 
 DNA Ligation 
DNA ligations were set up in a sterile 1.5 ml microcentrifuge tube by adding 1 µl 
T4 DNA Ligase buffer (10x) (Promega), plasmid DNA, insert DNA (in a 
plasmid:vector of 1:3 ratio), nuclease-free water (up to 10 µl) and 1 µl T4 DNA 
ligase (1 Weiss unit/ µl) (Promega). The ligation reaction was gently mixed, spun 
briefly and allowed to incubate at room temperature for 3 hr or at 4 °C overnight. 
The reaction was halted by heat-inactivating at 65 °C for 10 min followed by 
cooling down on ice prior to transformation (5 µl of the ligation mix) into 
competent cells. 
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 DNA sequencing 
Cloned genes of interest were sequence-verified by sending the plasmid DNA or 
PCR product and their respective primers to the DNA Sequencing Service, 
University of Dundee (http://www.dnaseq.co.uk/home.html). Sequencing of the 
MGC human cDNA library was performed by GATC Biotech, Konstanz, Germany. 
The sequencing results were analysed using BioEdit Sequence Alignment Editor 
and identification of the genes was accomplished using BLAST: Basic Local 
Alignment Search Tool (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
 Bacterial glycerol stock 
Glycerol stocks were prepared for long-term storage of plasmid clones. Glycerol 
stabilizes the frozen bacteria which prevents damage to the cell membrane. An 
overnight bacterial culture (250 µl) was added to 250 µl of 50% sterile glycerol in 
a 2 ml screw-cap vial (a final concentration of 25% glycerol). The suspension was 
mixed well by briefly vortexing and immediately stored at -80 °C. To recover 
bacteria from the glycerol stock, a sterile loop was used to scrape off the top part 
of the frozen culture and streaked onto LB agar plate containing the appropriate 
antibiotic, followed by incubating at 37 °C overnight. 
 
 Protein techniques 
 Protein sample preparation 
Preparation of protein samples was carried out on ice unless stated otherwise. 
Transfected mammalian cells were harvested by centrifugation at 1,500 rpm for 
5 min at 4 °C, washed in 1 ml ice-cold PBS and spun again at 1,500 rpm for 5 min 
at 4 °C. The cell pellet was lysed in Nonidet P-40 (NP40) cold lysis buffer 
containing protease inhibitor cocktail mix (Roche) and incubated on ice for 5 min 
with vigorous vortexing twice for 5-10 sec. The protein sample was allowed to 
incubate at 4 °C with constant agitation for 30 min and spun down at 10,000 rpm 
for 10 min at 4 °C prior to storage at -20 °C. 
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 Protein quantification 
Proteins were quantified using the BCA Protein Assay kit (Pierce) following the 
manufacturer’s instructions. In brief, the BCA working reagent was prepared by 
mixing 50 parts of Reagent A to 1 part of Reagent B, made up to a required volume 
as below: 
Vol. of working reagent = No. of samples x replicates x working vol. per sample 
 
Protein samples were thawed on ice and 25 µl was loaded into a 96-well plate. 
The BCA working reagent was added into each well (200 µl/ well) and the plate 
was covered with tin foil followed by incubation at 37 °C for 30 min. After cooling 
to room temperature, the protein absorbance was measured at 562 nm using 
GloMax® Multi Detection System (Promega) for Protein BCA Assay. The cell lysis 
buffer was used as a blank measurement to subtract the protein background 
absorbance and the resulting values were calculated against the BSA standard 
curve to determine the protein concentration. 
 Protein electrophoresis 
A pre-cast Bolt® 4-12% Bis-Tris Plus Gel (Invitrogen) was set up by placing the gel 
in a Bolt® Mini Gel Tank electrophoresis unit filled with 1x Bolt® MES [2-(N-
morpholino) ethane sulfonic acid] SDS Running buffer (Invitrogen) according to the 
manufacturer’s instructions. Protein samples (10 µg) were mixed with 5 µl lithium 
dodecyl sulfate sample buffer (4x) (Invitrogen) and 2 µl sample reducing agent 
(10x) (Invitrogen) followed by heating at 95 °C for 10 min. The proteins (20 µl) 
were loaded into the wells of the pre-cast gel along with SeeBlue® Plus2 Pre-
Stained Standard protein marker (Invitrogen) and resolved at 120 V for 1 hr. 
 Protein transfer 
After separation, the proteins were transferred onto a nitrocellulose membrane 
(GE Healthcare) using the Trans-Blot® Semi-Dry Electrophoretic Transfer Cell 
(BioRad). Prior to the transfer, the protein gels were removed from cassettes, 
using a gel knife and equilibrated in 1x Transfer buffer for 5 min. The 
nitrocellulose membrane and Whatman blotting papers (GE Healthcare) were cut 
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to the dimension of the gel and soaked in 1x Transfer buffer for 3-5 min. The 
materials were assembled in a sandwich layer by placing the pre-soaked Whatman 
blotting paper on the Trans-Blot anode platform surface followed by the 
membrane, protein gel and another piece of Whatman paper on top. The cathode 
safety cover unit were put in place and the proteins were transferred at 15 V, 0.3 
A for 30 min. 
 Immunoblotting 
Following protein transfer, the membrane was blocked with 5% milk powder in 
PBS/Tween-20 (0.001% Tween-20) for 1 hr at room temperature to prevent non-
specific binding of the antibodies to proteins on the membrane. After washing 
three times in PBS/Tween-20 for 5 min, an appropriate dilution of primary 
antibody (Table 2.5) was added and the membrane was incubated at 4 °C 
overnight with gentle shaking. After incubation, the membrane was washed in 
PBS/Tween-20 for 5 min three times followed by incubating in an appropriate 
dilution of secondary antibody (Table 2.5) at room temperature for 1-2 hr. The 
membrane was washed with PBS/Tween-20 for 5 min three times, followed by 
detection of the proteins using enhanced chemiluminescence (ECL) Western 
Blotting Substrate (Pierce). Lower expression of proteins was detected using 
Amersham ECL Select™ Western Blotting Detection Reagent (GE Healthcare).  
Table 2.5: List of antibodies used for immunoblotting. 
Antibody Target Host Dilution Distributor 
Primary BANP Rabbit 1:10,000 Bethyl Lab, Inc. 
Primary Kv1.3 Rabbit 1:1000 LSBio 
Primary Myc-NS2A Mouse 1:1000 Santa-Cruz 
Primary Human beta-Actin Rabbit 1:1000 Sigma-Aldrich 
Primary V5 epitope Mouse 1:3000 Pierce 
Primary EGFP Rabbit 1:3000 Abcam 
Secondary Anti-rabbit IgG conjugated 
with horseradish peroxidase 
Goat 1:3000 Abcam 
Secondary Anti-mouse IgG conjugated 
with horseradish peroxidase 
Goat 1:3000 Abcam 
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 Yeast two-hybrid interaction analysis 
 MGC cDNA library, plasmids and yeast strains  
The mammalian gene collection (MGC) human cDNA library, Gateway vectors and 
yeast strains used in the yeast two-hybrid (Y2H) experiments were kindly provided 
by Juergen Haas, University of Edinburgh. pDEST40 was a kind gift from Esther 
Schnettler, University of Glasgow. The Gateway vectors and their respective 
antibiotic selection markers are shown in Table 2.6. All antibiotics were purchased 
from Sigma-Aldrich. The yeast vector pGBKT7 was used to express DENV bait 
protein as a fusion with the GAL4 DNA-binding domain (Figure 2.2). For prey, 
pGADT7 expressed the MGC human cDNA library proteins downstream of the GAL4 
activation domain. Both bait and prey fusion proteins were highly expressed under 
the control of ADH1 yeast promoter and tagged respectively by c-Myc and 
haemagglutinin. Saccharomyces cerevisiae haploid strains AH109 and Y187 were 
used as hosts for protein expression of the bait and prey, respectively. 
Table 2.6: Gateway donor and destination vectors used in this study.  
 
  
Plasmid vector Clone Host Antibiotic 
selection 
Antibiotic 
concentration 
(µg/ ml) 
pDONR207 Entry Bacteria Gentamycin 10  
pDONR223 Entry Bacteria Spectinomycin 50 
pGBKT7 Destination Yeast Kanamycin 
sulfate 
50 
pGADT7 Destination Yeast Ampicillin 100 
pTREX-DEST30-
Protein A 
Destination Mammalian Ampicillin 100 
pcDNA3-RL-GW Destination Mammalian Ampicillin 100 
pDEST40 Destination Mammalian Ampicillin 100 
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 Dengue virus replicons 
Dengue virus type 2 New Guinea-C (NGC) sub-genomic replicon; pDVRepGP2A 
(Figure 2.1a), was used in this study as a template for amplification of DENV genes 
prior to Gateway cloning. The replicon contained DENV-2 non-structural genes and 
green fluorescent protein (GFP) as a fusion with a drug selectable marker 
puromycin N-acetyl-transferase (PAC) at the N-terminus. This is followed by small 
2A peptides from the foot and mouth disease virus in place of the DENV C, prM 
and E genes. In order to study DENV replication, DENV-2 NGC sub-genomic 
replicons expressing Firefly luciferase (FFLuc); pDVPACLuc (Figure 2.1b) (Massé et 
al. 2010; Pryor et al. 2004) and its derived mutant pDVW87I were used. Both 
replicons contained DENV non-structural and PAC genes in place of the DENV C, 
prM and E. pDVW87I has a mutation in NS5 gene (W87I) that prevents translation 
of the viral transcripts and thus abolishes replication. All replicons were kindly 
provided by Andrew Davidson, University of Bristol. The replicons were propagated 
and purified using Plasmid Maxi Kit following the manufacturer’s protocol for very 
low-copy plasmids (Section 2.2.11.2). 
 
(a)  
 
(b)  
 
Figure 2.1: DENV-2 New Guinea C replicons used in this study. 
(a) DENV-2 NGC replicon expressing GFP (pDVRepGP2A) and (b) DENV-2 NGC 
replicon expressing FFLuc (pDVPACLuc). Both replicons are fused to puromycin N-
acetyl-transferase (PAC) at the N-terminus. pDVW87I (not shown) is a mutant 
version of pDVPACLuc, consisting similar replicon organisation, except a mutation 
was introduced in NS5 (amino acid position 87, tryptophan to isoleucine) (Massé 
et al. 2010; Pryor et al. 2004).  
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Figure 2.2: A schematic map of DENV bait construct in pGBKT7 yeast vector. 
Below the plasmid map are sequences within the multiple cloning site (MCS). DENV 
genes were cloned into DNA Reading Frame Cassette B (RfB) within the SmaI 
restriction site of the vector MCS. The RfB contains ccdB and chloramphenicol 
resistance genes. Sequence in red is the Gateway attachment (att) sites for 
homologous recombination, blue is the Kozak sequence for expression of proteins 
in eukaryotic system, green is the stop codon. Highlighted in yellow is the DENV 
gene. 
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 Determination of DENV transmembrane domains 
Using structure prediction software available on the web (Table 2.7), DENV TMDs 
were identified based on the consistency of the predicted regions within NS2A, 
NS2B, NS4A and NS4B protein sequences. Removal of these regions resulted in the 
generation of nineteen intra/extracellular gene fragments. NS1, NS3 and NS5 were 
not included because they are cytoplasmic proteins, hence absent of TMDs.  
Table 2.7: Transmembrane prediction software used in this study. 
Software Website link 
TMPred http://www.ch.embnet.org/software/TMPRED_form.html 
TMHMM2 http://www.cbs.dtu.dk/services/TMHMM 
HMMTOP http://www.enzim.hu/hmmtop 
Pred-TMR http://www.enzim.hu/hmmtop 
SPLIT4 http://split4.pmfst.hr/split/4 
TopPred http://bioweb.pasteur.fr/seqanal/interfaces/toppred.html 
DAS http://www.sbc.su.se/~miklos/DAS 
SOSUI http://bp.nuap.nagoya-u.ac.jp/sosui/sosui_submit.html 
 
 Gateway cloning technology 
DENV bait constructs were generated using the Gateway technology (Invitrogen). 
This cloning technology was developed based on bacteriophage lambda site-
specific recombination (Landy 1989), and subsequently improved (Hartley et al. 
2000). The Gateway system provides an efficient way of cloning a gene of interest 
into multiple cloning vectors through DNA recombination at specific attachment 
sites (att). The recombination is mediated by proprietary enzymes mixes; BP 
clonase and LR clonase, which contains the necessary enzyme activities to excise 
and recombine the gene of interest. In order to express DENV proteins in yeast, 
entry clones containing DENV genes were generated through a BP reaction and 
subsequently transferred into the yeast expression vector through an LR reaction 
(Figure 2.3). BP clonase contains the phage lambda Integrase and the E. coli 
Integration Host Factor which catalyses recombination reaction between the DENV 
PCR-amplified fragment flanked by attB sequences and a donor vector containing 
attP sites, resulting in an entry clone (Figure 2.3). LR clonase has similar enzyme 
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components with additional lambda Excisionase, which catalyses the transfer of 
DENV fragments between attL of an entry clone and attR of a yeast destination 
vector, producing an expression clone (Figure 2.3). 
For efficient selection of positive clones in E. coli, the DNA Reading Frame 
Cassette of Gateway vectors contain a ccdB lethal gene. During recombination, 
the DNA cassette with flanking att sites is swapped with the gene of interest 
resulting in two products; one carries the empty vector ccdB and the other carries 
the gene of interest. Bacteria cells that take up the empty vector carrying the 
ccdB gene fail to grow because the toxic protein CcdB interferes with the activity 
of E. coli DNA gyrase, thus killing the cells. On the other hand, the bacteria cells 
carrying the gene of interest will grow on antibiotic-selective medium (dependent 
on the selection marker which the vector carries) and this enables efficient 
recovery of the desired clones.  
 
Figure 2.3: A schematic diagram of the Gateway cloning system.  
BP reaction catalyses the recombination of an attB-flanking PCR product with a 
donor vector containing an attP site (attB x attP), producing an attL-entry clone. 
LR reaction facilitates the recombination of the attL-entry clone with a 
destination vector containing an attR site (attL x attR), producing an expression 
clone containing attB. The specific att recombination sites are shown in red and 
yellow. Figure was adapted from the Gateway Cloning Handbook (Invitrogen) 
(https://tools.thermofisher.com/content/sfs/manuals/gatewayman.pdf).  
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 Amplification of DENV genes 
Primer sets were designed to amplify DENV genes with specific attachment (att) 
sites for use in the Gateway cloning. The genes were amplified using the high 
fidelity KOD DNA polymerase by two rounds of PCR (Figure 2.4), using the gene-
specific primers in the first round (Table 2.8), followed by the attB universal 
primers in the second PCR (Table 2.9). In the first PCR, the DENV genes were 
amplified from the DENV-2 NGC replicon, pDENRepGP2A, producing an amplified 
product containing Kozak consensus sequence (for initiation of translation in 
eukaryotic system), a DENV gene fragment with a stop codon and partial attB 
Gateway recombination sequence at both the 5’ and 3’ ends. The resulting PCR 
product (10 µl) was used as a template for the second PCR using the attB universal 
primers creating flanking attB sites (35 nucleotides) at both ends of the amplified 
products for insertion into the Gateway vector (Figure 2.4).  
 
 
 
Figure 2.4: PCR amplification of DENV genes incorporating attB sites. 
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Table 2.8: DENV gene-specific primers for Gateway cloning.  
Partial attB sequence overhangs (in blue), Kozak sequence (in red), DENV gene 
sequence (in black) and the stop codon (in bold black) are shown. 
DENV  Size 
(bp) 
Primer Sequence 5’ – 3’ 
NS1 1056 NS1-1F AAAAAGCAGGCTCCGCCGATAGTGGTTGCGTTGTGAGC 
NS1-1056R AGAAAGCTGGGTCCTAGGCTGTGACCAAGGAGTTG 
NS2A 654 NS2A-1F AAAAAGCAGGCTCCGCCGGACATGGGCAGATTGAC 
NS2A-218R AGAAAGCTGGGTCCTACCTTTTCTTGTTGGTTCTTG 
NS2B 390 NS2B-1F AAAAAGCAGGCTCCGCCAGCTGGCCACTAAATGAGGC 
NS2B-130R AGAAAGCTGGGTCCTACCGTTGTTTCTTCACTTCCCAC 
NS3  1854 NS3-1F AAAAAGCAGGCTCCGCCGCTGGAGTATTGTGGGATGTCC 
NS3-1854R AGAAAGCTGGGTCCTACTTTCTTCCAGCTGCAAACTCC 
NS4A 450 NS4A-1F AAAAAGCAGGCTCCGCCTCCCTGACCCTGAACCTAATC 
NS4A-150R  AGAAAGCTGGGTCCTATGCCATGGTTGCGGC 
NS4B  744 NS4B-1F AAAAAGCAGGCTCCGCCAACGAGATGGGTTTCCTGG 
NS4B-248R AGAAAGCTGGGTCCTACCTTCTCGTGTTGGTTGTG 
NS5  2701 NS5-1F AAAAAGCAGGCTCCGCCGGAACTGGCAACATAGGAGAG 
NS5-2700R AGAAAGCTGGGTCCTACCACAGGACTCCTGCCTCTTC 
NS2A1F  
 
87 NS2A-1F AAAAAGCAGGCTCCGCCGGACATGGGCAGATTGAC 
NS2A-29R AGAAAGCTGGGTCCTACGTTCCTACTCGGGTC 
NS2A58F  
 
249 NS2A-58F  AAAAAGCAGGCTCCGCCAGAGACCTGGGAAGAGTGATG 
NS2A-140R  AGAAAGCTGGGTCCTACATTTTTCTCACCATTTTAAGGACC 
NS2A187F  
 
96 NS2A-187F AAAAAGCAGGCTCCGCCCAGAAAGCGGATTGGATACC 
NS2A-218R AGAAAGCTGGGTCCTACCTTTTCTTGTTGGTTCTTG 
NS2B1F  
 
75 NS2B-1F AAAAAGCAGGCTCCGCCAGCTGGCCACTAAATGAGGC 
NS2B-25R AGAAAGCTGGGTCCTAGTCATTCTTTAGGAGTGAACTGGC 
NS2B49F  
 
141 NS2B-49F  AAAAAGCAGGCTCCGCCGCCGATTTGGAACTGGAG 
NS2B-95R  AGAAAGCTGGGTCCTACAGTGTTTGTTCTTCCTCTTCG 
NS4A1F  147 NS4A-1F AAAAAGCAGGCTCCGCCTCCCTGACCCTGAACCTAATC 
NS4A-49R AGAAAGCTGGGTCCTACGGCAGTTCACTGAGAG 
NS4A122F  87 NS4A-122F  AAAAAGCAGGCTCCGCCGAACCAGAAAAGCAGAGAACACC 
NS4A-150R  AGAAAGCTGGGTCCTATGCCATGGTTGCGGC 
NS4A101F  87 NS4A-101F  AAAAAGCAGGCTCCGCCCAGCCACACTGGATAGCAG 
NS4A-129R  AGAAAGCTGGGTCCTAGGGTGTTCTCTGCTTTTC 
NS4B1F 96 NS4B-1F AAAAAGCAGGCTCCGCCAACGAGATGGGTTTCCTGG 
NS4B-32R AGAAAGCTGGGTCCTATAGATCTATGTCCAGGATGTTGC 
NS4B58F  132 NS4B-58F  AAAAAGCAGGCTCCGCCAATTCCTCAGTGAACGTGTCC 
NS4B-101R  AGAAAGCTGGGTCCTATTGTGAGTAGCATCCAATGGC 
NS4B129F  108 NS4B-129F AAAAAGCAGGCTCCGCCGCAACCAGGGAAGCTCAGAAAAG 
NS4B-164R AGAAAGCTGGGTCCTAAAACTTTGGATCATAGGGTATTGG 
NS4B191F  174 NS4B-191F AAAAAGCAGGCTCCGCCTGTGAGGCGTTAACCTTAGCG 
NS4B-248R AGAAAGCTGGGTCCTACCTTCTCGTGTTGGTTGTG 
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Table 2.9: attB universal primers used in this study.  
The attB sequences are shown in bold. 
Primer  Sequence 5’ – 3’ 
attB1-F GGGGACAAGTTTGTACAAAAAAGCAGGCT 
attB2-R GGGGACCACTTTGTACAAGAAAGCTGGGT 
 
 BP reaction 
Purified PCR products with flanking attB recombination sites were introduced into 
a donor vector in a Gateway BP reaction with BP® Clonase II enzyme mix 
(Invitrogen). The enzyme catalyzes a recombination reaction at the attB sites 
which results in insertion of the fragments into the donor vector creating an entry 
clone. The BP reaction was set up by adding 1 µl attB-PCR product (150 ng), 1 µl 
donor vector (150 ng), nuclease-free water (to 5 µl) and 1 µl BP Clonase™ II enzyme 
mix. The reaction was mixed gently, briefly spun down and allowed to incubate 
at room temperature for 18-24 hr. After this incubation, 2 µl of the reaction was 
transformed into DH5 competent cells and plated onto an LB plate containing 10 
µg/ ml gentamycin (Section 2.2.9). The resulting entry clone was propagated and 
plasmid purified as described in Section 2.2.10. The gene insert was screened by 
PCR, enzymatic digested with EcoRI and BamHI and sequence-verified (Section 
2.2.12 and Section 2.2.14) using the primers listed in Table 2.10. 
Table 2.10: Sequencing primers for gene insert in pDONR207 entry vector.  
Primer  Sequence 5’ – 3’ 
attL-F TCGCGTTAACGCTAGCATGGATCTC 
attL-R GTAACATCAGAGATTTTGAGACAC 
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 LR reaction 
Genes within the entry clone were transferred into an appropriate destination 
vector in a Gateway LR reaction using LR® Clonase II enzyme mix (Invitrogen). The 
reaction was carried out in 1.5 ml tube by adding 1 µl plasmid-purified entry clone 
(150 ng), 1 µl destination vector (150 ng), nuclease-free water (added to 5 µl) and 
1 µl LR® Clonase II enzyme mix. After mixing and briefly spinning down, the 
reaction was incubated at room temperature for 18-24 hr followed by 
transformation of 2 µl of the reaction into DH5 competent cells and plating on 
an LB plate containing 50 µg/ ml kanamycin (as described in Section 2.2.9). The 
expression clones were screened by PCR, sequence-verified using the primers 
listed in Table 2.11 and enzymatic digested with EcoRI and BamHI as described in 
Section 2.2.12. 
Table 2.11: Sequencing primers for gene insert in pGBKT7 yeast vector. 
Primer  Sequence 5’ – 3’ 
GBKT-F TAATACGACTCACTATAGGGCGA 
GBKT-R TTTTCGTTTTAAAACCTAAGAGTC 
 
 BP/LR One Tube Format 
Cloning of the DENV gene fragments (<200 bp) into the yeast destination vector 
was performed in a single tube reaction following the Gateway One Tube Format 
protocol (Invitrogen) with minor adjustments. This protocol eliminated the 
transformation and plasmid isolation step of the entry clone prior to the LR 
reaction. After an overnight BP reaction, the LR mixture was set up as described 
above (Section 2.4.4.3) by adding 2 µl BP reaction mixture instead of the purified 
plasmid entry clone. The reaction was mixed gently and incubated at room 
temperature for 18-24 hr followed by 2 µl transformation of the reaction into DH5 
competent cells containing 50 µg/ ml kanamycin (as described in Section 2.2.9) 
and the expression clones were screened as described above (Section 2.4.4.3). 
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 Yeast two-hybrid protein-protein interaction assay 
Y2H is a powerful tool for investigation of protein-protein interactions within 
eukaryotic cells, rather than expression in bacterial systems or any in vitro 
techniques (Sobhanifar 2003). This method employs fully automated high-
throughput screening which enables identification of large-scale global protein 
interactions. The Y2H employs a GAL4 yeast plasmid that encodes for two hybrid 
proteins; one has a DNA-binding domain (DBD) fused to a bait, whereas, the other 
has an activation domain (AD) fused to a prey (Figure 2.5). Successful interaction 
between the bait and the prey brings the DBD and AD in close proximity under the 
regulation of an upstream activation sequence (UAS), thus initiates an expression 
of the downstream reporter gene resulting in a change of the cell phenotype. The 
yeast cells can then be selected based on this new phenotype, for example the 
ability to grow on a specific minimal media.  
The yeast host strain contains GAL4/UAS linked to the HIS3 and ADE2 reporter 
genes. These genes are responsible for histidine and adenine biosynthesis, 
respectively. By having these two reporters, the yeasts are capable to grow in the 
absence of histidine and adenine once the GAL4 promoter has been activated. 
Successful interaction between the bait and prey proteins that come in close 
proximity reconstituting the DBD and AD of the GAL4 system, thus activates the 
GAL4 promoter and synthesis of histidine and adenine (Figure 2.5). 
In this study, DENV non-structural proteins were used as baits and tested for 
interactions with protein preys generated from a human cDNA library. The DENV 
bait constructs were generated using the Gateway cloning system as described in 
Section 2.4.4. The DENV gene was cloned into the bait expression vector (pGBKT7) 
harbouring TRP1 gene, which allows the haploid yeast strain AH109 transformed 
with this plasmid to synthesise tryptophan. For expression of the human protein 
libraries, the haploid yeast strain Y187 was used. Human cDNA library was cloned 
into the prey expression vector (pGADT7) containing LEU2 gene, which encodes 
for leucine biosynthesis. Mating of these haploid yeasts by mixing the yeast 
cultures allows co-expression of the bait and prey proteins, resulting in the 
formation of diploids that are able to grow on minimal media lacking tryptophan 
and leucine.   
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Figure 2.5: A schematic diagram of the yeast two-hybrid system.  
The gene encoding the bait is cloned into the bait vector producing a protein 
fusion downstream of the GAL4 DNA-binding domain (DBD), while the gene 
encoding the prey is cloned into the prey vector, which fuses with GAL4 activation 
domain (AD). Both bait and prey are expressed in yeast. Interaction between the 
bait and the prey brings the two domains together and initiate the transcription 
of reporter genes (A). If the bait and prey are expressed alone (B and C), or they 
both are expressed but do not physically interact, the reporter genes are not 
expressed.  
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 Production of competent yeast AH109 
To make a starter culture, a single yeast AH109 colony was inoculated from a fresh 
agar plate into 50 ml yeast peptone dextrose (YPD) broth and incubated at 30 °C 
overnight with shaking at 250 rpm. Following this incubation, OD was measured at 
600 nm (OD600) followed by inoculation of the appropriate volume into 250 ml of 
fresh YPD and a further incubation at 30 °C with continuous shaking for 
approximately 3 hr. Once the OD600 reached 0.6, the cells were spun down at 2,000 
rpm for 5 min, re-suspended gently in 125 ml of sorbitol/bicine/polyethylene 
glycol (SBEG) to make them competent and spun again at 2,000 rpm for 5 min. 
The cell pellet was re-suspended in 5 ml SBEG and immediately stored in 100 µl 
aliquots at -80 °C. 
 Transformation of DENV bait constructs 
A bait plasmid harbouring a DENV NS gene fragment (1 µg) was added into 100 µl 
AH109 yeast competent cells and mixed gently. Transformation of the plasmid was 
carried out by adding 750 µl polyethylene glycol (PEG)/bicine solution followed by 
incubation at 30 °C for 1 hr on a thermomixer (Eppendorf) while shaking at 900 
rpm. After a heat-shock at 45 °C for 5 min, the yeast cells were spun down at 
3,500 rpm for 2 min, washed with 1 ml sodium chloride/bicine buffer and spun 
down again at 3,500 rpm for 5 min. The cell pellet was re-suspended in 200 µl 
sodium chloride/bicine buffer and plated on SD/-Tryptophan (SD/-Trp) prior to an 
incubation at 30 °C for 2-3 days.  
 Yeast two-hybrid screen 
A bait AH109 yeast colony from a fresh plate was inoculated into 15 ml SD/-Trp 
broth and incubated at 30 °C overnight with shaking at 250 rpm. An appropriate 
volume of the starter culture was used to inoculate 15 ml SD/-Trp to an OD600 0.1 
and allowed to incubate at 30 °C overnight with shaking at 160 rpm. Inoculation 
of an appropriate volume of Y187 prey human cDNA library in 15 ml SD/-Leucine 
(SD/-Leu) followed by incubation at 30 °C overnight with shaking at 160 rpm was 
also carried out concurrently.  
 
 73 
 
When the bait and prey cultures grew to an OD600 0.9-1, an equal number of bait 
and prey cells (3.6 x 108) were mixed in a 50 ml tube following the formula below: 
X culture volume (ml) =  (3.6 x 108 cells) 
 (A x 3 x 107 cells) 
= 12 ml 
   A 
A = Culture absorbance at OD600 
The mixed culture was spun down at 2,000 rpm for 2 min and the cell pellet was 
re-suspended in 25 ml yeast peptone dextrose adenine (YPDA) containing 20% PEG 
6000. Mating of the yeast cells was performed at 30 °C with shaking at 100 rpm 
for exactly 3 hr, followed by centrifugation at 2,000 rpm for 3 min. The cell pellet 
was re-suspended in 10 ml SD medium lacking leucine, tryptophan and histidine 
(SD/-Leu-Trp-His) and added into 220 ml SD/-Leu-Trp-His medium with 
appropriate concentration of yeast inhibitor 3-amino-1,2,4-triazole (3-AT). Using 
a multichannel pipette, the whole suspension was dispersed into a 96-well plate 
(200 µl of suspension/ well) and incubated at 30 °C for 4-5 days. To confirm 
successful mating between the bait and prey, 10 µl of the yeast suspension in SD/-
Leu-Trp-His was plated on SD/-Leu-Trp agar and incubated at 30 °C for 3 days to 
observe the growth of diploid cells.  
 Sequencing of human open reading frames 
Diploid yeast colonies were picked and transferred into a round-bottom 96-well 
plate. Using a 96-point inoculator, the colonies were introduced onto an SD/-Leu-
Trp-His agar plate containing 3-AT and the plate was incubated at 30 °C for 3 
days. A single yeast colony grown on the plate was scraped off using a sterile 
tooth-pick and re-suspended in 20 µl 0.02 M sodium hydroxide in a 94-well PCR 
plate with strip caps (Greiner Bio-One). The suspension was heated up to 95 °C 
for 10 min in a PCR machine, allowed to cool down on ice and spun down at 1,000 
rpm for 1 min. The supernatant (5 µl) was used as a template for amplification of 
the specific human gene using primers targeting the specific regions flanking the 
human cDNA insert in the prey vector. Two rounds of PCR were performed 
following the protocol in Section 2.2.3 with modified cycling conditions, using 
primers Oligo 136 and 137 (Table 2.12) in the first PCR followed by amplification 
using Oligo 80 and 81 primers (Table 2.12) in the second PCR. The PCR cycling 
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parameters were: initial denaturation at 95 °C for 5 min, followed by 20-25 cycles 
of denaturation at 95 °C for 30 sec, annealing at 55 °C for 1 min 30 sec, extension 
at 72 °C for 3 min 30 sec, and one cycle of final extension at 72 °C for 7 min. The 
final PCR products of the human transcripts were analysed by gel electrophoresis 
on 1% agarose and sent for sequencing in a 96-well PCR format to GATC Biotech, 
Germany (http://www.gatc-biotech.com/en/index.html) using the pAct2 primer 
(Table 2.12). The sequencing results were analysed as described in Section 2.2.14. 
Table 2.12: Primer sequences for gene insert in yeast pGADT7. 
Primer  Sequence 5’ – 3’ 
PCR amplification 
Oligo 136  
 
CTA GAG GGA TGT TTA ATA CCA CTA CAA TGG  
Oligo 137  GGT TAC ATG GCC AAG ATT GAA ACT TAG AGG  
Oligo 80  TGT TTA ATA CCA CTA CAA TGG ATG ATG  
Oligo 81  CAT AAA AGA AGG CAA AAC GAT G  
DNA sequencing 
pAct2  
 
GAT GAT GAA GAT ACC CCA C  
 
 Protein-protein interaction analysis  
The human interacting proteins identified from the Y2H screen were collated using 
the NCBI database of official gene name, gene ID and accession number, symbol 
and alias. Protein interaction network map was constructed using Cytoscape 3.0 
(http://www.cytoscape.org/) and analysis of the enriched Gene Ontology 
annotation terms of the human proteins targeted by DENV was performed using 
the Database for Annotation, Visualisation and Integrated Discovery (DAVID) 
(http://david.abcc.ncifcrf.gov/). Literature mining was conducted from Medline 
using the PubMed interface to gather information describing binary interactions 
between DENV and human proteins. 
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 Storage of yeast 
To prepare a yeast stock for storage, a single yeast colony was picked using a 
sterile inoculation loop and suspended in 0.5 ml of YPD or YPDA medium containing 
15–30% glycerol. The suspension was transferred into a 2-ml screw cap storage vial 
and the content was mixed well before immediate freezing at -80 °C. To recover, 
the top of the frozen stock was scraped off, streaked on YPD or YPDA agar and 
allowed to incubate at 30 °C for 4-5 days. For use in experiments, the yeast was 
sub-cultured fresh on agar plates or liquid media followed by a further incubation 
at 30 °C for 2-3 days.  
 
 Replication of DENV replicon 
 In vitro transcription 
Prior to in vitro transcription, DENV replicon pDVPACLuc and its derived mutant 
pDVW87I were linearised using XbaI according to the large-scale restriction 
digestion protocol (Section 2.2.12), examined on 0.8% agarose gel and purified 
using High Pure PCR Product Purification Kit (Roche). In vitro transcription 
reaction was carried out using MEGAscript® T7 Transcription Kit (Ambion) 
according to the manufacturer’s protocol. The reaction was assembled by adding 
nuclease-free water (made up to 30 µl), 2 µl each Ribonucleotide solutions (ATP, 
CTP, UTP and 1:5 diluted GTP), 3 µl Cap Analog (Ambion), 3 µl Reaction Buffer 
(10x), 1 µg linearised DENV replicon and 2 µl Enzyme Mix. The reaction was mixed 
gently, briefly spun down and incubated at 37 °C for 5 hr before stored at -70 °C. 
 Transfection of DNA and RNA 
Cells were seeded in a 24-well plate (Section 2.1.3) in order to achieve 70-90% 
confluence on the day of transfection. For each transfection reaction, 1 µl 
Lipofectamine® 2000 transfection reagent (Invitrogen) or proprietary animal 
origin-free Lipofectamine® 2000 CD (Invitrogen) was diluted in Opti-MEM® I 
reduced serum media and allowed to incubate for 5 min. Plasmid DNA (50-100 ng) 
or 2.5 µl in vitro-transcribed DENV replicon RNA (per well) was diluted in 50 µl 
Opti-MEM® I reduced serum media. The reaction was scaled up or down depending 
 76 
 
on the number of wells to be transfected. After 5 min, the diluted Lipofectamine 
reagent was added to the diluted DNA and incubated for 20 min at room 
temperature. The resulting Lipofectamine-DNA complex (100 µl) was added 
directly to each well and mixed gently by rocking the plate back and forth 
followed by incubation at the appropriate temperature for 18-24 hr. 
 Dual luciferase assay 
Following transfection, medium from the transfected cells was removed and the 
cells were lysed in passive lysis buffer (100 µl/ well) followed by freezing at -20 
°C. After thawing, the cell lysate was incubated for 15-20 min with shaking at 
room temperature and 25 µl was transferred into a 96-well white plate (Greiner 
CELLSTAR) for measurement of the luciferase activity using the dual-luciferase 
reporter® (DLR™) assay system (Promega). Prior to the measurement, luciferase 
assay reagent II (FFLuc) was prepared by re-suspension of lyophilised luciferase 
assay substrate in luciferase assay buffer II and stored in aliquots in -20 °C. Stop 
& Glo® reagent (RLuc) was prepared fresh to the required volume by diluting the 
Stop & Glo® substrate (50x) to a final 1x in Stop & Glo® buffer. Luciferase reagents 
were pre-warmed to room temperature prior to use, each diluted 1:10 with water 
(this was a minor adjustment) and fitted to the dual-injectors of the GloMax® multi 
detection system (Promega) luminometer. After priming both injectors, 70 µl of 
the diluted substrates was dispensed into the sample wells for measurement of 
luciferase activities. Once completed, the injector tubes were cleaned by flushing 
them through with water and 70% ethanol according to the recommended 
instructions. Data obtained from luciferase measurements was analysed using the 
Instinct® software (Promega) and Microsoft Excel. 
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 Functional assays 
 LUMIER assay 
The LUminiscence-based Mammalian IntERactome (LUMIER) assay was first 
introduced by Barrios-Rodiles et al. (2005) as a high-throughput method to map 
protein-protein interactions in mammalian cells. This assay is a variation of co-
immunoprecipitation (co-IP) technique using luciferase readout. Although the 
LUMIER assay is not widely used, there are several advantages of this assay over 
the conventional co-IP. This includes its high sensitivity, high-throughput 
capability and requirement of small amounts of DNA for assessing protein 
interactions. In LUMIER assays, an interaction between two proteins X and Y is 
determined through transient co-expression of Protein A-tagged protein X and 
RLuc-tagged protein Y (Figure 2.6a). Upon cell lysis, Protein A fused to protein X 
immunoprecipitates with IgG-coated magnetic beads and pulls down protein Y in 
case of an interaction, which generates a luciferase signal. If X and Y proteins do 
not interact, there is no luciferase activity measured (Figure 2.6b and Figure 
2.6c). 
 
Figure 2.6: A schematic diagram of LUMIER assay.  
Protein X is tagged with Protein A (PrA) and protein Y is tagged with RLuc. (a) If 
there is an interaction between X and Y, the protein complex is pulled down by 
immunoprecipitation of Pr A with IgG-coated beads. After extensive washing, RLuc 
readout shows a high luciferase activity indicating a positive X and Y interaction. 
In the case of (b) no interaction between X and Y, or (c) in the absence of X, no 
luciferase activity is measured. The diagram was adapted and re-drawn from 
reference (Blasche & Koegl 2013). 
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 Mammalian cell expression cloning 
LUminescence-based Mammalian IntERactome (LUMIER) assays were performed to 
confirm interactions between DENV and human proteins in HEK293 cells. Pre-
cloned human cellular genes were obtained from the MGC cDNA library in 
pDONR223, which had been transformed into E. coli DH5 and sub-cultured on 
fresh LB agar plates containing 50 µg/ ml spectinomycin. Plasmids were harvested, 
sequence-verified using the appropriate primers (Section 2.2.14,Table 2.13) and 
cloned into a mammalian expression vector pTREX-DEST30-Protein A (N-terminal 
Protein A tag fusion) by LR reaction (Section 2.4.4.3). After transformation into E. 
coli DH5, the resulting expression clones were purified and confirmed by 
digestion with XhoI and ApaI (Section 2.2.12). Corresponding DENV gene fragments 
interacting with the human proteins were sub-cloned from an entry vector 
pDONR207 into pcDNA3-RL-GW (N-terminal RLuc fusion) in a similar fashion. Both 
human and DENV expression plasmids (25 ng) were co-transfected into HEK293 
cells in a 96-well plate and incubated at 37 °C for 48 hr. Two plasmid constructs 
expressing interacting proteins JUN and FOS were co-transfected in parallel and 
used as positive control. 
Table 2.13: Primers sequences for MGC human insert in pDONR223. 
Primer  Sequence 5’ – 3’ 
DONR223-F TCGCGTTAACGCTAGCATG  
DONR223-R  TAATACGACTCACTATAGGG  
 
 
 Pull-down of interacting proteins  
Prior to cell lysis, sheep anti-rabbit IgG-coated magnetic beads (Dynabeads M280, 
Invitrogen) were washed in washing buffer (containing 1x PBS and 1 mM DTT) and 
added into 1x passive lysis buffer (Promega) containing protease inhibitor cocktail 
mix (Roche). Medium was removed from transfected cells and the cells were lysed 
with lysis buffer containing beads (10 µl/ well) followed by incubation at 4 °C with 
shaking for 30 min. PBS (90 µl) was added into each well and the cell lysate was 
transferred into a 96-well white plate (Greiner CELLSTAR).  
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To measure the background luciferase activity of samples, 10 µl of lysate was 
removed into another 96-well plate containing 90 µl PBS/ well and placed on ice. 
From the remaining cell lysate, magnetic beads were pulled down to the bottom 
of the plate using a handheld magnetic separator block (Millipore) and 80 µl of the 
supernatant was gently removed by pipetting. The beads were washed by adding 
200 µl washing buffer (containing 1x PBS and 1 mM DTT) and allowed to stand for 
1 min off-magnet before applying the magnet again for removal of supernatant. 
The washing step was repeated four times before the addition of 80 µl PBS after 
the final wash, followed by measuring the luciferase activity in the initial cell 
lysate (unwashed beads) and the washed beads. The luciferase values were 
normalised against wells transfected with empty pTREX-DEST30-PrA. Signal-to-
noise ratios and Z-scores were calculated for the lysate and washed beads as 
described previously (Tahoun et al. 2011).  
 Co-immunoprecipitation assay 
Homo sapiens BTG3-associated nuclear protein (BANP) ORF was sub-cloned from 
the pDONR223 entry clone (obtained from Juergen Haas) into a Gateway 
destination vector pcDNA™-DEST40 by LR reaction (Section 2.4.4.3). This produced 
the pDEST40-BANP expression construct in which BANP was fused upstream of the 
His/V5-tag. For the potassium voltage-gated channel Kv1.3, a plasmid construct 
expressing GFP fused to the entire coding region of the protein Kv1.3 in the 
Emerald-C1 vector was provided by Jamel Mankouri, University of Leeds.  
DENV NS2A was sub-cloned from the pDONR207 entry clone into the pTREX-
DEST30-Protein A vector resulting in the expression of NS2A as a fusion with 
Protein A of S. aureus. The interaction of BANP and Kv1.3 proteins with DENV NS2A 
was tested independently by co-transfecting each construct with pTREX-DEST30-
Protein A-NS2A in HEK293 cells. After 48 hr incubation, the cells were washed in 
ice-cold PBS and lysed in NP-40 lysis buffer containing protease inhibitor cocktail 
mix (Roche). Sheep anti-rabbit IgG-coated magnetic beads were added to cell 
lysate and incubated at 4 °C overnight with mixing on a tube rotator. After 
incubation, the beads were pulled down using a magnetic separator block and 
washed four times in washing buffer. Proteins bound to the washed beads were 
dissolved by adding 20 µl 1% SDS and heated up to 95 °C for 5 min, followed by 
Western blot analysis using the appropriate antibodies (see Table 2.5). 
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 siRNA gene silencing 
ON-TARGETplus SMART pool® small interfering (si) RNA BANP (Dharmacon) 
consisting a mixture of four individual siRNA (Table 2.14) was used to knockdown 
BANP protein. The lyophilised siRNA was dissolved in the siRNA buffer supplied to 
the required stock concentration. Transfection of the siRNA (100 nM) was carried 
out using Lipofectamine® 2000 CD as described in Section 2.6.2 in order to 
optimise knockdown conditions. Efficacy of the knockdown was evaluated by 
Western blot using anti-BANP and anti-V5 primary antibodies. -Gal siRNA-1 
targeting the human -galactosidase was used as a negative control (Table 2.14).  
Table 2.14: siRNA sequences of human BANP and -galactosidase. 
siRNA  Sequence 5’ – 3’ 
BANP CAAACCAGCAGUGUUGUUCUU 
UAACAGUAGACAGCUGACCUU 
UAUCUGUUAGGCGAGUUGCUU 
UAAAUAAUCAGCCAUCAGUUU 
-Gal UAAGGCUAUGAAGAGAUAC 
 
 
 Immunostaining 
Cells were seeded (Section 2.1.3) in a 24-well glass-bottom plate (Greiner Bio-
One) for immunostaining. After performing the transfection and incubation as 
required, the cell monolayer was fixed in 4% paraformaldehyde for 10 min and 
washed with PBS for 5 min, three times. To allow antibody penetration of the cell 
membrane, the cells were permeabilised by adding 0.3% Triton X-100/PBS for 20 
min and washed with PBS for 5 min, three times. The cells were then blocked with 
5% FBS/PBS for 30 min, followed by washing with PBS for 12 min, three times. 
Primary antibodies (Table 2.5) were applied at the appropriate dilutions in 5% 
FBS/PBS and the cells were allowed to incubate at 4°C overnight. Cells were 
washed three times with PBS for 10 min followed by incubating with the 
corresponding secondary antibodies Alexa Fluor® 488 donkey anti-rabbit IgG (H+L) 
antibody or Alexa Fluor® 594 donkey anti-mouse IgG (H+L) antibody (Molecular 
Probes) for 1 hr at room temperature protected from light. After the incubation, 
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the cells were washed three times with PBS for 10 min and nuclear-stained using 
VECTASHIELD® Mounting Medium with DAPI (Vector Laboratories). A coverslip was 
immediately applied to the cell monolayer and the plate was viewed with a 
confocal laser scanning 710 microscope (Carl Zeiss). Scanned images were 
analysed using the ZEN software (Carl Zeiss) and Imaris image processing software 
(Carl Zeiss). 
 Interferon reporter assay 
To test for the effect of over-expressed BANP in interferon (IFN) response, HEK293 
cells were seeded in a 24-well plate as described in Section 2.1.3. The cells were 
transiently co-transfected using Lipofectamine® 2000 CD (as described in Section 
2.6.2) with four plasmids; p125Luc (50 ng), pcDNA-mycNS2A (100 ng), pDEST40-
BANP or pDEST-MBP (100 ng), and pRL-CMV vector (0.5 ng) (Promega) (Table 2.15). 
pDEST40-MBP expressing maltose-binding protein (MBP) was used as a negative 
control for IFN stimulation. pRL-CMV expressing constitutive RLuc was used as an 
internal control to which expression of the FFLuc reporter gene was calculated 
relative to. p55A2Luc contained the positive regulatory domain II (PRDII) of NF-B 
elements which was used to test for regulation of NF-B. 
At 24 hr post-transfection (p.t), the transfected cells were stimulated by adding 
5 µg polyinosinic-polycytidylic acid [Poly(I:C)] (LMW) (InvivoGen) per well 
according to the manufacturer’s instructions to induce the production of IFN-. 
24 hr post-stimulation, the cells were lysed in passive lysis buffer and the 
luciferase activity was measured with the dual-luciferase reporter assay system 
as detailed in Section 2.6.3.  
The effect of DENV proteins on the cellular IFN response was also tested with IFN-
-induced IFN-stimulated gene response element (ISRE) promoter activity. HEK293 
cells was seeded as described in Section 2.1.3 and co-transfected with three 
plasmids; pGL4.17-ISREFluc (50 ng), plasmids expressing DENV proteins either 
pDEST40-NS2A, pDEST40-NS4B or pDEST40-NS5 (100 ng), and 0.5 ng pRL-CMV 
(Table 2.15). After 24 hr incubation at 37 °C, the cells were treated with 1000 IU/ 
ml recombinant human Universal Type I IFN Alpha (PBL Interferon Source). At 24 
hr post-treatment, the cells were lysed in passive lysis buffer and the luciferase 
activity was measured as described in Section 2.6.3. 
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Table 2.15: List of plasmids used in this study. 
Plasmid  Features Reference 
p125Luc murine IFN-beta promoter 
plasmid expressing FFLuc 
a kind gift from Takashi 
Fujita, (Yoneyama et al. 
1996) 
p55A2Luc multimerised PRDII element 
FFluc reporter  
a kind gift from Takashi 
Fujita, (Yoneyama et al. 
1998) 
pcDNA-mycNS2A DENV NS2A tagged with Myc 
epitope at the N-terminus in 
pcDNA3.1(+) 
purchased from ShineGene 
Bio-Technologies, Inc. 
pDEST40-BANP BANP tagged with V5 epitope and 
6x His  
constructed in-house using 
Gateway system (Section 
2.4.4) 
pDEST40-MBP MBP tagged with V5 epitope and 
6x His 
constructed in-house using 
Gateway system (Section 
2.4.4) 
pRL-CMV constitutive RLuc driven by CMV 
promoter 
Promega (Sherf et al., 1996) 
pGL4.17-ISREFluc  ISRE promoter expressing FFLuc a kind gift from Benjamin G 
Hale, University of Zurich 
pDEST40-NS2A DENV NS2A tagged with V5 
epitope and 6x His 
constructed in-house using 
Gateway system (Section 
2.4.4) 
pDEST40-NS4B DENV NS4B tagged with V5 
epitope and 6x His 
constructed in-house using 
Gateway system (Section 
2.4.4) 
pDEST40-NS5 DENV NS5 tagged with V5 epitope 
and 6x His 
constructed in-house using 
Gateway system (Section 
2.4.4) 
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 Cell proliferation assay 
Cell proliferation assays were carried out using the CellTiter 96® non-radioactive 
cell proliferation assay (Promega) according to the manufacturer’s instruction. 
This assay utilised the cellular conversion of tetrazolium salt into formazan 
product which reflected the number of viable cells. In brief, HEK293 cells were 
seeded (1.5 x 104 cells/ml) in a 96-well plate and transfected with varying 
concentrations of plasmid DNA or treated with potassium channel inhibitors (Table 
2.16) followed by an incubation at 37 °C. After 6 hr, 15 µl dye solution was added 
into each well and the incubation prolonged for an additional 4 hr. Stop solution 
(100 µl/ well) was then added and the plate was allowed to stand overnight in a 
humidified chamber to solubilise the formazan crystals. Absorbance in cultures 
was recorded using the GloMax detection system the next day. Mock-transfected 
cell absorbance were used as blank and subtracted from the test sample values. 
Graphs plotting the absorbance versus concentration of plasmid DNA or potassium 
channel inhibitors were generated from the data.  
 
 BANP and Kv1.3 effect on dengue virus replication 
 Dengue virus infection 
Experiments involving cell infection with infectious DENV were performed by 
Amjad Yousuf in a Containment Level 3 facility, University of Bristol. To determine 
the effect of BANP on DENV replication, HEK293 cells were transfected with either 
pDEST40-BANP or siRNA BANP (as described in 2.6.2 and 2.7.3). After an overnight 
incubation at 37 °C, the cells were infected with DENV-2 NGC strain at a 
multiplicity of infection (MOI) 10 for 1 hr and replaced with fresh medium, 
followed by an incubation at 37 °C. Transfection of the siRNA BANP was repeated 
in the designated wells the next day to ensure continuous BANP knockdown. All 
cells were incubated at 37 °C for 3-4 days post-infection followed by cell lysis in 
TRIzol® reagent and stored at -80 °C. 
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For Kv1.3 experiments, HEK293 cells were treated with the appropriate inhibitors 
(Table 2.16) to block the endogenous potassium channel Kv1.3 at concentrations 
pre-determined by the cell proliferation assay (Section 2.7.6) and incubated at 37 
°C for 4 hr. Some wells were left untreated or individually treated with the diluent 
of inhibitors (either PBSA or water) as negative controls. After the incubation 
period, the inhibitors were removed and the cells were infected with DENV-2 NGC 
strain for 1 hr. The virus was replaced with fresh medium containing the 
appropriate inhibitors and incubated at 37 °C for 3-4 days before lysing the cells 
in TRIzol® reagent. All cell lysates were then sent to Glasgow for further analysis. 
Table 2.16: Potassium channel inhibitors used in this study. 
Channel inhibitor Symbol Stock 
diluent 
Final concentration per 
well (diluted in DMEM) 
Tetraethylammonium 
chloride  
TEA Water 10 mM 
4-Aminopyridine 4-AP Water 1 mM 
Margatoxin Mar PBSA 10 nM 
 
 Quantitative real-time PCR 
RNA was extracted from the DENV-infected cells as described in Section 2.2.1 and 
stored at -80 °C. The cDNA was synthesised using random primers as detailed in 
Section 2.2.2 and used as a template to measure the DENV gene expression by 
Taqman quantitative real-time PCR (qRT-PCR). Primers (Eurofins Genomics) 
amplifying partial DENV-2 capsid gene and the probe [labeled with 5’ 6-
carboxyfluoroscein (6-FAM) and 3’ black hole quencher (BHQ-1)] fluorophores are 
listed in Table 2.17. Each reaction contained 12.5 µl Taqman Universal PCR master 
mix (2x) (Life Technologies), 1 µl forward and reverse primers (10 µM), 1 µl probe 
(5 µM) and 1 µl cDNA. The housekeeping human gene, hypoxanthine 
phosphoribosyltransferase 1 (HPRT1) was used as an internal control to which the 
expression of DENV capsid was normalised. The HPRT1 primer and probe (labeled 
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with FAM and minor groove binder (MGB) fluorophores) mixture was purchased 
from Life Technologies. Nuclease-free water was used as a negative control. qRT-
PCR parameters were: 95 °C for 15 min (holding stage) followed by 40 cycles of 
94 °C for 15 sec, 60 °C for 1 min.  
Table 2.17: Primer and probe sequences used for qRT-PCR. 
The primer and probe sequences were as established by Callahan et al. (2001). 
Primer/probe Sequence 5’ – 3’ 
DENV-2-forward CATGGCCCTKGTGGCG 
DENV-2-reverse CCCCATCTYTTCAGTATCCCTG 
DENV-2-probe TCCTTCGTTTCCTAACAATCC 
 
 
 Construction of Ae. aegypti cDNA library 
Various techniques can be used to construct a cDNA library. In this study, a 
mosquito cDNA library was generated using the Make Your Own ‘Mate and Plate™’ 
Library System (Clontech). This method utilised a switching mechanism at the 5’ 
end of the RNA transcript (SMART) oligonucleotides in the first-strand cDNA 
synthesis reaction which produced a pool of cDNA with SMART end sequences (Zhu 
et al. 2001) as described in Figure 2.7. The sequences are homologous to the 
linearised yeast expression vector pGADT7-Rec end sequences which allow in vivo 
recombination to occur between the vector and the mosquito cDNA following 
transformation into yeast (Figure 2.8). Colonies that have successful integration 
of the cDNA into the vector acquire the ability to synthesise leucine and thus are 
able to grow on a minimal media lacking leucine. 
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Figure 2.7: A schematic diagram of the SMART technology.  
SMART is a switching mechanism at the 5’ end of RNA transcript technology.  Step 
1: Oligo (dT) containing CDS III primer sequence binds to the poly(A) tail of the 
mRNA. Step 2: MMLV reverse transcriptase generates complementary DNA and 
adds additional deoxycytidine (CCC) nucleotides to the cDNA 3’ end due to its 
terminal transferase activity. Step 3: SMART III oligonucleotides with guanine 
(GGG) sequence at 3’ end binds to the CCC overhangs. Step 4: MMLV switches 
templates and continues incorporating nucleotides complementary to the SMART 
sequences to the 5’ end. The SMART technology results in known sequences at 
both 3’ and 5’ ends of the cDNA which serves as priming sites for subsequent LD-
PCR amplification. This diagram was adapted and re-drawn from the Make Your 
Own ‘Mate and Plate™’ Library System user manual (Clontech 2010). 
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Figure 2.8: A schematic diagram of the homologous recombination in yeast. 
The recombination reaction occurs between SmaI-linearised pGADT7-Rec vector 
and the mosquito cDNA in yeast. The linear pGADT7-Rec has sequence ends 
homologous to the SMART III and CDS III sequences of the Aag2 cDNA which allows 
integration of the cDNA into the vector through homologous recombination and 
gap repair (Fusco et al. 1999). In pGADT7-Rec, the gene of interest is expressed 
as a GAL4 activation domain (GAL4 AD) fusion under the constitutive ADH1 
promoter (PADH1) and ends with the ADH1 termination signal (TADH1). PT7 is T7 RNA 
polymerase promoter, HA is hemagglutinin epitope tag, LEU2 is yeast selection 
marker. This diagram was adapted and re-drawn from the Make Your Own ‘Mate 
and Plate™’ Library System user manual (Clontech, 2010).  
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 Preparation of cDNA 
A cDNA library obtained from Ae. aegypti-derived Aag2 cells was constructed using 
the “Mate and Plate™” library (Clontech) following the manufacturer’s protocols. 
 RNA extraction 
Total RNA was extracted from Aag2 cells using TRIzol® reagent following the 
manufacturer’s instructions. Briefly, 80% confluent Aag2 cells from a medium flask 
were detached and spun at 1,500 rpm for 5 min. The protocol detailing the RNA 
extraction process was described in Section 2.2.1. 
 cDNA synthesis 
To generate the first-strand cDNA, CDSIII primer (Table 2.18) containing the 
modified oligo (dT) was added to 2 µg Aag2 RNA and incubated at 72 °C for 2 min. 
After cooling down on ice, a reaction mix was added containing 2 µl First-strand 
buffer (5x), 1 µl DTT (100 mM), 1 µl dNTP mix (10 mM) and 1 µl SMART moloney 
murine leukemia virus reverse transcriptase. The mixture was incubated at 42 °C 
for 10 min followed by adding 1 µl SMART III Oligo (Table 2.18) and further 
incubated at 42 °C for 1 hr. The reaction was terminated by placing the tube at 
75 °C for 10 min. After cooling down to room temperature, excess RNA was 
removed by incubating the reaction with 1 µl RNAse H (2 U/ µl) at 37 °C for 20 
min and the resulting cDNA was stored at -20 °C. As a positive control, 1 µg mouse 
liver poly A+ RNA (Clontech) was used in parallel to generate first-strand cDNA. 
 LD-PCR  
The Aag2 first-strand cDNA was amplified by long-distance PCR (LD-PCR) using 
reagents purchased from Clontech according to the recommended protocol. Two 
PCR reactions (100 µl each) were set up as follows: 70 µl nuclease-free water, 10 
µl Advantage® 2 PCR buffer (10x), 2 µl dNTP mix (50x), 2 µl 5’ PCR primer (10 mM) 
(Table 2.18), 2 µl 3’ PCR primer (10 mM) (Table 2.18), 10 µl melting solution (10x), 
2 µl Advantage® 2 polymerase mix (50x) and 2 µl Aag2 first-strand cDNA. LD-PCR 
parameters are shown in Table 2.19. The PCR product (7 µl) was electrophoresed 
in a 1.2% agarose gel and stained with ethidium bromide. The first-strand cDNA of 
mouse liver poly A+ RNA was PCR-amplified alongside and used as a positive 
control. 
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Table 2.18: Oligonucleotide sequences for construction of Aag2 cDNA library. 
First-Strand cDNA Synthesis (Sequence 5’ – 3’) 
CDS III primer ATTCTAGAGGCCGAGGCGGCCGACATG-d(T)30VN 
SMART III Oligo AAGCAGTGGTATCAACGCAGAGTGGCCATTATGGCCGGG 
  
cDNA Amplification (Sequence 5’ – 3’) 
5’ PCR primer TTCCACCCAAGCAGTGGTATCAACGCAGAGTGG 
3’ PCR primer GTATCGATGCCCACCCTCTAGAGGCCGAGGCGGCCGACA 
 
Table 2.19: LD-PCR parameters. 
Step Temperature PCR cycle Time 
Initial denaturation 95 °C   30 sec 
Denaturation 95 °C  10 sec 
Extension 68 °C 20-35 cycles 6 min; 5 sec increased 
for each cycle 
Final extension 68 °C  5 min 
 
 
 cDNA size fractionation  
PCR-amplified Aag2 cDNA (3 µg) was size-fractionated using CHROMA SPIN™ +TE-
400 columns (Clontech). Prior to use, the spin column was inverted a few times to 
mix the gel matrix suspended in equilibration buffer. By holding the column 
upright, the break-away bottom of the column was snapped off followed by the 
top cap, before placing it into a 2 ml collection tube. The gel matrix was then 
spun down at 700 x g for 5 min to purge the equilibration buffer using a swing 
rotor centrifuge. This allowed liquid to pass through the gel matrix uniformly, 
leaving a semi-dry matrix bed in the column. The collection tube was then 
replaced with a nuclease-free 1.5 ml tube. PCR-amplified Aag2 cDNA (93 µl) was 
applied to the centre of the column and spun at 700 x g for 5 min. The flow-
through samples containing amplified cDNA from two PCR reactions were pooled 
and purified by ethanol precipitation as described below.   
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 Ethanol precipitation  
To purify cDNA, sodium acetate (3M) (Clontech) (1/10th volume of cDNA) was 
added into the size-fractionated cDNA followed by the addition of 95% ice-cold 
ethanol (2.5 volume of cDNA) and the mixture was frozen at -20 °C. After 1 hr, 
the cDNA was spun down at 14,000 rpm for 20 min at room temperature and the 
supernatant was discarded. To remove excess liquid, the DNA pellet was spun 
down again at 14,000 rpm for 30 sec and air-dried for 10 min. The purified Aag2 
cDNA was re-suspended in 20 µl nuclease-free water and stored at -20 °C. 
 Production of competent yeast Y187  
Competent S. cerevisiae yeast Y187 (Clontech) strain cells were prepared 
following the yeastmaker yeast transformation system 2 protocol (Clontech). In 
brief, fresh yeast was recovered from glycerol stocks and a starter culture was 
prepared in 3 ml YPDA. This was incubated at 30 °C with shaking at 250 rpm for 
8-12 hr. For larger volumes, 5 µl of the culture was inoculated into 50 ml YPDA in 
a conical flask and incubated at 30 °C with shaking at 250 rpm for 16-20 hr. 
Measurement of the culture absorbance was carried out using a 
spectrophotometer (Beckman) to obtain an OD600 0.15-0.3 and the appropriate 
density of yeast cells were spun down at 700 x g for 5 min at room temperature.  
The cell pellet was re-suspended in 100 ml YPDA broth and further incubated at 
30 °C for 3-5 hr with shaking at 250 rpm. When the OD600 reached 0.4-0.5, the 
yeast culture was divided into two 50 ml sterile tubes, spun down at 700 x g for 5 
min, followed by washing the cells in 30 ml sterile water. After centrifugation at 
700 x g for 5 min, the cells were re-suspended in 1.5 ml 1.1x Tris-EDTA/Lithium 
acetate (TE/LiAc) to make them competent and then transferred into two 1.5 ml 
tubes. Centrifugation was carried out at high speed for 15 sec and the cell pellet 
was re-suspended again in 600 µl 1.1x TE/LiAc. The competent cells were 
immediately used for transformation with plasmid DNA.  
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 Co-transformation and in vivo recombination in yeast  
The Aag2 cDNA library was generated by co-transformation of Aag2 cDNA and 
SmaI-linearised pGADT7-Rec vector into the competent yeast strain Y187 using the 
“Mate and Plate™” Library (Clontech) following the manufacturer’s protocol. 
Briefly, 3 µg Aag2 cDNA and 3 µg SmaI-linearised pGADT7-Rec vector (500 ng/ μl) 
were mixed in a pre-chilled sterile 15 ml tube. As a positive control, 3 μl plasmid 
SV40 large-T PCR fragment with flanking SMART sequences (25 ng/ μl) (supplied in 
the kit) was co-transformed with 1 μl SmaI-linearised pGADT7-Rec alongside with 
1 μl SmaI-linearised pGADT7-Rec alone.  
Prior to transformation, Yeastmaker™ carrier DNA (Clontech) (10 mg/ ml) was 
denatured by heating it up to 95 °C for 5 min followed by cooling down on ice and 
adding 20 µl into the reaction mixture. Next, 600 µl yeast competent cells were 
added, followed by 2.5 ml PEG/LiAc and the suspension was gently mixed. After 
incubating at 30 °C for 45 min with mixing every 15 min, 160 µl DMSO was added 
and the suspension was gently mixed. Transformation was carried out by placing 
the tube in a thermomixer and heat-shocked at 42 °C for 20 min with gentle 
mixing, followed by centrifugation at 700 x g for 5 min. The pellet was then re-
suspended in 3 ml specially formulated YPD plus medium (Clontech). After 
incubating at 30 °C for 90 min with shaking at 250 rpm, the yeast cells were 
recovered by centrifugation at 700 x g for 5 min. The cell pellet was re-suspended 
in 15 ml 0.9% sodium chloride (Clontech), plated on 50 SD/-Leu square plates 150 
mm x 150 mm (150 µl per plate) and allowed to incubate at 30 °C for 3-4 days.  
 Determination of cDNA library titre 
In order to determine the Aag2 cDNA library titre, 100 µl cDNA-transformed yeast 
was vortexed vigorously and diluted in 0.9% sodium chloride (1:100, 1:1000 and 
1:10,000). Each dilution (100 µl) was plated on SD/-Leu agar 100 mm diameter 
plates in triplicates and allowed to incubate at 30 °C for 3-4 days. Transformation 
of 1 μl pGBT9 (100 ng/ μl) was performed alongside as a positive control and 100 
µl was plated on SD/-Trp agar. The cDNA library titre was determined by 
calculating the transformation efficiency and the number of independent clones 
following the formulas:  
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Transformation efficiency = CFU x suspension volume (ml) 
 volume plated (ml) x amount of DNA (µg) 
 
No. of independent clones = No. of CFU/ ml on SD/-Leu x resuspension volume (ml) 
  
CFU = Colony Forming Units 
 
 Harvest of Aag2 cDNA library 
SD/-Leu agar plates containing the Aag2 cDNA-transformed yeast colonies were 
chilled at 4 °C for 3-4 hr. Freezing medium (1 ml) containing YPDA and 75% glycerol 
was pipetted onto the agar surface. Under sterile conditions, the colonies were 
detached from the agar surface using a sterile spreader and pooled into a sterile 
tube. The cell density was estimated using a haemocytometer, divided into 1 ml 
aliquots and stored at -80 °C.  
 Mosquito innate immune signalling  
Ae. aegypti-derived Aag2, Ae. albopictus-derived C6/36 and Ae. albopictus-
derived U4.4 were seeded in 24-well plates (Section 2.1.3). Mosquito STAT, IMD 
and Toll immune signalling pathways were studied by transfecting individual 
reporter plasmids (Table 2.20) into each cell line (as described in 2.6.2). To study 
the STAT pathway, p6x2DRAF-Luc (50 ng) was transfected using 1 µl 
Lipofectamine™ 2000 as previously described (Fragkoudis et al. 2008). IMD was 
studied by transfecting pJL169 (50 ng) into the cells, whereas the Toll pathway 
was studied by co-transfection with pJM648 (500 ng) and pJL195 (400 ng). pAct-
Renilla (12.5 ng) expressing constitutive RLuc was transfected into all wells which 
used as an internal control. The transfection mixture was removed 5 hr post-
transfection, replaced with fresh medium and incubated at 28 °C overnight.  
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After the overnight incubation, the STAT and IMD pathways were stimulated by 
introducing the Gram-negative E. coli JM109 (approximately 3 x 109 CFU/ ml) into 
the mosquito cells, while the Toll pathway was activated using the Gram-positive 
Bacillus sp. To prepare the inoculum, an overnight bacteria culture was spun down 
at 2,500 rpm for 10 min at 4 °C and re-suspended in 500 µl PBS. The bacteria 
suspension was heat-inactivated at 80 °C for 10 min and 5 µl was inoculated into 
each well of the transfected mosquito cells. After 1 hr, the medium was replaced 
with fresh medium followed by incubation of the cells for an additional 11 hr at 
28 °C. The cells were lysed in 100 µl passive lysis buffer (Promega) and luciferase 
activity was measured using GloMax luminometer (as described in Section 2.6.3).  
 
Table 2.20: Reporter plasmids used in mosquito innate immune signalling.  
Plasmid Reporter Immune 
pathway 
Features Reference 
p6x2DRAF-
Luc 
FFLuc STAT multimerised Drosophila 
STAT-responsive element 
(Müller et al. 2005), 
(Hombría et al. 
2005) 
pJL169 FFLuc IMD IMD-responsive Drosophila 
Attacin A promoter 
(Fragkoudis et al. 
2008) 
pJM648 FFLuc Toll Toll-responsive Drosophila 
Drosomycin promoter 
(Tauszig et al. 2000) 
pJL195  Toll Drosophila constitutively 
active Toll delta leucine-
rich repeat (LRR) mutant 
under control of Drosophila 
Actin 5C gene promoter 
(Tauszig et al. 2000) 
pAct-
Renilla 
RLuc Internal 
control 
Drosophila Actin 5C gene 
promoter 
(Müller et al. 2005), 
(Karsten et al. 2006) 
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 Commonly Used Solutions 
Western blot 
5x Transfer buffer 
58.14 g Tris-base, 29.28 g glycine, 3.75 g SDS, water to 2 L 
 
Nonidet-P40 buffer 
150 mM sodium chloride, 1.0% NP-40, 50 mM Tris, pH 8.0 
 
10x PBS 
80 g sodium chloride NaCl, 2 g potassium chloride KCl, 14.4 g sodium hydrogen 
phosphate Na2HPO4, 2.4 g Potassium dihydrogen phosphate KH2PO4 
Water was added to 800 ml, pH adjusted to 7.4 with hydrochloric acid. Water 
was added to 1L. 10x PBS was diluted to 1x before use. 
 
1x PBS-Tween 
100 ml 10x PBS, 1 ml Tween-20 (final conc 0.1%), Water was added to 1L 
 
Yeast media/reagents 
YPD 
20 g peptone, 10 g yeast extract, 30 g agar (eliminated if making broth), water 
was added to make up 900 ml and autoclaved. After cooled down, 100 ml 20% 
filter-sterilised glucose was added (final conc 2%). 
 
YPDA 
YPD medium was prepared as above and autoclaved. After cooled down, 15 ml of 
0.2% Adenine hemisulfate solution was added (final conc is 0.003%). Total 
volume was added to 1 L with sterile water. 
 
SD Minimal Medium 
26.7 g minimal SD base, 0.64 g -Leu-Trp drop-out supplement, 20 g agar 
Water was added to 1L and autoclaved. After cooled down, 100 ml amino acid 
supplement (10x) was added (Trp for AH109 minus Leu, Leu for Y187 minus Trp) 
10x Tryptophan 
0.2 g Trp in 1 L water 
10x Leucine 
1 g Leu in 1L water 
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Sorbitol/ Bicine/ PEG 
91.1 g sorbitol (final conc 1M), 5 ml 1M Bicine, pH 8.35 adjusted with sodium 
hydroxide (final conc 10 mM), 15 ml PEG. Water was added to 500 ml and filter-
sterilised. 
 
PEG/ Bicine 
40 g PEG powder, 20 ml 1M Bicine adjusted pH 8.35 with sodium hydroxide (final 
conc 0.2 M), water was added to 100 ml and filter-sterilised 
 
Sodium chloride/ Bicine buffer 
0.88 g sodium chloride (final conc 0.15 M), 1 ml 1M Bicine (final conc 0.01 M), 
water was added to 100 ml and filter-sterilised 
 
Mating medium  
120 ml YPDA, 80 ml 50% PEG6000 (final conc 20%) 
 
Freezing Medium 
100 ml sterile YPDA, 50 ml 75% sterile glycerol 
1.1XTE/LiAc  
(Prepared fresh prior to transformation) 
1.1 ml TE Buffer (10x), 1.1 ml 1 M LiAc (10x), 10 ml sterile water was added  
 
PEG/LiAc 
(Prepared 10 ml fresh solution prior to transformation)  
8 ml 50% PEG 3350, 1 ml TE Buffer (10x), 1 ml 1 M LiAc (10x) 
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3 CHAPTER 3: DENGUE VIRUS-HUMAN PROTEIN-PROTEIN 
INTERACTIONS 
 Introduction 
The study of protein-protein interactions is essential to understand the natural 
behaviour of proteins to form dynamic structures in order to become biologically 
functional. Physical interactions between proteins form the basis for diverse 
molecular processes, such as regulation of signalling networks, gene transcription 
or cell metabolism. In the context of viral infection of host cells, analysis of 
protein-protein interaction facilitates the identification of potential host cellular 
factors, leading to a better understanding of the mechanism of virus infection and 
thus progression of disease. Various techniques have been developed to 
systematically identify the host factors that underlie the various steps of the viral 
replicative processes and their functional role in virus replication. These include 
the genome-wide RNAi screens, proteomic profiling, gene expression microarrays 
and yeast two-hybrid (Y2H) screens. The Y2H assay in particular, is a powerful tool 
which has produced substantial quantities of interaction data in several model 
organisms (Li 2004; Giot et al. 2003; Uetz et al. 2000).  
With regard to protein-protein interaction in virus infection of human cells, a large 
number of host proteins associated with virus infections have been identified by 
Y2H screens (Watanabe et al. 2010; Zhang et al. 2009). For example, the most 
extensively studied interactomes are those of the human immunodeficiency virus 
(HIV) and human, identified 8,024 protein-protein interactions in which 743 are 
unique human targets (Dyer et al. 2008). Identification of these interactors has 
elucidated various pathways known to be important in HIV. In contrast, the 
number of established DENV Y2H screens are very limited, in which only four 
studies have been reported (Mairiang et al. 2013; Silva et al. 2013; Khadka et al. 
2011; Le Breton et al. 2011). The overlap between these protein datasets is 
relatively small with only a few proteins that have been functionally validated. 
Given this data constraint, additional Y2H screens are required in order to fill in 
the gaps of the DENV-human protein-protein interaction network. With these 
interaction data, the previously identified interactions can be supported with a 
higher confidence level and this can also increase the identification of potential 
new host factors.  
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The Y2H screen performed by Khadka et al. (2011) reported at least 105 human 
host proteins interacting with DENV-2 proteins, where the proteins identified were 
enriched in complement activation and coagulation cascade, centrosome and 
cytoskeleton. DENV have been reported interacting with six of the identified 
human proteins, and knockdown of these proteins has caused a significant 
decrease in DENV replicon replication (Khadka et al. 2011). These proteins include 
the calreticulin (CALR), DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 X-linked 
(DDX3X), ELKS/RAB6-interacting/CAST family member 1 (ERC1), golgin subfamily 
a, 2 (GOLGA2) (GOLGA2), thyroid receptor-interacting protein 11 (TRIP11) and 
ubiquitin-conjugating enzyme E2I (UBE2I). CALR in particular, may have a 
potential role in DENV RNA synthesis as the protein has been shown to co-localize 
with the viral NS3 and NS5 proteins, as well as the viral dsRNA in DENV-infected 
cells. Additionally, 45 other human proteins that were shown to bind DENV 
proteins have been found associated with other virus infections including Hepatitis 
C virus (HCV), HIV and influenza virus (Khadka et al. 2011). 
Due to the importance of NS1 during viral infection and its potential involvement 
in liver dysfunction (Chung et al. 2006), Silva et al. (2013) conducted a search for 
DENV-2 NS1 interacting partners from a human liver cDNA library. The screen 
putatively identified 50 host proteins. Mostly these are plasma-secreted and 
classified as acute-phase proteins, including the complement component 1 (C1q), 
plasminogen, haptoglobin, hemopexin, a-2-HS-glycoprotein, retinol binding 
protein 4, transferrin, and C4. C1q in particular, would appear promising. It is 
suggested to play an important role in the human complement response. NS1 
interaction is thought to be important in immune evasion during DENV infection 
(Silva et al. 2013). Further to this, Mairiang et al. (2013) have identified 35 host 
factors from a cDNA library of human peripheral blood leukocytes screened against 
DENV proteins, C, NS3 and NS5. Of these, six proteins have been found to be 
similar to the previous DENV interactions including HBB and RPL5; NFBIA, NRBP1, 
GOLGB1 and RILPL2 (Khadka et al. 2011; Doolittle & Gomez 2011; Le Breton et al. 
2011; Chua et al. 2004).  
Accumulating evidence indicates that identification of host proteins interacting 
among viruses within a family or genus may provide insights into the common 
interactors shared within the group (Dolan et al. 2013; Krishnan et al. 2008). In a 
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search of host proteins interacting with either NS3 or NS5 of Flaviviruses, Le Breton 
et al. (2011) have identified 108 proteins. The majority of these proteins are 
involved in RNA binding, transcription regulation, vesicular transport and 
regulation of innate immune responses. Of these, five proteins have been found 
interacting with both NS3 and NS5, including CAMTA2, CEP250, SSB, ENO1, and 
FAM184A. Several other proteins were found to overlap with findings from previous 
RNAi studies (Sessions et al. 2009; Krishnan et al. 2008), while some are novel 
involving intracellular trafficking such as kinesin family member and centrosomal 
components. Although numerous DENV-human host factors have been identified 
by several large-scale screens, only a limited number of proteins have been 
validated. While there is also a marked difference between independent studies, 
this suggests the DENV-human protein interaction networks are still incomplete 
and require further elucidation. 
Overall, Y2H has been used in many large-scale protein-protein interaction 
studies. This technique has several advantages and has been selected as a 
screening method in this study because it is robust, cost-effective, and allows 
analysis of the protein interaction in vivo. This technology is easily scalable and 
can be performed using an automated robotic system for high throughput 
screening (Brückner et al. 2009). In addition, Y2H allows the use of various prey 
protein libraries derived from various tissues or cell types, thus serves as a flexible 
screening tool. This facilitates the study of various organisms by simply generating 
the yeast constructs expressing the protein of interest. Such constructs can be 
transformed into a suitable yeast host strain with specific reporter gene and 
growth selection marker.  
In this study, a systematic protein-protein interaction analysis between DENV NS 
proteins and the human MGC cDNA library was performed using Y2H technique 
(Section 2.4). The interactions were further validated using LUMIER assay in 
mammalian cells (Section 2.7.1).  
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 Objectives 
 
1. Generation of DENV bait constructs for Y2H experiments. 
2. Identification of human host proteins interacting with DENV NS proteins. 
3. Bioinformatic analysis of DENV-human protein-protein interaction network. 
4. Validation of the human interactors using LUMIER assay.  
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 Results 
 Generation of DENV bait constructs 
3.3.1.1 Amplification of DENV genes 
DENV bait constructs generated for Y2H comprised of full length and fragments of 
DENV non-structural genes. The gene fragments were generated by eliminating 
the viral transmembrane domains (TMDs). This was performed on the basis that 
TMDs are unlikely to be translocated into the yeast nucleus for transcription and 
translation of functional proteins (Brückner et al. 2009; von Mering et al. 2002),  
and therefore may cause false negatives in Y2H screen. Using the available TMD 
prediction software (Table 2.7), the TMDs of DENV protein were mapped on NS2A, 
NS2B, NS4A and NS4B, and the corresponding gene sequences were removed, 
resulting in 12 intra/extracellular gene fragments (Table 3.1, Figure 3.1). DENV 
NS1, NS3 and NS5 are cytoplasmic proteins, thus they do not contain TMDs. While 
there was no absolute requirement regarding elimination of the TMDs, the full 
length gene constructs were also generated for comparative analysis. In total, 19 
bait constructs, representing 7 full length NS genes and 12 gene fragments were 
generated (Table 3.1, Figure 3.1). 
In order to generate these constructs, DENV NS genes were PCR-amplified from 
DENV-2 NGC replicon, pDVRepGP2A (Section 2.4.2, Figure 2.1) using specific 
primers containing attB sites (Table 2.8, Table 2.9). This is followed by separation 
of the amplified PCR products on a 1.2% agarose gels (Figure 3.2a lanes 2-8, Figure 
3.2b lanes 2-13). As described above, the full length gene constructs encoded for 
the complete full length DENV NS proteins, while the fragment constructs encoded 
the viral protein fragments (without the TMDs).  
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Table 3.1: List of DENV bait gene constructs used in this study. 
DENV bait Description of gene  Size of 
insert (bp) 
NS1  Full-length  1056 
NS2A  Full-length  654 
NS2A1F  Fragment  87 
NS2A58F  Fragment  249 
NS2A187F  Fragment  96 
NS2B  Full-length  390 
NS2B1F  Fragment  75 
NS2B49F  Fragment  141 
NS3  Full-length  1854 
NS4A  Full-length  450 
NS4A1F  Fragment  147 
NS4A122F  Fragment  87 
NS4A101F  Fragment  87 
NS4B  Full-length  744 
NS4B1F  Fragment  96 
NS4B58F  Fragment  132 
NS4B129F  Fragment  108 
NS4B191F  Fragment  174 
NS5  Full-length  2700 
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Figure 3.1: A schematic diagram of the DENV gene constructs.  
Full length genes are shown in black and the gene fragments of NS2A, NS2B, NS4A 
and NS4B are indicated in gray. Scale denotes the size of the genes in basepairs. 
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(a) 
 
 
(b) 
 
Figure 3.2: Amplification of DENV genes. 
(a) Full length genes and (b) Gene fragments of DENV. Lanes 1 in both gels are 
water negative control. (a) Lanes 2-8 are NS1 (1056 bp), NS2A (654 bp), NS2B (390 
bp), NS3 (1854 bp), NS4A (450 bp), NS4B (744 bp) and NS5 (2701 bp), respectively. 
(b) Lanes 2-13 are DENV fragments NS2A1F (87 bp), NS2A58F (249 bp), NS2A187F 
(96 bp), NS2B1F (75 bp), NS2B49F (141 bp), NS4A1F (147 bp), NS4A122F (87 bp), 
NS4A101F (87 bp), NS4B1F (96 bp), NS4B58F (132 bp), NS4B129F (108 bp) and 
NS4B191F (174 bp), respectively. Both lanes 1 in (a) and (b) are water negative 
control. Both lanes M1 and M2 are 1 kb DNA ladder (NEB) and 100 bp DNA ladder 
(NEB), respectively.  
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3.3.1.2 Cloning of DENV genes 
Amplified products were sequence-verified and sub-cloned into a donor vector, 
pDONR207, according to the protocols described in the Gateway cloning (Section 
2.4.4). The resulting DENV genes in the entry clones were then transferred into 
the yeast destination vector pGBKT7 to allow expression of the NS proteins. These 
proteins were fused to the yeast GAL4 DNA-binding domain and tagged with a c-
Myc epitope at the N-terminus. While cloning of the full length DENV genes was 
done in independent BP and LR reactions, the smaller gene fragments were cloned 
in a combined single tube BP/LR reaction (Section 2.4.4.4) which was simpler, 
cost-effective and time-saving. To verify the clones, each construct was double-
digested with EcoRI and BamHI and sequence-verified (Figure 3.3a, lanes 2-8 and 
Figure 3.3b, lanes 2-13).   
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(a)  
 
(b) 
 
Figure 3.3: Enzymatic digestion of DENV bait constructs. 
Digestion of DENV constructs using EcoRI and BamHI. (a) DENV full length gene 
constructs; NS1, NS2A, NS2B, NS3, NS4A, NS4B and NS5 (Lanes 2-8). (b) DENV gene 
fragments constructs; NS2A1F, NS2A58F, NS2A187F, NS2B1F, NS2B49F, NS4A1F, 
NS4A122F, NS4A101F, NS4B1F, NS4B58F, NS4B129F, NS4B191F (Lanes 2-13). Both 
U and 1 lanes, in each gel are undigested and digested empty pGBKT7 vector, 
respectively. Both lanes M1 and M2 are 1 kb DNA ladder (NEB) and 100 bp DNA 
ladder (NEB), respectively.   
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3.3.2 Yeast two-hybrid screen 
In order to identify the human proteins targeted by DENV, the 19 DENV baits were 
screened against the human Mammalian Gene Collection (MGC) prey library. In 
brief, the bait constructs expressing DENV NS proteins were transformed into the 
haploid yeast strain AH109 (mating type a) and mated with the human cDNA library 
transformed into the haploid yeast strain Y187 expressing the prey. For each 
pairwise interaction, the two yeast haploids of the opposite mating types were 
allowed to mate by mixing the cultures together and the resulting diploid colonies 
were selected on media lacking histidine, supplemented with the yeast growth 
inhibitor 3-AT. To identify the human proteins responsible for this interaction, the 
diploid yeast were subjected to gene amplification by colony-PCR using the 
primers targeting a region flanking the human cDNA insert of the prey vector. 
As the Y2H employs the GAL4 promoter and there is a chance of auto-activation 
during the screen. Auto-activation occurs despite the lack of interaction between 
the test proteins which wrongly activates the transcription of histidine reporter 
gene, and thus promotes the yeast growth on minimal media. To assay for auto-
activation, all DENV baits were tested against the empty prey expressing GAL4 AD 
alone, and the prey library against the empty bait expressing GAL4 DBD alone. The 
interaction was tested by growth on drop-out media lacking amino acid histidine. 
From the assay, only one bait fragment (NS2A1F) resulted in an auto-activation 
activity, thus it was removed from further analysis (data not shown). 
Analysis of the Y2H screen revealed 141 interactions between 94 human proteins 
and 16 of the 19 DENV baits as shown in the protein interaction map (Figure 3.4a). 
A complete list of the identified human proteins and a brief description of their 
functions is shown in Appendix A. Only one of the bait fragments (NS2A1F) was 
omitted due to auto-activation (as mentioned above), while two fragments 
(NS2A58F and NS4B58F) produced very limited number of diploid colonies with 
very poor sequence data. Thus, information of the human interactors was 
unavailable for these proteins. It was also noted that only one protein (VPS28), 
was found to interact with NS1. 
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A number of human proteins interacted with more than one viral protein, as seen 
in previous interactomes (Khadka et al. 2011; de Chassey et al. 2008; Calderwood 
et al. 2007). By grouping of DENV bait fragments into their respective full length 
proteins, the results indicate 78 (83%) of the human proteins interacted with one 
virus protein, while 8 (8.5%) interacted with 2 viral proteins and 8 (8.5%) 
interacted with 3 or more virus proteins as shown in the protein interaction map 
(Figure 3.4b, Appendix A).  
 
 
  
(a) 
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     (b) 
 
Figure 3.4: Graphical representation of the DENV-human protein-protein 
interaction network.  
(a) This interaction map shows an interaction between DENV full length proteins 
or protein fragments and their corresponding human interactors. The DENV NS full 
length and proteins fragments are shown in yellow, whereas the human proteins 
are indicated in blue. (b) In this map, all protein fragments of DENV were grouped 
and displayed as their respective full length proteins on the same nodes. NS full 
length proteins are shown in yellow, whereas the human proteins are indicated in 
blue. All graphical assembly network and manipulations were performed on 
Cytoscape version 3.2.1.  
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Only four human proteins (4.3%) from this data set; STAT2, UBE2I, EMILIN1 and 
NUMA1 have been previously reported to specifically interact with DENV proteins, 
(Khadka et al. 2011; Le Breton et al. 2011) while two proteins (2.1%); GOPC and 
GRN have been reported to interact with other Flavivirus proteins (Le Breton et 
al. 2011) (Figure 3.5, Table 3.2). Interaction between STAT2 and NS5, and UBE2I 
with NS2B, NS4B and NS5, was in agreement to those observed by Khadka et al. 
(2011). It is noteworthy to detect STAT2 and NS5 interaction because STAT2 is a 
well-known NS5 targeted host cellular protein in the immune response pathway 
(Mazzon et al. 2009; Jones et al. 2005). This indicates that our methodology is 
validated.  
Similarly, the ubiquitin-proteasome degradation pathway is an important pathway 
in DENV infection (Kanlaya et al. 2010a). Detection of the ubiquitin-conjugating 
enzyme UBE2I associated with more than one DENV NS protein in this study is not 
surprising. The protein has also been reported to interact with the viral envelope 
protein, E (Doolittle & Gomez 2011; Chiu et al. 2007). UBE2I interaction with 
multiple DENV proteins was also seen by Khadka et al. (2011) which signifies the 
importance of this protein in modulating many cellular processes. Silencing of this 
gene in particular, has been shown to reduce DENV replication (Khadka et al. 
2011), and this is also true in WNV infection (Krishnan et al. 2008). UBE2I has also 
been detected in Influenza A (IAV) virus-host interactomes as well as in an Epstein-
Barr virus (EBV) RNAi screen as shown in Table 3.3, indicating its significance in 
virus infection (de Chassey et al. 2013; Calderwood et al. 2007). 
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Figure 3.5: A Venn diagram representing the overlap DENV-human proteins. 
Comparison between human proteins identified in the present study and the 
previous DENV/Flavivirus Y2H studies. DENV NS proteins in this study are shown in 
green, while the other three independent Y2H studies are performed by Khadka 
et al. (2011) (pink), Mairiang et al. (2013) (blue), and Le Breton et al. (2011) 
(gray). The overlap regions indicate similar proteins detected between the two or 
three screens. This diagram was generated using the SmartDraw software. 
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Table 3.2: List of the human proteins interacting with DENV or Flaviviruses. 
DENV protein Human 
protein 
Gene 
ID 
Description Literature Virus type Virus 
protein 
Method 
NS5 STAT2 6773 Homo sapiens signal 
transducer and activator of 
transcription 2 
(Khadka et al. 2011) DENV-2 NS5 Y2H 
       (Le Breton et al. 2011) DENV-1 NS5 Y2H 
NS2A, NS2B, NS4B, 
NS5  
UBE2I 7329 Homo sapiens ubiquitin-
conjugating enzyme E2I  
(Khadka et al. 2011) DENV-2  NS2B, NS4B, 
NS5 
Y2H 
        (Doolittle & Gomez 2011) DENV-2 E stuctural 
prediction 
        (Krishnan et al. 2008) DENV-2 whole virus RNAi 
NS4B, NS5 EMILIN1 11117 Homo sapiens elastin 
microfibril interfacer 1 
(Khadka et al. 2011) DENV-2 NS3 Y2H 
        (Le Breton et al. 2011) TBEV NS5 Y2H 
NS3 NUMA1 4926 Homo sapiens nuclear 
mitotic apparatus protein 1  
(Khadka et al. 2011) DENV-2 NS5 Y2H 
NS5 GOPC 57120 Homo sapiens golgi-
associated PDZ and coiled-
coil motif 
(Le Breton et al. 2011) TBEV NS5 Y2H 
NS4B GRN 2896 Homo sapiens granulin  (Le Breton et al. 2011) ALKV, TBEV NS5 Y2H 
NS3 LACRT 90070 Homo sapiens lacritin  (Krishnan et al. 2008) WNV whole virus  RNAi 
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Table 3.3: List of the human proteins interacting with DENV or implicated in replication of other viruses. 
DENV protein Human 
protein 
Description Literature Virus type Virus protein Method 
NS5 STAT2 Homo sapiens signal transducer 
and activator of transcription 2 
(Khadka et al. 2011) DENV NS5 Y2H 
NS2A, NS2B, 
NS4B, NS5  
UBE2I Homo sapiens ubiquitin-
conjugating enzyme E2I  
(Khadka et al. 2011) DENV NS2B, NS4B, 
NS5 
Y2H 
      (Doolittle & Gomez 2011) DENV E stuctural 
prediction 
      (Krishnan et al. 2008) WNV, DENV   RNAi 
      (de Chassey et al. 2008) IAV NS1 Y2H 
NS4B, NS5 EMILIN1 Homo sapiens elastin microfibril 
interfacer 1 
(Khadka et al. 2011) DENV NS3 Y2H 
      (Le Breton et al. 2011) TBEV NS5 Y2H 
NS3 NUMA1 Homo sapiens nuclear mitotic 
apparatus protein 1  
(Khadka et al. 2011) DENV NS5 Y2H 
NS5 GOPC Homo sapiens golgi-associated 
PDZ and coiled-coil motif  
(Le Breton et al. 2011) TBEV NS5 Y2H 
NS3 
 
LACRT Homo sapiens lacritin  (Krishnan et al. 2008) WNV   RNAi 
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NS4B GRN Homo sapiens granulin  (Le Breton et al. 2011) ALKV, TBEV NS5 Y2H 
      (Calderwood et al. 2007) EBV  Y2H 
      (de Chassey et al. 2008) HCV CORE Y2H 
      (Bouraï et al. 2012) CHIKV nsP2 Y2H 
NS5 TRIM27  Homo sapiens tripartite motif 
containing 27  
(Bouraï et al. 2012) CHIKV nsP2 Y2H 
      (de Chassey et al. 2008) IAV NS1  Y2H 
      (de Chassey et al. 2008) HCV NS2 Y2H 
      (de Chassey et al. 2008) HCV NS3 Y2H 
NS3 KHDRBS1 Homo sapiens KH domain 
containing, RNA binding, signal 
transduction associated 1  
(de Chassey et al. 2008) HCV NS3 Y2H 
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While EMILIN1 and NUMA1 have been previously reported to specifically interact 
with DENV proteins (Khadka et al. 2011; Le Breton et al. 2011), these proteins 
were found interacting with a different DENV protein in this study. EMILIN1 
interacts with DENV NS5, whereas NUMA1 with NS3 in this study, however Khadka 
et al. (2011) reported vice versa. While this is relatively predictable in the Y2H 
studies, and could be due to the interaction of host proteins with multiple DENV 
proteins (Dolan et al. 2013; Khadka et al. 2011), there is also a possibility of false-
positive interactors. EMILIN1 is associated with elastic cell fibres and is expressed 
in lymphatic capillaries and is abundant in large blood vessels, lung, intestines and 
lymph nodes (Danussi et al. 2008; Bressan et al. 1993). NUMA1 plays an important 
role in organisation of mitotic spindles during cell division (Seo et al. 2014; Kotak 
et al. 2014). Although NUMA1 has not been reported to associate with DENV 
infection, the protein is prominent during virus-induced apoptosis (Taimen et al. 
2004).  
Aside from the additional testing required to confirm the interactions, literature 
curation from different experimental settings may also be useful to further 
support the findings. Le Breton et al. (2011) identified EMILIN1 and GOPC 
interacting with NS5 similar to this study, during TBEV infection. GOPC is 
associated with the host cellular Golgi apparatus and is expressed in all tissues, 
suggesting that it plays a housekeeping role and takes part in multiple functions 
such as in vesicular trafficking in secretory and endocytic pathways (Yao et al. 
2001; Charest et al. 2001). This is interesting because processing of DENV occurs 
in the Golgi prior to production of new infectious virions (Kuhn et al. 2002), thus 
GOPC may have a potential role in viral maturation. In this study the human 
protein granulin, GRN interacted with DENV NS4B, however the protein was found 
interacting with NS5 in other Flavivirus infections (Le Breton et al. 2011). Although 
there is no study that has shown the association of GRN with DENV, this protein 
has been implicated in other virus interactions including Hepatitis C virus (HCV) 
and Chikungunya virus (CHIKV) (Bouraï et al. 2012; de Chassey et al. 2008). Of 
note, there was no overlap of the proteins identified in this study with those 
generated using the bacterial two-hybrid screen (Folly et al. 2011), neither with 
the host proteins interacting with DENV-2 NS1 identified by Silva et al. (2013). 
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Apart from EMILIN1, GOPC and GRN, three other human proteins; KHDRBS1, 
TRIM27 and LACRT, have been reported to associate with other viruses proteins. 
Similar to this study, KHDRBS1 (or the Src-associated substrate in mitosis of 68 
kDa, Sam68) was found interacting with NS3, during a screen between HCV and 
human spleen and fetal brain cDNA libraries (de Chassey et al. 2008) however, its 
functional role in supporting HCV replication was unclear. This protein regulates 
alternative splicing by recognising specific RNA sequences in the cell nucleus 
(Matter et al. 2002). While alternative splicing can be regulated by host or viral 
proteins, this produces transcripts of different outcomes which are important 
during virus replication. For instance, herpesvirus has been shown to inhibit 
several host splicing factors, preventing the synthesis of antiviral proteins such as 
PML (Tavalai & Stamminger 2009; Nojima et al. 2009). 
TRIM27 has been reported to be important for herpes simplex virus-1 (HSV-1) 
infection and known to target IkappaB kinases, thereby negatively regulating the 
pattern recognition receptor pathways (Conwell et al. 2015). This protein has been 
shown to interact with many different virus NS proteins (de Chassey et al. 2013; 
Bouraï et al. 2012; de Chassey et al. 2008) which suggests its potential role in viral 
infection, although additional testing is required for validation. LACRT has been 
identified as a host susceptibility factor in WNV infection by which silencing the 
gene reduced the viral infectivity (Krishnan et al. 2008). The protein however did 
not act in the same manner with regard to DENV as shown by Krishnan et al. 
(2008). Overall, although the mechanism of action of all the host proteins 
identified in this study with regard to DENV infection is not precisely known, their 
structural association with DENV or other viruses provides a strong basis for their 
possible involvement in the interaction, which requires validation by additional 
functional assays.  
The human-DENV interactome obtained from this screen was further analysed for 
functional relationships between putative interactions using the Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) ver. 6.7 (Huang et al. 
2009). It was interesting to observe the DENV targeted human proteins are 
particularly enriched for components of the transcriptional process and negative 
regulation of transcriptional activity as shown in the Gene Ontology (GO) 
annotations (Table 3.4, Figure 3.6). This also includes down-regulation of cellular 
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biosynthetic processes of certain pathways (Table 3.4, Figure 3.6), which is in 
agreement with previous reports that down-regulation of processes may occur as 
a result of viral infection (Lee et al. 2013; Wang et al. 2012). The data also 
indicate the enrichment of the identified human proteins in cellular compartments 
including the ER membrane and intracellular organelle lumen. Identification of 
these proteins highlights their possible interaction or modulation during virus 
replication and assembly in the ER membranous compartments.  
 
Table 3.4: Summary of the key functional description of enriched Gene 
Ontology terms.  
The human proteins associated with the GO terms and the corresponding P-values 
are shown. 
Functional description P-value  Human proteins 
Negative regulation of  
nucleobase-containing 
compound, transcription and 
cellular biosynthetic process 
0.000033352  KHDRBS1, DLX2, SUMO1, ID2, 
HEXIM2, SMARCE1, RPS14, TRIM27, 
PER1, UBE2I, PDZD3, ALX1 
DNA-binding 
region:Homeobox 
0.00185233  DLX2, MEOX2, OTX2, LHX4, ALX1, 
CRX 
Regulation of transcription 
and DNA-binding 
0.002008  KHDRBS1, CREB3, OTX2, ZXDC, 
TRIM27, ELAVL2, BANP, UBE2I, ZNF3, 
CRX, STAT2, DLX2, SUMO1, 
SMARCE1, MEOX2, HEXIM2, ID2, 
RPS14, LHX4, ZNF578, PER1, MESP1, 
APBB2, ALX1 
Somitogenesis, 
regionalisation and 
development protein 
0.01189356  DLX2, ID2, MEOX2, OTX2, BANP, 
AXIN2, MESP1, ZNF3, ALX1, ATM 
PDZ/DHR/GLGF domain 0.03171946  RGS3, GOPC, GIPC2, PDZD3 
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Figure 3.6: Enriched Gene Ontology annotation terms of the human proteins.  
Data were analysed using DAVID Bioinformatics database. The graph displays -
log10-transformed Benjamini-corrected P-values for each term. Analysis of the 
enrichment was set as the following, stringency = high, threshold of EASE score = 
0.05 to obtain significant values. BP, MF and CC are biological process, molecular 
function and cellular compartment, respectively.  
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GO:0045934~negative regulation of nucleobase,…
GO:0016481~negative regulation of transcription
GO:0031327~negative regulation of cellular biosynthetic…
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3.3.3 Confirmation of interactions 
In order to validate the protein interaction in mammalian cells, LUMIER assays 
were performed. This assay uses luciferase-tags which are able to determine if 
two test proteins are interacting (Blasche & Koegl 2013) (as described in Section 
2.7.1). HEK293 was the cell line used in this assay and for use in the downstream 
experiments because they are easily transfected, easy to grow and have been 
widely used as an excellent mammalian system for expression of recombinant 
proteins (Thomas & Smart 2005).  
Data from the Y2H screen revealed 94 human proteins physically interacting with 
DENV NS proteins. Of these proteins, 15 were selected (Table 3.5), based on their 
potential involvement in virus infection. Aside from that, they were chosen 
considering the available tools in the lab to carry out the downstream 
experiments. cDNA clones expressing 15 of the 94 human proteins were obtained 
in pDONR223 (kindly provided by Juergen Hass, University of Edinburgh). The 
genes were cloned into the LUMIER vectors, pcDNA3-RLuc-GW and pTREX-dest30-
Protein A as described in Section 2.7.1. Human proteins (tagged with S. aureus 
Protein A) and the corresponding DENV interacting partner (tagged with RLuc) 
were transiently co-expressed in HEK293 cells. Successful interaction between 
both test proteins formed a complex which then bound to the IgG-coated magnetic 
beads that have high binding affinity to the Protein A. This protein complex was 
separated from the non-interacting/unbound proteins by magnetic pull-down and 
the protein interaction was determined by the luciferase activity (as described in 
Section 2.6.3). Similarly, the interaction was also tested in the opposite 
orientation, in which the human proteins were tagged with RLuc and tested with 
DENV tagged with Protein A. This was expected to support the interaction data of 
the former pairwise orientation. A known protein interaction between JUN and 
FOS was used as positive control in this study. An interaction showing a z-score >1 
was considered a weak interaction and >2 as a strong interaction. 
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Table 3.5: List of interactions tested by LUMIER assay.  
A total of 15 human proteins were selected from Y2H data and tested for pairwise 
interaction with their corresponding DENV proteins. Interactions that occur with 
the protein fragments of DENV were also tested with the corresponding full length 
proteins. 
Human protein DENV protein 
BANP NS2A 
KCNA3 NS2A 
BANP NS2A187F  
UBE2I NS2A187F  
UBE2I NS2A 
UBE2I NS2B 
TRAPP NS2B 
JAKMIP1 NS3 
IFI30 NS3 
HEXIM2 NS3 
TNFSF13B NS4A 
UBE2I NS4B129F 
KCNS2 NS4B129F 
EMILIN1 NS4B129F 
SUMO1 NS4B129F 
PRR7 NS4B191F 
UBE2I NS4B 
KCNS2 NS4B 
EMILIN1 NS4B 
SUMO1 NS4B 
PRR7 NS4B 
UBE2I NS5 
TRIM27 NS5 
EMILIN1 NS5 
STAT2 NS5 
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The first set of LUMIER experiments were performed to assess an interaction 
between the human proteins fused to Protein A, while the DENV NS proteins fused 
to RLuc reporter. At a z-score cut-off value >2, BANP, KCNA3, ARL6IP1, UBE2I, 
TRAPPC, HEXIM2, KCNS2, EMILIN1, PRR7 and TRIM27 were detected as strong 
interactors for DENV (Figure 3.7). However JAKMIP1 and IFI30 are weak interactors 
(z-score 1), and TNFSF13B has a z-score below 1 suggesting it does not interact 
with DENV NS proteins. It was interesting to observe that BANP interacted with 
both full length and truncated DENV NS2A and NS2A187F with strong z-scores. This 
suggests the potential association of BANP with NS2A and indicates the possible 
binding region of the interaction. Similarly, ARL6IP1 was also shown to interact 
with these proteins. Interaction between STAT2 and NS5 is well-established 
(Mazzon et al. 2009; Best et al. 2005), and was detected in our LUMIER assay. 
Human proteins interacting with DENV fragments, NS2A187F, NS4B129F and 
NS4B191F were also tested for interaction with the full length DENV proteins. In 
the majority of human proteins, interaction with the full length DENV proteins 
resulted in z-scores >1, indicating these interactions are well-supported. The 
interactions however, did not occur during Y2H screen which could be due to the 
TMDs that are present in the full length DENV proteins.  
Further examination using the opposite orientation of the interacting proteins 
(human proteins fused to RLuc reporter, while the DENV NS proteins fused to the 
Protein A) however, was unable to give a significant interactions (Figure 3.8). Most 
interactions have z-scores <1 which indicates there was almost no interaction 
between the human and DENV proteins. Although JUN and FOS have shown to 
interact with a lower z-score, it was observed form this data set that the STAT2 
and NS5 did not show an interaction. Thus, it was expected that there was a 
technical error with this set of experiments, which need further repetition. 
Nonetheless, interaction of human and DENV NS proteins using former orientation 
has shown promising results, which needs further validation by co-
immunoprecipitation and co-localisation studies. 
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Figure 3.7: Interactions between Protein A-tagged human proteins and the RLuc-tagged DENV NS proteins by LUMIER assay.     
Protein A-tagged human proteins and the RLuc-tagged DENV NS proteins were co-expressed in HEK293 cells and then pulled down by the 
IgG-coated magnetic beads. The cells were lysed and washed to remove unbound proteins. Luciferase activity was determined and the 
values were normalised to the negative control, Protein A. The bars indicate luciferase expression during an interaction between the 
human proteins and their DENV interacting partners (x-axis). Error bars represent a standard error of triplicates in three independent 
experiments. The z-zcores (y-axis) were calculated as described previously (Braun et al. 2009). A z-score cut-off value above 1 (one 
standard deviation higher than the mean) indicates the score is positive. Known interaction between the proto-oncogenes; c-FOS and c-
JUN, were used as a positive control.  
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Figure 3.8: Interactions between RLuc-tagged human proteins and the Protein A-tagged DENV NS proteins by LUMIER assay.     
RLuc-tagged human proteins and the Protein A-tagged DENV NS proteins using similar techniques as described above. Error bars represent 
a standard error of triplicates in three independent experiments. A z-score cut-off value above 1 (one standard deviation higher than the 
mean) indicates the score is positive. Known interaction between the proto-oncogenes; c-FOS and c-JUN, were used as a positive control.  
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 Discussion 
DENV-2 is the predominant dengue virus serotype causing infection in humans 
(Gubler 1998). It is known that the viral structural proteins, E, M and C proteins, 
play an important role during initiation of virus infection however, the roles of 
the NS proteins are less well-defined (Mukhopadhyay et al. 2005). Due to the 
importance of this serotype and in order to gain a better understanding of the 
roles of DENV NS proteins, analysis of their interacting partners in humans was 
carried out using Y2H.  
In order to screen for protein-protein interaction between DENV-2 and human 
cDNA library, the DENV-2 bait constructs were first generated using the Gateway 
cloning technology (Invitrogen). It is believed that baits containing TMDs are 
unlikely to be translocated into the cell nucleus, where their presence may lead 
to transcription of the reporter gene (Brückner et al. 2009; von Mering et al. 2002). 
Therefore, the gene segments encoding for DENV TMDs were eliminated from the 
constructs, leaving the truncated segments encoding the intra/extracellular 
domains. Although the resulting protein fragments may cause some non-specific 
interactions due to improper folding, this is expected to be minimal as the 
fragments are generated based on their predicted specific intracellular domain 
boundaries. Previous studies have shown the use of protein fragments or 
polypeptides in many Y2H experiments (Dolan et al. 2013; Calderwood et al. 
2007). This includes the shortest, 31 amino acids of DENV NS2A which were found 
interacting with 25 human proteins  (Khadka et al. 2011). The use of well-defined 
smaller fragments may facilitate protein binding by making the polypeptides more 
accessible to interaction. Furthermore, the use of full length genes along with 
their overlapping fragments provides an additional support for a specific 
interaction which increases its confidence level. 
At least four studies have been reported in which DENV-human interactions 
characterised by Y2H provided reliable data, hence these have been used as a 
comparison to this study (Mairiang et al. 2013; Silva et al. 2013; Khadka et al. 
2011; Le Breton et al. 2011). Khadka et al. (2011) reported 105 human host 
proteins enriched in complement activation and coagulation cascade by which six 
have been previously reported interacting with DENV. The functional role of 
certain proteins, including STAT2 and ubiquitin-conjugating enzyme UBE2I was 
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confirmed by gene silencing (Khadka et al. 2011). This is consistent with the 
present study which detected similar interactions validated by the LUMIER assay. 
Interaction between STAT2 and NS5 during flavivirus infection is well-established 
(Shi 2014). NS5 binds to STAT2 and blocks its phosphorylation, hence inhibiting 
the downstream stimulation of the host IFN response (Mazzon et al. 2009). The 
role of UBE2I protein is known to be involved in conjugation of the small ubiquitin-
like modifier (SUMO) to substrate proteins for alteration of subcellular functions 
including localisation, degradation and DNA repair (Mao et al. 2000; Müller & 
Dejean 1999). Such events are important in virus infection, thus interaction of the 
virus proteins with UBE2I and SUMO components may create a favourable 
environment for virus replication and survival in the host cells. Of note, SUMO1 
was also detected interacting with one of NS4B fragment in this study, however 
the protein showed a marginal interaction by LUMIER assay.  
There are several limitations to this study such as the difficulties in assessing the 
reliability of each DENV-human protein interactions. This is due to the fact that 
the yeast cells are dissimilar to the human cells, which makes it difficult to 
evaluate the reliability of DENV-human protein interactions in this setting. For 
example, there is no post-translational modification of proteins in yeast which 
may generate false-positive interactions while other interactions might not take 
place. It is also possible that both N- and C-terminal tagging resulted from fusion 
with the GAL4 may have altered the protein folding. This could be resolved by 
assessing the protein-protein interaction through both orientation of fusion tags 
that indicate any possible binding. The uncertain protein expression level and 
distribution of the bait and prey proteins, the lack of other binding partners to 
stabilise an interaction or protein misfolding may also contribute to the false-
negatives or missed interactions in the Y2H screen. Therefore, it is imperative 
that results derived from the screen are confirmed by additional experiments to 
support the findings. Aside from that, the presence of TMDs may interfere with 
the nuclear translocation of proteins for activation of transcription. This however, 
can be resolved through the generation of truncated proteins as carried out in this 
study.  
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To make the Y2H test more stringent and prevent false-positives, the yeast 
inhibitor 3-AT was used in this study. 3-AT acts by inhibiting the histidine 
biosynthetic enzyme imidazoleglycerolphosphate dehydratase, which prevents 
the histidine biosynthesis in yeast thus, inhibits the yeast growth. While Y2H 
employs a HIS3 reporter encoding this enzyme, the 3-AT growth inhibition effect 
can be counteracted only in the case of a successful Y2H interaction. The addition 
of 3-AT in the medium therefore reduces the number of false-positives by giving 
a higher stringency to protein interactions. Overall, the Y2H system allows 
identification of putative DENV-human factors which may reveal cellular 
interactions and this could be translated into larger biological functions. 
The limited overlap between data from this study and other data sets may be 
partly because of the different sources of the prey cDNA library used. Khadka et 
al. (2011) screened an interaction between DENV and the human library derived 
from liver, however other libraries such as peripheral blood leucocytes and mixed 
liver, brain, spleen and bronchial epithelia, have also been used (Mairiang et al. 
2013; Le Breton et al. 2011). This resulted in a different level of interaction 
because the cellular host libraries contained different gene enrichments. 
Moreover, the different experimental conditions applied in independent large-
scale screens may cause low reproducibility (Friedel & Haas 2011). Thus it is 
imperative to validate the human host factors identified from various Y2H screens 
by additional functional assays.  
Results obtained from the Y2H screen revealed 94 human proteins interacting with 
DENV NS proteins. Of these proteins, 15 proteins including BANP, KCNA3, ARL6IP1, 
UBE2I, TRAPPC, HEXIM2, KCNS2, EMILIN1, PRR7 and TRIM27 have shown to be DENV 
interacting partners. This indicates the potential involvement of these proteins in 
viral infections, although further validation by functional tests is required. The 
importance of the remaining proteins in association with virus infection is 
unknown. However their specific roles such as vesicular transport from ER to Golgi 
(TRAPPC5), or in mediating DNA damage and repair (ATM) may imply their 
essential involvement in maintaining cellular conditions in response to viral 
infections. 
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Although little is known about human BANP, its mouse homolog SMAR1 (95% gene 
homology), has been reported to suppress NF-B transactivation (Singh et al. 2009) 
in human cells. SMAR1 binds to the matrix attachment regions, and is able to form 
a complex with p53 which negatively regulates p53 transcription, and functions as 
a tumour suppressor and cell cycle regulator (Singh et al. 2009). It has also been 
shown that SMAR1 is involved in histone complexes and chromatin remodelling 
(Sinha et al. 2012; Malonia et al. 2011). Due to the capacity of SMAR1 to modulate 
NF-B immune signaling, it is therefore important to investigate if BANP acts in a 
similar fashion, and is involved in any stage of the virus infection in humans, 
particularly in association with DENV NS2A. It was also observed that two human 
proteins; KCNA3 and KCNS2, interacted with NS2A and NS4B129F, respectively. 
Both proteins are potassium voltage-gated channels, which are responsive to the 
voltage changes of cell membrane potential. Potassium channels play a crucial 
role in the activation and proliferation of leukocytes. It has been shown there is 
an interaction between human immunodeficiency virus glycoprotein subunit and 
the cytoplasmic C-terminus of a voltage-gated potassium channel that represses 
the channel activity and prevents the release of virus (Herrmann et al. 2010). 
During virus infection, potassium channels are phosphorylated and translocated to 
the cell membrane, therefore mediating an outward potassium current resulting 
in the induction of apoptosis (Redman et al. 2007). This apoptotic response 
however, has been shown to be inhibited by HCV infection (Mankouri et al. 2009).  
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4 CHAPTER 4: FUNCTIONAL ANALYSIS OF BANP PROTEIN IN DENGUE 
VIRUS INFECTION 
4.1 Introduction 
4.1.1 MAR elements 
The nuclear matrix is an extensive fibrogranular network within a cell nucleus, 
which functions as a dynamic support or scaffold for nuclear components. It 
maintains architectural features of the nucleus, hence it is involved in various 
nuclear events such as transcription, recombination, repair and splicing. 
Chromatin fibres are folded into DNA loops or highly structured DNA domains by 
tethering to this nuclear matrix. Such attachment occurs at specific non-coding 
regions on genomic DNA, termed matrix attachment regions (MARs) (Gasser & 
Laemmli 1987). MARs, also known as scaffold associated regions (SARs) or 
scaffold/matrix attachment regions (S/MARs), are unique cis-regulatory elements 
found on eukaryotic genomes (Pienta et al., 1991). Such sequences are AT-rich 
(>70%), representing 0.6-1 kb and have recognition sites for topoisomerase II 
(Gasser & Laemmli 1987). Although certain sequence characteristics have been 
suggested for MARs, many are highly polymorphic (Wang et al. 2010). MARs are 
mostly located upstream of various transcriptional promoters and enhancers, 
therefore, they act as platforms for the assembly of basal transcriptional factors 
complex controlling gene expression (Girod & Mermod 2003; Pienta et al., 1991). 
Interestingly, a recent report also suggests a role of MAR elements in viral 
integration, replication and transcription affecting the host immune system 
(Chakraborty et al. 2014; Sreenath et al. 2010).  
MAR elements have also been used as epigenetic regulators responsible for 
enhancing transgene expression (Kim et al. 2004; Petersen et al. 2002), and stable 
cell line development (Zahn-Zabal et al. 2001). Although the functional role of 
MAR elements in transgene expression is not well understood, several models have 
been proposed. Spiker & Thompson (1996) suggested that integration of MAR 
allows formation of a transcriptionally active independent domain into an existing 
inactive DNA domain which makes binding sites accessible to transcriptional 
factors. Other findings described the formation of nucleation sites for 
displacement of histones to reduce DNA supercoiling (Käs et al. 1993), formation 
of nucleation points for DNA unwinding (Bode et al. 1992) and stabilisation of the 
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chromosomal structure resulted from hyperacetylation of histones (Schlake et al. 
1994). Taken together, these findings indicate the significant role of MAR elements 
in mediating the topology of functional chromatin domains. 
4.1.2 MAR-binding proteins 
Matrix attachment region-binding proteins (MARBPs) which bind to the MAR 
elements are mostly found as components of the nuclear matrix (Wang et al. 
2010). Several MARBPs have been characterised, such as the special AT-rich-
binding protein 1 (SATB1), B cell regulator of IgH transcription (Bright), cut-like 
protein x/CCAAT displacement protein (Cux/CDP) in humans, and MAR binding 
filament-like protein 1 (MFP1) in plants (Goebel et al. 2002; Zong et al. 2000; 
Alvarez et al. 2000; Gindullis 1999). Most MARBPs are present as co-repressor/co-
activator complexes which are involved in gene regulation (Chattopadhyay & 
Pavithra 2007). They play diverse roles in regulation of chromatin structure, gene 
transcription and progression of cell cycle (Chattopadhyay & Pavithra 2007). This 
means that any changes in the regulation or levels of MARBPs may directly 
contribute to the change in gene expression.  
4.1.3 BANP/SMAR1 
BTG3-associated nuclear protein (BANP) is a human MARBP and was identified from 
a protein-protein interaction study (Birot et al. 2000). The protein is ubiquitous 
and is commonly expressed in various organs and may act as a transcription factor 
or suppressor protein (Birot et al. 2000). Although the functional role of BANP is 
presently unknown, its mouse homolog, scaffold/matrix-associated region-binding 
protein 1 (SMAR1) has been extensively studied (Malonia et al. 2011). SMAR1 is a 
MARBP, first identified in murine thymocytes and multiple transcript variants 
encoding different protein isoforms have been found for this gene (Chattopadhyay 
et al. 2000a). The protein shares significant homology with other MARBPs such as 
SATB1, Bright and Cux/CDP in the MAR binding domains. SMAR1 contains a nuclear 
localisation signal, arginine-serine rich motifs which serve as a protein interaction 
domain, and C-terminal DNA binding domain (Chattopadhyay et al. 2000a). In 
addition, SMAR1 also contains the BEN domain mediating protein-DNA and protein-
protein interactions during organisation of chromatin.  
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SMAR1 is a tumour suppressor, in which ectopic expression of SMAR1 in mouse 
melanoma cells leads to growth arrest (Kaul et al. 2003). SMAR1 expression is 
down-regulated in later stages of breast cancer cells, but can be induced upon 
treatment with the chemotherapeutic drug doxorubicin (Singh et al. 2007). 
Interestingly, SMAR1 has been shown interacting with the p53 tumour suppressor, 
which accounts for stabilisation in the nucleus by promoting serine 
phosphorylation and displacement of the p53 negative regulator mouse double 
minute 2 homolog (MDM2) (Jalota et al. 2005). Due to its association with p53, 
SMAR1 is induced during DNA damage in a p53 dependent manner (Singh et al. 
2007), and is involved in modulation of the cell cycle by regulating cyclin D1 (Kaul 
et al. 2003). In regulation of cyclin D1, SMAR1 interacts with histone deacetylase 
complex 1 (HDAC1), SIN3 and pocket retinoblastoma protein (p130 and p107) 
forming a multiprotein repressor complex which is recruited to MAR site on cyclin 
D1 promoter (Rampalli et al. 2005). This results in deacetylation of chromatin and 
inhibition of gene transcription.  
Apart from its role in tumorigenesis and cell cycle, SMAR1 has been reported to 
be involved in regulation of NF-B signalling pathway and apoptosis. Molecular 
mechanisms revealed that SMAR1 binds to the MAR element present in IκB 
promoter, recruits the HDAC1 dependent complex, together with p65/p50 to the 
locus and thus inhibits its transcription (Singh et al. 2009). Overall, given the 
diverse roles of SMAR1 and its ability to modulate the function of several genes, 
SMAR1 is a potential target for development of therapy for cancer or immune 
diseases. 
  
 130 
 
4.1.4 Relevance of study 
In the previous chapter describing a Y2H screen of DENV-host interactions, a total 
of 94 human proteins were found interacting with DENV NS proteins. Literature 
curation of the available data regarding these proteins, including the known host-
virus interactions, roles in virus infections as well as potential tools to determine 
the importance of these interactions, was carried out in order to narrow down the 
interactions that are to be analysed further. In particular, the protein BANP 
interacting with DENV NS2A, was among the proteins of particular interest. BANP 
interacts with the full length NS2A and its fragment (NS2A187F) which indicates 
the potential NS2A binding region involved in the interaction.  
BANP was first identified from a yeast two-hybrid approach in a search for a BTG3 
interacting partner (Birot et al. 2000). BANP gene is located on the 16q24 region 
of the human chromosome and encodes for 509 amino acids (~55.4 kDa) (Birot et 
al. 2000). Further analysis of the amino acid composition suggests BANP is most 
probably a transcription factor (Birot et al. 2000). The knowledge about functional 
roles of BANP is very limited at present, however, its mouse homolog SMAR1 has 
been extensively studied (Malonia et al. 2011), as described earlier in this chapter.  
Recent evidence indicates that SMAR1 can recruit HDAC1 and bind to a conserved 
MAR within the long terminal repeats (LTRs) promoter of proviral HIV-1, resulting 
in inhibition of viral transcription (Sreenath et al. 2010). Other small tumour 
viruses such as human papillomavirus (HPV16), simian virus 40 (SV40), HBV and 
human T-cell leukemia virus type 1 (HTLV-1) are also capable of integrating into 
the chromosomes through MAR (Kulkarni et al. 2004; Shera et al. 2001). In HIV-1, 
MAR elements account for 92.5% of the genome integration sites and many of these 
MAR sites have been documented (Kulkarni et al. 2004). Further to this, SMAR1 
has been shown to repress E6 oncogene expression by inhibiting the recruitment 
of tumour promoting factor c-Fos to the E6 promoter in HPV18-infected HeLa cells 
(Chakraborty et al. 2014). Binding of SMAR1 and HDAC1 to the HPV-18 E6 promoter 
results in deacetylation of chromatin, thus transcriptional repression of E6 
(Chakraborty et al. 2014). 
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Although SMAR1 is a multi-functional protein, this chapter particularly focused on 
SMAR1 capability in regulating NF-B signalling. A previous study has shown that 
SMAR1 is capable of down-regulating IB and inhibit the NF-B signalling pathway 
(Singh et al. 2009). A proposed mechanism suggesting this event is shown in Figure 
4.1 This process occurs through the over-expression of SMAR1 which recruits the 
HDAC1 repressor complex and binds to the MAR elements located upstream of the 
NF-B binding sites on the IB promoter. As a result, IB transcription is 
repressed and p65/p50 of NF-B subunits in the cytoplasm are released to the cell 
nucleus forming a p65/p50-SMAR1-HDAC1 repressor complex. This complex is 
subsequently recruited to the MAR binding site of NF-B target genes which 
inhibits transactivation of NF-B. In addition, SMAR1 has been shown to repress 
numerous NF-B target genes containing MAR elements through a similar fashion 
in MRC-7 cells (Singh et al. 2009). A decrease in expression of these genes including 
IL-8, IL-10, CASP8, IBKB, MAP3K1, NFB1 and CCL2 have been shown during NF-
B-mediated IFN stimulation (Singh et al. 2009). 
With regard to the BANP potential involvement in DENV infection, it is therefore 
interesting to investigate if BANP mediates or regulates the human IFN response 
or other signalling pathways that may affect DENV replication. This chapter thus 
focused on investigation of BANP functional properties based on prior knowledge 
of SMAR1 and its potential involvement in DENV replication. 
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Figure 4.1: Regulation of NF-B transactivation by SMAR1.  
Left: In a classical NF-B pathway, TNF- mediates NF-B activation through 
phosphorylation of IB by enzyme IB kinase and subsequent ubiquitination (Ub), 
resulting in proteasome-mediated degradation. This allows nuclear translocation 
of p65/p50, which interacts with p300 co-activator and other proteins, leading to 
transcription of downstream IB target genes. Right: In the atypical pathway, 
over-expression of SMAR1 (either by SMAR1 transfection or doxorubicin treatment) 
causes down-regulation of IB which subsequently allows translocation of 
p65/p50 NF-B subunits into the cell nucleus. These subunits form an association 
with SMAR1-HDAC1 repressor complex and the complex is recruited to the MAR 
sites of κB target genes, resulting in repression of the NF-B signalling pathway. 
The MAR site is shown in blue rectangles. Blue and red arrows indicate up-
regulation and down-regulation of proteins, respectively. This figure was adapted 
from Singh et al. 2009. 
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4.2   Objectives 
 
1. To confirm the interaction of BANP and NS2A.  
2. To determine the cellular localisation of BANP and NS2A. 
3. To determine the viability of cells during overexpression of BANP and NS2A. 
4. To investigate the type I IFN-regulatory properties of BANP. 
5. To analyse the effect and influence of BANP on DENV (replicon) replication. 
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4.3 Results 
4.3.1 BANP amino acid sequences 
There are seven variants of human BANP mRNA transcripts (namely transcript 
variant 1 to 7) documented on Genbank. These transcripts are translated into 
seven BANP isoforms, designated a to g, respectively. Aside from known amino 
acid sequence similarities (Figure 4.2), there is however a lack of knowledge 
describing functional capacity of each BANP isoform. The BANP identified as 
interacting with DENV NS2A belongs to the transcript variant 1 (isoform a) and has 
81.3% sequence similarity with SMAR1. There are two stretches of BANP missing 
amino acids, position 131-169 (39 a.a) and position 443-484 (42 a.a) compared to 
SMAR1. 
4.3.2 Confirmation of BANP-NS2A interaction 
4.3.2.1  Construction and use of BANP expression construct 
Previous results of the LUMIER assay showed a high luciferase activity following 
over-expression of Protein A-BANP and NS2A-Rluc indicating a strong interaction 
between the proteins (Section 3.3.3). The interaction was further validated in this 
study by a co-immunoprecipitation (co-IP)/pull-down assay. A BANP expression 
construct was initially generated using the Gateway cloning strategy (Section 
2.4.4). The BANP ORF (1.4 kb) was cloned into the mammalian expression vector 
pDEST40 downstream of a CMV promoter and fused to a V5 epitope at the C-
terminus. The resulting plasmid pDEST40-BANP was sequence-verified and used to 
transfect HEK293 cells for protein expression analysis. Results from Western blots 
detected the expression of BANP (~53-56 kDa) in the plasmid-transfected HEK293 
cells and the presence of an endogenous BANP in the mock-transfected cells 
(Figure 4.3a). There were two bands in each sample indicating the BANP is present 
as isoforms, which is consistent with the previous study by Kaul et al. (2003). 
Given that BANP was fused to an epitope tag V5, the protein was also detected 
using anti-V5 antibody which was not seen in the mock-transfected cells (Figure 
4.3b).  
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BANP isoform_e MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
BANP isoform_b MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
BANP isoform_d MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
BANP isoform_a MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
BANP# MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
SMAR1 MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
BANP* MRVRCAIIPSDMLHISTNCRTAEKMALTLLDYLFHREVQAVSNLSGQGKHGKKQLDPLTIYGIRCHLFYKFGITESDWYR
Clustal Consensus ********************************************************************************
330 340 350 360 370 380 390 400
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
BANP isoform_c IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP isoform_f IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP isoform_g IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP isoform_e IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP isoform_b IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP isoform_d IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP isoform_a IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
BANP# IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPNSSSYCPSEPMMSTPPPASELPQPQPQPQALHYALANAQQVQIHQIGE
SMAR1 IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPSSSSYSASETMMGTPPPTSELQQSQP--QALHYALANAQQVQIHQIGE
BANP* IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPSSSSYSASETMMGTPPPTSELQQSQP--QALHYALANAQQVQIHQIGE
Clustal Consensus ********************************.****..**.**.****:*** *.**  ********************
410 420 430 440 450 460 470 480
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
BANP isoform_c DGQVQVG---HLHIAQVPQGEQVQITQDSEGNLQIHHVGQDG--------------------------------------
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Figure 4.2: Sequence similarities of BANP isoforms and SMAR1. 
Amino acid sequence alignment of BANP isoforms, a to g. Sequences derived from 
the Genbank and aligned using the ClustalX and BioEdit tools. Highlighted in 
rectangular boxes are sequence comparison between the human BANP in present 
study (BANP#) with the mouse SMAR1 from Chattopadhyay et al. 2000b. BANP* 
indicates sequences from Birot et al. 2000.  
  
SMAR1 IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPSSSSYSASETMMGTPPPTSELQQSQP--QALHYALANAQQVQIHQIGE
BANP* IKQSIDSKCRTAWRRKQRGQSLAVKSFSRRTPSSSSYSASETMMGTPPPTSELQQSQP--QALHYALANAQQVQIHQIGE
Clustal Consensus ********************************.****..**.**.****:*** *.**  ********************
410 420 430 440 450 460 470 480
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
BANP isoform_c DGQVQVG---HLHIAQVPQGEQVQITQDSEGNLQIHHVGQDG--------------------------------------
BANP isoform_f DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDG--------------------------------------
BANP isoform_g DGQVQVG---HLHIAQVPQGEQVQITQDSEGNLQIHHVGQDGQLLEATRIPCLLAPSVFKASSG----------------
BANP isoform_e DGQVQVG---HLHIAQVPQGEQVQITQDSEGNLQIHHVGQDG--------------------------------------
BANP isoform_b DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDGQLLEATRIPCLLAPSVFKASSG----------------
BANP isoform_d DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDGQLLEATRIPCLLAPSVFKASSG----------------
BANP isoform_a DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDG--------------------------------------
BANP# DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDG--------------------------------------
SMAR1 DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDGQSWGLCQNPIPVSGDSVAQANPSQLWPLGGDTLDLPAG
BANP* DGQVQVIPQGHLHIAQVPQGEQVQITQDSEGNLQIHHVGQDGQSWGLCQNPIPVSGDSVAQANPSQLWPLGGDTLDLPAG
Clustal Consensus ******    ********************************                                      
490 500 510 520 530 540 550
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.
BANP isoform_c ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP isoform_f ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP isoform_g ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP isoform_e ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP isoform_b ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP isoform_d ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP isoform_a ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
BANP# ----QVLQGAQLIAVASSDPAAAGVDGSPLQGSDIQVQYVQLAPVSDHTAGAQTAEALQPTLQPEMQLEHGAIQIQ
SMAR1 NEMIQVLQGAQLIAVASSDPAATGVDGSPLQGSDIQVQYVQLAPVSDHTAAAQTAEALQPTLQPDMQLEHGAIQIQ
BANP* NEMIQVLQGAQLIAVASSDPAATGVDGSPLQGSDIQVQYVQLAPVSDHTAAAQTAEALQPTLQPDMQLEHGAIQIQ
Clustal Consensus     ******************:***************************.*************:***********
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Figure 4.3: Over-expression of BANP and the endogenous BANP. 
V5-tagged BANP was over-expressed in HEK293 cells and the proteins were 
detected by immunoblotting using (a) anti-BANP and (b) anti-V5 primary 
antibodies, followed by an anti-rabbit IgG conjugated with HRP. Actin was used as 
a loading control. 
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4.3.2.2 Co-immunoprecipitation of BANP and NS2A 
In order to confirm the BANP and NS2A interaction in a mammalian system, 
pDEST40-BANP V5-tagged (from above) and the DENV NS2A construct (previously 
generated for LUMIER assays) pTREX-DEST30-Protein A-NS2A expressing Protein A-
tagged NS2A were used for co-IP assays. In this assay, the IgG-coated magnetic 
beads have high affinity for Protein A which consequently pulls down NS2A. In 
brief, HEK293 cells were co-transfected with pTREX-DEST30-Protein A-NS2A 
and/or pDEST40-BANP. An empty pTREX-DEST30-Protein A expressing Protein A 
alone was used as a negative control. At 24 hr p.t, the proteins were harvested 
and pulled-down by incubation with IgG-coated magnetic beads. After several 
washing steps, proteins bound to the beads were eluted in SDS and analysed by 
Western blot. As shown in Figure 4.4(a) and Figure 4.4(b), overexpressed BANP 
was detected in the pull-down of NS2A co-expressed with BANP-V5 (lane 4). No 
endogenous BANP was detected in NS2A pull-down (lane 3); this is likely because 
its presence in the sample is insufficient to result in co-precipitation with the IgG-
coated beads. In the absence of NS2A (lane 5), BANP did not react with Protein A 
which suggests its pull-down was only accomplished by the presence of NS2A. This 
data thus confirmed that physical interactions take place between BANP and NS2A. 
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Figure 4.4: Validation of BANP and NS2A interaction by co-IP.  
Proteins were harvested from transfected-cells and pulled down using IgG-coated 
magnetic beads. The bound proteins were subjected to immunoblotting and 
detected using (a) anti-BANP and (b) anti-V5 antibodies. The figure indicates pull-
down protein samples from: mock (lane 1), Protein A alone (lane 2), Protein A-
NS2A (lane 3), Protein A-NS2A and BANP-V5 (lane 4), Protein A and BANP-V5 (lane 
5). Cell lysates probed with anti-c-Myc indicate the detection of NS2A. Actin was 
used as a loading control. 
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4.3.3 Localisation of BANP and NS2A 
4.3.3.1 Expression of c-Myc-tagged NS2A 
Initial experiments were carried out to test the DENV NS2A expression level and 
demonstrate its cellular co-localisation with BANP in HEK293 cells. The pcDNA-
mycNS2A construct purchased from ShineGene Bio-Technologies, Inc. (Table 2.15) 
was used to express NS2A as a fusion with c-Myc epitope (N-EQKLISEEDL-C) at the 
N-terminus. From Western blot analysis, transiently transfected pcDNA-mycNS2A 
into HEK293 cells resulted in an expression of DENV NS2A, detected at 25 kDa using 
c-Myc antibody (Figure 4.5). The NS2A protein was expressed at a relatively low 
level and was detected using the hypersensitive chemiluminescent detection 
method (Section 2.3.5). pcDNA-EGFP expressing EGFP (constructed in-house) was 
used as a negative control for expression. 
 
 
 
Figure 4.5: Expression of DENV NS2A in HEK293 cells. 
The proteins were detected by immunoblotting using c-Myc antibody. pcDNA-
mycNS2A and pcDNA-EGFP were individually transfected (100 ng, 500 ng) into 
HEK293 cells and the cells were lysed in NP-40 lysis buffer after 24 hr. The 
resulting proteins were subjected to immunoblotting and probed using c-Myc 
antibody, followed by an anti-mouse IgG conjugated HRP. pcDNA-EGFP was used 
as a negative control in this experiment.  
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4.3.3.2 Cellular localisation  
In principal, two proteins can interact when both are located within the same 
cellular compartment. Although BANP and NS2A were successfully expressed in 
HEK293 cells (as seen in Section 4.3.2.1 for BANP and in the above Section for 
NS2A), it was important to know their sub-cellular localisation. This was studied 
by immunostaining using the protocols and primary antibodies as listed in Table 
2.5 (Section 2.3.5). Transfected cells were fixed in 4% paraformaldehyde, probed 
with their corresponding antibodies and viewed with a confocal laser scanning 
microscope. Images were analysed using the ZEN software.   
As shown in Figure 4.6a, endogenous BANP was found dispersed throughout the 
cell nucleus and cytoplasm. Overexpressed BANP was seen accumulated in the cell 
nucleus detected by the high signal intensity in the cell nucleus (Figure 4.6b), 
while a small amount of the protein was retained in the cytoplasm. This however 
is not surprising as BANP is nuclear-associated and therefore mainly localised in 
the cell nucleus (Jalota et al. 2005). In contrast, DENV NS2A was located 
exclusively in the cell cytoplasmic region (Figure 4.6c) which correlates with 
previous observations (Xie et al. 2013; Leung et al. 2008). In Figure 4.6d, it was 
noticeable that both endogenous BANP and NS2A are present in the cell cytoplasm. 
However, due to the narrow cytoplasmic region of HEK293 cells, their precise 
localisation within such limited space is difficult to be assessed. Additionally, NS2A 
remained in the cytoplasm during overexpression of BANP (Figure 4.6e), whereas 
most of BANP accumulates in the cell nucleus. 
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Figure 4.6: Cellular localisation of BANP and NS2A in HEK293 cells.  
The cells were transfected and/or co-transfected with the following expression plasmids to examine the protein expression as follows: 
(a) endogenous BANP, (b) over-expressed BANP, (c) NS2A expression, (d) endogenous BANP during NS2A expression, and (e) co-expression 
of BANP and NS2A. The cells were fixed and stained with either anti-BANP or/and anti-c-Myc antibodies. Alexa Fluor® 488 anti-rabbit IgG 
(green) and Alexa Fluor® 594 anti-mouse IgG (red) were used to stain for BANP and NS2A, respectively. The cells were counterstained with 
DAPI to localise the nucleus. 
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4.3.4 Assessment of cell viability 
It is important to determine the dose-response effect of BANP and NS2A on HEK293 
cell viability. This ensures the over-expressed BANP and NS2A are not toxic to the 
cells which may affect the experimental outcome. This test was carried out using 
the CellTiter 96® Non-Radioactive Cell Proliferation Assay which measures the 
activity of NAD(P)H-dependent cellular oxidoreductase present in metabolically 
active cells. The enzyme reduces methyl-thiazolyl-tetrazolium (MTT) to its 
quantifiable formazan product (Mosmann 1983) which is directly proportional to 
the number of living cells (van Meerloo et al. 2011). Varying concentrations of 
pDEST40-BANP, pcDNA-mycNS2A or pDEST40-MBP (5 ng to 1 µg) were transiently 
transfected into the HEK293 cells followed by adding the tetrazolium solution at 
24 hr p.t and incubated at 37 °C for 4 hr to allow cellular conversion of tetrazolium 
to formazan (Section 2.7.6). The reaction was halted by adding stop solution and 
the culture absorbance was recorded the next day. E. coli maltose-binding protein 
(MBP) was used as a positive control. 
Results from the MTT assay (Figure 4.7) showed a concentration-dependent effect 
of BANP, NS2A and MBP expression on cell viability. Within the plasmid 
concentration range of 10-1000 ng/ ml, the expression of BANP resulted in at least 
81% of the cells remaining viable, while 87% was observed with DENV NS2A. MBP 
expression revealed at least 80% of cell viability up to 250 ng/ ml of plasmid and 
subsequently reduced to 78% for higher plasmid concentration. This gives an 
overall number of viable cells: NS2A>BANP>MBP with all constructs and 
concentrations behaving very similar. While this data is useful to assess cell 
viability, it is a matter of considerable importance that all the cells remain above 
80% viable at 100 ng/ ml plasmid concentration with the various constructs 
described here, as used in most experiments described herein.  
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Figure 4.7: Effect of over-expressed BANP and NS2A on HEK293 cell viability.  
This assay was carried out using the CellTiter 96® Non-Radioactive Cell 
Proliferation Assay (Promega) and the OD was measured at 570 nm using Glomax® 
Multi Detection System. The absorbance values of viable cells were calculated as 
a percentage relative to the mock (cells treated with Lipofectamine® 2000 CD 
alone). Data was expressed as the mean±standard deviation of triplicates from 
three independent experiments.  
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4.3.5 Effect of BANP on type I interferon response 
The BANP mouse homolog, SMAR1, has been previously shown to inhibit NF-B 
activation during its over-expression in cancer cell lines (Malonia et al. 2011). Due 
to the fact that BANP and SMAR1 has 81.3% amino acid sequence similarity (from 
our sequence data), initial experiments were carried out to investigate if human 
BANP caused a similar inhibitory effect on type I IFN signalling, which also depends 
on NF-B (Yoneyama et al. 1998; Yoneyama et al. 1996).  
4.3.5.1 Poly(I:C)-induced interferon responses 
An initial experiment was performed to test the IFN production in HEK293 cells by 
stimulating with a synthetic dsRNA substrate, Poly(I:C). Poly(I:C) transfected into 
cells using a liposome-mediated procedure resembles intracellular dsRNA 
produced during viral infection and thus induces a strong type I IFN response 
(Matsumoto & Seya 2008; Kumar et al. 2006). In brief, HEK293 cells grown in 24-
well plates were co-transfected with either p125Luc, a plasmid containing FFLuc 
expressed under the IFN- promoter or p55A2Luc which contained repeated PRDII 
elements for NF-B binding sites, and pRL-CMV a construct that constitutively 
expresses Rluc as an internal control (Section 2.7.5).  
At 24 hr p.t of the plasmids, the cells were transfected with increasing 
concentrations of Poly(I:C) using Lipofectamine® 2000 CD and lysed 24 hr post-
stimulation to determine the luciferase activity. Ratio of FFLuc values were 
calculated against the RLuc internal control and normalised to the mock-
stimulated control. Treatment of HEK293 cells with Poly(I:C) resulted in an 
increase in FFLuc expression (Figure 4.8) which corresponded to the activation of 
the IFN- promoter, in a concentration-dependent manner. The cells transfected 
with p125Luc were responsive to Poly(I:C) given as low as 0.1 µg/ ml concentration 
which resulted in an approximately 10-fold increase in FFLuc compared to the 
non-stimulated control. The production of IFN- gradually increased to a 
maximum level (59-fold increase) at 5 µg/ ml, before decreasing thereafter. A 
similar trend of IFN induction was observed in cells transfected with p55A2Luc 
reporter construct upon Poly(I:C) stimulation. Although the overall luciferase 
signals were reduced compared to the cells transfected with p125Luc, results show 
an increase of IFN induction with increasing Poly(I:C). The maximum induction was 
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with 10 µg/ ml Poly(I:C) generating a 12-fold increase compared to the non-
stimulated control. Similar observations have been made in different cell lines by 
others (Reimer et al. 2008; Zhang et al. 2012), thus indicating a successful IFN 
activation induced by Poly(I:C) in HEK293 cells. 
 
 
Figure 4.8: Poly(I:C)-induced interferon response in HEK293 cells.  
Cells were co-transfected with either p125Luc (black bars) or p55A2Luc (gray 
bars), and pRL-CMV RLuc reporter (internal control) for 24 hr before transfection 
with increasing concentrations of Poly(I:C). The cells were lysed and luciferase 
activity was measured using the Dual-Luciferase Reporter Assay System. Ratio of 
IFN-β FFLuc was calculated against the RLuc internal control and normalised to 
the mock-stimulated negative control, which was cells treated with 
Lipofectamine® 2000 CD instead of Poly(I:C). Error bars indicate standard errors 
of triplicate wells from three independent experiments. Mock is Poly(I:C) non-
stimulated cells. 
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4.3.5.2 BANP inhibits Poly(I:C)-induced IFN response 
It is known from previous results that stimulation with Poly(I:C) in HEK293 cells 
was able to induce IFN-. This effect was further analysed in cells expressing 
BANP. In brief, BANP or MBP were expressed in HEK293 cells transfected with 
either p125Luc IFN- enhancer plasmid, or p55A2Luc containing repeated PRDII 
elements, and pRL-CMV RLuc reporter (as mentioned in the previous section). The 
total amount of transfected DNA was kept constant at 500 ng by adding empty 
vector backbone, pDEST40. This avoids concentration variables and prevents an 
IFN response resulting from unequal accumulation of plasmids. MBP served as a 
negative control to indicate a successful IFN stimulation. At 24 hr post-stimulation 
with 5 µg/ ml Poly(I:C), the cells were lysed and the luciferase activity was 
measured. The ratio of the over-expressed BANP FFLuc values were calculated 
against the RLuc internal control and normalised to MBP non-stimulated cells.  
In Figure 4.9 (top panel), there was a decrease in FFLuc activity with increasing 
BANP expression. At least a 2.2-fold and 3.8-fold reduction of IFN induction was 
seen (relative to the stimulated MBP control) in cells transfected with 50 and 100 
ng/ ml BANP plasmid, respectively (Student’s t-test, p-values <0.05). A larger 
reduction, 5.3-fold and 6.4-fold was observed in 200 and 500 ng/ ml BANP plasmid, 
respectively (Student’s t-test, p-values <0.05). A similar trend was also observed 
in cells transfected with p55A2Luc as shown in Figure 4.9 (bottom panel). The 
luciferase signals however, were significantly less. Overall, this indicates an 
inhibition of NF-B response with increasing concentrations of BANP. It was also 
clear that there was a high level of IFN- and NF-B induction following 
stimulation with Poly(I:C) in MBP over-expressed samples (Figure 4.9, top and 
bottom panels). This indicates that MBP does not inhibit IFN and NF-B responses, 
thus is a suitable negative control for inhibition. Overall, these findings show that 
overexpression of BANP leads to inhibition of IFN- induction, which suggests BANP 
acts as an IFN- negative regulator in stimulated HEK293 cells.  
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Figure 4.9: Overexpression of BANP inhibits IFN- production. 
Transfected HEK293 cells containing either p125Luc IFN- promoter (top panel) or 
p55A2Luc PRDII elements (bottom panel), with increasing concentrations of BANP 
were stimulated with 5 µg/ ml Poly(I:C) and lysed at 24 hr post-stimulation. The 
luciferase activity was determined using Dual-Luciferase Reporter Assay System. 
Ratio of FFLuc values were calculated against the RLuc internal control and 
normalised by assigning a value of 1 to the level of non-stimulated MBP. Error bars 
indicate standard errors of triplicate wells in three independent experiments. 
Asterisk (*) indicates Student’s t-test, p-value <0.05. 
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4.3.5.3 BANP-NS2A inhibits Poly(I:C)-induced IFN response 
To observe an effect of IFN response in BANP and NS2A co-expression, a similar 
experiment was carried out as outlined above, but in the presence of NS2A. Similar 
to BANP and MBP, NS2A expression construct (pDEST40-NS2A without c-Myc tag) 
was generated in the same vector backbone pDEST40, using the Gateway cloning 
system (Section 2.4.4). Cells were transfected with either BANP and/or NS2A, 
along with the luciferase reporter plasmids p125Luc and pRL-CMV. Due to the low 
luciferase signals obtained from p55A2Luc PRDII plasmid, this construct was 
omitted from further analysis. At 24 hr post-transfection the cells were stimulated 
with 5 µg/ ml Poly(I:C) and lysed the next day, followed by measurement of the 
luciferase activities. The total amount of transfected DNA was kept constant at 
200 ng by adding an empty vector pDEST40. MBP served as a negative control to 
indicate successful type I IFN pathway stimulation by the dsRNA RNA mimic. 
At least a 3.5-fold decrease of FFLuc expression was observed in stimulated BANP 
over-expressing cells relative to its stimulated MBP control (Figure 4.10) 
(Student’s t-test, p-values <0.05), indicating an inhibition of IFN- activity. NS2A 
also showed a small reduction of IFN- induction compared to MBP. NS2A has been 
reported to be an IFN-antagonist (Muñoz-Jordan et al. 2003), thus an inhibitory 
effect is expected. Interestingly, co-expression of both BANP and NS2A diminishes 
IFN- induction though at least in this system no enhancement or additive effect 
is seen. To what effect BANP and NS2A interacts is thus presently not clear, and 
at least in this reporter system not obvious. 
Data from the IFN- experiments (Section 4.3.5.2 and 4.3.5.3) indicate that over-
expression of BANP inhibits the IFN response, which correlates to a similar 
observation with mouse SMAR1 (Singh et al. 2009). Over-expression of SMAR1 
results in a decrease in IB promoter activity upon TNF stimulation, resulting 
in down-regulation of IB transcription. This effect however is reversible using 
siRNA SMAR1 knockdown. Furthermore, SMAR1 over-expression recruits histone 
deacetylase 1 (HDAC1) complex to the MAR-binding sites of NF-B target genes 
and thus decreases gene expression (Singh et al. 2009). Taken together, data from 
this study provide evidence that both BANP-NS2A are responsible for inhibition of 
IFN induction in Poly(I:C)-stimulated cells.   
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Figure 4.10: Co-expression of BANP-NS2A inhibits IFN-.  
Transfected cells were stimulated with 5 µg/ ml Poly(I:C), lysed at 24 hr post-
stimulation and the luciferase activity was determined. Ratio of FFLuc values were 
calculated against the RLuc internal control and normalised by assigning a value 
of 1 to the level of non-stimulated MBP control. Error bars indicate standard errors 
of triplicate wells from three independent experiments. Asterisk (*) indicates 
Student’s t-test, p-value <0.05. 
 
  
0
2
4
6
8
10
12
14
16
18
MBP BANP NS2A BANP+NS2A
Fo
ld
-c
h
an
ge
 o
f 
FF
Lu
c 
ra
ti
o
 n
o
rm
al
iz
ed
 t
o
 
n
o
n
-s
ti
m
u
la
te
d
 M
B
P
non-stimulated
Poly(I:C)-stimulated
*
 152 
 
4.3.5.4 BANP and NS2A inhibits IFN-induced IFN response 
To examine whether a type I IFN response induced by interferons may be affected 
by this interaction or by the two proteins individually, an IFN response was induced 
by treatment with a high concentration of Universal Type I IFN protein units in 
HEK293 cells. This stimulates the IFN response through the JAK-STAT signaling 
cascade after activation of the IFNAR receptor (Ivashkiv & Donlin 2014; O’Neill & 
Bowie 2010).  
DENV proteins NS4B and NS5 were also tested for their IFN inhibitory effect. NS5 
in particular, was used as a control for the IFN stimulation as it should inhibit this 
pathway (Laurent-Rolle et al. 2014; Mazzon et al. 2009; Best et al. 2005). All DENV 
expression plasmids were generated in the same pDEST40 vector to minimise 
variability. The total amount of transfected DNA was kept constant at 200 ng by 
adding empty vector. A similar experiment was carried out as outlined in the 
previous section but pGL4.17-ISREFluc (Table 2.15) was used instead of p125Luc. 
pGL4.17-ISREFluc has an IFN-stimulated gene response element (ISRE) promoter 
expressing FFLuc. HEK293 cells were transfected with the expression plasmids 
(either BANP, MBP, NS2A, NS4B or NS5) along with the luciferase reporter plasmids 
pGL4.17-ISREFluc and pRL-CMV. The cells were treated with 1000 U/ ml Universal 
Type I IFN 24 hr p.t and lysed the next day.  
As shown in Figure 4.11, either BANP alone or the combination of BANP and NS2A 
inhibited IFN- induction (Student’s t-test, p-values <0.05). This indicates 
regardless of the method of IFN- induction (either through Poly(I:C) stimulation 
or IFN treatment), data show consistent inhibition of IFN induction. Again there 
was no combined or additive effect by expressing NS2A and BANP in this assay, as 
strong inhibition was observed. It was also observed that DENV protein NS5 has 
the most inhibitory effect (Student’s t-test, p-values <0.05), followed by NS2A and 
NS4B. NS5 is a known Flavivirus IFN-antagonist and has been reported to inhibit 
JAK-STAT signaling by blocking STAT2 phosphorylation (Best et al. 2005; Mazzon 
et al. 2009). Besides NS5, DENV NS2A and NS4B have also been previously reported 
to inhibit IFN responses (Muñoz-Jordan et al. 2003; Muñoz-Jordán et al. 2005). 
Furthermore, JEV NS2A blocks IFN-induced dsRNA-activated protein kinase R (Tu 
et al. 2012), while KUNV NS2A has also shown to be IFN antagonist (Liu et al. 
2006).   
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Figure 4.11: Inhibition of IFN--mediated gene expression. 
Inhibition of IFN--mediated gene expression by BANP and/or NS2A, NS4B and NS5 
during type I IFN-induced activation. HEK293 cells were co-transfected with 
pGL4.17-ISREFluc FFLuc reporter plasmid, pRL-CMV (RLuc internal control) and 
expression plasmids as follows: BANP, NS2A, NS4B or NS5. MBP was used as a 
negative control for IFN inhibition. The cells were stimulated with Universal Type 
I IFN (1000 U/ ml), lysed at 24 hr post-stimulation and the luciferase activity was 
determined. The ratio of luciferase was calculated and normalised to the level of 
non-stimulated MBP. Data reflects the mean±standard error of triplicates from 
three independent experiments. Asterisk (*) indicates Student’s t-test, p-value 
<0.05. 
  
0
5
10
15
20
25
30
MBP BANP BANP+NS2A NS2A NS4B NS5
Fo
ld
-c
h
an
ge
 o
f 
FF
Lu
c 
ra
ti
o
 n
o
rm
al
iz
ed
 t
o
 
n
o
n
-s
ti
m
u
la
te
d
 M
B
P
non-stimulated
IFN-stimulated
*
 154 
 
4.3.6 Effect of BANP knockdown in DENV infection 
Due to the difficulty in working with the live DENV strains which requires specific 
regulations and safety control measurements in a Containment Level 3 facility (not 
available at the CVR at the time of this work), cell culture-based experiments 
using a DENV sub-genomic replicon were carried out. This study aimed to 
investigate the effect of BANP silencing on translational DENV replicon which may 
indicate its importance in the viral life cycle. Initial experiments focused on 
testing whether the mammalian cell lines were suitable for DENV replicon 
replication. This was followed by optimising the concentration of siRNA BANP to 
achieve knockdown of this protein in the chosen cell line. 
4.3.6.1 Dengue virus replicon 
A sub-genomic DENV-2 NGC-derived replicon expressing FFLuc, pDVPACluc was 
initially tested for luciferase expression in mammalian cells (Section 2.6.3). The 
in vitro transcribed DENV replicon RNA was transfected into BHK-21, A549 and 
HEK293 cell lines using Lipofectamine® 2000 CD, followed by lysing the cells at 24 
hr post-transfection and measuring the FFLuc activity. Although BHK-21 was a non-
human cell line, it was included in this test because of its high transfection 
efficiency which enabled a significant FFLuc expression. As shown in Figure 4.12, 
all cell lines demonstrated higher FFLuc expression in the DENV replicon RNA-
transfected cells compared to the mock-transfected control. BHK-21 gave the 
highest luciferase expression indicating the cells were permissive for replicon 
replication, followed by HEK293 and A549 cells. Due to the relatively higher FFLuc 
expression in HEK293 cells compared to A549 and their previous use in 
experiments, this cell line was therefore selected for subsequent experiments.  
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Figure 4.12: FFLuc expression of DENV replicon in mammalian cell lines. 
The cells were lysed at 24 hr p.t and the luciferase activity was measured. Mock 
was cells transfected with Lipofectamine® 2000 CD alone. Data represent the 
average standard deviation of triplicate samples from three independent 
experiments. 
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4.3.6.2  Replication kinetics of the DENV replicon 
Based on the above results, the replication kinetics of the DENV replicon was 
further tested in BHK-21 and HEK293 cells by a time-course study. Similar 
experiments were performed as detailed above, however the FFLuc activity was 
determined at various time-points; 6, 24, 48, 72, 96 and 120 hr post-transfection, 
which allowed detection of the initiation of replicon replication. In this 
experiment, pDVPACluc was used alongside its derived mutant, pDVW87I, as a 
negative control. pDVW87I has a mutation in NS5 gene (tryptophan to isoleucine 
at the amino acid position 87) that allows transcription, but prevents translation 
of the viral transcripts to NS proteins (Massé et al. 2010).  
In both cell lines, FFLuc activity of wild-type pDVPACluc and the mutant pDVW87I 
was observed at its highest peak as early as 6 hour post-transfection (Figure 4.13, 
Figure 4.14). This corresponded to the direct translation of DENV NS proteins 
coming from the input in vitro-transcribed replicon RNA. At 96-120 hr post-
transfection, a low level luciferase peak of the wild-type pDVPACluc replicon was 
detected in BHK-21, indicating a replication activity (Figure 4.13). This however, 
was not observed in HEK293 cells (Figure 4.14), which could be due to the ability 
of cells to induce immune responses against the replicon preventing its 
replication. In both cell lines, no FFLuc expression derived from replication was 
observed in the pDVW87I mutant at the given time-points, as expected (Figure 
4.13, Figure 4.14).  
The overall results from this study concluded an absence or very poor replication 
of the wild-type DENV replicon in HEK293 cells. Although it was possible to carry 
out the studies by examining the initial FFLuc expression level, the lack of suitable 
DENV construct for negative control (a failure in generating a DENV GDD mutant 
replicon in-house and inability to detect the DENV anti-genome), suggested that 
the experiment was not achievable as planned. A collaborative project was 
therefore set up with Dr. Andrew Davidson and his team at the University of Bristol 
to determine the effect BANP had on DENV replication using a live DENV strain, 
from which all our DENV proteins were derived. These subsequent experiments 
are described in Section 4.3.7.   
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Figure 4.13: Expression of FFLuc in BHK-21 cells.  
The cells were transfected with in vitro transcribed DENV replicon RNA (either the 
wild-type pDVPACluc or mutant pDVW87I), and cells were harvested at various 
time-points (6-120 hr p.t) and luciferase activity was measured. Data reflects the 
mean±standard error of triplicates from three independent experiments. 
 
Figure 4.14: Expression of FFLuc in HEK293 cells.  
The cells were transfected with in-vitro transcribed DENV replicon RNA (as above) 
and the luciferase activity was determined at time points as indicated. Data 
reflects the mean±standard error of triplicates from three independent 
experiments.  
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4.3.6.3 BANP knockdown 
BANP knockdown in HEK293 cells was tested by transfecting a varying 
concentration of BANP siRNAs (ON-TARGETplus SMART pool® consisting a mixture 
of four individual siRNA) (Section 2.7.3). A non-targeting control siRNA for E. coli 
-galactosidase (-gal), was used in parallel as a negative control. At 24 hr p.t, 
the cells were lysed and protein levels analysed by immunoblotting.  
Down-regulation of BANP was observed in BANP siRNA-transfected cells compared 
to mock-transfected and control -gal siRNA-transfected cells (Figure 4.15). The 
signal intensity of BANP was quantified using the ImageJ software and the relative 
percentage of BANP was normalised to the housekeeping Actin protein level. The 
highest knockdown of the target protein was observed with 100 nM BANP siRNA 
(73.8% reduction) compared to control.  
 
 
Figure 4.15: Validation of BANP knockdown in HEK293 cells. 
Validation of BANP knockdown in HEK293 cells by using different concentration of 
BANP siRNA. Lane 1 is mock-transfected cells representing endogenous BANP, lane 
2 is overexpressed BANP, lanes 3-5 are siRNA BANP; 10 nM, 50 nM and 100 nM, 
respectively. Lanes 6-8 are -gal siRNA negative controls; 10 nM, 50 nM and 100 
nM, respectively. Actin was used as a loading control. 
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4.3.7 Effect of BANP knockdown and overexpression in DENV production 
4.3.7.1 Dengue virus infection and effect of BANP 
This study aimed to determine the effect of BANP knockdown on DENV replication. 
Due to the poor replication of the DENV replicon in HEK293 cells (Section 4.3.6.2), 
these experiments were carried out using the live DENV-2 NGC strain. These 
experiments were performed by Amjad Yousuf in a Containment Level 3 facility, 
University of Bristol. In brief, HEK293 cells were transfected with BANP siRNA or 
expression plasmid. After an overnight incubation at 37 °C, the cells were infected 
with DENV-2 NGC at MOI 10 (Section 2.6.7). Transfection of the BANP siRNA was 
repeated in the knockdown cells the next day to ensure continuous BANP 
knockdown. Cells were lysed in TRIzol® reagent at 3 days post-infection. Each cell 
lysate was pooled from three-well replicates into a single tube and sent to Glasgow 
for further analysis.  
4.3.7.2 Gene expression analysis 
RNA was isolated from DENV-infected cell lysates (Section 2.2.1) and processed 
for gene expression studies as described (Section 2.7.7). Primers and fluorophore-
labelled TaqMan probes targeting the DENV-2 capsid region (Callahan et al. 2001) 
were used. The human HPRT1 housekeeping gene was selected as an endogenous 
control as it has been previously validated for expression stability (Żyżyńska-
Granica & Koziak 2012). The RNA samples were subjected to cDNA synthesis 
followed by qRT-PCR which was run in triplicates on a 96-well plate. As shown in 
Figure 4.16, DENV capsid gene expression was higher in BANP knockdown cells 
than the -gal negative control knockdown. This indicated a 1.6-fold difference 
between the two samples. The expression of DENV in both the control knockdown 
and the mock DENV-infected cells was fairly consistent, given only a slight 
difference in their gene expression. DENV was detected at a very high level in 
BANP overexpressing cells, giving a 3-fold increase over mock DENV-infected cells. 
This finding was very interesting however it remained inconclusive as there was 
indeed no negative control (transfection with empty plasmid) for the 
overexpressed BANP. This experiment therefore needs repeated. Clearly at 
present, the results from BANP knockdown and overexpression experiments would 
appear to be contradictory and the experiment needs to be repeated under better 
conditions. 
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Figure 4.16: DENV replication in BANP overexpression and knockdown.  
The data represents average viral copy numbers from triplicate wells of qRT-PCR 
reactions, with error bars showing standard errors. The viral copy numbers were 
generated from a standard curve based on cycle threshold (Ct) values and 
normalised to the human HPRT1 internal control. Data obtained in this study was 
derived from pooled samples in a single experiment. 
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4.3.7.3 mRNA expression of BANP 
To investigate possible reasons for the inconclusive results, we sought to analyse 
the BANP knockdown efficiency. The protein cell lysates infected with DENV 
however, were unavailable due to the presence of infectious virus. BANP 
knockdown was therefore validated by analysing mRNA gene expression using the 
RNA samples obtained from Bristol. cDNA was synthesised from the RNA samples 
using oligo(dT) (Section 2.2.2) and subsequently amplified by standard PCR using 
the specific BANP primers. As shown in Figure 4.17 (lanes 1, 2, 4 and 5), the BANP 
fragment (501 bp) was not detected in all samples which made the analysis of 
knockdown inconclusive. Amplified BANP fragment was only detected in the cells 
transfected with BANP plasmid which results in a high mRNA expression (Figure 
4.17, lane 3). The housekeeping human gene Actin (436 bp) was consistently 
observed in all samples. 
 
 
 
Figure 4.17: mRNA expression of BANP knockdown.  
Amplified samples are: mock siRNA non-infected (lane 1), mock siRNA infected 
with DENV (lane 2), over-expressed BANP infected with DENV (lane 3), BANP 
knockdown infected with DENV (lane 4) and -gal knockdown (BANP non-targeting) 
infected with DENV (lane 5). mRNA expression of the human Actin housekeeping 
gene corresponding to all samples are also shown (lanes 1-5 labelled Actin). –ve is 
a PCR water control. 
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4.4 Discussion 
Identification of virus-targeted host proteins provides a better understanding of 
the mechanisms involved in regulating or fostering virus infection. Our previous 
Y2H study identified BANP as a potential DENV NS2A interacting partner. A smaller 
NS2A protein fragment (NS2A187F) has also been shown to interact with BANP and 
hence indicates a potential NS2A-BANP interaction binding site. Although BANP 
has 81.3% amino acid similarity with the mouse homolog SMAR1, the protein is not 
well-characterised and it is not known to possess similar functional properties as 
SMAR1. SMAR1 is a multi-functional protein and has been reported to modulate 
cell cycle, apoptosis, DNA damage and several pathways involving tumorigenesis 
(Malonia et al. 2011). As of yet, SMAR1 has not been implicated in any viral life 
cycle except that it can interfere with the LTR-mediated transcription of HIV-1 
(Sreenath et al. 2010). SMAR1 has also been shown to down-regulate the NF-B 
signalling through the proposed model described in Figure 4.1 (Singh et al. 2009). 
In this study, interaction between BANP and NS2A was further confirmed, and its 
potential role in regulating NF-B pathway (as similar to SMAR1) was investigated 
(Malonia et al. 2011; Singh et al. 2009).  
BANP was first tested for expression in HEK293 cells using a V5-tagged BANP 
construct. Two bands were detected by Western blot using anti-BANP antibody, 
which indicates the protein maybe present as isoforms.This could be explained by 
the fact that BANP/SMAR1 gene is able to go through alternative splicing which 
produces transcript variants, and subsequently translated into different protein 
isoforms (Kaul et al. 2003; Chattopadhyay et al. 2000b). In the previous chapter, 
interaction between BANP and NS2A has been validated by LUMIER assay showing 
promising results. This interaction was further confirmed using similar co-IP pull 
down assay, an efficient technique to investigate protein interactions (Bonifacino 
et al. 2001), and the protein lysates were used for detection by Western blots. 
Results from this study demonstrated that BANP was indeed observed in the NS2A 
pull-down but not detected during the absence of NS2A. Although NS2A187F was 
not tested in this assay, this finding thus confirms a physical interaction exists 
between BANP-NS2A. There was however no pull down of the BANP native protein 
by NS2A, which could be due to its presence is insufficient for precipitation with 
IgG-coated beads or it binds weakly.  
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Observation by immunofluorescence staining revealed the native BANP was 
equally dispersed intracellularly, whereas overexpression of BANP causes 
accumulation of the protein in the cell nucleus. This is consistent with the 
expression of SMAR1 (Kaul et al. 2003; Chaudhary et al. 2014), suggesting BANP 
may be involved in a specific cell nuclear activity. It has also been shown that 
SMAR1 is found in the cytoplasmic fractions of various cancer cell lines, and able 
to interact with a member of Aldo-keto reductase family, AKR1a4 (S. Singh et al. 
2010). Disruption of the SMAR1-AKR1a4 interaction by DNA damage results in 
nuclear translocation of SMAR1 and restoration of AKR1a4 function in scavenging 
free radical waste in the cytoplasm. Hence, this supports the findings that 
endogenous BANP is localised in both the cell nucleus and cytoplasm.  
From the IF staining, DENV NS2A was exclusively localised in the cell cytoplasmic 
region. Although NS2A appears to be present in the cytoplasm where cytoplasmic 
BANP is localised, it is difficult to define if they co-localised, due to the narrow 
cytoplasmic space of HEK293 cells. In addition, there was no detection of native 
BANP in the NS2A pull down during co-IP, which indicates there may not have been 
a specific interaction, perhaps due to partitions in cellular compartments. 
Although there was no NS2A co-localisation with the over-expressed nuclear BANP, 
this does not necessarily indicate that interactions between BANP and NS2A are 
artefactual. Is it also possible that the interaction may have been affected by 
alteration in subcellular localisation. In Y2H, both proteins were directed to the 
nucleus via nuclear localisation signal on GAL4 system. However in subsequent 
expression by IF and co-IP, other signals may have directed the proteins to 
different cellular compartments where the proteins might never encounter each 
other. The properties of BANP clearly need further investigations to understand 
these observations. It is at present not clear why overexpression of BANP leads to 
re-distribution unless this is linked to transfected DNA of the expression vector 
itself. In the future, stable cell lines for example expressing BANP from retroviral 
constructs could be used to verify these processes. 
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While SMAR1 over-expression has an important role in the cellular transcriptional 
regulation (Malonia et al. 2011), the potential role of BANP and its involvement in 
DENV infection is unknown. Previous studies have indicated that SMAR1 plays a 
role in down-regulation of NF-B in cancer cells (Singh et al. 2009). Although NF-
B is known to play a role in immune responses, it has many other roles in cellular 
processes including cancer (Hoesel & Schmid 2013; Tergaonkar 2006). In this 
study, the potential role of BANP in regulating type I IFN response and NF-B was 
studied using a luciferase-based reporter gene assay. Plasmid-encoded luciferase 
gene controlled by the entire IFN- promoter (p125Luc) or repeated PRDII 
elements responsive to NF-B (p55A2Luc) were used.  
IFN-β expression has been shown to be induced by dsRNA or other products of virus 
infection (Jiajia Liu et al. 2012). A synthetic dsRNA mimic, Poly(I:C), known to 
induce a strong IFN-β response was used in this study (Reimer et al. 2008; 
Matsumoto & Seya 2008; Kumar et al. 2006). Transfection of Poly(I:C) into cells 
resembles intracellular dsRNA generated during virus infection, which results in 
potent stimulation of the IFN-β promoter (Li et al. 2005). Within the cell, Poly(I:C) 
is recognised by cytoplasmic receptors such as RIG-I and MDA-5. Upon recognition 
of viral components, both RIG-I and MDA5 activate MAVS on the mitochondrial 
membranes. MAVS interacts with STING/MITA and recruits TRAF3 and TRAF6 
resulting in production of IFN response (Liu et al. 2013). Poly(I:C) is also recognised 
by TLR3 and activates IRF3 leading to the production of type I IFN, or through a 
second pathway involving TNF receptor-associated 6 (TRAF6) which activates the 
transcription factors NF-B and activator protein-1 (AP-1) (Reimer et al. 2008; 
Kawai & Akira 2008; Yamamoto et al. 2003).  
Expression of IFN is tightly controlled by transcription factors, which are activated 
upon recognition of viral components by cytoplasmic receptors. In typical NF-B 
signalling pathway, NF-B transcription factors translocate from the cytoplasm to 
the nucleus and bind to the PRDII elements within the IFN- promoter, and 
subsequently activate the expression of IFN. Transcriptional activation of B 
target genes which includes the IFN- can lead to substantial production of IFN 
(Pahl 1999). Results from the assay indicate that expression of IFN- and NF-B is 
successfully induced by Poly(I:C) and is repressed in non-stimulated cells. Further 
tests in the presence of increasing BANP indicate that BANP is capable to inhibit 
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the IFN- and NF-B induction. The NF-B luciferase signal is less compared to 
IFN- as it detects a component of the IFN induction pathway. Nonetheless, the 
fact that NF-B is inhibited during BANP over-expressed signifies the importance 
of BANP in NF-B regulation. BANP inhibits IFN- activation; the same is true for 
NS2A but the effect of the interaction of both is not clear. These observations 
were supported by previous findings, as it has been shown that SMAR1 interacts 
with HDAC1 and NF-B subunits to repress transcription of NF-B target genes 
(Singh et al. 2009). Furthermore, SMAR1 inhibits TNF- mediated induction of IL-
8 mRNA through NF-B dependent, in which the knockdown of SMAR1 using shRNA 
resulted in an increase in IL-8 (Malonia et al. 2014).  
Further studies with type I IFN-induced IFN responses show an inhibition of the 
type I IFN response, during expression of BANP and NS2A independently and during 
co-expression of both BANP-NS2A, which demonstrated this inhibition is 
independent of NF-B signaling. Through type I IFN stimulation via the IFNAR 
receptor, the JAK/STAT signaling cascade was activated resulting in nuclear 
translocation and binding of phosphorylated STAT to the ISRE promoter and 
transcription of IFN-stimulated genes. While BANP is inhibiting this process, and 
NS2A also inhibits these signalling events, the interaction of both BANP-NS2A 
modulating this event is not clear. Perhaps other pathways are affected by this 
interaction or the signalling assay is not sensitive enough to pick up differences, 
which requires further experiments.  
Poly(I:C)-mediated IFN response has been shown to induce IRF3 and NF-B 
signalling which activates the NF-B and IFN target genes leading to the production 
of type I IFN (Reimer et al. 2008). In this study, BANP could possibly repress the 
transcriptional activation of NF-B target genes, which also include the IFN- 
promoter genes. This mechanism is based on the recruitment of SMAR1-HDAC1-
p65/p50 co-repressor complex that binds to the MAR elements, thus resulted in 
an inhibition of IFN as described previously (Singh et al. 2009). In the IFN-mediated 
IFN response, the ectopic IFN- induction is recognised by IFNAR which 
subsequently activates the JAK/STAT pathway. Activation of this pathway triggers 
the ISRE activation, resulting in production of type I IFN and induction of an 
antiviral state. In this study however, an activation of the JAK/STAT pathway by 
treatment with the Universal Type I IFN Alpha in the presence of overexpressed 
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BANP resulted in an inhibition of IFN. The mechanism by which BANP governs this 
inhibition is unknown, which suggests other pathways or interacting molecules 
may be involved in this event. The inhibition of IFN response by DENV NS2A 
correlates to previous studies as the protein has been implicated in inhibition of 
IFN signalling (Muñoz-Jordán et al. 2005; Muñoz-Jordan et al. 2003). Furthermore, 
the role of NS2A as an IFN-antagonist has also been reported in WNV and KUNV 
(Liu et al. 2006; Liu et al. 2004).  
Although BANP is capable of inhibiting an IFN response (through both NF-B-
mediated and JAK/STAT), the precise mechanism of inhibition and how its 
interaction with DENV might govern the inhibition is still unclear. Since SMAR1 is 
known as a tumour suppressor and all SMAR1 experiments have been carried out 
by researchers in tumour cell lines (which express less SMAR1), the precise role of 
BANP and how it regulates biological function in non-tumour cells is not known. 
Another possible explanation is that BANP could be involved in maintaining the 
intracellular conditions consequent to cellular stress. Similar to SMAR1, BANP is 
thought to be capable of regulating cell cycle arrest and DNA repair via a 
mechanism involving HDAC1 and p53 (Sinha et al. 2010). It has been shown that 
following a mild stress or DNA damage, SMAR1 is activated in association with 
HDAC1 and p53 tumour suppressor and recruited to the MAR sites upstream of 
promoter p53 apoptotic targets, Bax and Puma, leading to cell cycle arrest. This 
process inhibits apoptosis and favours cell cycle arrest for DNA repair. However, 
in a case of severe DNA damage, SMAR1 can activate Bax and Puma genes which 
leads to induction of apoptosis (Sinha et al. 2010). It is also possible that the use 
of a whole virus instead of a single NS2A protein might be informative as other NS 
proteins are likely to participate during viral infection and the effect can be 
assessed in the presence of BANP. Hence, this would be useful to evaluate the 
global IFN response as a result of BANP over-expression.  
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To further explore the role of BANP in DENV replication, an in vitro-transcribed 
RNA of sub-genomic DENV-2 NGC replicon with FFLuc reporter (pDVPACluc), was 
first tested in BHK-21, HEK293 and A549 cells. After 24 hr p.t, the replicon shows 
the highest FFLuc activity in BHK-21, followed by HEK293 and A549, corresponding 
to the translation of viral NS proteins. BHK-21 is recognised as having a defect in 
IFN production (Otsuki et al. 1979), which could be the reason why the cells 
exhibited the highest viral translational activity. In contrast, A549 cells are known 
to be highly IFN-/ inducible (Tanabe et al. 2003). This may explain why they do 
not support translation. Given the aim of this study to assess the replication of a 
DENV replicon that mimics viral replication, further analysis was performed by 
transfecting the in vitro-transcribed replicon RNA into BHK-21 and HEK293, and 
measuring the FFLuc activities within an extended period. Although BHK-21 cells 
are known to be IFN-defective, the replicon was found to replicate very poorly. 
There was also no replication of the replicon in HEK293 which could be due to its 
capability of inducing an IFN response. As HEK293 are the required cells for use in 
the downstream experiments, it was decided to perform experiments using the 
live DENV NGC strain with collaborators at the University of Bristol.  
In order to determine the importance of BANP in the DENV life cycle, experiments 
were carried out to test viral replication upon BANP gene silencing. Analysis of 
DENV replication was achieved by detecting the capsid gene expression and 
revealed a remarkably high level of virus replication during BANP overexpression 
(relative to DENV alone). This could be due to the down-regulation of IFN response 
regulated by BANP, as well as the existing IFN inhibition effect induced by the high 
virus MOI. However, the absence of a negative control (empty vector) within this 
experiment, makes the results at present inconclusive. It was also clear that the 
replication of DENV in BANP knockdown cells was higher (by 1.6-fold) compared 
to its knockdown control which has a basal level of native BANP. Results obtained 
from this study are therefore at present inconclusive. It is important to perform a 
more detailed study of the biology of BANP before these experiments can be 
redesigned. BANP seems to respond or react differently depending on conditions. 
Nonetheless its negative regulatory activity on type I IFN signalling makes it an 
interesting target for future experiments. 
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4.5  Conclusion 
In this study, interaction between BANP and DENV NS2A was confirmed by co-IP 
pull-down assay. Further IF analysis has shown the cellular localisation of NS2A 
with BANP in the cytoplasm or ER/Golgi, however this is uncertain due to the small 
cytoplasmic space of HEK293 cells. It is clear that BANP is capable of inhibiting 
NF-B and IFN response similar to NS2A, and this inhibition is retained during co-
expression of both proteins within the cells, however the mechanism of BANP-
NS2A interaction that contribute to the IFN inhibition requires further analysis. 
Besides IFN signalling, other cellular processes of BANP such as regulation of the 
cell cycle, DNA damage or apoptosis may be alternate explanations for the 
interaction with NS2A. Due to the fact that the DENV replicon did not replicate in 
HEK293 cells, further experiments using the infectious DENV were carried out. 
There were however inadequate controls which rendered the data inconclusive. 
Thus these experiments require redesign and repetition. Although the importance 
of BANP in DENV life cycle is as yet unknown, further experiments are called for 
to indicate its function in human cells. 
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5 CHAPTER 5: FUNCTIONAL ANALYSIS OF Kv1.3 IN DENGUE VIRUS 
INFECTION 
 Introduction 
 Voltage-gated potassium channel Kv1 
Kv1 shaker-related delayed rectifier sub-family, comprising of at least six genes 
(Kv1.1, Kv1.2, Kv1.3, Kv1.4, Kv1.5 and Kv1.6) which exhibit distinct physiological 
roles (Pongs et al. 1988; Chandy 1991). This protein family shares a common pore-
forming -subunit comprising of six transmembrane segments (S1-S6) and a P loop 
region containing K+ selectivity sequence (Miller 2000; Kreusch et al. 1998) (Figure 
5.1). The fourth segment (S4) has positively charged amino acid residues at every 
third position which acts as an intrinsic voltage sensor that regulates protein 
conformational changes. Kv proteins consist of four -subunits arranged as homo- 
or heterotetramers around a central pore that associates with different types of 
peripheral -subunits (Sokolov 1997; Kreusch et al. 1998). Upon stimulation and 
membrane depolarisation, functional K+ channels generate K+ diffusion potentials 
across the cell membrane, which in turn facilitate the influx of calcium ions (Ca2+) 
to maintain the cell resting membrane potential (Lin 1993). This leads to 
modulation of Ca2+ signalling and activation of lymphocytes in the antigen-driven 
activation of T lymphocytes (Nicolaou et al. 2009; Lewis & Cahalan 1995). 
 Potassium-gated channel Kv1.3 
Screening of the DENV-2-targeted human proteins by Y2H identified two potassium 
ion (K+) channel proteins; Kv1.3 and Kv9.2 (KCNA3 or KCNS2), as interacting 
partners for DENV-2 NS2A. Both proteins belong to the voltage-gated K+ channel 
(Kv) family, which plays an important role in regulating passive flow of K+ upon 
changes in cell transmembrane potential (Yellen 2002; Bezanilla 2000). Kv1.3 was 
first described in human T lymphocytes (Cahalan et al. 1985), whereas Kv9.2 was 
identified more recently and is known to act through co-assembly with the Kv2 
channel subunit (Salinas et al. 1997). There is however limited knowledge of Kv9.2 
function in modulating the Kv2 channel. Kv1.3 in contrast, has been a subject of 
many medical and scientific studies and is reported to be involved in T lymphocyte 
proliferation and functional Kv in platelets (Panyi et al. 2004; McCloskey et al. 
2010). Previous studies have demonstrated the activation of T lymphocytes and 
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macrophages upon DENV infection and a significant decrease in the number of 
platelets in dengue patients (Kurane et al. 1991a). Since Kv1.3 channels are highly 
expressed in lymphocytes and platelets, which may contribute to the progression 
of the disease, further investigations are required to evaluate the channel 
association with DENV-2 infection. 
 
 
Figure 5.1: Schematic diagram of a voltage-gated K+ channel.  
Figure denotes: (a) an -subunit of Kv, (b) a tetrameric structure comprising of 
four -subunits forming Kv channel. Six transmembrane domains (S1-S6) and the 
P loop region (in red) are shown. This figure is adapted and re-drawn from Judge 
& Bever 2006. 
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Besides expression in T lymphocytes (Cahalan et al. 1985), Kv1.3 is also expressed 
in other immune cells, such as B-cells and macrophages (Vicente et al. 2006; Wulff 
et al. 2004), and other types of tissues including the brain, kidney and epithelia 
(Grunnet et al. 2003; Gazula et al. 2010; Yao et al. 1996). Enhanced expression of 
Kv1.3 has been previously reported in cancer cells, although the level of Kv1.3 
expression does not correlate with the stage of tumour malignancy (Preußat et al. 
2003). Notably, knockdown of Kv1.3 by gene silencing in many types of cancer 
cells resulted in inhibition of cell proliferation in vitro and in vivo and activation 
of the cellular caspase pathway, leading to apoptosis (Wu et al. 2013; Jang et al. 
2011). Abolishment of  Kv1.3 in gene knockout mice resulted in other interesting 
phenotypes including an increased metabolic rate and enhanced cellular anion 
currents to compensate for the Kv1.3 depletion (Xu 2003; Koni et al. 2003). Several 
K+ channel blockers, such as those derived from scorpion toxins; Margatoxin (MgTx) 
and Charybdotoxin (Ctx), have been widely used to inhibit Kv1.3 expression (Hu 
et al. 2013; Sands 1989). Blockade of Kv1.3 by these toxins is able to suppress 
proliferation in cancer cell lines, suggesting the potential use of Kv1.3 as a target 
for cancer therapy (Comes et al. 2013; Jang et al. 2009; Felipe et al. 2012).  
Although there is no known mechanism describing the specific involvement of 
Kv1.3 in DENV infection at present, several reports indicate its association with 
HIV-associated neurocognitive disorders. Data suggest an up-regulation of Kv1.3 
and increase in K+ current was induced by HIV type1 surface subunit glycoprotein 
120 (gp 120) in microglia leading to neurotoxicity (Xu et al. 2011; J Liu et al. 
2012). Similar observations in Kv1.3 using HIV-1 Tat (HIV transactivator of 
transcription) protein induced apoptosis via activation of the p38 mitogen 
activated protein kinase (MAPK) signaling (J. Liu et al. 2013). Further to this, other 
K+ channels have been described participating with virus infection. For instance, 
the HIV-1 surface subunit glycoprotein 120 (gp 120) envelope protein has been 
shown to bind to the cytoplasmic C-terminus of a K+ channel BEC1 (brain-specific 
ether-a-go-go-like channel 1) (Herrmann et al. 2010). As a result, the channel 
activity was suppressed which prevented the release of virus into the supernatant 
(Herrmann et al. 2010). It is also demonstrated that Kv2.1 has been a target for 
HCV replication. During virus infection, this channel is phosphorylated and 
translocated to the cell membrane which mediates an outward K+ current, 
resulting in the induction of apoptosis (Redman et al. 2007). It is interesting 
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however, that HCV NS5A is capable of modulating the function of Kv2.1, inhibiting 
apoptosis through modulation of MAPK signaling (Mankouri et al. 2009).  
Severe illnesses resulting from DENV infection are characterised by haemodynamic 
disturbances, increased vascular permeability, bleeding and shock (WHO, 1997). 
These clinical features are commonly associated with thrombocytopenia and 
platelet dysfunction which greatly impact progression of the disease (Schexneider 
& Reedy 2005; de Azeredo et al. 2015). The mechanisms underlying 
thrombocytopenia during DENV infection are poorly understood, however 
accumulating evidence suggests the suppression of bone marrow, destruction of 
platelets and alteration in platelet functions (Michels et al. 2014; Noisakran et al. 
2012; Alonzo et al. 2012; Honda et al. 2009). More recently, gene expression and 
patch-clamp analysis revealed that Kv1.3 represents the Kv subunit in human 
platelet and megakaryocytes which are responsible for the K+ conductance and 
resting potential of platelets (McCloskey et al. 2010). These findings are 
interesting which suggest that Kv1.3 is likely to contribute to the platelet 
dysfunction during DENV infection. This study aimed to validate the interaction 
between DENV-2 NS2A and Kv1.3, as detected in previous chapter by Y2H and 
LUMIER assay. The importance of Kv1.3 will be investigated in its involvement with 
DENV-2 infection. 
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 Objectives 
 
1. To confirm the interaction of Kv1.3 and NS2A.  
2. To determine the cellular localisation of Kv1.3 and NS2A. 
3. To determine the viability of cells during overexpression of Kv1.3. 
4. To investigate the effect of Kv1.3 to DENV-2 replication.  
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 Results 
 Confirmation of Kv1.3-NS2A interaction 
 Use of Kv1.3 expression construct 
An interaction between Kv1.3 and NS2A has been shown by Y2H and LUMIER assay 
(Section 3.3.2 and 3.3.3). To further validate this interaction by co-
immunoprecipitation/pull-down assay, an EGFP-tagged construct expressing Kv1.3 
(a kind gift from Jamel Mankouri, University of Leeds), was used. This construct 
contained rat Kv1.3 full length coding region (GenBank accession no. M30312.1) 
fused to an EGFP reporter at the N-terminus. The gene encoded 525 amino acids 
resulting 89.1% protein similarity with the human Kv1.3 (NP_002223.3).  
Kv1.3 expression was initially tested by transfecting the construct into HEK293 
cells and immunoblotting using anti-Kv1.3 antibody (as described in Section 2.3.5). 
An empty vector pEGFP-C1 was used as an EGFP expression control. The western 
blot revealed Kv1.3 expression as a fusion with EGFP at 84 kDa (Figure 5.2a). A 
protein band at 58 kDa was also detected in all protein samples corresponding to 
a monomeric Kv1.3 subunit (lanes 1-3), suggesting the presence of endogenous 
Kv1.3 as previously reported (Holmes et al. 1996; Cai & Douglass 1993). A higher 
MW protein ~168 kDa was observed in Kv1.3-transfected cells which could be due 
to dimerisation of Kv1.3. Monomeric, dimeric and tetrameric forms of Kv1.3 have 
been previously demonstrated (Gulbins et al. 2010). Further analysis using anti-
EGFP (Figure 5.2b) similarly detected the presence of Kv1.3-EGFP (84 kDa) (lane 
3). Cells transfected with empty EGFP plasmid expressed EGFP (26 kDa) (lane 2) 
as expected, which was absent in mock (lane 1). 
In order to confirm the presence of endogenous Kv1.3 in HEK293 cells, RNA was 
extracted from Kv1.3-transfected cells and subjected to mRNA expression analysis 
by semi-quantitative RT-PCR. The amplified PCR product show an expected 138 
bp fragment (Figure 5.3, lane 1 to 3), indicating the endogenous Kv1.3. Although 
the expression of Kv1.3 genes at the mRNA level does not necessarily indicate 
translation of the corresponding protein, the data support the presence of 
endogenous Kv1.3 as shown by Western blot. The overall results conclude that 
Kv1.3 is successfully over-expressed, while the endogenous forms are present at 
detectable levels in HEK293 cells.  
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Figure 5.2: Expression of Kv1.3-EGFP and its native form in HEK293 cells.  
Dimeric Kv1.3 is also shown. The proteins were detected by immunoblotting using 
(a) anti-Kv1.3 and (b) anti-EGFP antibodies. Each figure shows: mock (lane 1), 
EGFP (lane 2) and Kv1.3-EGFP (lane 3). Arrow indicates the MW size of proteins in 
kDa. Actin was used as a loading control. 
 
 
Figure 5.3: mRNA gene expression of endogenous Kv1.3 by RT-PCR.  
Figure denotes cells transfected with the following plasmids: Kv1.3-EGFP (lane 1), 
empty EGFP (lane 2), mock-transfected endogenous Kv1.3 (lane 3), and mock-
transfected (without SuperScript® II) as a negative control for RT-PCR (lane 4). A 
100 bp DNA ladder (New England Biolabs) is shown. Arrow indicates the size of 
amplified products in basepair. 
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 Co-immunoprecipitation of Kv1.3 and NS2A 
Kv1.3 was further tested for interaction with DENV-2 NS2A by co-
immunoprecipitation/pull-down assay as described in Section 2.7.2. EGFP-tagged 
Kv1.3 (as above) was co-expressed with Protein A-tagged NS2A and lysed 24 hour 
p.t. The cell lysates were immobilised on IgG-coated magnetic beads followed by 
several washing steps and subjected to immunoblotting using anti-EGFP. Empty 
EGFP co-expressed with Protein A-tagged NS2A was run as a negative control. 
Based on the western blot probed with anti-EGFP, Kv1.3-EGFP was shown to co-
precipitate with NS2A and was present in the NS2A pull-down lane at the expected 
size (84 kDa) (Figure 5.4, lane 4). There was no detection of EGFP in the NS2A pull 
down of co-expressed Protein A-NS2A and untagged EGFP (Figure 5.4, lane 3), 
which indicates NS2A does not co-precipitate with EGFP. This ruled out the 
possibility that EGFP binds to NS2A instead of Kv1.3. 
While it has been shown that NS2A was capable to interact with the recombinant 
Kv1.3-EGFP, further analysis was performed to investigate if NS2A could interact 
with the native Kv1.3. Pull-down proteins and cell lysates were subjected to 
immunoblotting on the same membrane and probed using anti-Kv1.3 antibody. 
Interestingly, the native Kv1.3 (58 kDa) was captured by NS2A in all pull-down 
samples (Figure 5.5a, lane 2-4, second arrow). However, the band detection was 
very poor in lane 4 and there was no expression of the recombinant Kv1.3-EGFP 
(84 kDa) in either the pull-down or cell lysates (Figure 5.5b, lane 4, first arrow), 
which indicated the transfection did not work properly. It was also clear that the 
native Kv1.3 was not detected in the pull-down sample of mock (Figure 5.5a, lane 
1, second arrow), due to the absence of NS2A to mediate the interaction. Taken 
together the results obtained from Y2H, LUMIER assay and current co-IP/pull-down 
assays using EGFP and Kv1.3 antibodies lead to the conclusion that NS2A interacts 
with Kv1.3. 
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Figure 5.4: Interaction of Kv1.3-EGFP and NS2A by co-IP/pull-down assay.  
Proteins were harvested from transfected-cells and captured by IgG-coated 
magnetic beads. Protein A-tagged NS2A was used to pull-down proteins and were 
detected with anti-EGFP, analysed by immunoblotting. Figure indicates: mock 
(lane 1), Protein A-NS2A (lane 2), co-expression of Protein A-NS2A and EGFP (lane 
3), co-expression of Protein A-NS2A and Kv1.3-EGFP (lane 4), and empty Protein 
A (lane 5). Cell lysates probed with anti-c-Myc indicate the detection of NS2A. 
Actin was used as a loading control. 
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Figure 5.5: Interaction of Kv1.3 and NS2A detected with anti-Kv1.3 by co-
immunoprecipitation/pull-down assay.  
Proteins were harvested from transfected-cells and captured by IgG-coated 
magnetic beads. The pull-down proteins (a), and cell lysates (b), were subjected 
to immunoblotting and detected using anti-Kv1.3 antibody. Each figure indicates: 
mock (lane 1), Protein A-NS2A (lane 2), co-expression of Protein A-NS2A and EGFP 
(lane 3), co-expression of Protein A-NS2A and Kv1.3-EGFP (lane 4). Top arrows 
indicate overexpressed Kv1.3, bottom arrows indicates the native Kv1.3. Actin was 
used as a loading control.  
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 Cellular localisation of Kv1.3 and NS2A 
It is important to know where Kv1.3 resides within the cell as this may provide 
insights into the protein function. To determine the cellular localisation of Kv1.3, 
EGFP-tagged Kv1.3 was expressed in HEK293 cells and the protein localisation was 
examined through EGFP imaging by confocal microscopy.  
Cells transfected with an EGFP plasmid construct (500 ng) showed a disperse 
intracellular distribution of EGFP across the cell cytoplasm (Figure 5.6a, left 
panel). In contrast, cells transfected with Kv1.3-EGFP plasmid (500 ng) 
demonstrated the expression of Kv1.3 mainly on the plasma membrane 
surrounding the cells (Figure 5.6a, right panel). Due to the fact that HEK293 cells 
contain a small cytoplasmic space, over-expression of proteins also led to patches 
of green spots resulting from accumulation of EGFP in the cell cytoplasm or 
ER/Golgi, which could also be due to cleavage of EGFP. The location of Kv1.3 
surrounding the cell is consistent with previous observations on the presence of 
Kv1.3 on the plasma membrane (Szabò et al. 2005; Panyi et al. 2003). More 
recently, Kv1.3 was identified in the nuclear fraction of several types of cancer 
cells and in human brain tissues, which suggests its potential role in the regulation 
of the nuclear membrane potential and activation of transcription factors (Jang 
et al. 2015).  
It was also clear in this study that endogenous Kv1.3 was expressed in the mock-
transfected cells as shown in Figure 5.6c, which was consistent with the results 
from western blot. Mock-transfected cells probed with PBS (Figure 5.6b) was used 
as a negative control to indicate the Kv1.3 detection was not an artefact resulted 
from binding of antibody to non-specific proteins. Previous patch clamp analysis 
study has shown the presence of endogenous Kv1.3 in HEK293 cells which supports 
this finding (Yu & Kerchner 1998; Jiang et al. 2002). Notably, DENV-2 NS2A was 
localised exclusively in the cytoplasmic region (as shown in the previous chapter) 
(Figure 5.6d). Endogenous Kv1.3 co-expressed with NS2A was observed in Figure 
5.6e, whereas overexpression of both Kv1.3 and NS2A (both transfected with 100 
ng plasmid constructs) was observed in Figure 5.6f. 
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Figure 5.6: Cellular localisation of Kv1.3 and NS2A detected by immunofluorescence staining.   
Proteins were co/expressed as follows: (a) EGFP (left panel) and Kv1.3-EGFP (right panel), (b) Mock-transfected cells detected with Alexa 
Fluor® 488 anti-rabbit IgG (green) secondary antibody (as a control for endogenous Kv1.3), (c) endogenous Kv1.3, (d) NS2A, (e) endogenous 
Kv1.3 and NS2A, (f) Kv1.3-EGFP and NS2A. Overexpressed Kv1.3 tagged with EGFP was determined by EGFP expression, endogenous Kv1.3 
was detected using anti-Kv1.3 and Alexa Fluor® 488 anti-rabbit IgG (green). NS2A was detected using anti-c-Myc and Alexa Fluor® 594 anti-
mouse IgG (red). The cells were nuclear-stained with DAPI (blue).  
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 Kv1.3 effect on cell viability 
Information derived from previous experiments indicates Kv1.3 is membrane-
bound. Excessive amounts of this protein resulting from overexpression (driven by 
a CMV promoter) may cause improper cell function. It is therefore essential to 
determine the effective dose of DNA used for transfection that does not affect 
the overall cell viability. In brief, HEK293 cells were transfected with increasing 
concentrations of Kv1.3-EGFP plasmid and tested for cell viability 24 hr p.t 
(Section 2.7.6). As shown in Figure 5.7, the percentage of viable cells decreased 
to 85.5% during transfection with 25 ng/ ml plasmid and decreased further to 69.9-
83.7% for transfection between 50-500 ng/ ml plasmid. Further increase of the 
plasmid to 1000 ng/ ml resulted in less than 50% of cells remaining viable. Overall, 
this indicates that Kv1.3 overexpression directly affects the cell proliferation and 
therefore should be used in concentrations of 100 ng/ ml during transfection. 
 
 
Figure 5.7: Effect of over-expressed Kv1.3 on HEK293 cell viability.  
The cells were transfected with 10-1000 ng/ ml Kv1.3-EGFP plasmid and subjected 
to the cell viability test using CellTiter 96® Non-Radioactive Cell Proliferation 
Assay. The absorbance values of viable cells were calculated and shown as a 
percentage relative to the mock (cells treated with Lipofectamine® 2000 CD 
alone). Data reflects the mean ± standard error of triplicates from three 
independent experiments.  
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 Effect of Kv1.3 blockade on DENV-2 infection 
In order to investigate if Kv1.3 plays a significant role in DENV-2 infection, the 
channel function was inhibited and the effect was subsequently examined on 
DENV-2 FFluc expression replicon, pDVPACluc (Section 2.4.2). This study was 
performed by assessing endogenous Kv1.3 which are present at detectable levels 
in HEK293 cells and relatively mimicked natural cellular condition. Blocking of the 
Kv1.3 channels was induced through treatment with several K+ channel blockers, 
TEA, 4-AP and MgTx. 
 Effect of potassium channel blockers on cell viability 
The effect of K+ channel blockers on cell viability was initially evaluated to select 
the suitable dose for K+ channel inhibition before testing on the replicon. TEA, 4-
AP and MgTx blockers were gifts from Dr Jamel Mankouri, the University of Leeds. 
Specific information regarding the blockers is listed in Table 5.1. Briefly, K+ 
channel blockers were dissolved in suitable diluents (water for TEA and 4-AP, PBSA 
for MgTx) and further diluted with DMEM medium to achieve required 
concentrations (Section 2.7.7, Table 2.16). The effective concentration range 
varied among inhibitors due to their different inhibitory potency (Judge & Bever 
2006). Cells were treated with the blockers for 4 hr, prior to adding the MTT dye 
for cell viability assay.  
The percentage of cell viability was calculated relative to their respective 
negative controls, though there was no significant difference between the 
negative controls (water- and PBSA-treated cells) compared to the untreated 
cells. As shown in Figure 5.8, there was a clear dose-dependent effect of 
increasing concentration of blockers with a decrease in the percentage of viable 
cells. Given the low concentration range of MgTx (in nanomolar), MgTx was shown 
to be the most potent, followed by 4-AP and TEA, respectively. The percentage 
of viable cells decreased approximately to 80% (a cut-off value for in-vitro 
cytotoxicity) (Sambrook et al., 1989) for treatment with 50 mM, 2.5 mM and 250 
nM of TEA, 4-AP and MgTx, accordingly. The suggested dose for use (based on 
personal communication with Jamel Mankouri), was found to be applicable only 
for MgTx, as TEA and 4-AP were quickly becoming more toxic at higher doses. 
Jiang et al. (2002) suggested that less TEA concentrations of 1-10 mM are sufficient 
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to efficiently inhibited Kv currents as shown by patch-clamp analysis. Overall, 
concentration of the Kv1.3 inhibitors were selected at 10 mM TEA, 1 mM 4-AP and 
10 nM MgTx for use in subsequent experiments.  
 
Table 5.1: List of relevant information describing the potassium channel 
blockers. 
Blocker Description Specificity 
Suggested 
dose for 
use* 
Tetraethylammonium 
chloride (TEA) 
Quaternary 
ammonium salt 
Non-selective K+ 
channel blocker 
10-100 mM 
4-Aminopyridine (4-
AP) 
Drug prescribed for 
multiple sclerosis/ 
neuromuscular 
disorders 
Non-selective voltage 
gated K+ channel 
blocker 
0.5-2 mM 
Margatoxin (MgTx) 
Venom-derived 
peptide of scorpion 
Centruroides 
margaritatus 
Kv1.3 blocker  20-100 nM 
    
* personal communication with Jamel Mankouri  
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Figure 5.8: Effect of potassium channel blockers on cell viability.  
The cells were treated with K+ channel blockers; TEA, 4-AP and MgTx at various 
concentrations and subjected to the cell viability assay. The absorbance values 
were determined at 570 nm reference wavelength using the GloMax multi-
detection system. The absorbance values were normalised against their respective 
negative controls (either PBSA or water) by assigning their values as 100% cell 
viability. Data reflects the mean±standard error of triplicates from three 
independent experiments.  
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 Effect of MgTx-blocked Kv1.3 on DENV-2 infection 
The effect of Kv1.3 blockade on DENV-2 replicon FFluc expression was tested using 
MgTx because of its specific inhibition of Kv1.3 (Helms et al. 1997; Knaus et al. 
1995). As it is unclear how DENV-2 interacts with this channel and at which stage 
would the MgTx affect the replicon, these experiments were performed in two 
ways: 1) MgTx pre-treatment, by blocking the endogenous Kv1.3 and subsequently 
introducing DENV-2 NS proteins, and 2) MgTx post-treatment, by expressing DENV-
2 NS proteins intracellularly for 6 hr and subsequently inhibiting the endogenous 
Kv1.3. DENV-2 replicon (pDVPACluc) was in vitro transcribed to produce RNA as 
described in Section 2.6.1 for use in this assay.  
MgTx was dissolved in PBSA and diluted with DMEM to achieve required 
concentrations (0.1-100 nM). These concentrations were used where >80% cells 
were viable, to ensure the results were not affected by other cellular factors. The 
diluted MgTx was used to treat HEK293 cells for 4 hr (pre-treatment) followed by 
co-transfecting the cells with in vitro transcribed DENV-2 replicon RNA and pRL-
CMV expressing RLuc (internal control). After 6 hr p.t (based on results in Section 
4.3.6.2 which demonstrated a high FFLuc expression as early as 6 hr p.t), the cells 
were lysed and luciferase activities were measured. Similar experiments were 
performed but in the opposite sequence to test the replicon for MgTx post-
treatment.  
There was a slight increase (1.3-fold) in DENV-2 FFLuc expression resulting from 
Kv1.3 blockade using 1 nM MgTx (Figure 5.9, top panel) (Student’s t-test, p-value 
<0.05). The expression remained constant at this level despite increasing 
concentrations of MgTx up to 100 nM. A small increase (1.3-fold) in FFLuc 
expression was observed in MgTx post-treatment using 1-10 nM MgTx (Figure 5.9, 
bottom panel), but the increase was not significant. Increasing doses of MgTx to 
50-100 nM subsequently decreased the FFLuc expression to its initial basal level, 
similar to the PBSA negative control. Considering the small differences in FFLuc 
expression which resulted in non-significant statistical values (except as shown in 
the figure for MgTx pre-treatment), there was no clear or very minimal effect of 
Kv1.3 blockade on DENV-2 gene expression. This may require a longer incubation 
time as a result of MgTx treatment to observe a clearer effect. Furthermore, the 
efficiency of Kv1.3 blockade was not validated in this study. It is thus unknown if 
 187 
 
the channel was completely inhibited which may give more reliable FFLuc 
expression. Further to this, the DENV-2 replicon has not been shown to replicate 
in HEK293 cells (as described in previous chapter), hence resulting in unconvincing 
FFLuc expression.   
 
Figure 5.9: Effect of MgTx on FFLuc expression from DENV-2 replicon.  
Top panel shows MgTx pre-treatment, in which Kv1.3 was inhibited prior to 
introducing the in vitro transcribed DENV-2 replicon RNA. Bottom panel shows 
MgTx post-treatment, where the replicon RNA was introduced into the cells 
followed by Kv1.3 inhibition. Data represents the fold change of FFLuc expression 
normalised to the PBSA negative control performed in triplicates from three 
independent experiments. Asterisk (*) indicates Student’s t-test, p-value <0.05. 
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 Effect of Kv1.3 on dengue virus replication 
As experiments with DENV-2 replicon FFLuc expression were unable to produce 
reliable data, subsequent experiments were carried out by using infectious DENV-
2. This study aimed to investigate the importance of K+ channel in DENV-2 
replication by inhibiting the functional Kv1.3 using K+ inhibitors prior to virus 
infection. As mentioned in the previous chapter, work concerning the infectious 
DENV-2 was performed by Amjad Yousuf in a Containment Level 3 facility, 
University of Bristol. In brief, HEK293 cells were treated with K+ channel blockers 
(Table 2.16) (10 mM TEA, 1 mM 4-AP and 10 nM MgTx) for 4 hr and subsequently 
infected with DENV-2 NGC strain. The infectious material was replaced by fresh 
medium containing the appropriate blockers to inhibit the K+ channel. Isolated 
RNA samples were subjected to qRT-PCR with TaqMan probes and primers 
targeting the DENV-2 capsid region. 
There was a clear decrease in DENV-2 gene expression as a result of the K+ channel 
blockade (Figure 5.10). The most significant effect was caused by 4-AP (52%- 
decrease relative to PBSA), followed by MgTx and TEA giving approximately 30% 
and 26% decrease, respectively. Although there was no water control for TEA and 
4-AP (as they were initially dissolved in water), these blockers have been diluted 
100x in DMEM prior to the treatment, which greatly diluted the effect of water 
diluent. The overall data indicates blockade of Kv1.3 affects DENV-2 replication 
suggesting this channel may have a pro-viral activity that facilitates virus 
replication. Further biological replicates and assessment of potential mechanism 
(especially the role of NS2A) are required to support this finding.  
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Figure 5.10: Gene expression of DENV-2 capsid region in HEK293 cells 
exhibiting Kv1.3 blockade.  
The activity of K+ channels was inhibited by TEA, 4-AP and MgTx. PBSA was used 
as a negative control for MgTx treatment. Data represents an average viral copy 
numbers from triplicate wells of qRT-PCR reactions. The viral copy numbers were 
generated from a standard curve based on cycle threshold (Ct) values and 
normalised to the human HPRT1 internal control. Error bars indicate standard 
error of triplicate wells. Data obtained in this study was derived from pooled of 
triplicate samples, generated in a single experiment.  
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 Discussion 
HEK293 cells were used in this study to assess the interaction between DENV-2 
NS2A and Kv1.3. Although this cell line has been previously reported to be lacking 
the expression of endogenous Kv1.3 (Levitan & Barrantes 2012), the channel was 
successfully over-expressed and its endogenous form has been detected in this 
study by western blot and IF staining. This is supported by several patch-clamp 
studies which demonstrated endogenous Kv currents (Yu & Kerchner 1998; Jiang 
et al. 2002). Kv1.3 is a membrane-bound protein (Cahalan et al. 1985) and 
therefore is difficult to dissociate during cell lysis. The use of a lysis buffer such 
as 1% NP-40 is capable to efficiently disintegrate the cell membrane properties. It 
is noteworthy that Kv1.3 has been identified in the nucleus (Jang et al. 2015), 
mitochondrial inner membrane (Szabò et al. 2005; Bednarczyk et al. 2010) and is 
highly expressed in cancer cell lines (Jang et al. 2009; Wu et al. 2013; Preußat et 
al. 2003). 
Further examinations by co-IP/pull-down assay using Protein A-tagged DENV-2 
NS2A and EGFP-tagged Kv1.3 demonstrated both proteins co-precipitate and are 
detected in the pull-down samples. Moreover, it is interesting that NS2A was able 
to capture the endogenous Kv1.3 and detected in the pull-down samples which 
confirms interaction exists between both proteins. It is known that different cell 
lines express different types and different Kv channel expression level. HEK293 
cells seem to have a detectable level of endogenous Kv1.3 as shown by western 
blot and IF. Based on these observations and the fact that endogenous Kv1.3 more 
likely resembles the natural condition, experiments analysing the effects of 
blocked endogenous Kv1.3 on DENV-2 infection were performed. 
In order to determine the importance of Kv1.3, the effect of endogenous Kv1.3 
blockade was evaluated using a DENV-2 replicon. While both experiments showed 
a small increase in translation of DENV-2 NS proteins resulting from Kv1.3 blockade 
at 1-10 nM MgTx, results from the experiments in general did not indicate a clear 
effect (based on statistical analysis) to derive a conclusion. It is known that MgTx 
has a reversible effect (Garcia-Calvo et al. 1993). Thus, removing MgTx from the 
culture cells during pre-treatment with MgTx may have restored the activity of 
Kv1.3 and the normal cellular functions, which allows DENV-2 translation to take 
place. This has led to a small increase in DENV-2 translation as seen with an 
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increase in FFLuc expression. Besides that, patch-clamp experiments were not 
performed in this study to confirm the channel blockade. It is therefore unknown 
if the Kv1.3 function was completely inhibited prior to testing with the DENV 
replicon assay. It is also possible that this assay would require the use of whole 
infectious virus particles to modulate specific host cellular interactions as 
naturally occuring virus infection. An alternative explanation would be that Kv1.3 
is not necessarily involved in DENV replication but is needed for an earlier or later 
stage in the virus life cycle. This has been previously reported in K+ (K2P) channel 
during infection with Bunyamwera virus (BUNV) (Hover et al. 2016). Using specific 
K+ channel modulating agent, the K+ channel function has shown to be critical to 
events shortly after virus entry but prior to viral replication.  
Further analysis was carried out to study the effect of Kv1.3 blockade on DENV-2 
replication using the infectious DENV-2 NGC strain. Three blockers, TEA, 4-AP and 
MgTx, exhibiting different specificity towards K+ channels (Table 5.1), were used 
to inhibit the channel function. TEA and 4-AP have been described to block the K+ 
channels from the cytoplasmic side of the cell membrane, which occurs through 
modulation of conformational changes to these channels rendering them closed 
(Armstrong & Loboda 2001; Choquet & Korn 1992). MgTx in contrast, was proposed 
to act in either of two ways; through binding on the extracellular side of the 
channel pores therefore obstructing the pore, or by binding and modulating the 
voltage sensor region (S1-S4) of the K+ channel (Judge & Bever 2006). Inhibition of 
K+ channels by these blockers usually resulted in abrogated Kv currents analysed 
by patch-clamp (Kazama 2015; Hu et al. 2007; Gazula et al. 2010). 
The effect of Kv1.3 blockade on DENV-2 replication was demonstrated by gene 
expression qRT-PCR analysis of the DENV-2 capsid gene. Data were normalised to 
the human housekeeping gene, hypoxanthine phosphoribosyltransferase 1 (HPRT1) 
which has removed any effect of blockers on the cells. It was interesting to 
observe a clear decrease in DENV replication as a result of the K+ channel blockade 
in 4-AP, MgTx and TEA, accordingly. As TEA blocks all K+ channels due to its 
capacity as a non-selective K+ blocker, reduction of the virus replication signifies 
the importance these ion channels in regulating DENV-2 infection. The most 
prominent effect that decreased DENV-2 replication occurs during blockade of all 
voltage-gated channel including Kv1.3 by 4-AP, whereas blockade of Kv1.3 using 
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MgTx exhibited almost similar DENV-2 replication level to TEA. This suggests 
rather than Kv1.3, other Kv channels may be involved in DENV-2 replication. 
Therefore, although functional Kv1.3 is abrogated, other Kv channels are 
functional and able to facilitate infection.  
While blocking the K+ channels using chemical ion blockers or peptides represents 
a reliable assessment tool to develop potential pharmacological therapy, co-
inhibition of other unspecific channels or the entire sub-family of the same 
channels makes it difficult to interpret the effect of a specific cellular response. 
Although MgTx has a high affinity to Kv1.3 (Helms et al. 1997; Garcia-Calvo et al. 
1993), recent report suggests that the action was non-specific as the peptide 
concurrently inhibited Kv1.1 and Kv1.2 (Bartok et al. 2014). This complicates the 
findings, thus analysis by Kv1.3 gene silencing may be an effective way to ensure 
a specific target for inhibition. Apart from that, other highly-specific Kv blockers 
such as ShK derived from sea anemone Stichodactyla helianthus toxin (Kalman 
1998), and non-peptide blocker PAP-1 (Schmitz et al. 2005) can be tested in 
parallel to block Kv1.3 activity. Reversal of the inhibitory effect of K+ channel by 
removing the blockers from the test system may confirm the specific effect of this 
channel to DENV-2 infection. 
Other relevant issues in this study include the fact that the native HEK293 cells 
are not homogenous in terms of the expression of Kv channels (Jiang et al. 2002). 
Besides Kv1.3, other Kv -subunit genes are present including the Kv1.1, Kv1.2, 
Kv1.6, the transient outward Kv channels, Kv1.4, Kv3.3, Kv3.4, Kv4.1, and other 
Kv subunit genes (Jiang et al. 2002). This also creates diversity of functional Kv 
channels due to heterogeneous assembly of different Kv subunits rather than by 
assembly of four homogenous subunits. In particular, Kv1.3 can form 
heterotetrameric channel arrangements in vivo with other subunits from Kv1 sub-
family including Kv.1.1, Kv1.2, and Kv1.6 (Gazula et al. 2010).  
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 Conclusion 
Interaction between DENV-2 NS2A and Kv1.3 was observed through co-IP/pull-
down assay which confirms the previous findings from Y2H and LUMIER assay. K+ 
channels, in particular the voltage-gated channels, seem to play a role in DENV-2 
replication. Although it was difficult to conclude the importance of Kv1.3 due to 
its heterogenous native form in HEK293 cells, this channel, together with other Kv 
channels may contribute to the virus infection. It is also possible that Kv1.3 is not 
necessarily involved in DENV replication but is needed for an earlier or later stage 
in the virus life cycle. Further analysis including the experiments in mice model 
may extend our understanding of the role of Kv1.3 channels in DENV infection.  
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6 CHAPTER 6: ESTABLISHMENT OF Ae. aegypti cDNA LIBRARY 
6.1 Introduction 
Ae. aegypti and Ae. albopictus are primary vectors that transmit DENV (Gubler 
1998). The virus is ingested during a mosquito blood meal, and infects the midgut 
epithelial cells and disseminates to the salivary glands (Salazar et al. 2007). During 
infection, the mosquito mounts innate immune responses, however the virus 
persists in the mosquito and is capable of being transmitted to the next vertebrate 
host (Sánchez-Vargas et al. 2009). It is therefore of particular interest to 
investigate the way mosquitoes control DENV infection, particularly through their 
antiviral defence mechanisms to ensure survival. This would also contribute to a 
greater understanding of protein-protein interactions between DENV-mosquito 
systems thus providing insights into the mechanism by which specific proteins 
and/or pathways play an important role during virus infection.  
Several studies have predicted protein-protein interactions between DENV and its 
mosquito host (Mairiang et al. 2013; Doolittle & Gomez 2011; Guo et al. 2010). 
Although a large number of DENV-interacting mosquito proteins have been 
identified, very little has been validated to reveal their biological importance. 
This limits the knowledge of a precise mechanism contributing to successful virus 
replication in the mosquito. A genome-wide RNAi screen using DENV-2 strain 
adapted to D. melanogaster identified 116 host factors, including vacuolar 
ATPases and alpha-glucosidases that facilitate virus replication (Sessions et al. 
2009). A number of cellular events occur in DENV-infected Ae. albopictus 
proteomes suggesting the involvement of oxido-reduction stress and activation of 
glycolysis pathways and cellular damage (Patramool et al. 2011). It has also been 
shown that alteration of protein expression in DENV-2 infected salivary glands of 
Ae. aegypti, including aegyptin, enhances virus replication (Chisenhall et al. 2014; 
Wasinpiyamongkol et al. 2012), and upregulation of cadherin on the surface of 
mosquito cells suggests a potential receptor for DENV (Colpitts et al. 2011). Using 
virus overlay protein binding assay (VOPBA), Cao-Lormeau (2009) identified 
several DENV-binding proteins between 37 and 77 kDa from Ae. aegypti salivary 
glands, however the protein identities were unknown.  
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Aside from various non-immune host proteins expressed as a result of virus 
infection, proteins involved in immune signalling pathways are equally important. 
This is due to the fact that innate immunity plays an important role in insects to 
counter microbial challenges (Kingsolver et al. 2013; Hoffmann 1995). Most studies 
of insect immunity have been conducted in D. melanogaster as an insect model. 
Innate immune pathways including the Janus kinase signal transducer and 
activator of transcription (JAK-STAT), immune deficiency (IMD), Toll pathways, 
are known to respond to microbial infection, which activates the transcription of 
genes involved in defense (Sim et al. 2014; Sabin et al. 2010). Activation of these 
genes triggers proteolytic cascades in the haemolymph that leads to melanisation 
of the invading microbe at the site of injury, cellular responses such as 
phagocytosis or encapsulation of foreign material, and production of effector 
molecules through the secretion of antimicrobial peptides from the fat body 
(Ferrandon et al. 2007; Agaisse & Perrimon 2004; Hoffmann 1995). Seven inducible 
antimicrobial peptides have been described in Drosophila, exhibiting defense 
against Gram-negative bacteria (attacins, cecropins, drosocin, diptericins), Gram-
positive bacteria (defensin) and fungi (drosomycins, metchnikowin) (Bulet 1999).  
The JAK-STAT pathway has been demonstrated to be involved in Ae. aegypti 
antiviral response against DENV (Souza-Neto et al. 2009), as well as in Drosophila 
against Drosophila C virus (Dostert et al. 2005). Knockdowns and mutations in JAK 
kinase have been shown to cause an increase in viral infection, indicating 
JAK/STAT plays a role in the antiviral response as a result of STAT-dependent 
expression of regulated effector molecules (Souza-Neto et al. 2009; Dostert et al. 
2005). The IMD pathway in Drosophila produces antimicrobial peptides mainly to 
counteract Gram-negative bacteria (Lemaitre et al. 1995). This pathway is also 
involved in defence against viruses and has been shown to enhance Sindbis virus 
replication when pathway components were mutated (Avadhanula et al. 2009). 
The Toll pathway is activated against fungi, Gram-positive bacteria, and viruses 
(Zambon et al. 2005; Rutschmann et al. 2002; Lemaitre et al. 1996) and has been 
reported as an antiviral defence against DENV (Xi et al. 2008). Although the JAK-
STAT, IMD and Toll pathways have been implicated in many virus infections, the 
exogenous RNAi pathway is thought to be the most significant antiviral response 
(Donald et al. 2012; Blair 2011). This type of defence pathway has been shown to 
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be induced by DENV and SFV in mosquitoes and their derived cell lines (Siu et al. 
2011; Sánchez-Vargas et al. 2009).  
A search for host factors or finding relevant genes involved in virus infection, can 
be achieved through screening of an appropriate host cDNA library. Construction 
of cDNA libraries derived from tissue specific organisms or cell cultures can be 
established for investigation of their functions as well as for protein-protein 
interaction analysis (Mayhew et al. 2007; Gomez et al. 2005). The available Ae. 
aegypti genome sequence has revealed 15,419 putative genes and 80% were 
protein coding regions (Nene et al. 2007). This data, in combination with the high-
throughput gene expression and reverse genetic studies, provides opportunities to 
study the mosquito immune responses against DENV infection. Transcriptomic 
analysis has been able to identify specific genes potentially involved in xenobiotic 
response and insecticide tolerance (David et al. 2010). In this study, the use of an 
Ae. aegypti cDNA library is useful to screen for protein-protein interactions 
between DENV and its primary host. There is however, a lack of a commercially 
available Ae. aegypti cDNA library expressed in yeast, thus an attempt to 
construct the library was initiated. Although an Ae. aegypti cDNA library 
generated from tissue midguts has been successfully established in yeast (Tham 
et al. 2014), the present study was undertaken to construct a library from Ae. 
aegypti-derived Aag2 cells.  
There are two techniques commonly used for construction of Y2H libraries, which 
include the ligation-assisted cloning and recombination-based cloning. The 
ligation-assisted technique has several limitations, such as an additional digestion-
ligation step, the risk of enzymatic cleavage of cDNA clones containing the 
restriction enzyme sites and size bias in the ligation reaction (Ohara & Temple 
2001). In contrast, the recombination-based technique is much simple and 
requires only a single step to incorporate cDNA inserts into the vector. The 
recombination technique has a higher transformation efficiency and has been 
shown to produce a high number of full-length cDNA clones (Ohara & Temple 2001; 
Zhu et al. 2001). In this study, the recombination-based strategy was adopted 
using the Make Your Own ‘Mate and Plate™’ Library System (Clontech). This 
technique uses the cap-switch mechanism to incorporate SMART sequences and 
allow enrichment of full-length cDNA (as described in Section 2.8)(Zhu et al. 2001; 
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Chenchik et al., 1998). Directional cloning occurs through homologous 
recombination of highly specific att sites between the cDNA and cloning vectors, 
which can take place either in vitro or in vivo. This study took advantage of the 
capability of yeast, S. cerevisiae, which is known to carry out homologous 
recombination efficiently in vivo through double-strand break repair mechanism 
(Oldenburg et al. 1997; Ma et al. 1987). 
 
 
6.2 Objectives 
 
1. To generate an Ae. aegypti cDNA library for Y2H screen against DENV NS 
proteins. 
2. To establish mosquito immune signalling experiments. 
3. To assess the expression of DENV non-structural proteins in mosquito cells. 
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6.3 Results 
6.3.1 Construction of Ae. aegypti cDNA library 
6.3.1.1 Isolation of Aag2 RNA 
To construct a cDNA library, isolation of high integrity RNA is essential. A crude 
method to determine the RNA integrity is through analysis of the highly abundant 
28S and 16S ribosomal RNA (rRNA). Prior to generating a mosquito cDNA pool, total 
RNA was harvested from Ae. aegypti-derived Aag2 mosquito cells using TRIzol® 
reagent (Section 2.2.1) and the RNA yield was determined using NanoDrop™ 1000 
spectrophotometer (Section 2.2.8). The isolated RNA was estimated at 950 ng/µl 
and A260/280 ratio 2.05, which complied with the recommended range for pure RNA 
(Sambrook et al., 1989). Further analysis of the Aag2 rRNA profiles on a non-
denaturing agarose gel demonstrated two distinct bands approximately at 0.8 and 
1.2 kb corresponding to the 28S and 18S rRNA (Figure 6.1), which indicated intact 
rRNA. There was an absence of a smear along the gel with no indication of RNA 
degradation. High integrity RNA isolated from Anopheles sp. tissues has been 
shown to produce similar rRNA profiles, which correlated to this study (Macharia 
et al. 2015). 
 
Figure 6.1: 28S and 18S ribosomal RNA profile analysis of Aag2 cells.  
The RNA was harvested from Aag2 cells and separated on a 1.2% non-denaturing 
agarose gel. Marker is 1 kb DNA ladder (NEB). 
28S 
18S 
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6.3.1.2 Amplification of Aag2 cDNA 
The RNA obtained from Aag2 cells (described above) was immediately used for 
construction of the Ae. aegypti cDNA library using the Make Your Own `Mate & 
Plate™’ Library System (Clontech). In brief, the RNA was reverse-transcribed by 
MMLV reverse transcriptase using an oligo (dT) primer containing CDS III sequences 
followed by SMART oligonucleotides to generate cDNA. During this process, SMART 
sequences were introduced to both 5’ and 3’ ends of the cDNA. This was followed 
by LD-PCR amplification of the cDNA using Advantage® 2 Polymerase Mix 
(Clontech) for 20 and 25 cycles according to the manufacturer’s instructions 
(Section 2.8.1.3). A mouse liver poly A+ RNA was run in parallel as a positive 
control. In order to check the quality of ds cDNA, the amplified products were 
separated on agarose gel electrophoresis. As shown in Figure 6.2 (lane 3), Ae. 
aegypti cDNA had a size range of between 0.1-2 kb after 20 cycles of PCR 
amplification. Increasing the PCR cycles to 25 (the maximum number of cycles 
suggested by the manufacturer) produced cDNA between 0.3-2 kb (Figure 6.2, lane 
4). As this has higher MW and generated a more uniform smear indicating good 
cDNA (Islam et al. 2012), the sample was selected for construction of the mosquito 
library. It was shown that the positive control mouse liver poly A+ exhibited cDNA 
smear ranging between 0.3-6 kb (Figure 6.2, lane 2). A more intense smear 
covering a larger MW range was seen in this sample as it came from purified poly 
A+, therefore produced a good amplification signal. 
Prior to transformation into yeast, the cDNA was size-fractionated to obtain >200 
bp transcripts followed by ethanol precipitation to purify the cDNA. This step 
removed the low MW ds cDNA or unincorporated nucleotides which allowed 
enrichment of the cDNA with full-length and larger inserts (Wellenreuther et al. 
2004). Following resuspension of the cDNA in nuclease-free water, the total ds 
cDNA was 86.4 ng/ µl which gave 1.7 µg in total, A260/280 ratio 1.7 and A260/230 ratio 
2.59. The cDNA yield was lower due to removal of lower MW cDNA, however the 
amount did not achieve the expected 2-5 μg, as suggested by Clontech. Due to the 
low cDNA yield, the above steps with regard to PCR amplification, size 
fractionation and purification of the cDNA were repeated using a fresh aliquot of 
the first-strand cDNA. The resulting ds cDNA (A260/280 ratio 1.72 and A260/230 ratio 
2.3) was pooled and 3 µg was used for construction of the mosquito cDNA library.   
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Figure 6.2: Amplification of Aag2 mosquito cDNA by LD-PCR.  
The amplified products were separated on 1.2% agarose gel. Figure denotes: Lane 
1: water negative control; Lane 2: cDNA of mouse liver poly A+ positive control; 
Lane 3: cDNA of Aag2 amplified for 20 cycles; Lane 4:  cDNA of Aag2 amplified for 
25 cycles. Markers are 1 kb DNA ladder (NEB) and GeneRuler™ 100 bp DNA ladder 
(Thermo Scientific). 
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6.3.1.3 Complexity and titre of library 
Prior to transformation into yeast, the Aag2 cDNA was further evaluated for 
complexity. This determined if the library was representative enough for 
comprehensive cDNA analysis. Three mosquito gene fragments; Actin, Dicer-2 and 
Argonaute-2, were amplified by standard PCR using the cDNA as a template. Actin 
represents highly conserved housekeeping gene which is present in all stages of 
mosquito development (Salazar et al. 2007; Mounier et al. 1992), therefore should 
be picked up during PCR. Dicer-2 and Argonaute-2 are key factors responsible for 
mosquito RNAi immune pathway (Blair 2011), and should be present in Aag2 as the 
cells are RNAi competent (Scott et al. 2010). As shown in Figure 6.3, the gene 
fragments were detected at their corresponding sizes, indicating the cDNA library 
was likely to be satisfactory. Although only fragments of the genes were amplified, 
this would normally indicate a full length gene. 
In order to allow the expression of mosquito proteins in yeast, the Aag2 cDNA was 
co-transformed with SmaI-linearised pGADT7-Rec into competent yeast strain 
Y187 (Section 2.8.3). As described in Figure 2.7, the linear pGADT7-Rec has 
compatible sequence ends to the SMART III and CDS III sequences of the Aag2 cDNA 
which allows homologous recombination in yeast. As a positive control, SV40 large-
T PCR fragment with flanking SMART sequences was co-transformed with linear 
pGADT7-Rec, alongside transformation of the linear pGADT7-Rec alone. The 
resulting library titer was determined as described by Clontech. Based on the 
number of yeast colonies grown on the dilution plates, the Aag2 cDNA library titer 
was estimated at 2.3 x 103 cfu/ ml. The total number of independent clones which 
served as an indication of the library complexity was 3.45 x 104. This data however 
does not meet the standard number of independent clones suggested by Clontech 
(>1 x 106).  
Furthermore, co-transformation of the positive control SV40 large-T PCR and 
linear pGADT7-Rec was expected to obtain ten times more yeast colonies than 
those transformed with linear pGADT7-Rec alone (as suggested by Clontech). 
Results from this study however, failed to obtain any colonies on both 
transformation plates. As it was not known if yeast competency could be the 
reason of this failure, further assessment was performed by making a competent 
yeast strain AH109, using the same protocol and reagents that were used to make 
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competent Y187 yeast, and transformed with a positive control pGBT9 (supplied 
by Clontech). Although a different yeast host strain was used, a transformation 
efficiency of 3 x 105 cfu/ µg plasmid DNA was obtained as suggested by Clontech, 
which is also in agreement to previous study (Cao & Yan 2013). This indicates a 
satisfactory transformation efficiency, nearly equivalent to 1 x 106 cfu/ µg plasmid 
as required for transformation (Gietz & Schiestl 2007; Klickstein 2001). 
 
 
 
 
Figure 6.3: Amplification of mosquito gene fragments.  
Standard PCR amplification was performed using Aag2 cDNA template. 
Amplification of Actin (250 bp), Dicer-2 (800 bp) and Argonaute-2 (780 bp) are 
shown in lane 2, 3 and 4, respectively. Lane 1 is a PCR water negative control. 
Markers are 1 kb DNA ladder (NEB). 
  
 203 
 
 
6.3.2 Mosquito immune signaling pathways  
The use of mosquito-derived cell lines to study innate immunity is important to 
reflect the natural host immune response restricting DENV infection in 
mosquitoes. Immune-competent Aag2 cells have been widely used to study 
immune signalling pathways in response to arbovirus infection (Barletta et al. 
2012; Sim & Dimopoulos 2010a). Ae. albopictus-derived C6/36 cells have been 
previously shown to be permissive for a wide range of arboviruses and are able to 
promote DENV replication (White 1987). In order to test for an interaction or 
functional correlations between DENV and any mosquito interacting partners 
resulting from Y2H, downstream experiments involving the mosquito immune 
signalling pathways were initially optimised. 
6.3.2.1 Activation of JAK/STAT, IMD and Toll pathways 
The present study was carried out using Aag2 and C6/36 cells to assess activation 
of STAT, IMD and Toll pathways upon exogenous stimulation (as described in 
Section 2.8.6). Three FFLuc reporter constructs; p6x2DRAF-Luc containing 
multimerised Drosophila STAT-responsive element, pJL169 containing IMD-
responsive Drosophila Attacin A promoter, and pJM648 containing Toll-responsive 
Drosophila Drosomycin promoter, were used to test for activation of JAK/STAT, 
IMD and Toll pathways, respectively. The JAK/STAT and IMD pathways were 
stimulated by introducing heat-inactivated E. coli as previously described 
(Fragkoudis et al. 2008), whereas Toll pathway was stimulated by co-transfecting 
pJL195, a constitutively active Toll LRR mutant under control of Drosophila Actin 
5C gene promoter (Tauszig et al. 2000). PBS was used as negative control for STAT 
and IMD stimulation, whereas for Toll, the negative control was cells not 
transfected with pJL195. pAct-Renilla expressing RLuc under the control of 
Drosophila Actin promoter was used as internal control for transfection.  
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There was a significant increase of FFLuc expression (Student’s t-test, p-value 
<0.05) corresponding to JAK/STAT and IMD pathways of Aag2 cells upon 
stimulation with E. coli (Figure 6.4, top panel). Similarly, an increase of FFLuc 
expression (Student’s t-test, p-value <0.05) was also seen in JAK/STAT and IMD 
pathways of C6/36 cells (Figure 6.4, bottom panel), suggesting the mosquitoes are 
responsive to the E. coli exogenous stimulus, therefore triggering the activation 
of JAK/STAT and IMD pathways. In contrast, there was no clear activation of Toll 
pathway in both Aag2 and C6/36 cell lines as a result of pJL195 stimulation. This 
was quite surprising as Toll activation has been previously demonstrated in Ae. 
albopictus-derived U4.4 cells (Fragkoudis et al. 2008).  
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Figure 6.4: Activation of JAK/STAT, IMD and Toll immune signaling pathways. 
Activation of JAK/STAT, IMD and Toll immune signaling pathways in Aag2 (top 
panel) and C6/36 cells (bottom panel). Both cell types were transfected with 
either p6x2DRAF-Luc, pJL169 or pJM648 expressing FFLuc corresponding to the 
JAK/STAT, IMD and Toll antimicrobial peptide promoters respectively. For 
JAK/STAT and IMD, the cells were stimulated with heat-inactivated E. coli or PBS 
(non-stimulated cells). For Toll pathway, the cells were either co-transfected with 
pJL195 for stimulation or without pJL195 (non-stimulated cells). Ratio of FFLuc 
values were calculated against the RLuc internal control and normalised by 
assigning a value of 1 to the level of the corresponding non-stimulated cells. Graph 
represents the average ratio of FFLuc to RLuc activities  standard error of 
triplicates from three independent experiments. Statistical significance was 
determined by paired Student’s t-test (p-value <0.05) indicated by an asterisk (*).  
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6.3.2.2 Activation of Toll pathway by pJL195-expressed Toll receptor mutant 
Activation of the Toll pathway was further optimised in Aag2, C6/36 and Ae. 
albopictus U4.4 cells. U4.4 was tested in parallel because this cell line has 
previously shown an activation of the Toll pathway using similar experimental 
settings (Fragkoudis et al. 2008). In order to allow for comparable Toll stimulation, 
an empty insect expression vector pIB/V5 and pIB-MBP plasmid expressing MBP 
were used as negative controls for stimulation. Due to the fact that the efficiency 
of pJL195 in stimulating Toll pathway was unknown, two methods of Toll pathway 
activation were tested: 1) by co-transfecting Toll reporter plasmid pJM648 with 
either pIB/V5, pIB-MBP or pJL195 followed by cell lysis 24 hr p.t, and 2) by pre-
stimulating cells with pIB/V5, pIB-MBP or pJL195, followed by transfecting pJM648 
Toll reporter plasmid after 24 hr. Pre-stimulation of the Toll pathway prior to 
transfection with the Toll reporter pJM648 was expected to allow longer time for 
stimulation to be assessed. pAct-Renilla internal control was co-transfected with 
pJM648 in each set of experiments. 
In the first co-stimulation test, a significant increase of FFLuc expression (8.8-
fold, Student’s t-test p-value <0.05) was seen in stimulated U4.4 cells compared 
to the negative controls pIB/V5 and pIB-MBP (Figure 6.5). This correlates with 
previous data reflecting the activation of Toll pathway upon stimulation with 
pJL195 (Fragkoudis et al. 2008). C6/36 cells showed a similar increase of FFLuc 
expression (Student’s t-test, p-value <0.05) upon stimulation with pJL195, though 
with less expression level. In contrast, there was a suppression of Toll pathway in 
Aag2 cells as FFLuc significantly decreased in expression following the stimulation. 
In the second pre-stimulation test, the Toll pathway was pre-stimulated prior to 
adding the Toll reporter. This was done to allow sufficient stimulation of the cells 
because the efficiency of the pJL195 Toll stimulant was unknown. Data from this 
set of experiments revealed an activation of the Toll pathway in U4.4 cells, giving 
a two-fold increase of FFLuc expression (Figure 6.6, Student’s t-test, p-value 
<0.05). This is consistent with the findings in the first test and correlates with 
previous data (Fragkoudis et al. 2008). The Toll immune pathway was also 
activated in Aag2 cells but not in C6/36 (Figure 6.6), which contrasts to the results 
of the first test. Taken together, Toll pathway is activated by pJL195, dependent 
on the mosquito cell types and manner of introduction of the stimulation.  
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Figure 6.5: Activation of Toll through co-stimulation with pJL195.  
Cells were co-transfected with Toll reporter pJM648 and either pIB/V5, pIB-MBP 
or pJL195 and lysed 24 hr p.t. Average ratios of FFLuc to RLuc internal control 
were calculated and normalised by assigning a value of 1 to the level of pIB-MBP 
of the corresponding cells (non-stimulated control). Error bars indicate standard 
error of triplicate wells from three independent experiments. Statistical 
significance was determined by paired Student’s t-test (p-value <0.05) indicated 
by an asterisk (*).  
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Figure 6.6: Activation of Toll through pre-stimulation with pJL195.  
Cells were pre-stimulated with either pIB/V5, pIB-MBP or pJL195 prior to 
transfection with Toll reporter pJM648 at 24 hr post-stimulation and the cells were 
lysed 48 hr post-stimulation. Average ratios of FFLuc to RLuc internal control were 
calculated and normalised by assigning a value of 1 to the level of pIB-MBP of the 
corresponding cells (non-stimulated control). Error bars indicate standard error of 
triplicate wells from three independent experiments. Statistical significance was 
determined by paired Student’s t-test (p-value <0.05) indicated by an asterisk (*). 
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6.3.2.3 Activation of Toll pathway by Bacillus sp. 
Toll immune signalling pathway is known to be activated by Gram-positive 
bacteria (Rutschmann et al. 2002). Although this pathway could be stimulated by 
introduction of pJL195 particularly in U4.4 cells (as shown in previous section), 
the activation caused by Gram-positive Bacillus sp. was investigated due to the 
poor activation of the receptor plasmid in Aag2 cells. The experiments were 
performed in a similar fashion as described for JAK/STAT and IMD pathways, thus 
reducing experimental variables, allowing a more reliable comparison among the 
immune signalling pathways. Following transfection of pJM648 Toll reporter 
plasmid into mosquito cells, Bacillus sp. heat-inactivated and live cultures were 
used to stimulate the Toll pathway. The bacteria were introduced to the cells for 
1 hr and subsequently removed and fresh medium added, or exposed to the cells 
for 12 hr stimulation. PBS was used as a negative control for stimulation. The cells 
were lysed 12 hr post-stimulation and luciferase activities were determined. The 
total number of bacteria cells in the suspension was calculated to be 108-109 cfu/ 
ml (105-106 bacteria cells were used for stimulation on the mosquito cells).  
There was a two-fold increase of FFLuc expression (Student’s t-test, p-value 
<0.05) in U4.4 when exposed to heat-inactivated Bacillus sp. for 12 hr (Figure 6.7, 
top panel). Increased FFLuc expression was also seen after 1 hr stimulation with 
freshly grown culture, suggesting the Toll pathway was activated in response to 
Bacillus sp. It is noteworthy that 1 hr-stimulation with heat-inactivated Bacillus 
sp. did not significantly activate Toll, as seen by Fragkoudis et al. (2008) with 
Staphylococcus aureus. In C6/36 cells, the Toll pathway was mainly activated 
through stimulation with the live bacteria exhibiting a marked increase in Toll 
immune response (Figure 6.7, middle panel). This resulted in a nine-fold and 
seven-fold increase of FFLuc expression (Student’s t-test, p-value <0.05) upon 1 
hr and 12 hr exposure to the live bacteria, respectively. Toll activation was also 
seen by 12-hr stimulation with heat-inactivated bacteria but with less activity. It 
was clear that Aag2 cells responded efficiently to both forms of bacteria by 
activating the Toll pathway particularly within 1 hr exposure to the stimulant 
(Figure 6.7, bottom panel). Overall, exposure to Bacillus sp. particularly freshly 
grown bacteria activates the Toll pathway in mosquito cells. The use of heat-
inactivated bacteria as a stimulant requires an extended exposure time in Ae. 
albopictus cells for activation of this pathway.  
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Figure 6.7: Toll activation through ectopic stimulation with Bacillus sp.  
Activation of Toll pathway in U4.4 (top panel), C6/36 (middle panel) and Aag2 
(bottom panel) mosquito cells upon exposure to heat-inactivated and live bacteria 
(for 1 or 12 hr where indicated), prior to cell lysis. Data represents the average 
fold change of FFLuc expression relative to PBS negative controls  standard error 
of triplicate samples. Statistical significance was determined by paired Student’s 
t-test (p-value <0.05) indicated by an asterisk (*).   
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6.3.3 Replication of DENV replicon in mosquito cells 
6.3.3.1 Expression of DENV GFP  
In order to investigate the mosquito host defence pathways in response to DENV, 
a sub-genomic DENV-2 NGC replicon pDENrepGP2A (a kind gift from Andrew 
Davidson, University of Bristol) encoding the virus non-structural proteins was 
used. The replicon contains a GFP-PAC-2A fusion protein under the control of T7 
promoter replacing the C-prM-E genes at the N-terminus (Section 2.4.2) (Massé et 
al. 2010). This construct enabled the visualisation of DENV translation by 
examining GFP, without interfering with the luciferase reporter system used to 
test immune signalling. An initial study was firstly attempted to assess the replicon 
translation in mosquito cells by examining the GFP expression, followed by 
analysing the effect of DENV replication on mosquito host immune signalling. In 
brief, in vitro transcribed DENV replicon RNA was transfected into Aag2, C6/36 
and BHK-21 cells, and continuously monitored for GFP expression. BHK-21 was 
included in this study because this cell line has been previously shown to allow 
DENV translation using DENV replicon, pDVPACLuc expressing FFluc (Section 
4.3.6.1). A construct expressing EGFP in insect cells (provided by Margus Varjak, 
University of Glasgow) was used as a positive control.  
EGFP expression was observed beginning at 24 hr p.t in Aag2, C6/36 and BHK-21 
cells transfected with the positive control plasmid. Figure 6.8 shows the 
expression of EGFP at 48 hr p.t in positive control cells, but GFP was not seen in 
cells transfected with DENV replicon RNA. In BHK-21, the cells looked unhealthy 
(deterioration in cell numbers caused by cell death), which was similarly seen in 
the mosquito cells at 72 hr p.t onwards. Continuous examination up to 120 hr p.t 
was unable to detect the GFP expression, as most of the cells had died off whereas 
the EGFP in the positive control cells reduced in number due to proliferation of 
untransfected cells outnumbering the transiently transfected cells.  
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Figure 6.8: Expression of DENV NS proteins in Aag2 and C6/36 cells.  
The cells were transfected with either positive control EGFP plasmid (left panels) 
or in vitro-transcribed DENV replicon RNA, pDVRepGP2A expressing GFP reporter 
(right panels) and continuously examined for 120 hr p.t. The live-cell images were 
captured at using EVOS f1 fluorescence digital microscope (Advanced Microscopy 
Group, USA). Only EGFP/GFP expression at 48 hr p.t is shown. 
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6.3.3.2 Expression of DENV luciferase 
In order to assess the expression of DENV non-structural proteins in mosquito cells, 
the DENV-2 NGC replicon, pDVPACLuc expressing FFLuc (as described in Section 
2.4.2) was used. In vitro-transcribed viral RNA was transfected into U4.4, C6/36 
and Aag2 cells and expression of FFLuc was determined 24 hr p.t. There was a 
significant increase in FFLuc expression upon transfection with pDVPACluc 
compared to the mock-transfected cells (Figure 6.9). This corresponded to the 
expression of DENV non-structural proteins in the mosquito cell lines, while 
enhanced FFLuc expression was seen in C6/36 cells, followed by U4.4 and Aag2, 
respectively.  
 
 
Figure 6.9: Expression of DENV NS proteins in mosquito cells. 
The U4.4, C6/36 and Aag2 cells were transfected with in vitro-transcribed DENV 
replicon RNA pDVPACLuc, and lysed at 24 hr p.t, followed by determination of the 
luciferase activity. Negative control was cells transfected with Lipofectamine® 
2000 CD alone. Data represent FFLuc relative light units (RLU) mean  standard 
error of triplicate samples from a single experiment. 
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6.4 Discussion 
An Aag2 cDNA library was constructed for use in Y2H screen to search for potential 
mosquito host factors (prey) interacting with DENV non-structural proteins (bait). 
Since construction of the library requires high quality RNA, a general assessment 
of the RNA quality was carried out by analysis of the mosquito 28S and 18S rRNA 
profiles. It is believed that a clear resolution of 28S and 18S rRNA profiles indicates 
a high integrity of the isolated RNA, which reflects the quality of other RNA 
fractions including the mRNA population. The A260/280 ratio of RNA isolated from 
Aag2 cells was within the expected range (Sambrook et al., 1989) indicating a 
good RNA preparation. Further rRNA profile analysis demonstrated two clear bands 
corresponding to the 28S and 16S rRNA, visualised under non-denaturing 
conditions. Although a 2:1 ratio of 28S to 18S intensity has been suggested for 
mammalian total RNA (Sambrook and Russell., 2001), this was not the case for 
RNA samples of insects (Winnebeck et al. 2010). Insects may exhibit rRNA profiles 
as a single 18S rRNA band under denaturing conditions due to the presence of an 
endogenous ‘hidden break’ in the mid region of 28S rRNA (Fujiwara & Ishikawa 
1986). It may also display both 16S and 28S rRNA together regardless of intensity 
under non-denaturing conditions (Matz 2002), as seen in this study. This finding is 
consistent with previous studies of high integrity RNA observed in insects 
(Macharia et al. 2015; Winnebeck et al. 2010).  
In an attempt to generate a cDNA library derived from mRNA of Aag2 cells, the 
Make Your Own ‘Mate and Plate™’ Library System incorporating SMART technology 
was used according to the manufacturer’s instructions (Clontech). LD-PCR has 
been reported to be suitable for low quantities of starting material of cDNA which 
was used to generate ds cDNA after first strand cDNA synthesis (Cheng et al. 1994). 
Following these procedures, a homogenous smear, which indicated a reasonably 
good cDNA library was observed (Islam et al. 2012). It is noteworthy that increasing 
LD-PCR cycles generated longer fragments of amplified cDNA because the 
extension time was increased by 5 sec of each additional cycle. It was however, 
not advisable to go above the recommended PCR cycles to avoid overcycling that 
may generate a smear at the high MW region (Bogdanov et al. 2010). cDNA with 
higher MW up to 2 kb (25 PCR cycles) was selected for use in the current library 
construction as a study reported an invertebrate cDNA library between 2-3 kb 
(Shcheglov et al. 2007). While the protocol used in this study most probably has 
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been optimised for mammalian libraries, for libraries derived from cells or tissues 
of different organisms such as mosquitoes, it is not known whether it is 
appropriate to use similar amplification cycles due to differences in gene 
composition. Optimisation of cycling parameters allows knowledge of when the 
reaction has reached an amplification plateau, thus giving better amplification 
products (Bogdanov et al. 2010).  
In this study, size-fractionated cDNA using a CHROMA SPIN TE-400 column followed 
by ethanol precipitation has reduced the cDNA yield due to removal of low MW 
cDNA, however it also reduced the DNA purity. The yield of cDNA was 1.7 µg in 
total, lower than the expected 2-5 µg as suggested by Clontech. The DNA purity 
was A260/280 1.7, slightly lower than the standard range (A260/280 1.8-2.0) (Sambrook 
et al., 1989). This may suggest DNA degradation or possible contamination with 
proteins or organic solvents during purification step, such as ethanol (NanoDrop 
Technical Support Bulletin, 2007). Size-fractionation is known to eliminate low 
MW cDNA, resulting in enrichment of the cDNA with full length transcripts 
(Wellenreuther et al. 2004). It is however unknown if intervention by this step, 
followed by ethanol purification may increase the chances of DNA loss. This has 
been shown by Cao & Yan (2013) who obtained a larger cDNA library (~2.5×106 
independent clones, with an average insert size of ~ 1.5 kb) via low-melting point 
gel fractionation. Consistent with this study, gel purification of human cDNA 
followed by PCR-amplification has been shown to produce 70% full length clones 
with an average insert of 7 kb (Wellenreuther et al. 2004). Besides fractionation, 
cDNA pellets resulting from ethanol purification are sometimes difficult to re-
dissolve and the ethanol residues can remain in the samples, which affects both 
the DNA quantity and quality. Since the initial cDNA obtained from this 
preparation was not sufficient for library construction, the whole process was 
repeated to make more cDNA. However, even with the fact that subsequent steps 
including size-fractionation and ethanol precipitation were applied, this 
repetition was unable to improve the DNA quality. 
There are several factors which may contribute to these difficulties. First, it is 
possible that partially transcribed cDNA occurs in most transcripts during first-
strand cDNA synthesis, which is caused by mRNA degradation or the presence of 
high levels of secondary structures in mosquito mRNA. MMLV RT may thus be 
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unable to initiate terminal transferase activity and synthesize complementary 
SMART sequences at the 5’ end. Given the switching mechanism occurs at the 5’ 
end of template, partially transcribed cDNA lacks the SMART sequences thus are 
unavailable for amplification by LD-PCR using SMART primers, which contributes 
to a low yield of amplified cDNA. Second, it was difficult to assess the quality of 
amplified cDNA by visualisation of a cDNA smear. Hence, the success of LD-PCR 
through performing a specific number of cycles has not been accurately 
determined and may be misleading. Third, synthesis of cDNA using oligo(dT) 
primers have a strong bias towards having cDNA 3’ fragments (Nam et al. 2002). 
In the event of incomplete PCR cycling conditions, this produces high percentage 
of 5'-truncated cDNA lacking the SMART sequences as mentioned above, which 
likely generates a smear.  
Ideally, cDNA libraries have to be representative in which they should contain DNA 
copies for nearly all transcripts (Brown & Song 2005). Thus, a pre-assessment of 
complexity of the cDNA library was done by amplification of gene fragments; 
Actin, Dicer-2 and Argonaute-2. It was shown that the gene fragments were 
successfully amplified, an early indication of a representative library. Given the 
time constraint however, only these genes were tested prior to transformation 
into yeast. Further analysis of full length cDNA clones would be achievable once 
they have been transformed into yeast which may also indicate the complexity of 
the library.  
In order to allow expression of the mosquito proteins in yeast, the Aag2 cDNA was 
co-transformed with the yeast expression vector pGADT7-Rec into yeast strain 
Y187. The resulting Aag2 cDNA library however did not produce a sufficient 
number of independent clones as required. This outcome is contrary to other 
studies from mouse cDNA and Ae. aegypti midguts using the same SMART cloning 
strategy which produced 106-107 clones (Tham et al. 2014; Zhang et al. 2013). In 
addition, transformation of the positive control SV40 large-T PCR fragment with 
flanking SMART sequences failed to obtain any yeast transformants. All these 
difficulties may be accounted for by the following explanations:  
1) Quality of cDNA used for transformation: There could be a low yield of first-
strand cDNA to begin with, which produced cDNA with low quality. Although up to 
5 µg was suggested by Clontech for transformation into yeast, only 3 µg was 
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obtained from pooled cDNA preparations and thus was entirely transformed. 
Actin, Dicer-2 and Argonaute-2 gene fragments have been shown to be present in 
the cDNA, but it was not tested if they were present as full length transcripts. 
2) Linearisation of yeast vector pGADT7-Rec: The commercial yeast vector 
pGADT7-Rec harbouring recombination sites was supplied in a linearized form. The 
linearization however was not confirmed by gel electrophoresis in this study due 
to the limited supply of the vector in the library kit. Although re-circularization 
of pGADT7-Rec generated from SmaI blunt-end digestion is rare, this may still 
occur and might affect the vector’s ability to perform a specific recombination 
with the cDNA. In the event of re-circularization, transformed pGADT7-Rec 
produces empty yeast colonies which were able to grow on selective media. There 
was no transformant however, resulting from the transformation of pGADT7-Rec 
alone, which indicates other factors may contribute to this failure. 
3) Recombination strategy in vivo: Although many have shown a high yield of cDNA 
clones using a recombination strategy, subsequent recombination steps in the 
majority of studies were performed in vitro such as using E. coli or phage as host 
(Ohara & Temple 2001; Zhu et al. 2001). In this study, there was no transformant 
being produced as a result of co-transformation of the positive control SV40 large-
T PCR fragment containing SMART sequences and pGADT7-Rec. It has been shown 
that at least 30 bp of a homologous sequence is sufficient for recombination (Fusco 
et al. 1999; Hua et al. 1997), thus a 40 bp overlap in SMART sequence should work. 
Other issues could be the condition of yeast where the recombination activity 
takes place involving the yeast repair enzymes (Fusco et al. 1999).  
4) Transformation efficiency of yeast: We were unable to assess the 
transformation efficiency in yeast Y187 due to the lack of a suitable control 
plasmid for this strain. However, assessing the transformation efficiency of a yeast 
strain AH109 using similar reagents and experimental settings has produced 
transformants very close to the required standard efficiency. This indicates that 
the procedure used to generate competent yeast in this study was able to generate 
highly competent yeast suitable for transformation. Although this was achieved 
through a completely different yeast host strain, it is conceivable from this study 
that failure in generating a good cDNA library was not a consequence of issues 
with the method of producing competent yeast.  
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Each step throughout the construction of a cDNA library contributes greatly to the 
final product. It is likely that synthesis of the first-strand cDNA plays the most 
important role in obtaining full length molecules for downstream experiments. 
The limitation of making a full length cDNA from 3′ terminus produced partial 
lengths could be the main reason of failure which maybe subsequently intensified 
by the downstream experiments. In summary, it is clear that the Aag2 cDNA library 
generated from this study does not fulfil the required criteria of a standard library, 
this library is thus not suitable to be used for a comprehensive analysis by Y2H 
screen. 
In parallel work, a cellular assay system involving mosquito immune signalling 
experiments was characterised for any subsequent analysis of DENV-targeted 
mosquito proteins identified from Y2H. While the pathways involved in regulating 
antiviral defense against DENV; the JAK/STAT, IMD, Toll and RNAi pathways have 
been reported (Sim et al. 2014), the specific mechanism underlying each pathway 
is still poorly understood. In an attempt to investigate the importance of these 
pathways against DENV infection, an initial study was carried out to explore the 
activation of these pathways through stimulation procedures described by 
Fragkoudis et al. (2008). It is important to mention that in their study, 
experiments were carried out only in Ae. albopictus U4.4 cells. 
In the first set of experiments, plasmids expressing FFLuc (either p6x2DRAF-Luc, 
pJL169 or pJM648) driven by promoters responsive to the JAK/STAT, IMD and Toll 
pathways, respectively, were transiently transfected into Aag2 and C6/36 cells. 
Stimulation of both cells using E. coli was shown to successfully activate the 
JAK/STAT and IMD pathways which correlates to previous observations in U4.4 
cells (Fragkoudis et al. 2008). This is also consistent with previous findings that 
both the JAK/STAT and IMD have been implicated in insect immune responses 
against Gram-negative bacteria (Costa et al. 2009; Hombría et al. 2005). 
Stimulation of the Toll pathway was carried out using an expression construct 
pJL195, containing a Drosophila Toll receptor mutant (Toll LRR) under control of 
Drosophila Actin 5C gene promoter (Tauszig et al. 2000). This construct has a 
deletion of leucine-rich repeats in the Toll ectodomain, resulting in a 
constitutively active mutant Toll receptor. It has been previously reported that 
expression of this mutant receptor significantly enhanced the activation of the 
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Toll drosomycin promoter in Drosophila S2 cells by 5-10 fold (Tauszig et al. 2000). 
Furthermore, expression of the Toll LRR receptor did not seem to stimulate the 
production of antimicrobial peptides other than drosomycin (Tauszig et al. 2000). 
In this study, stimulation of the Toll pathway with pJL195 however, was unable to 
activate the Toll pathway in both Aag2 and C6/36 cells. This could be due to the 
lack of proper negative control (un-transfected cells), which results in FFLuc data 
unsuitable for comparison. 
Subsequent tests of the Toll pathway were performed by stimulation with pJL195, 
and the negative controls were transfected with either an empty insect expression 
vector (pIB/V5), or a plasmid expressing the E. coli protein MBP (pIB-MBP). It has 
been shown that pJL195 was capable of expressing the mutant Toll LRR receptor 
and inducing the Toll pathway in U4.4 cells (Fragkoudis et al. 2008), however it’s 
activity in both Aag2 and C6/36 cells is unknown. Thus, two sets of experiments 
(co-stimulation and pre-stimulation with pJL195) were performed, as described in 
Section 6.3.2.2. The procedure for the co-stimulation test (co-transfection of 
pJL195 and the drosomycin FFluc reporter pJM648), was similar to those 
performed by (Fragkoudis et al. 2008) in U4.4 cells and has been shown to work, 
therefore would give an indication of any response in Aag2 and C6/36 cells. The 
pre-stimulation test aimed to allow sufficient expression of the mutant Toll LRR 
receptor with the hope of better stimulation, before transfecting the pJM648. 
Stimulation of Toll was clearly seen in U4.4 regardless of the way stimulation was 
being introduced, which correlates with previous observations (Fragkoudis et al. 
2008). This however was not consistent in Aag2 and C6/36 cells in both stimulation 
tests, which suggests the stimulation by pJL195 is dependent on the mosquito cell 
types and the duration of stimulation. One possible reason could be that the 
Drosophila Toll receptor mutant although expressed constitutively in Drosophila 
S2 cells, may not be suitable or potent enough for stimulation in these mosquito 
cells. Besides, it is not known if the mutant Toll receptor was properly expressed 
in Aag2 and C6/36 cells. While C6/36 cells in general give a low Toll response 
almost similar to background, Aag2 cells show a suppression of Toll during co-
stimulation. Aag2 cells are known to be efficient in mounting an immune response 
(Barletta et al. 2012), it is possible that over-stimulation of the cells causes a 
negative feedback reaction, which reduces the immune response in order to 
stabilize the mosquito cells (Gupta et al. 2009).  
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The Toll pathway is activated in response to Gram-positive bacteria (Rutschmann 
et al. 2002). This study therefore attempted to activate the Toll pathway using 
Gram-positive Bacillus sp. Additional parameters were determined by testing the 
stimulation exposure time (1 or 12 hr stimulation) and the nature of bacteria 
stimulants (live bacteria or heat-inactivated) used for stimulation. Various 
patterns of the Toll pathway activation following stimulation were observed. In 
general, the stimulation was optimal when exposed for 1 hr to live bacteria. This 
could be due to the fact that the live bacteria are capable of causing injury to the 
cells, therefore a stronger Toll immune response was produced to overcome this 
effect. It was also clear that the use of heat-inactivated bacteria as a stimulant 
was less potent, requiring longer exposure time particularly in Ae. albopictus U4.4 
and C6/36 cells. While it is known that C6/36 cells are RNAi pathway deficient 
(Brackney et al. 2010), it is unknown whether these cells are less efficient in 
triggering the Toll pathway. This effect was also seen during pJL195 stimulation, 
where a low activation or almost no activation of Toll pathway was observed in 
C6/36, indicating inefficient Toll activation. In contrast, Aag2 cells are immune-
competent (Scott et al. 2010), in most cases the Toll immune response was rapidly 
activated at 1 hr post-stimulation regardless of the nature of stimulant. The 
differential levels of Toll induction by Bacillus sp. in different mosquito cell lines, 
may suggest a degree of selectivity in the Toll response and indicates that the 
activation requires a specific induction exposure time and stimulant.  
Procedures concerning the activation of JAK/STAT, IMD and Toll pathways have 
been optimised in this study, a further attempt was carried out in order to 
investigate the effect of DENV on these activation pathways. A DENV-2 replicon 
harbouring GFP reporter pDVRepGP2A (Section 2.4.1) (a kind gift from Andrew 
Davidson, University of Bristol) was used. The replicon contained DENV-2 non-
structural genes and GFP as a fusion with a drug selectable marker PAC at the N-
terminus (Massé et al. 2010). Previous studies demonstrated that the alphaviruses, 
chikungunya virus (CHIKV) and Semliki Forest virus (SFV) are able to inhibit the 
JAK/STAT, IMD and Toll pathways in mosquito cells (McFarlane et al. 2014; 
Fragkoudis et al. 2008). While the specific action of DENV on these pathways is 
unclear, the virus has been previously shown to suppress these pathways as a 
strategy for replication in Ae. aegypti (Sim & Dimopoulos 2010a).  
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GFP or FFLuc expression corresponding to DENV non-structural protein production 
was first tested in mosquito cells. An increase in the luciferase activity was shown 
in DENV replicon-transfected cells expressing FFLuc, with the highest luciferase 
activity in C6/36, U4.4 and Aag2, respectively. Since C6/36 cells are known to 
have a dysfunctional antiviral RNAi response (Brackney et al. 2010), it is however 
unknown if the cells were able to tolerate DENV translation, thus giving rise to 
elevated FFLuc activity. Overall, this set of experiments shows the ability of 
pDVPACLuc replicon to initiate translation in insect cells. This replicon however, 
was unable to be used because the FFLuc activity would interfere with the plasmid 
constructs encoding FFLuc under control of promoters activated in response to 
JAK/STAT, IMD and Toll stimulation. Hence, a DENV replicon harbouring a GFP 
reporter was used. EGFP expression was observed in positive control cells however 
the GFP was not seen in cells transfected with DENV replicon RNA up to 120 hr 
p.t. It was also seen that transfection of the DENV replicon in the mosquito cells 
resulted in deterioration of the cellular conditions, and cell death. Taken 
together, this reflects the unsuitability of the replicon to be used for the assay.   
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6.5 Conclusion 
Although the quality of the mosquito library generated in this study is based on 
suggestions by Clontech and standard published literatures, the exact quality of 
the library remain unknown unless tested extensively. Further analysis of the 
library could be performed by amplification of the mosquito genes or enzymatic 
digestion of randomly-picked yeast colonies and sequencing of the cDNA clones. 
This gives information of the percentage of clones containing full-length cDNA, 
the average sizes of insert and gives a representative image of the library, which 
are important criteria in determining a cDNA library quality. Another important 
criteria is the normalization of the library, which is done by decreasing the highly 
abundant transcripts to increase the chances of discovering rare transcripts. 
Normalization is usually performed by treating ds cDNA with duplex-specific 
nuclease (DSN) before cloning into any host for plasmid propagation or protein 
expression (Shagin et al. 2002; Young & Anderson, 1985). In this process, ds cDNA 
is firstly denatured, followed by renaturation where most abundant transcript re-
anneal efficiently than the rare transcripts, forming ds cDNA. Treatment with DSN 
subsequently degrades the ds cDNA and the remaining normalized ss DNA is PCR-
amplified and used for library cloning (Bogdanov et al. 2010). Through this 
experience of generating a mosquito cDNA library, it was realized that many 
technical problems exist. Future improvements as to reverse-transcriptase 
conditions and cloning strategies might be possible to overcome these limitations. 
Optimization of assays to test JAK/STAT, IMD and Toll immune pathways has been 
successfully achieved. It is clear that the Toll pathway can either be activated 
through the use of pJL195 Toll receptor mutant or Bacillus sp. dependent on the 
type of mosquito cells used. Further attempts were carried out in order to 
investigate the effect of these activation pathways on DENV, however failure of 
the DENV GFP replicon in the mosquito cells prevented us from achieving the aim 
of the study. Given more time, experiments such as RNAi-mediated silencing of 
the JAK/STAT, IMD and Toll immune pathway components and testing with the 
DENV FFLuc replicon may provide information on which pathway is affected in 
DENV replication in the mosquito cells. 
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7. CHAPTER 7: CONCLUDING REMARKS 
Dengue is a global health threat and causes a burden in many countries. Although 
numerous attempts have been made to develop effective vaccines, most are 
hampered by an inability to provide significant protective immunity to all four 
DENV serotypes. Further to clinical efforts, many researchers have focused on 
identifying specific host determinants, known to be essential for DENV replication, 
which are potential targets for diagnostics or antiviral strategies. Systematic 
mapping of protein-protein interactions is essential for identification of host 
factors and for prediction of functional biological systems at the molecular level. 
To date, high throughput genome-wide interactions and global systematic analysis 
of large screen protein-protein interactions mapping have been reported. These 
include a large-screen of DENV-human protein-protein interactions established 
recently using the Y2H approach (Mairiang et al. 2013; Silva et al. 2013; Le Breton 
et al. 2011; Khadka et al. 2011). Although several potential DENV interacting 
proteins have been described, only a few of these proteins overlap between the 
independent screens and only a small number of proteins have been shown to be 
involved in DENV replication thus far. 
In Chapter 3 of this study, analysis of protein-protein interaction between DENV-
2 NS proteins and the MGC human cDNA library was performed using a Y2H assay. 
A total of 94 human proteins were identified, of which four have been reported in 
the previous DENV screens, these were STAT2, UBE2I, EMILIN1 and NUMA1 (Khadka 
et al. 2011; Le Breton et al. 2011). At least five proteins GOPC, GRN, LACRT, 
KHDRBS1 and TRIM27 have been implicated in other viral infections (Bouraï et al. 
2012; Krishnan et al. 2008; Calderwood et al. 2007). The small number of overlap 
proteins with other studies, could be due to the different experimental conditions 
and also the different cDNA library used for screening that are enriched with 
different sets of genes (Friedel & Haas 2011). Data from this study indicate the 
enrichment of human proteins that are components of the ER membrane, and 
transcriptional processes including negative regulation of transcriptional activity 
which may occur during viral infections (Lee et al., 2013; Wang et al., 2012). 
Further validation of 15 selected human protein interactions in a human system 
was performed using the LUMIER pull-down assay. Of these, BANP, KCNA3, 
ARL6IP1, UBE2I, TRAPPC, HEXIM2, KCNS2, EMILIN1, PRR7 and TRIM27 have been 
detected as strong interactors for DENV. As BANP interacts with the full length 
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and a truncated DENV NS2A, and has been shown to be involved in NF-B signalling, 
this strongly supports the potential interaction of BANP with NS2A thus, the 
interaction was tested further and described in Chapter 4 of this thesis. In 
addition, the voltage-gated K+ channel, KCNA3 (or Kv1.3) was also selected for 
further analysis due to its potential role in virus life cycle, which was discussed 
further in Chapter 5 (Mankouri et al. 2009; Redman et al. 2007; Herrmann et al. 
2010). Although only two proteins, BANP and Kv1.3 were investigated in this study, 
other human proteins identified from this screen require further elucidation of 
their specific roles and involvement in DENV infection. 
In Chapter 4, a human protein BANP that was identified as interacting with DENV 
NS2A was further investigated. As previously mentioned, there was limited 
information about BANP, thus knowledge about this protein was inferred from its 
mouse homolog, SMAR1 (Malonia et al. 2011). BANP has been shown to be localised 
in the cell nucleus during its overexpression which may indicate its essential role 
in regulating cellular transcriptional activities (Birot et al. 2000; Chattopadhyay 
et al. 2000a). In this study, the potential role of BANP in regulating NF-B and the 
type I IFN response was investigated. Both Poly(I:C)-mediated or the Universal 
Type I IFN-mediated stimulation in HEK293 cells clearly showed that NF-B and 
the type I IFN response was inhibited in overexpressed BANP. This finding is 
consistent with prior knowledge of SMAR1 which is capable of inhibiting TNF-
mediated activation of NF-B, hence repressing transcriptional activation of NF-
B target genes (Singh et al. 2009). The mechanism involves an interaction 
between SMAR1 with HDAC1 and other cofactors by forming a repressor complex 
which is recruited to the MAR elements present upstream of the NF-B promoter, 
leading to deacetylation of histones and hence transcriptional repression of the 
NF-B target genes (Malonia et al. 2011; Singh et al. 2009). Likewise, stimulation 
of these cells in the presence of DENV NS2A has been shown to inhibit the type I 
IFN response. The role of interaction between BANP and DENV NS2A in inhibiting 
the type I IFN however is unclear, as both proteins were found to be IFN-
antagonist.  
It could also be that BANP is involved in other cellular functions than the immune 
signalling given the diverse roles of SMAR1. BANP is thought to be capable of 
regulating the cell cycle arrest through DNA repair by a mechanism involving 
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HDAC1, p53 and other cofactors in order to maintain the cell survival during viral 
infection (Sinha et al. 2010; Kaul et al. 2003; Sinha et al. 2012). In cases of severe 
DNA damage, it has been shown that SMAR1 activates Bax and Puma genes which 
leads to induction of apoptosis (Sinha et al. 2010). SMAR1 has been shown to be 
capable of regulating the cell cycle and cellular stress by modulation of the cyclin 
D1 and the tumour suppressor p53 (Sinha et al. 2012; Rampalli et al. 2005; Kaul 
et al. 2003). Interaction between SMAR1 and p53 delays the cell cycle progression 
at G2/M phase (Kaul et al. 2003), and the interaction of SMAR1 with Ku70 regulates 
the induction of cell death or repair (Chaudhary et al. 2014). It is possible that 
these mechanisms are useful to the cells in order to respond to viral infection. 
Further studies by overexpression or gene silencing of BANP during DENV infection 
incorporating the assessment of DNA damage, regulation of p53 and apoptotic 
pathway will be able to indicate the functional properties of BANP and whether it 
plays an important role in DENV life cycle.  
In Chapter 5, the importance of voltage-gated protein channel Kv1.3 in DENV 
infection was studied. Kv1.3 is expressed mainly on the plasma membrane in many 
cell types and tissues particularly in T lymphocytes (Grunnet et al. 2003; Gazula 
et al. 2010; Yao et al. 1996). Kv1.3 is involved in T lymphocyte activation by 
expression of significantly higher levels, and has been reported as the major 
constituent of voltage-gated channel in platelets (Panyi et al. 2004; McCloskey et 
al. 2010; Wulff et al. 2003). Although there was no report of direct correlation of 
Kv1.3 to DENV infection, previous studies have demonstrated the activation of T 
lymphocytes and macrophages upon DENV infection and a significant decrease in 
the number of platelets in dengue patients (Alonzo et al. 2012; Kurane et al. 
1991b). This seems very interesting as Kv1.3 has been identified in this study.  
Further experimentation confirmed the physical interaction of Kv1.3 with DENV 
NS2A by LUMIER and co-IP/pull-down assay in this study. The effect of Kv1.3 
blockade using MgTx on translation of a DENV-2 replicon containing FFLuc reporter 
was unable to produce significant results, as the replicon was not found to 
replicate in HEK293 cells. In order to improve the assay, the effect of Kv1.3 
blockade should also be tested by patch-clamp analysis to indicate a complete 
inhibition of Kv1.3. Alternatively, the use of a fluorogenic indicator dye, such as 
the FluxOR™ potassium ion channel assay can be used to measure the K+ ion flux. 
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Another explanation of the effect seen on DENV replicon during channel blockade 
would be that Kv1.3 is not involved in DENV replication. However the channel is 
needed for an earlier or later stage of the virus life cycle as previously observed 
in BUNV infection (Hover et al. 2016). Further analysis of DENV-2 replication by 
qRT-PCR shows a clear decrease in DENV replication as a result of the K+ channel 
blockade in 4-AP, MgTx and TEA, accordingly which signifies the importance these 
K+ channels in regulating DENV-2 infection. Although it is difficult to conclude the 
importance of Kv1.3 due to its heterogenous native form in HEK293 cells (Jiang et 
al. 2002), this channel, together with other Kv channels may contribute to the 
enhancement of DENV infection. Further analysis including experiments in mouse 
models may prove informative. Although further investigations are required to 
gather data on the specific contribution of Kv1.3, our data suggest that 
development of drugs that specifically inhibit Kv channels may provide a 
treatment for dengue.  
In Chapter 6, an attempt at generating a mosquito cDNA library was described. 
The initial study was intended to analyse protein-protein interactions between 
DENV and its mosquito host by Y2H assay. Ae. aegypti-derived Aag2 cells were the 
chosen cell line due to the fact that the insect serves as a primary vector for 
DENV, possesses an efficient innate immune system and there is a complete 
genome annotation available (Barletta et al. 2012; Gubler 1998). Due to the lack 
of a commercial Ae. aegypti cDNA library in the yeast expression system, the 
construction of an in-house library using the Clontech library cloning kit was 
carried out. The resulting Aag2 cDNA library however, resulted in a poor number 
of cDNA clones unlike a previously reported cDNA library obtained from Ae. 
aegypti midgut using similar techniques (Tham et al. 2014), thus making it 
unsuitable for use in Y2H assay. There were several possible explanations for this, 
including the generation of truncated cDNA during the first-strand synthesis, sub-
optimal PCR cycling conditions, yeast transformation efficiency and in-vivo 
recombination cloning (Shcheglov et al. 2007; Wellenreuther et al. 2004; Fusco et 
al. 1999). Nonetheless, the Aag2 cDNA library has not been fully evaluated, and 
further analysis is required to provide sufficient information of the quality of 
library with regard to its gene sequence composition and representation of the 
mosquito transcripts.  
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This chapter also described an optimisation of innate immune signalling 
experiments to test for potential DENV-mosquito interacting partners obtained 
from Y2H screen. In an assessment of these mosquito proteins for downstream 
experiments, one selection criteria would be that the candidate has a certain 
degree of involvement in the immune signalling pathways. This is because the 
related tools, expression constructs and knowledge of the innate immune 
responses are readily available in the lab. Innate immune responses play an 
important role as defense mechanisms in mosquitoes against viruses (Sim et al. 
2014; Kingsolver et al. 2013; Sabin et al. 2010). Previous studies have indicated 
the involvement of JAK/STAT, IMD and Toll pathways in controlling DENV 
infections (Sim & Dimopoulos 2010b; Souza-Neto et al. 2009; Xi et al. 2008). 
Further attempts were carried out in order to investigate the effect of these 
activation pathways on DENV, however failure of getting the DENV GFP replicon 
to replicate in the mosquito cells hampered the aim of this study. Given more 
time, experiments such as RNAi-mediated silencing of the JAK/STAT, IMD and Toll 
immune pathway components and testing with the DENV FFLuc replicon may 
provide information on which immune pathway affects DENV replication in 
mosquito cells and their mechanism of action. Furthermore, establishment of a 
good Aag2 cDNA library would allow identification of mosquito host factors 
interacting with DENV by Y2H screen. These proteins can be used as a target for 
development of genetically-modified mosquitoes in order to control the spread of 
DENV in mosquito populations. In addition, these genes can also be manipulated 
for preventing DENV attachment or replication in mosquito, thus prevent the 
spread of dengue in the future. 
Overall, the work presented in this thesis, in particular the Y2H screen provides a 
number of human factors potentially targeted by DENV during infection. 
Nonetheless, more work is required in order to validate these proteins and 
determine their functional properties, as well as testing them with infectious 
DENV to establish a biological significance. Additionally, it is also important to 
assess the quality of the mosquito cDNA library established in this study, which 
can then be considered for use in the future. In the long term, data from this study 
are useful to investigate potential human or mosquito target candidates for 
development of an antiviral strategy against dengue.
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APPENDIX 
DENV Full 
length/Fragment 
DENV 
protein 
MGC 
interactor 
GeneID   Gene Details 3-AT 
conc 
No. of 
clones 
NS3 NS3 NUMA1 4926 NM_006185.2  Homo sapiens nuclear mitotic apparatus protein 1 (NUMA1), mRNA 0.25 1 
NS5 NS5 STAT2 6773 NM_005419.3  Homo sapiens signal transducer and activator of transcription 2, 113kDa (STAT2), transcript 
variant 1, mRNA 
0.25 1 
NS4B129F NS4B EMILIN1 11117 NM_007046.3  Homo sapiens elastin microfibril interfacer 1 (EMILIN1), mRNA 1 1 
NS5 NS5 EMILIN1      0.25 9 
NS2A187F NS2A UBE2I 7329 NM_194261.2  Homo sapiens ubiquitin-conjugating enzyme E2I (UBE2I), transcript variant 4, mRNA 0.25 1 
NS2B49F  NS2B  UBE2I      0.5 1 
NS4B129F NS4B UBE2I      1 6 
NS5 NS5 UBE2I       0.25 3 
NS5 NS5 GOPC 57120 NM_001017408.2  Homo sapiens golgi-associated PDZ and coiled-coil motif containing (GOPC), transcript variant 
2, mRNA 
0.25 3 
NS1 NS1 VPS28 51160 NM_183057.1  Homo sapiens vacuolar protein sorting 28 homolog (S. cerevisiae) (VPS28), transcript variant 2, 
mRNA 
0 1 
NS2A NS2A TMEM159 57146 NM_020422.4  Homo sapiens transmembrane protein 159 (TMEM159), mRNA 0.25 3 
NS2B1F NS2B AXIN2 8313 NM_004655.3  Homo sapiens axin 2 (AXIN2), mRNA 0 1 
NS5 NS5 TRIM27 5987 NM_006510.4  Homo sapiens tripartite motif containing 27 (TRIM27), mRNA 0.25 1 
NS2B NS2B ZNF3 7551 NM_032924.3  Homo sapiens zinc finger protein 3 (ZNF3), transcript variant 2, mRNA 0.5 1 
NS2B49F NS2B ZNF578 147660 NM_001099694.1  Homo sapiens zinc finger protein 578 (ZNF578), mRNA 0.5 4 
NS5 NS5 ZNF578       0.25 2 
NS3 NS3 ANKRD6 22881 NM_014942.4  Homo sapiens ankyrin repeat domain 6 (ANKRD6), transcript variant 3, mRNA 0.25 1 
NS3 NS3 APBB2 323 NM_173075.4  Homo sapiens amyloid beta (A4) precursor protein-binding, family B, member 2 (APBB2), 
transcript variant 3, mRNA 
0.25 1 
NS2B49F NS2B FAM226A 203429 NR_026595.1  Homo sapiens family with sequence similarity 226, member A (non-protein coding) 
(FAM226A), non-coding RNA 
0.5 1 
NS4A NS4A TNFSF13B 10673 NM_006573.4  Homo sapiens tumour necrosis factor (ligand) superfamily, member 13b (TNFSF13B), 
transcript variant 1, mRNA 
0.25 1 
NS5 NS5 CCDC57 284001 NM_198082.2  Homo sapiens coiled-coil domain containing 57 (CCDC57), mRNA 0.25 1 
NS2B NS2B CCDC155 147872 NM_144688.4  Homo sapiens coiled-coil domain containing 155 (CCDC155), mRNA 0.5 6 
NS4B NS4B CCDC155       1 3 
NS2B49F NS2B SMARCE1 6605 NM_003079.4  Homo sapiens SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily e, member 1 (SMARCE1), mRNA 
 
0.5 1 
 229 
 
NS2A NS2A RAB3IP 117177 NM_022456.3 Homo sapiens RAB3A interacting protein (rabin3) (RAB3IP), transcript variant alpha 1, mRNA 0.25 5 
NS3 NS3 RAB3IP      0.25 1 
NS4A NS4A RAB3IP      0.25 3 
NS2A NS2A ARL6IP1 23204 NM_015161.1 Homo sapiens ADP-ribosylation factor-like 6 interacting protein 1 (ARL6IP1), mRNA 0.25 5 
NS2A187F NS2A ARL6IP1      0.25 2 
NS2B NS2B ARL6IP1      0.5 4 
NS4A NS4A ARL6IP1       0.25 7 
NS2A NS2A KCNA3 3738 NM_002232.3 Homo sapiens potassium voltage-gated channel, shaker-related subfamily, member 3 
(KCNA3), mRNA 
0.25 1 
NS2A NS2A RTN4 57142 NM_207520.1 Homo sapiens reticulon 4 (RTN4), transcript variant 4, mRNA 0.25 1 
NS2B NS2B RTN4       0.5 9 
NS2A NS2A CRX 1406 NM_000554.4 Homo sapiens cone-rod homeobox (CRX), mRNA 0.25 3 
NS2A187F NS2A CRX      0.25 1 
NS3 NS3 CRX      0.25 6 
NS4A1F NS4A CRX      0 2 
NS4A122F NS4A CRX      0.25 1 
NS4B1F NS4B CRX      0.5 4 
NS4B129F NS4B CRX      1 2 
NS4B191F NS4B CRX      0 2 
NS5 NS5 CRX       0.25 4 
NS2A NS2A BEND7 222389 NM_001100912.1 Homo sapiens BEN domain containing 7 (BEND7), transcript variant 2, mRNA 0.25 1 
NS2B49F NS2B BEND7      0.5 1 
NS5 NS5 BEND7      0.25 1 
NS2A NS2A ALX1 8092 NM_006982.2 Homo sapiens ALX homeobox 1 (ALX1), mRNA 0.25 2 
NS2A187F NS2A ALX1       0.25 1 
NS2B1F NS2B ALX1       0 1 
NS3 NS3 ALX1       0.25 8 
NS4A1F NS4A ALX1       0 5 
NS4A101F NS4A ALX1       0.25 1 
NS4A122F NS4A ALX1       0.25 7 
NS4B1F NS4B ALX1       0.5 1 
NS4B129F NS4B ALX1       1 4 
NS5 
 
NS5 ALX1       0.25 8 
NS2A NS2A BANP 54971 NM_001173541.1 Homo sapiens BTG3 associated nuclear protein (BANP), transcript variant 5, mRNA 0.25 3 
NS2A187F NS2A BANP       0.25 2 
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NS2A187F NS2A OTX2 5015 NM_001270525.1 Homo sapiens orthodenticle homeobox 2 (OTX2), transcript variant 5, mRNA 0.25 1 
NS3 NS3 OTX2       0.25 2 
NS4A1F NS4A OTX2       0 1 
NS4A101F NS4A OTX2       0.25 1 
NS4A122F NS4A OTX2       0.25 1 
NS4B NS4B OTX2       1 1 
NS4B1F NS4B OTX2       0.5 3 
NS4B129F NS4B OTX2       1 2 
NS4B191F NS4B OTX2       0 1 
NS5 NS5 OTX2       0.25 8 
NS2A NS2A ZDHHC7 55625 NM_001145548.1 Homo sapiens zinc finger, DHHC-type containing 7 (ZDHHC7), transcript variant 1, mRNA 0.25 1 
NS2B NS2B CREB3 10488 NM_006368.4 Homo sapiens cAMP responsive element binding protein 3 (CREB3), mRNA 0.5 10 
NS3 NS3 CREB3       0.25 1 
NS4A NS4A CREB3       0.25 5 
NS4B NS4B CREB3       1 5 
NS2B NS2B AQP4 361 NM_001650.4 Homo sapiens aquaporin 4 (AQP4), transcript variant a, mRNA 0.5 1 
NS4A NS4A AQP4       0.25 1 
NS2B NS2B BSCL2 26580 NR_037949.1 Homo sapiens Berardinelli-Seip congenital lipodystrophy 2 (seipin) (BSCL2), transcript variant 
5, non-coding RNA 
0.5 1 
NS2B NS2B DDHD2 23259 NM_001164232.1 Homo sapiens DDHD domain containing 2 (DDHD2), transcript variant 2, mRNA 0.5 1 
NS2B NS2B TUG1 55000 NR_002323.1 Homo sapiens taurine upregulated 1 (non-protein coding) (TUG1), non-coding RNA 0.5 1 
NS2B NS2B OR2C3 81472 NM_198074.4 Homo sapiens olfactory receptor, family 2, subfamily C, member 3 (OR2C3), mRNA 0.5 1 
NS2B NS2B COMMD8 54951 NM_017845.3 Homo sapiens COMM domain containing 8 (COMMD8), mRNA 0.5 1 
NS2B NS2B FTMT 94033 NM_177478.1 Homo sapiens ferritin mitochondrial (FTMT), nuclear gene encoding mitochondrial protein, 
mRNA 
0.5 1 
NS2B NS2B AGXT2L2 85007 NM_153373.2 Homo sapiens alanine-glyoxylate aminotransferase 2-like 2 (AGXT2L2), mRNA 0.5 1 
NS2B NS2B STAG3L1 54441 NR_040583.1 Homo sapiens stromal antigen 3-like 1 (STAG3L1), non-coding RNA 0.5 1 
NS2B NS2B DNAL1 83544 NM_001201366.1 Homo sapiens dynein, axonemal, light chain 1 (DNAL1), transcript variant 2, mRNA 0.5 1 
NS2B1F NS2B BAG6 7917 NM_001199698.1 Homo sapiens BCL2-associated athanogene 6 (BAG6), transcript variant 6, mRNA 0 1 
NS2B1F NS2B SGTB 54557 NM_019072.2 Homo sapiens small glutamine-rich tetratricopeptide repeat (TPR)-containing, beta (SGTB), 
mRNA 
0 1 
NS4A122F NS4A SGTB      0.25 7 
NS2B1F NS2B GLYR1 84656 NM_032569.3 Homo sapiens glyoxylate reductase 1 homolog (Arabidopsis) (GLYR1), mRNA 0 1 
NS2B49F NS2B SETBP1 26040 NM_001130110.1 Homo sapiens SET binding protein 1 (SETBP1), transcript variant 2, mRNA 0.5 3 
NS5 NS5 SETBP1       0.25 4 
NS2B49F NS2B EXOSC7 23016 NM_015004.3 Homo sapiens exosome component 7 (EXOSC7), transcript variant 1, mRNA 0.5 3 
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NS2B49F NS2B ATM 472 NM_000051.3 Homo sapiens ataxia telangiectasia mutated (ATM), mRNA 0.5 1 
NS2B49F NS2B GAL 51083 NM_015973.3 Homo sapiens galanin prepropeptide (GAL), mRNA 0.5 1 
NS2B49F NS2B RPS14 6208 NM_001025071.1 Homo sapiens ribosomal protein S14 (RPS14), transcript variant 1, mRNA 0.5 1 
NS2B49F NS2B RBMS1 5937 NM_016836.3 Homo sapiens RNA binding motif, single stranded interacting protein 1 (RBMS1), transcript 
variant 1, mRNA 
0.5 1 
NS2B49F NS2B ELAVL2 1993 NM_001171197.1 Homo sapiens ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 (Hu antigen B) 
(ELAVL2), transcript variant 3, mRNA 
0.5 1 
NS2B49F NS2B RGS3 5998 NM_144489.2 Homo sapiens regulator of G-protein signaling 3 (RGS3), transcript variant 5, mRNA 0.5 1 
NS2B49F NS2B LYSMD3 116068 NM_198273.1 Homo sapiens LysM, putative peptidoglycan-binding, domain containing 3 (LYSMD3), mRNA 0.5 1 
NS2B49F NS2B NDUFA2 4695 NM_002488.4 Homo sapiens NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa (NDUFA2), 
nuclear gene encoding mitochondrial protein, transcript variant 1, mRNA 
0.5 1 
NS2B49F NS2B DLX2 1746 NM_004405.3 Homo sapiens distal-less homeobox 2 (DLX2), mRNA 0.5 1 
NS2B49F NS2B TRAPPC5 126003 NM_174894.2 Homo sapiens trafficking protein particle complex 5 (TRAPPC5), transcript variant 1, mRNA 0.5 1 
NS2B49F NS2B MESP1 55897 NM_018670.3 Homo sapiens mesoderm posterior 1 homolog (mouse) (MESP1), mRNA 0.5 1 
NS2B49F NS2B WDR45 11152 NM_007075.3 Homo sapiens WD repeat domain 45 (WDR45), transcript variant 1, mRNA 0.5 1 
NS3 NS3 TAGLN3 29114 TAGLN3 NM_001008273.1 Homo sapiens transgelin 3 (TAGLN3), transcript variant 3, mRNA 0.25 1 
NS3 NS3 USMG5 84833 USMG5 NM_001206426.1 Homo sapiens up-regulated during skeletal muscle growth 5 homolog (mouse) (USMG5), 
transcript variant 1, mRNA 
0.25 1 
NS3 NS3 AGSK1 80154 AGSK1 NR_026811.1 Homo sapiens golgin subfamily A member 2-like (AGSK1), non-coding RNA 0.25 1 
NS3 NS3 PER1 5187 PER1 NM_002616.2 Homo sapiens period homolog 1 (Drosophila) (PER1), mRNA 0.25 1 
NS3 NS3 LSMD1 84316 LSMD1 NM_032356.3 Homo sapiens LSM domain containing 1 (LSMD1), mRNA 0.25 1 
NS3 NS3 JAKMIP1 152789 NM_001099433.1 Homo sapiens janus kinase and microtubule interacting protein 1 (JAKMIP1), transcript variant 
1, mRNA 
0.25 1 
NS3 NS3 ZXDC 79364 NM_025112.4 Homo sapiens ZXD family zinc finger C (ZXDC), transcript variant 1, mRNA 0.25 1 
NS3 NS3 APCDD1 147495 NM_153000.4 Homo sapiens adenomatosis polyposis coli down-regulated 1 (APCDD1), mRNA 0.25 1 
NS3 NS3 CCL22 6367 NM_002990.4 Homo sapiens chemokine (C-C motif) ligand 22 (CCL22), mRNA 0.25 1 
NS3 NS3 HEXIM2 124790 NM_144608.1 Homo sapiens hexamethylene bis-acetamide inducible 2 (HEXIM2), mRNA 0.25 1 
NS3 NS3 WDR62 284403 NM_173636.4 Homo sapiens WD repeat domain 62 (WDR62), transcript variant 2, mRNA 0.25 1 
NS3 NS3 LHX4 89884 NM_033343.3 Homo sapiens LIM homeobox 4 (LHX4), mRNA 0.25 2 
NS3 NS3 CRP 1401 NM_000567.2 Homo sapiens C-reactive protein, pentraxin-related (CRP), mRNA 0.25 1 
NS3 NS3 ERLEC1 27248 NM_001127397.2 Homo sapiens endoplasmic reticulum lectin 1 (ERLEC1), transcript variant 2, mRNA 0.25 1 
NS3 NS3 KHDRBS1 10657 NM_006559.1 Homo sapiens KH domain containing, RNA binding, signal transduction associated 1 
(KHDRBS1), mRNA 
0.25 1 
NS3 NS3 VTN 7448 NM_000638.3 Homo sapiens vitronectin (VTN), mRNA 0.25 1 
NS3 NS3 C16orf87 388272 NM_001001436.2 Homo sapiens chromosome 16 open reading frame 87 (C16orf87), mRNA 0.25 1 
NS3 NS3 HYAL3 8372 NM_001200029.1 Homo sapiens hyaluronoglucosaminidase 3 (HYAL3), transcript variant 5, mRNA 0.25 1 
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NS3 NS3 LACRT 90070 NM_033277.1 Homo sapiens lacritin (LACRT), mRNA 0.25 1 
NS3 NS3 CELA2A 63036 NM_033440.2 Homo sapiens chymotrypsin-like elastase family, member 2A (CELA2A), mRNA 0.25 1 
NS3 NS3 IFI30 10437 NM_006332.3 Homo sapiens interferon, gamma-inducible protein 30 (IFI30), mRNA 0.25 1 
NS3 NS3 SH3GL1 6455 NM_003025.3 Homo sapiens SH3-domain GRB2-like 1 (SH3GL1), transcript variant 1, mRNA 0.25 1 
NS3 NS3 TPD52L3 89882 NM_001001875.3 Homo sapiens tumour protein D52-like 3 (TPD52L3), transcript variant 3, mRNA 0.25 1 
NS3 NS3 MRPL27 51264 NM_016504.2 Homo sapiens mitochondrial ribosomal protein L27 (MRPL27), nuclear gene encoding 
mitochondrial protein, mRNA 
0.25 1 
NS3 NS3 YARS2 51067 NM_001040436.2 Homo sapiens tyrosyl-tRNA synthetase 2, mitochondrial (YARS2), nuclear gene encoding 
mitochondrial protein, mRNA 
0.25 1 
NS4A1F NS4A MEOX2 4223 NM_005924.4 Homo sapiens mesenchyme homeobox 2 (MEOX2), mRNA 0 1 
NS4A122F NS4A SGTA 6449 SGTA NM_003021.3 Homo sapiens small glutamine-rich tetratricopeptide repeat (TPR)-containing, alpha (SGTA), 
mRNA 
0.25 1 
NS4B1F NS4B MT1X 4501 NM_005952.3 Homo sapiens metallothionein 1X (MT1X), mRNA 0.5 1 
NS4B1F NS4B APOM 55937 NM_019101.2 Homo sapiens apolipoprotein M (APOM), transcript variant 1, mRNA 0.5 1 
NS4B129F NS4B SUMO1 7341 NM_001005781.1 Homo sapiens SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae) (SUMO1), transcript 
variant 2, mRNA 
1 4 
NS4B129F NS4B SUMO1P1 391257 NR_002189.3 Homo sapiens SUMO1 pseudogene 1 (SUMO1P1), non-coding RNA 1 3 
NS4B129F NS4B KCNS2 3788 NM_020697.2 Homo sapiens potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 
(KCNS2), mRNA 
 
1 1 
NS4B191F NS4B PRR7 80758 NM_001174102.1 Homo sapiens proline rich 7 (synaptic) (PRR7), transcript variant 3, mRNA 0 1 
NS4B191F NS4B GRN 2896 NM_002087.2 Homo sapiens granulin (GRN), mRNA 0 1 
NS5 NS5 RPGRIP1 57096 RPGRIP1 NM_020366.3 Homo sapiens retinitis pigmentosa GTPase regulator interacting protein 1 (RPGRIP1), mRNA 0.25 1 
NS5 NS5 PDZD3 79849 NM_024791.3 Homo sapiens PDZ domain containing 3 (PDZD3), transcript variant 2, mRNA 0.25 1 
NS5 NS5 ID2 3398 NM_002166.4 Homo sapiens inhibitor of DNA binding 2, dominant negative helix-loop-helix protein (ID2), 
mRNA 
0.25 1 
NS5 NS5 GIPC2 54810 NM_017655.4 Homo sapiens GIPC PDZ domain containing family, member 2 (GIPC2), mRNA 0.25 1 
 
 
  
  
 
REFERENCES 
Ackermann, M. & Padmanabhan, R., 2001. De novo synthesis of RNA by the dengue virus RNA-
dependent RNA polymerase exhibits temperature dependence at the initiation but not 
elongation phase. The Journal of biological chemistry, 276(43), pp.39926–37. Available at: 
http://www.jbc.org/content/276/43/39926.long [Accessed November 2, 2015]. 
Adams, B. & Boots, M., 2010. How important is vertical transmission in mosquitoes for the persistence 
of dengue? Insights from a mathematical model. Epidemics, 2(1), pp.1–10. Available at: 
http://www.sciencedirect.com/science/article/pii/S1755436510000022 [Accessed August 20, 
2015]. 
Agaisse, H. & Perrimon, N., 2004. The roles of JAK/STAT signaling in Drosophila immune responses. 
Immunological reviews, 198, pp.72–82. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/15199955 [Accessed November 8, 2015]. 
Alcon, S. et al., 2002. Enzyme-linked immunosorbent assay specific to Dengue virus type 1 
nonstructural protein NS1 reveals circulation of the antigen in the blood during the acute phase 
of disease in patients experiencing primary or secondary infections. Journal of clinical 
microbiology, 40(2), pp.376–81. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=153354&tool=pmcentrez&renderty
pe=abstract [Accessed October 26, 2015]. 
Allison, S. et al., 1995. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins 
induced by an acidic pH. J. Virol., 69(2), pp.695–700. Available at: 
http://jvi.asm.org/content/69/2/695.abstract [Accessed October 20, 2015]. 
Alonzo, M.T.G. et al., 2012. Platelet apoptosis and apoptotic platelet clearance by macrophages in 
secondary dengue virus infections. The Journal of infectious diseases, 205(8), pp.1321–9. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/22383677 [Accessed August 31, 2015]. 
Alphey, L. et al., 2000. Insect Population Suppression Using Engineered Insects. Available at: 
http://www.ncbi.nlm.nih.gov/books/NBK6570/ [Accessed October 28, 2015]. 
Alvarez, J.D. et al., 2000. The MAR-binding protein SATB1 orchestrates temporal and spatial 
expression of multiple genes during T-cell development. Genes &amp; Dev., 14(5), pp.521–535. 
Available at: http://genesdev.cshlp.org/content/14/5/521.short [Accessed November 1, 2015]. 
Angel, B. & Joshi, V., 2008. Distribution and seasonality of vertically transmitted dengue viruses in 
Aedes mosquitoes in arid and semi-arid areas of Rajasthan, India. Journal of vector borne 
diseases, 45(1), pp.56–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18399318 
[Accessed October 23, 2015]. 
Angleró-Rodríguez, Y.I., Pantoja, P. & Sariol, C.A., 2014. Dengue virus subverts the interferon 
induction pathway via NS2B/3 protease-IκB kinase epsilon interaction. Clinical and vaccine 
immunology : CVI, 21(1), pp.29–38. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3910921&tool=pmcentrez&rendert
ype=abstract [Accessed November 13, 2015]. 
Arias, C.F., Preugschat, F. & Strauss, J.H., 1993. Dengue 2 virus NS2B and NS3 form a stable complex 
that can cleave NS3 within the helicase domain. Virology, 193(2), pp.888–99. Available at: 
http://www.sciencedirect.com/science/article/pii/S0042682283711980 [Accessed October 27, 
2015]. 
Arima, Y. et al., 2013. Epidemiologic update on the dengue situation in the Western Pacific Region, 
2011. Western Pacific surveillance and response journal : WPSAR, 4(2), pp.47–54. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3762964&tool=pmcentrez&rendert
ype=abstract [Accessed November 2, 2015]. 
Arima, Y. & Matsui, T., 2011. Epidemiologic update on the dengue situation in the Western Pacific 
Region, 2010. Western Pacific Surveillance and Response Journal, 2(2), pp.4–8. Available at: 
http://www.wpro.who.int/wpsar/volumes/02/2/2011_RA_Arima_Matsui/en/ [Accessed October 
27, 2015]. 
 234 
 
Armstrong, C.M. & Loboda, A., 2001. A model for 4-aminopyridine action on K channels: similarities 
to tetraethylammonium ion action. Biophysical journal, 81(2), pp.895–904. Available at: 
http://www.sciencedirect.com/science/article/pii/S0006349501757499 [Accessed August 17, 
2015]. 
Arunachalam, N. et al., 2008. Natural vertical transmission of dengue viruses by Aedes aegypti in 
Chennai, Tamil Nadu, India. The Indian journal of medical research, 127(4), pp.395–7. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/18577796 [Accessed October 23, 2015]. 
Ashour, J. et al., 2009. NS5 of dengue virus mediates STAT2 binding and degradation. Journal of 
virology, 83(11), pp.5408–18. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2681973&tool=pmcentrez&rendert
ype=abstract [Accessed June 13, 2015]. 
Avadhanula, V. et al., 2009. A novel system for the launch of alphavirus RNA synthesis reveals a role 
for the Imd pathway in arthropod antiviral response. PLoS pathogens, 5(9), p.e1000582. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2738967&tool=pmcentrez&rendert
ype=abstract [Accessed November 4, 2015]. 
Avirutnan, P. et al., 2007. Secreted NS1 of dengue virus attaches to the surface of cells via 
interactions with heparan sulfate and chondroitin sulfate E. PLoS pathogens, 3(11), p.e183. 
Available at: http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.0030183 
[Accessed October 24, 2015]. 
Avirutnan, P. et al., 2006. Vascular Leakage in Severe Dengue Virus Infections: A Potential Role for 
the Nonstructural Viral Protein NS1 and Complement. The Journal of Infectious Diseases, 193(8), 
pp.1078–1088. Available at: http://jid.oxfordjournals.org/content/193/8/1078.long [Accessed 
October 17, 2015]. 
de Azeredo, E.L., Monteiro, R.Q. & de-Oliveira Pinto, L.M., 2015. Thrombocytopenia in Dengue: 
Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and 
Inflammatory Mediators. Mediators of inflammation, 2015, p.313842. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4427128&tool=pmcentrez&rendert
ype=abstract [Accessed August 31, 2015]. 
Barletta, A.B.F., Silva, M.C.L.N. & Sorgine, M.H.F., 2012. Validation of Aedes aegypti Aag-2 cells as a 
model for insect immune studies., Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3419682&tool=pmcentrez&rendert
ype=abstract [Accessed September 14, 2015]. 
Barrios-Rodiles, M. et al., 2005. High-throughput mapping of a dynamic signaling network in 
mammalian cells. Science (New York, N.Y.), 307(5715), pp.1621–5. Available at: 
http://www.sciencemag.org/content/307/5715/1621.abstract [Accessed September 18, 2015]. 
Bartelma, G. & Padmanabhan, R., 2002. Expression, Purification, and Characterization of the RNA 5 ′-
Triphosphatase Activity of Dengue Virus Type 2 Nonstructural Protein 3. Virology, 299(1), 
pp.122–132. Available at: 
http://www.sciencedirect.com/science/article/pii/S0042682202915047 [Accessed October 27, 
2015]. 
Bartholomeusz, A.I. & Wright, P.J., 1993. Synthesis of dengue virus RNA in vitro: initiation and the 
involvement of proteins NS3 and NS5. Archives of Virology, 128(1-2), pp.111–121. Available at: 
http://link.springer.com/10.1007/BF01309792 [Accessed October 30, 2015]. 
Bartok, A. et al., 2014. Margatoxin is a non-selective inhibitor of human Kv1.3 K+ channels. Toxicon : 
official journal of the International Society on Toxinology, 87, pp.6–16. Available at: 
http://www.sciencedirect.com/science/article/pii/S0041010114001287 [Accessed August 21, 
2015]. 
Basurko, C. et al., 2009. Maternal and foetal consequences of dengue fever during pregnancy. 
European Journal of Obstetrics & Gynecology and Reproductive Biology, 147(1), pp.29–32. 
Available at: http://www.ejog.org/article/S0301211509004345/fulltext [Accessed September 
23, 2015]. 
 235 
 
Bednarczyk, P. et al., 2010. Identification of a voltage-gated potassium channel in gerbil hippocampal 
mitochondria. Biochemical and biophysical research communications, 397(3), pp.614–20. 
Available at: http://www.sciencedirect.com/science/article/pii/S0006291X10011149 [Accessed 
September 4, 2015]. 
Benarroch, D. et al., 2004. A structural basis for the inhibition of the NS5 dengue virus mRNA 2’-O-
methyltransferase domain by ribavirin 5'-triphosphate. The Journal of biological chemistry, 
279(34), pp.35638–43. Available at: http://www.jbc.org/content/279/34/35638.long [Accessed 
November 2, 2015]. 
Best, S.M. et al., 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne 
flavivirus and identification of NS5 as an interferon antagonist. Journal of virology, 79(20), 
pp.12828–39. Available at: http://jvi.asm.org/content/79/20/12828.long [Accessed August 15, 
2015]. 
Bezanilla, F., 2000. The Voltage Sensor in Voltage-Dependent Ion Channels. Physiol Rev, 80(2), 
pp.555–592. Available at: http://physrev.physiology.org/content/80/2/555 [Accessed August 31, 
2015]. 
Bhatt, S. et al., 2013. The global distribution and burden of dengue. Nature, 496(7446), pp.504–7. 
Available at: http://dx.doi.org/10.1038/nature12060 [Accessed July 11, 2014]. 
Birot, A.-M. et al., 2000. Identification and molecular analysis of BANP. Gene, 253(2), pp.189–196. 
Available at: http://www.sciencedirect.com/science/article/pii/S0378111900002444 [Accessed 
October 29, 2015]. 
Blacksell, S.D. et al., 2011. Evaluation of six commercial point-of-care tests for diagnosis of acute 
dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to 
achieve acceptable levels of accuracy. Clinical and vaccine immunology : CVI, 18(12), pp.2095–
101. Available at: http://cvi.asm.org/content/18/12/2095 [Accessed October 29, 2015]. 
Blair, C.D., 2011. Mosquito RNAi is the major innate immune pathway controlling arbovirus infection 
and transmission. Future microbiology, 6(3), pp.265–77. Available at: 
http://www.futuremedicine.com/doi/abs/10.2217/fmb.11.11 [Accessed August 6, 2015]. 
Blasche, S. & Koegl, M., 2013. Analysis of protein-protein interactions using LUMIER assays. Methods 
in molecular biology (Clifton, N.J.), 1064, pp.17–27. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23996247 [Accessed June 22, 2015]. 
Bode, J. et al., 1992. Biological significance of unwinding capability of nuclear matrix-associating 
DNAs. Science (New York, N.Y.), 255(5041), pp.195–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1553545 [Accessed October 30, 2015]. 
Bogdanov, E.A. et al., 2010. Normalizing cDNA libraries. Current protocols in molecular biology / 
edited by Frederick M. Ausubel ... [et al.], Chapter 5, p.Unit 5.12.1–27. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20373503 [Accessed October 4, 2015]. 
Bonifacino, J.S., Dell’Angelica, E.C. & Springer, T.A., 2001. Immunoprecipitation. Current protocols 
in molecular biology / edited by Frederick M. Ausubel ... [et al.], Chapter 10, p.Unit 10.16. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/18265056 [Accessed August 15, 2015]. 
Bouraï, M. et al., 2012. Mapping of Chikungunya virus interactions with host proteins identified nsP2 
as a highly connected viral component. Journal of virology, 86(6), pp.3121–34. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3302312&tool=pmcentrez&rendert
ype=abstract [Accessed November 3, 2015]. 
Brabant, M. et al., 2009. A flavivirus protein M-derived peptide directly permeabilizes mitochondrial 
membranes, triggers cell death and reduces human tumor growth in nude mice. Apoptosis : an 
international journal on programmed cell death, 14(10), pp.1190–203. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19693674 [Accessed September 30, 2015]. 
Brackney, D.E. et al., 2010. C6/36 Aedes albopictus cells have a dysfunctional antiviral RNA 
interference response. PLoS neglected tropical diseases, 4(10), p.e856. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2964293&tool=pmcentrez&rendert
ype=abstract [Accessed September 12, 2015]. 
 236 
 
Brault, J.-B. et al., 2011. The interaction of flavivirus M protein with light chain Tctex-1 of human 
dynein plays a role in late stages of virus replication. Virology, 417(2), pp.369–78. Available at: 
http://www.sciencedirect.com/science/article/pii/S0042682211002868 [Accessed September 9, 
2015]. 
Braun, P. et al., 2009. An experimentally derived confidence score for binary protein-protein 
interactions. Nature methods, 6(1), pp.91–7. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2976677&tool=pmcentrez&rendert
ype=abstract [Accessed October 23, 2015]. 
Bray, M. & Lai, C.-J., 1991. Dengue virus premembrane and membrane proteins elicit a protective 
immune response. Virology, 185(1), pp.505–508. Available at: 
http://www.sciencedirect.com/science/article/pii/004268229190809P [Accessed October 26, 
2015]. 
Bressan, G.M. et al., 1993. Emilin, a component of elastic fibers preferentially located at the elastin-
microfibrils interface. The Journal of cell biology, 121(1), pp.201–12. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2119774&tool=pmcentrez&rendert
ype=abstract [Accessed November 3, 2015]. 
Le Breton, M. et al., 2011. Flavivirus NS3 and NS5 proteins interaction network: a high-throughput 
yeast two-hybrid screen. BMC microbiology, 11(1), p.234. Available at: 
http://www.biomedcentral.com/1471-2180/11/234 [Accessed May 2, 2015]. 
Brown, J.C. & Song, C., 2005. High quality cDNA libraries for discovery and validation of novel drug 
targets. Emerging Therapeutic Targets. Available at: 
http://www.tandfonline.com/doi/abs/10.1517/14728222.4.1.113 [Accessed September 29, 
2015]. 
Brückner, A. et al., 2009. Yeast two-hybrid, a powerful tool for systems biology. International journal 
of molecular sciences, 10(6), pp.2763–88. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2705515&tool=pmcentrez&rendert
ype=abstract [Accessed August 27, 2015]. 
Bulet, P., 1999. Antimicrobial peptides in insects; structure and function. Developmental & 
Comparative Immunology, 23(4-5), pp.329–344. Available at: 
http://www.sciencedirect.com/science/article/pii/S0145305X99000154 [Accessed November 8, 
2015]. 
Cahalan, M.D. et al., 1985. A voltage-gated potassium channel in human T lymphocytes. The Journal 
of Physiology, 358(1), pp.197–237. Available at: 
http://doi.wiley.com/10.1113/jphysiol.1985.sp015548 [Accessed August 29, 2015]. 
Cai, Y.C. & Douglass, J., 1993. In vivo and in vitro phosphorylation of the T lymphocyte type n (Kv1.3) 
potassium channel. J. Biol. Chem., 268(31), pp.23720–23727. Available at: 
http://www.jbc.org/content/268/31/23720 [Accessed August 28, 2015]. 
Calderwood, M.A. et al., 2007. Epstein-Barr virus and virus human protein interaction maps. 
Proceedings of the National Academy of Sciences of the United States of America, 104(18), 
pp.7606–11. Available at: http://www.pnas.org/content/104/18/7606.long [Accessed June 16, 
2015]. 
Callahan, J.D. et al., 2001. Development and evaluation of serotype- and group-specific fluorogenic 
reverse transcriptase PCR (TaqMan) assays for dengue virus. Journal of clinical microbiology, 
39(11), pp.4119–24. Available at: http://jcm.asm.org/content/39/11/4119.long [Accessed 
August 3, 2015]. 
Cao, S. & Yan, L., 2013. Construction of a high-quality yeast two-hybrid (Y2H) library and its 
application in identification of interacting proteins with key vernalization regulator TaVRN-A1 in 
wheat. BMC research notes, 6(1), p.81. Available at: http://www.biomedcentral.com/1756-
0500/6/81 [Accessed October 4, 2015]. 
Cao-Lormeau, V.-M., 2009. Dengue viruses binding proteins from Aedes aegypti and Aedes 
polynesiensis salivary glands. Virology journal, 6(1), p.35. Available at: 
http://www.virologyj.com/content/6/1/35 [Accessed October 22, 2015]. 
 237 
 
Cardosa, M.J. et al., 2002. Antibodies against prM protein distinguish between previous infection with 
dengue and Japanese encephalitis viruses. BMC microbiology, 2, p.9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=113253&tool=pmcentrez&renderty
pe=abstract [Accessed November 2, 2015]. 
Carnec, X. et al., 2015. The Phosphatidylserine and Phosphatidylethanolamine Receptor CD300a Binds 
Dengue Virus and Enhances Infection. Journal of virology, 90(1), pp.92–102. Available at: 
http://jvi.asm.org/content/90/1/92.long?hwshib2=authn%3A1460187267%3A20160408%253A1bd4
e719-4a5f-4867-aba9-35c256d81831%3A0%3A0%3A0%3ARae0%2B5BeBmuqPE%2BM5j95eg%3D%3D 
[Accessed March 1, 2016]. 
Carvalho, F.A. et al., 2012. Dengue virus capsid protein binding to hepatic lipid droplets (LD) is 
potassium ion dependent and is mediated by LD surface proteins. Journal of virology, 86(4), 
pp.2096–108. Available at: 
http://jvi.asm.org/search?author1=Ivo+C.+Martins&sortspec=date&submit=Submit [Accessed 
October 27, 2015]. 
Catteau, A. et al., 2003. Dengue virus M protein contains a proapoptotic sequence referred to as 
ApoptoM. The Journal of general virology, 84(Pt 10), pp.2781–93. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.19163-0 [Accessed 
October 26, 2015]. 
Cervantes-Salazar, M. et al., 2015. Dengue virus NS1 protein interacts with the ribosomal protein 
RPL18: This interaction is required for viral translation and replication in Huh-7 cells. Virology, 
484, pp.113–26. Available at: http://www.ncbi.nlm.nih.gov/pubmed/26092250 [Accessed 
November 2, 2015]. 
Chadee, D.D., 2013. Resting behaviour of Aedes aegypti in Trinidad: with evidence for the re-
introduction of indoor residual spraying (IRS) for dengue control. Parasites & vectors, 6(1), 
p.255. Available at: http://www.parasitesandvectors.com/content/6/1/255 [Accessed October 
22, 2015]. 
Chakraborty, S. et al., 2014. Nuclear matrix protein SMAR1 represses c-Fos-mediated HPV18 E6 
transcription through alteration of chromatin histone deacetylation. The Journal of biological 
chemistry, 289(42), pp.29074–85. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4200262&tool=pmcentrez&rendert
ype=abstract [Accessed November 3, 2015]. 
Chakravarti, A. & Kumaria, R., 2006. Circulating levels of tumour necrosis factor-alpha & interferon-
gamma in patients with dengue & dengue haemorrhagic fever during an outbreak. The Indian 
journal of medical research, 123(1), pp.25–30. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16567864 [Accessed October 21, 2015]. 
Chandy, K.G., 1991. Simplified gene nomenclature. Nature, 352(6330), p.26. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/2062374 [Accessed August 31, 2015]. 
Chareonsirisuthigul, T., Kalayanarooj, S. & Ubol, S., 2007. Dengue virus (DENV) antibody-dependent 
enhancement of infection upregulates the production of anti-inflammatory cytokines, but 
suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. The 
Journal of general virology, 88(Pt 2), pp.365–75. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.82537-0 [Accessed 
October 2, 2015]. 
Charest, A. et al., 2001. Association of a novel PDZ domain-containing peripheral Golgi protein with 
the Q-SNARE (Q-soluble N-ethylmaleimide-sensitive fusion protein (NSF) attachment protein 
receptor) protein syntaxin 6. The Journal of biological chemistry, 276(31), pp.29456–65. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11384996 [Accessed November 3, 2015]. 
de Chassey, B. et al., 2008. Hepatitis C virus infection protein network. Molecular systems biology, 4, 
p.230. Available at: /pmc/articles/PMC2600670/?report=abstract [Accessed June 17, 2015]. 
de Chassey, B. et al., 2013. The interactomes of influenza virus NS1 and NS2 proteins identify new 
host factors and provide insights for ADAR1 playing a supportive role in virus replication. PLoS 
pathogens, 9(7), p.e1003440. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3701712&tool=pmcentrez&rendert
 238 
 
ype=abstract [Accessed March 9, 2015]. 
Chattopadhyay, S. et al., 2000a. SMAR1, a novel, alternatively spliced gene product, binds the 
Scaffold/Matrix-associated region at the T cell receptor beta locus. Genomics, 68(1), pp.93–6. 
Available at: http://www.sciencedirect.com/science/article/pii/S0888754300962797 [Accessed 
August 15, 2015]. 
Chattopadhyay, S. et al., 2000b. SMAR1, a novel, alternatively spliced gene product, binds the 
Scaffold/Matrix-associated region at the T cell receptor beta locus. Genomics, 68(1), pp.93–6. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/10950932 [Accessed October 30, 2015]. 
Chattopadhyay, S. & Pavithra, L., 2007. MARs and MARBPs: key modulators of gene regulation and 
disease manifestation. Sub-cellular biochemistry, 41, pp.213–30. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17484130 [Accessed November 1, 2015]. 
Chaudhary, N. et al., 2014. SMAR1 coordinates HDAC6-induced deacetylation of Ku70 and dictates cell 
fate upon irradiation. Cell death & disease, 5, p.e1447. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4237237&tool=pmcentrez&rendert
ype=abstract [Accessed August 15, 2015]. 
Chee, H.Y. & AbuBakar, S., 2004. Identification of a 48 kDa tubulin or tubulin-like C6/36 mosquito 
cells protein that binds dengue virus 2 using mass spectrometry. Biochemical and Biophysical 
Research Communications, 320(1), pp.11–17. 
Chen, S.-T. et al., 2008. CLEC5A is critical for dengue-virus-induced lethal disease. Nature, 
453(7195), pp.672–676. Available at: http://dx.doi.org/10.1038/nature07013 [Accessed October 
21, 2015]. 
Chen, Y. et al., 1997. Dengue virus infectivity depends on envelope protein binding to target cell 
heparan sulfate. Nature medicine, 3(8), pp.866–71. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9256277 [Accessed September 28, 2015]. 
Cheng, S. et al., 1994. Effective amplification of long targets from cloned inserts and human genomic 
DNA. Proceedings of the National Academy of Sciences of the United States of America, 91(12), 
pp.5695–9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44063&tool=pmcentrez&rendertyp
e=abstract [Accessed November 5, 2015]. 
Chisenhall, D.M. et al., 2014. Effect of dengue-2 virus infection on protein expression in the salivary 
glands of Aedes aegypti mosquitoes. The American journal of tropical medicine and hygiene, 
90(3), pp.431–7. Available at: http://www.ajtmh.org/content/90/3/431.long [Accessed 
September 30, 2015]. 
Chiu, M.-W. et al., 2007. The type 2 dengue virus envelope protein interacts with small ubiquitin-like 
modifier-1 (SUMO-1) conjugating enzyme 9 (Ubc9). Journal of biomedical science, 14(3), pp.429–
44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/17265167 [Accessed November 3, 
2015]. 
Choquet, D. & Korn, H., 1992. Mechanism of 4-aminopyridine action on voltage-gated potassium 
channels in lymphocytes. The Journal of general physiology, 99(2), pp.217–40. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2216608&tool=pmcentrez&rendert
ype=abstract [Accessed September 3, 2015]. 
Chua, J.J.E., Ng, M.M.L. & Chow, V.T.K., 2004. The non-structural 3 (NS3) protein of dengue virus 
type 2 interacts with human nuclear receptor binding protein and is associated with alterations 
in membrane structure. Virus research, 102(2), pp.151–63. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168170204000437 [Accessed November 
18, 2015]. 
Chung, K.M. et al., 2006. West Nile virus nonstructural protein NS1 inhibits complement activation by 
binding the regulatory protein factor H. Proceedings of the National Academy of Sciences of the 
United States of America, 103(50), pp.19111–6. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1664712&tool=pmcentrez&rendert
ype=abstract [Accessed November 18, 2015]. 
 239 
 
Chye, J.K. et al., 1997. Vertical transmission of dengue. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America, 25(6), pp.1374–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9431381 [Accessed October 22, 2015]. 
Clontech, 2010. Make Your Own “ Mate & Plate TM ” Library System User Manual, Clontech 
Laboratories, Inc. Takara Bio Company [Accessed July 30, 2015]. 
Colpitts, T.M. et al., 2011. Use of a tandem affinity purification assay to detect interactions between 
West Nile and dengue viral proteins and proteins of the mosquito vector. Virology, 417(1), 
pp.179–87. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3166580&tool=pmcentrez&rendert
ype=abstract [Accessed September 30, 2015]. 
Comes, N. et al., 2013. The voltage-dependent K(+) channels Kv1.3 and Kv1.5 in human cancer. 
Frontiers in physiology, 4, p.283. Available at: 
http://journal.frontiersin.org/article/10.3389/fphys.2013.00283/abstract [Accessed August 29, 
2015]. 
Condreay, L.D. & Brown, D.T., 1986. Exclusion of superinfecting homologous virus by Sindbis virus-
infected Aedes albopictus (mosquito) cells. J. Virol., 58(1), pp.81–86. Available at: 
http://jvi.asm.org/content/58/1/81.short [Accessed July 30, 2015]. 
Conwell, S.E. et al., 2015. Identification of TRIM27 as a novel degradation target of herpes simplex 
virus 1 ICP0. Journal of virology, 89(1), pp.220–9. Available at: 
http://jvi.asm.org/content/89/1/220.short [Accessed June 17, 2015]. 
Costa, A. et al., 2009. The Imd pathway is involved in antiviral immune responses in Drosophila. PloS 
one, 4(10), p.e7436. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007436 [Accessed October 5, 
2015]. 
Crill, W.D. & Roehrig, J.T., 2001. Monoclonal antibodies that bind to domain III of dengue virus E 
glycoprotein are the most efficient blockers of virus adsorption to Vero cells. Journal of 
virology, 75(16), pp.7769–73. Available at: http://jvi.asm.org/content/75/16/7769.long 
[Accessed October 29, 2015]. 
Cuzzubbo, A.J. et al., 1998. Detection of specific antibodies in saliva during dengue infection. 
Journal of clinical microbiology, 36(12), pp.3737–9. Available at: 
http://jcm.asm.org/content/36/12/3737.abstract [Accessed October 28, 2015]. 
Dame, D.A. et al., 2009. Historical applications of induced sterilisation in field populations of 
mosquitoes. Malaria Journal, 8(Suppl 2), p.S2. Available at: 
http://www.malariajournal.com/content/8/S2/S2 [Accessed October 22, 2015]. 
Danussi, C. et al., 2008. Emilin1 deficiency causes structural and functional defects of lymphatic 
vasculature. Molecular and cellular biology, 28(12), pp.4026–39. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2423131&tool=pmcentrez&rendert
ype=abstract [Accessed November 3, 2015]. 
David, J.-P. et al., 2010. Transcriptome response to pollutants and insecticides in the dengue vector 
Aedes aegypti using next-generation sequencing technology. BMC genomics, 11(1), p.216. 
Available at: http://www.biomedcentral.com/1471-2164/11/216. 
Dolan, P.T. et al., 2013. Identification and comparative analysis of hepatitis C virus-host cell protein 
interactions. Molecular bioSystems, 9(12), pp.3199–209. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4171131&tool=pmcentrez&rendert
ype=abstract [Accessed May 20, 2015]. 
Domon, B. & Aebersold, R., 2006. Mass spectrometry and protein analysis. Science (New York, N.Y.), 
312(5771), pp.212–7. Available at: http://www.sciencemag.org/content/312/5771/212 
[Accessed July 10, 2014]. 
Donald, C.L., Kohl, A. & Schnettler, E., 2012. New Insights into Control of Arbovirus Replication and 
Spread by Insect RNA Interference Pathways. Insects, 3(4), pp.511–531. Available at: 
http://www.mdpi.com/2075-4450/3/2/511/htm [Accessed August 17, 2015]. 
 240 
 
Doolittle, J.M. & Gomez, S.M., 2011. Mapping protein interactions between Dengue virus and its 
human and insect hosts. PLoS neglected tropical diseases, 5(2), p.e954. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000954 [Accessed June 8, 
2015]. 
Dostert, C. et al., 2005. The Jak-STAT signaling pathway is required but not sufficient for the 
antiviral response of drosophila. Nature immunology, 6(9), pp.946–53. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16086017 [Accessed September 2, 2015]. 
Dreux, M. et al., 2009. The autophagy machinery is required to initiate hepatitis C virus replication. 
Proceedings of the National Academy of Sciences of the United States of America, 106(33), 
pp.14046–51. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2729017&tool=pmcentrez&rendert
ype=abstract [Accessed February 22, 2016]. 
Duan, X. et al., 2008. Novel binding between pre-membrane protein and vacuolar ATPase is required 
for efficient dengue virus secretion. Biochemical and biophysical research communications, 
373(2), pp.319–24. Available at: 
http://www.sciencedirect.com/science/article/pii/S0006291X08011674 [Accessed October 26, 
2015]. 
Durbin, A.P. et al., 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue 
illness demonstrates infection and increased activation of monocytes in severe cases compared 
to classic dengue fever. Virology, 376(2), pp.429–35. Available at: 
/pmc/articles/PMC2546568/?report=abstract [Accessed November 2, 2015]. 
Dussart, P. et al., 2006. Evaluation of an enzyme immunoassay for detection of dengue virus NS1 
antigen in human serum. Clinical and vaccine immunology : CVI, 13(11), pp.1185–9. Available at: 
http://cvi.asm.org/content/13/11/1185.abstract [Accessed October 28, 2015]. 
Dyer, M.D., Murali, T.M. & Sobral, B.W., 2008. The landscape of human proteins interacting with 
viruses and other pathogens. PLoS pathogens, 4(2), p.e32. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2242834&tool=pmcentrez&rendert
ype=abstract [Accessed June 8, 2015]. 
Eckels, K.H. et al., 2003. Modification of dengue virus strains by passage in primary dog kidney cells: 
preparation of candidate vaccines and immunization of monkeys. The American journal of 
tropical medicine and hygiene, 69(6 Suppl), pp.12–6. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/14740950 [Accessed November 2, 2015]. 
Edelman, R., 2007. Dengue vaccines approach the finish line. Clinical infectious diseases : an official 
publication of the Infectious Diseases Society of America, 45 Suppl 1(Supplement_1), pp.S56–60. 
Available at: http://cid.oxfordjournals.org/content/45/Supplement_1/S56.long [Accessed 
November 2, 2015]. 
Egloff, M.-P. et al., 2002. An RNA cap (nucleoside-2’-O-)-methyltransferase in the flavivirus RNA 
polymerase NS5: crystal structure and functional characterization. The EMBO journal, 21(11), 
pp.2757–68. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=125380&tool=pmcentrez&renderty
pe=abstract [Accessed November 2, 2015]. 
Elshuber, S. et al., 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-
borne encephalitis virus. The Journal of general virology, 84(Pt 1), pp.183–91. Available at: 
http://jgv.microbiologyresearch.org/content/view.action?itemId=http%3A%2F%2Fsgm.metastore
.ingenta.com%2Fcontent%2Fjournal%2Fjgv%2F10.1099%2Fvir.0.18723-
0&view=&itemType=http%3A%2F%2Fpub2web.metastore.ingenta.com%2Fns%2FArticle [Accessed 
October 19, 2015]. 
Espinosa, M. et al., 2014. Vertical transmission of dengue virus in Aedes aegypti collected in Puerto 
Iguazú, Misiones, Argentina. Revista do Instituto de Medicina Tropical de São Paulo, 56(2), 
pp.165–7. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4085839&tool=pmcentrez&rendert
ype=abstract [Accessed October 23, 2015]. 
Esteva, L. & Vargas, C., 2000. Influence of vertical and mechanical transmission on the dynamics of 
 241 
 
dengue disease. Mathematical Biosciences, 167(1), pp.51–64. Available at: 
http://www.sciencedirect.com/science/article/pii/S0025556400000249 [Accessed October 25, 
2015]. 
Falgout, B. et al., 1991. Both nonstructural proteins NS2B and NS3 are required for the proteolytic 
processing of dengue virus nonstructural proteins. Journal of virology, 65(5), pp.2467–75. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=240601&tool=pmcentrez&renderty
pe=abstract [Accessed October 27, 2015]. 
Fan, J., Liu, Y. & Yuan, Z., 2014. Critical role of Dengue Virus NS1 protein in viral replication. 
Virologica Sinica, 29(3), pp.162–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24903593 [Accessed October 26, 2015]. 
Faustino, A.F. et al., 2014. Dengue virus capsid protein interacts specifically with very low-density 
lipoproteins. Nanomedicine : nanotechnology, biology, and medicine, 10(1), pp.247–55. 
Available at: http://www.sciencedirect.com/science/article/pii/S1549963413002724 [Accessed 
October 27, 2015]. 
Felipe, A. et al., 2012. Targeting the voltage-dependent K(+) channels Kv1.3 and Kv1.5 as tumor 
biomarkers for cancer detection and prevention. Current medicinal chemistry, 19(5), pp.661–74. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/22204339 [Accessed August 31, 2015]. 
Fernandez-Garcia, M.-D. et al., 2009. Pathogenesis of Flavivirus Infections: Using and Abusing the 
Host Cell. Cell Host & Microbe, 5(4), pp.318–328. Available at: 
http://www.sciencedirect.com/science/article/pii/S1931312809001024 [Accessed October 10, 
2015]. 
Ferrandon, D. et al., 2007. The Drosophila systemic immune response: sensing and signalling during 
bacterial and fungal infections. Nature reviews. Immunology, 7(11), pp.862–74. Available at: 
http://dx.doi.org/10.1038/nri2194 [Accessed November 8, 2015]. 
Fink, J. et al., 2007. Host gene expression profiling of dengue virus infection in cell lines and 
patients. PLoS neglected tropical diseases, 1(2), p.e86. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2100376&tool=pmcentrez&rendert
ype=abstract [Accessed June 6, 2015]. 
Fischl, W. & Bartenschlager, R., 2011. Exploitation of cellular pathways by Dengue virus. Current 
opinion in microbiology, 14(4), pp.470–5. Available at: 
http://www.sciencedirect.com/science/article/pii/S1369527411000968 [Accessed June 28, 
2015]. 
Flamand, M. et al., 1999. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from 
mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. Journal of virology, 
73(7), pp.6104–10. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=112675&tool=pmcentrez&renderty
pe=abstract [Accessed October 26, 2015]. 
Flipse, J., Wilschut, J. & Smit, J.M., 2013. Molecular mechanisms involved in antibody-dependent 
enhancement of dengue virus infection in humans. Traffic (Copenhagen, Denmark), 14(1), 
pp.25–35. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22998156 [Accessed October 28, 
2015]. 
Folly, B.B. et al., 2011. Dengue-2 structural proteins associate with human proteins to produce a 
coagulation and innate immune response biased interactome. BMC infectious diseases, 11(1), 
p.34. Available at: http://www.biomedcentral.com/1471-2334/11/34 [Accessed June 2, 2015]. 
Fragkoudis, R. et al., 2008. Semliki Forest virus strongly reduces mosquito host defence signaling. 
Insect molecular biology, 17(6), pp.647–56. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2710796&tool=pmcentrez&rendert
ype=abstract [Accessed July 31, 2015]. 
Friedel, C.C. & Haas, J., 2011. Virus-host interactomes and global models of virus-infected cells. 
Trends in microbiology, 19(10), pp.501–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21855347 [Accessed October 28, 2015]. 
 242 
 
Friedman, E.E. et al., 2014. Symptomatic Dengue infection during pregnancy and infant outcomes: a 
retrospective cohort study. PLoS neglected tropical diseases, 8(10), p.e3226. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0003226 [Accessed October 
25, 2015]. 
Fritz, R., Stiasny, K. & Heinz, F.X., 2008. Identification of specific histidines as pH sensors in 
flavivirus membrane fusion. The Journal of cell biology, 183(2), pp.353–61. Available at: 
http://jcb.rupress.org/content/183/2/353 [Accessed October 21, 2015]. 
Fujiwara, H. & Ishikawa, H., 1986. Molecular mechanism of introduction of the hidden break into the 
28S rRNA of insects: implication based on structural studies. Nucleic acids research, 14(16), 
pp.6393–401. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=311653&tool=pmcentrez&renderty
pe=abstract [Accessed October 3, 2015]. 
Fusco, C., Guidotti, E. & Zervos, A.S., 1999. In vivo construction of cDNA libraries for use in the yeast 
two-hybrid system. Yeast (Chichester, England), 15(8), pp.715–20. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10392448 [Accessed September 12, 2015]. 
Gao, F. et al., 2010. Novel binding between pre-membrane protein and claudin-1 is required for 
efficient dengue virus entry. Biochemical and biophysical research communications, 391(1), 
pp.952–7. Available at: http://www.sciencedirect.com/science/article/pii/S0006291X09023687 
[Accessed October 26, 2015]. 
Garcia-Calvo, M. et al., 1993. Purification, characterization, and biosynthesis of margatoxin, a 
component of Centruroides margaritatus venom that selectively inhibits voltage-dependent 
potassium channels. J. Biol. Chem., 268(25), pp.18866–18874. Available at: 
http://www.jbc.org/content/268/25/18866 [Accessed August 28, 2015]. 
Gasser, S.M. & Laemmli, U.K., 1987. A glimpse at chromosomal order. Trends in Genetics, 3, pp.16–
22. Available at: http://www.sciencedirect.com/science/article/pii/0168952587901569 
[Accessed November 1, 2015]. 
Gazula, V.-R. et al., 2010. Localization of Kv1.3 channels in presynaptic terminals of brainstem 
auditory neurons. The Journal of comparative neurology, 518(16), pp.3205–20. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2894291&tool=pmcentrez&rendert
ype=abstract [Accessed August 29, 2015]. 
Giard, D.J. et al., 1973. In vitro cultivation of human tumors: establishment of cell lines derived from 
a series of solid tumors. Journal of the National Cancer Institute, 51(5), pp.1417–23. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/4357758 [Accessed April 14, 2015]. 
Gietz, R.D. & Schiestl, R.H., 2007. High-efficiency yeast transformation using the LiAc/SS carrier 
DNA/PEG method. Nature protocols, 2(1), pp.31–4. Available at: 
http://dx.doi.org/10.1038/nprot.2007.13 [Accessed July 10, 2014]. 
Gindullis, F., 1999. Matrix Attachment Region Binding Protein MFP1 Is Localized in Discrete Domains 
at the Nuclear Envelope. The Plant Cell Online, 11(6), pp.1117–1128. Available at: 
http://www.plantcell.org/content/11/6/1117.full [Accessed November 1, 2015]. 
Giot, L. et al., 2003. A protein interaction map of Drosophila melanogaster. Science (New York, N.Y.), 
302(5651), pp.1727–36. Available at: 
http://www.sciencemag.org/content/302/5651/1727.abstract [Accessed October 25, 2015]. 
Girod, P.-A. & Mermod, N., 2003. Gene Transfer and Expression in Mammalian Cells, Elsevier. 
Available at: http://www.sciencedirect.com/science/article/pii/S0167730603380226 [Accessed 
October 30, 2015]. 
Goebel, P. et al., 2002. High frequency of matrix attachment regions and cut-like protein x/CCAAT-
displacement protein and B cell regulator of IgH transcription binding sites flanking Ig V region 
genes. Journal of immunology (Baltimore, Md. : 1950), 169(5), pp.2477–87. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12193717 [Accessed November 1, 2015]. 
Le Goff, G. et al., 2011. Natural vertical transmission of dengue viruses by Aedes aegypti in Bolivia. 
Parasite (Paris, France), 18(3), pp.277–80. Available at: 
 243 
 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3671471&tool=pmcentrez&rendert
ype=abstract [Accessed October 23, 2015]. 
Gomez, S.M. et al., 2005. Pilot Anopheles gambiae full-length cDNA study: sequencing and initial 
characterization of 35,575 clones. Genome biology, 6(4), p.R39. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1088967&tool=pmcentrez&rendert
ype=abstract [Accessed September 5, 2015]. 
Graham, F.L. et al., 1977. Characteristics of a Human Cell Line Transformed by DNA from Human 
Adenovirus Type 5. Journal of General Virology, 36(1), pp.59–72. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-36-1-59 [Accessed 
May 4, 2015]. 
Green, A.M. et al., 2014. Innate immunity to dengue virus infection and subversion of antiviral 
responses. Journal of molecular biology, 426(6), pp.1148–60. Available at: 
http://www.sciencedirect.com/science/article/pii/S0022283613007341 [Accessed February 28, 
2015]. 
Grunnet, M. et al., 2003. The voltage-gated potassium channel subunit, Kv1.3, is expressed in 
epithelia. Biochimica et Biophysica Acta (BBA) - Biomembranes, 1616(1), pp.85–94. Available at: 
http://www.sciencedirect.com/science/article/pii/S0005273603001986 [Accessed August 29, 
2015]. 
Gubler, D., 1998. Dengue and Dengue Hemorrhagic Fever. Clin. Microbiol. Rev., 11(3), pp.480–496. 
Available at: http://cmr.asm.org/content/11/3/480.full [Accessed October 15, 2015]. 
Gubler, D., 1997. Epidemic Dengue/Dengue Haemorrhagic Fever: a global public health problem in 
the 21st century. Dengue Bulletin, 21, pp.1–19. Available at: 
http://repository.searo.who.int/handle/123456789/16283 [Accessed October 28, 2015]. 
Gubler, D., 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic 
problem in the 21st century. Trends in Microbiology, 10(2), pp.100–103. Available at: 
http://www.sciencedirect.com/science/article/pii/S0966842X01022880 [Accessed October 1, 
2015]. 
Gubler, D. & Clark, G., 1995. Dengue/dengue hemorrhagic fever: the emergence of a global health 
problem. Emerging infectious diseases, 1(2), pp.55–7. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2626838&tool=pmcentrez&rendert
ype=abstract [Accessed October 16, 2015]. 
Gubler, D.J., 2006. Dengue/dengue haemorrhagic fever: history and current status. Novartis 
Foundation symposium, 277, pp.3–16; discussion 16–22, 71–3, 251–3. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17319151 [Accessed October 27, 2015]. 
Guirakhoo, F., Bolin, R.A. & Roehrig, J.T., 1992. The Murray Valley encephalitis virus prM protein 
confers acid resistance to virus particles and alters the expression of epitopes within the R2 
domain of E glycoprotein. Virology, 191(2), pp.921–31. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1280384 [Accessed October 25, 2015]. 
Gulbins, E. et al., 2010. Role of Kv1.3 mitochondrial potassium channel in apoptotic signalling in 
lymphocytes. Biochimica et Biophysica Acta (BBA) - Bioenergetics, 1797(6-7), pp.1251–1259. 
Available at: http://www.sciencedirect.com/science/article/pii/S0005272810000198 [Accessed 
July 1, 2015]. 
Guo, X. et al., 2010. Response of the mosquito protein interaction network to dengue infection. BMC 
genomics, 11, p.380. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3091628&tool=pmcentrez&rendert
ype=abstract [Accessed September 30, 2015]. 
Guo, X. et al., 2007. Survival and Replication of Dengue-2 Virus in Diapausing Eggs of Aedes albopictus 
(Diptera: Culicidae). Journal of Medical Entomology, 44(3), pp.492–497. Available at: 
http://jme.oxfordjournals.org/content/44/3/492.abstract [Accessed September 23, 2015]. 
Gupta, L. et al., 2009. The STAT pathway mediates late-phase immunity against Plasmodium in the 
mosquito Anopheles gambiae. Cell host & microbe, 5(5), pp.498–507. Available at: 
 244 
 
http://www.sciencedirect.com/science/article/pii/S1931312809001048 [Accessed November 
22, 2015]. 
Gutsche, I. et al., 2011. Secreted dengue virus nonstructural protein NS1 is an atypical barrel-shaped 
high-density lipoprotein. Proceedings of the National Academy of Sciences of the United States 
of America, 108(19), pp.8003–8. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3093454&tool=pmcentrez&rendert
ype=abstract [Accessed October 21, 2015]. 
Guy, B. et al., 2011. From research to phase III: preclinical, industrial and clinical development of the 
Sanofi Pasteur tetravalent dengue vaccine. Vaccine, 29(42), pp.7229–41. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21745521 [Accessed July 23, 2015]. 
Guzman, M.G. et al., 2010. Dengue: a continuing global threat. Nature Reviews Microbiology, pp.S7–
S16. 
Guzman, M.G., Alvarez, M. & Halstead, S.B., 2013. Secondary infection as a risk factor for dengue 
hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-
dependent enhancement of infection. Archives of virology, 158(7), pp.1445–59. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23471635 [Accessed November 2, 2015]. 
Guzman, M.G. & Harris, E., 2014. Dengue. The Lancet, 385(9966), pp.453–465. Available at: 
http://www.sciencedirect.com/science/article/pii/S0140673614605729. 
Hadinegoro, S.R. et al., 2015. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of 
Endemic Disease. The New England journal of medicine, 373(13), pp.1195–206. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/26214039 [Accessed July 28, 2015]. 
Halstead, S., 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-
neutralizing antibody. Journal of Experimental Medicine, 146(1), pp.201–217. Available at: 
http://jem.rupress.org/content/146/1/201 [Accessed October 29, 2015]. 
Halstead, S.B., 2008. Dengue virus-mosquito interactions. Annual review of entomology, 53, pp.273–
91. Available at: 
http://www.annualreviews.org/doi/abs/10.1146/annurev.ento.53.103106.093326?url_ver=Z39.8
8-2003&rfr_dat=cr_pub%3Dpubmed&rfr_id=ori%3Arid%3Acrossref.org&journalCode=ento 
[Accessed October 6, 2015]. 
Halstead, S.B., 2007. Dengue. Lancet (London, England), 370(9599), pp.1644–52. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17993365. 
Halstead, S.B., 2003. Neutralization and antibody-dependent enhancement of dengue viruses. 
Advances in virus research, 60, pp.421–67. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/14689700 [Accessed September 23, 2015]. 
Hanley, K.A. & Weaver, S.C., 2010. Frontiers in Dengue Virus Research, Horizon Scientific Press. 
Available at: https://books.google.com/books?hl=en&lr=&id=Z4o4zZ4vqbEC&pgis=1 [Accessed 
November 22, 2015]. 
Hartley, J.L., Temple, G.F. & Brasch, M.A., 2000. DNA Cloning Using In Vitro Site-Specific 
Recombination. Genome Research, 10(11), pp.1788–1795. 
Heaton, N.S. & Randall, G., 2010. Dengue virus-induced autophagy regulates lipid metabolism. Cell 
host & microbe, 8(5), pp.422–32. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3026642&tool=pmcentrez&rendert
ype=abstract [Accessed February 3, 2016]. 
Helms, L.M. et al., 1997. Margatoxin binds to a homomultimer of K(V)1.3 channels in Jurkat cells. 
Comparison with K(V)1.3 expressed in CHO cells. Biochemistry, 36(12), pp.3737–44. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9132027 [Accessed August 27, 2015]. 
Henchal, E.A. et al., 1983. Rapid identification of dengue virus isolates by using monoclonal 
antibodies in an indirect immunofluorescence assay. The American journal of tropical medicine 
and hygiene, 32(1), pp.164–9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/6401944 
[Accessed October 28, 2015]. 
 245 
 
Hermann, L.L. et al., 2014. Evaluation of a dengue NS1 antigen detection assay sensitivity and 
specificity for the diagnosis of acute dengue virus infection. PLoS neglected tropical diseases, 
8(10), p.e3193. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4183466&tool=pmcentrez&rendert
ype=abstract [Accessed August 23, 2015]. 
Herrmann, M. et al., 2010. Interaction of human immunodeficiency virus gp120 with the voltage-
gated potassium channel BEC1. FEBS letters, 584(16), pp.3513–8. Available at: 
http://www.sciencedirect.com/science/article/pii/S0014579310005715 [Accessed June 22, 
2015]. 
Higa, L.M. et al., 2008. Secretome of HepG2 cells infected with dengue virus: implications for 
pathogenesis. Biochimica et biophysica acta, 1784(11), pp.1607–16. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18639654 [Accessed November 22, 2015]. 
Ho, L.-J. et al., 2005. Dengue Virus Type 2 Antagonizes IFN-  but Not IFN-  Antiviral Effect via Down-
Regulating Tyk2-STAT Signaling in the Human Dendritic Cell. The Journal of Immunology, 
174(12), pp.8163–8172. Available at: http://www.jimmunol.org/content/174/12/8163.full 
[Accessed August 16, 2015]. 
Hober, D. et al., 1993. Serum levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), 
and interleukin-1 beta (IL-1 beta) in dengue-infected patients. The American journal of tropical 
medicine and hygiene, 48(3), pp.324–31. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8470771 [Accessed October 2, 2015]. 
Hoesel, B. & Schmid, J.A., 2013. The complexity of NF-κB signaling in inflammation and cancer. 
Molecular cancer, 12(1), p.86. Available at: http://www.molecular-
cancer.com/content/12/1/86 [Accessed July 10, 2014]. 
Hoffmann, J.A., 1995. Innate immunity of insects. Current Opinion in Immunology, 7(1), pp.4–10. 
Available at: http://www.sciencedirect.com/science/article/pii/0952791595800220 [Accessed 
September 15, 2015]. 
Holmes, E. & Twiddy, S., 2003. The origin, emergence and evolutionary genetics of dengue virus. 
Infection, Genetics and Evolution, 3(1), pp.19–28. Available at: 
http://www.sciencedirect.com/science/article/pii/S1567134803000042 [Accessed November 
24, 2014]. 
Holmes, T.C., Fadool, D.A. & Levitan, I.B., 1996. Tyrosine phosphorylation of the Kv1.3 potassium 
channel. The Journal of neuroscience : the official journal of the Society for Neuroscience, 
16(5), pp.1581–90. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8774427 [Accessed 
August 28, 2015]. 
Hombría, J.C.-G. et al., 2005. Characterisation of Upd2, a Drosophila JAK/STAT pathway ligand. 
Developmental biology, 288(2), pp.420–33. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16277982 [Accessed July 31, 2015]. 
Honda, S. et al., 2009. Increased Phagocytosis of Platelets from Patients with Secondary Dengue Virus 
Infection by Human Macrophages. Am J Trop Med Hyg, 80(5), pp.841–845. Available at: 
http://www.ajtmh.org/content/80/5/841.long [Accessed August 31, 2015]. 
Hotta, S., 1952. Experimental studies on dengue. I. Isolation, identification and modification of the 
virus. The Journal of infectious diseases, 90(1), pp.1–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/14888958 [Accessed October 27, 2015]. 
Hover, S. et al., 2016. Modulation of Potassium Channels Inhibits Bunyavirus Infection. The Journal of 
biological chemistry, 291(7), pp.3411–22. Available at: 
http://www.jbc.org/content/early/2015/12/16/jbc.M115.692673.abstract [Accessed April 13, 
2016]. 
Hu, L. et al., 2013. Blockade of Kv1.3 potassium channels inhibits differentiation and granzyme B 
secretion of human CD8+ T effector memory lymphocytes. PloS one, 8(1), p.e54267. Available 
at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0054267#pone.0054267-
Koo1 [Accessed July 27, 2015]. 
 246 
 
Hu, L. et al., 2007. Characterization of the Functional Properties of the Voltage-Gated Potassium 
Channel Kv1.3 in Human CD4+ T Lymphocytes. The Journal of Immunology, 179(7), pp.4563–
4570. Available at: http://www.jimmunol.org/content/179/7/4563.full [Accessed August 29, 
2015]. 
Hua, S.B. et al., 1997. Minimum length of sequence homology required for in vivo cloning by 
homologous recombination in yeast. Plasmid, 38(2), pp.91–96. 
Huang, D.W., Sherman, B.T. & Lempicki, R.A., 2009. Systematic and integrative analysis of large gene 
lists using DAVID bioinformatics resources. Nature protocols, 4(1), pp.44–57. Available at: 
http://www.nature.com/nprot/journal/v4/n1/pdf/nprot.2008.211.pdf [Accessed July 9, 2014]. 
Huang, K.-J. et al., 2006. The dual-specific binding of dengue virus and target cells for the antibody-
dependent enhancement of dengue virus infection. Journal of immunology (Baltimore, Md. : 
1950), 176(5), pp.2825–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16493039 
[Accessed November 2, 2015]. 
Hunsperger, E.A. et al., 2009. Evaluation of commercially available anti-dengue virus immunoglobulin 
M tests. Emerging infectious diseases, 15(3), pp.436–40. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2681117&tool=pmcentrez&rendert
ype=abstract [Accessed October 28, 2015]. 
Innis, B. & Eckels, K., 2003. Progress in development of a live-attenuated, tetravalent dengue virus 
vaccine by the United States Army Medical Research and Materiel Command. Am J Trop Med 
Hyg, 69(90060), pp.1–4. Available at: http://www.ajtmh.org/content/69/6_suppl/1.long 
[Accessed November 2, 2015]. 
Islam, S. et al., 2012. Highly multiplexed and strand-specific single-cell RNA 5’ end sequencing. 
Nature protocols, 7(5), pp.813–28. Available at: http://dx.doi.org/10.1038/nprot.2012.022 
[Accessed September 13, 2015]. 
Ivashkiv, L.B. & Donlin, L.T., 2014. Regulation of type I interferon responses. Nature reviews. 
Immunology, 14(1), pp.36–49. Available at: http://dx.doi.org/10.1038/nri3581 [Accessed July 
10, 2014]. 
Jackson, A.L. & Linsley, P.S., 2010. Recognizing and avoiding siRNA off-target effects for target 
identification and therapeutic application. Nature reviews. Drug discovery, 9(1), pp.57–67. 
Available at: http://dx.doi.org/10.1038/nrd3010 [Accessed September 22, 2015]. 
Jalota, A. et al., 2005. Tumor suppressor SMAR1 activates and stabilizes p53 through its arginine-
serine-rich motif. The Journal of biological chemistry, 280(16), pp.16019–29. Available at: 
http://www.jbc.org/content/280/16/16019.long [Accessed August 14, 2015]. 
Jang, S.H. et al., 2011. Anti-proliferative effect of Kv1.3 blockers in A549 human lung 
adenocarcinoma in vitro and in vivo. European journal of pharmacology, 651(1-3), pp.26–32. 
Available at: http://www.sciencedirect.com/science/article/pii/S0014299910010939 [Accessed 
August 28, 2015]. 
Jang, S.H. et al., 2015. Nuclear localization and functional characteristics of voltage-gated potassium 
channel Kv1.3. The Journal of biological chemistry, 290(20), pp.12547–57. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25829491 [Accessed August 21, 2015]. 
Jang, S.-H. et al., 2009. Kv1.3 voltage-gated K + channel subunit as a potential diagnostic marker and 
therapeutic target for breast cancer. BMB Reports, 42(8), pp.535–539. Available at: 
http://www.researchgate.net/publication/26772513_Kv1.3_voltage-
gated_K_channel_subunit_as_a_potential_diagnostic_marker_and_therapeutic_target_for_breas
t_cancer [Accessed August 31, 2015]. 
Jiang, B. et al., 2002. Endogenous KV channels in human embryonic kidney (HEK-293) cells. Molecular 
and Cellular Biochemistry, 238(1-2), pp.69–79. Available at: 
http://link.springer.com/article/10.1023/A%3A1019907104763 [Accessed August 27, 2015]. 
Jiang, L. et al., 2009. Polypyrimidine tract-binding protein influences negative strand RNA synthesis 
of dengue virus. Biochemical and biophysical research communications, 385(2), pp.187–92. 
Available at: http://www.sciencedirect.com/science/article/pii/S0006291X09009577 [Accessed 
 247 
 
November 2, 2015]. 
Jones, M. et al., 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. 
Journal of virology, 79(9), pp.5414–20. Available at: 
http://jvi.asm.org/content/79/9/5414.long [Accessed August 14, 2015]. 
Joshi, V., Mourya, D.T. & Sharma, R.C., 2002. Persistence of dengue-3 virus through transovarial 
transmission passage in successive generations of Aedes aegypti mosquitoes. The American 
journal of tropical medicine and hygiene, 67(2), pp.158–61. Available at: 
http://www.ajtmh.org/content/67/2/158.abstract [Accessed October 23, 2015]. 
Judge, S.I. V & Bever, C.T., 2006. Potassium channel blockers in multiple sclerosis: neuronal Kv 
channels and effects of symptomatic treatment. Pharmacology & therapeutics, 111(1), pp.224–
59. Available at: http://www.sciencedirect.com/science/article/pii/S0163725805002287 
[Accessed August 1, 2015]. 
Kakumani, P.K. et al., 2013. Role of RNA interference (RNAi) in dengue virus replication and 
identification of NS4B as an RNAi suppressor. Journal of virology, 87(16), pp.8870–83. Available 
at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3754049&tool=pmcentrez&rendert
ype=abstract [Accessed November 2, 2015]. 
Kalman, K., 1998. ShK-Dap22, a Potent Kv1.3-specific Immunosuppressive Polypeptide. Journal of 
Biological Chemistry, 273(49), pp.32697–32707. Available at: 
http://www.jbc.org/content/273/49/32697.full [Accessed September 4, 2015]. 
Kanlaya, R. et al., 2010a. The ubiquitin-proteasome pathway is important for dengue virus infection 
in primary human endothelial cells. Journal of proteome research, 9(10), pp.4960–71. Available 
at: http://dx.doi.org/10.1021/pr100219y [Accessed June 16, 2015]. 
Kanlaya, R. et al., 2010b. Vimentin interacts with heterogeneous nuclear ribonucleoproteins and 
dengue nonstructural protein 1 and is important for viral replication and release. Molecular 
bioSystems, 6(5), pp.795–806. Available at: 
http://pubs.rsc.org/en/content/articlehtml/2010/mb/b923864f [Accessed November 22, 2015]. 
Kapoor, M. et al., 1995. Association between NS3 and NS5 Proteins of Dengue Virus Type 2 in the 
Putative RNA Replicase Is Linked to Differential Phosphorylation of NS5. Journal of Biological 
Chemistry, 270(32), pp.19100–19106. Available at: 
http://www.jbc.org/content/270/32/19100.long [Accessed November 2, 2015]. 
Kaptein, S.J.F. et al., 2010. A derivate of the antibiotic doxorubicin is a selective inhibitor of dengue 
and yellow fever virus replication in vitro. Antimicrobial agents and chemotherapy, 54(12), 
pp.5269–80. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2981273&tool=pmcentrez&rendert
ype=abstract [Accessed July 8, 2015]. 
Karsten, P. et al., 2006. Mutational analysis reveals separable DNA binding and trans-activation of 
Drosophila STAT92E. Cellular signalling, 18(6), pp.819–29. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16129580 [Accessed July 31, 2015]. 
Käs, E. et al., 1993. A model for chromatin opening: stimulation of topoisomerase II and restriction 
enzyme cleavage of chromatin by distamycin. The EMBO journal, 12(1), pp.115–26. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=413181&tool=pmcentrez&renderty
pe=abstract [Accessed October 30, 2015]. 
Kassim, F.M. et al., 2011. Use of dengue NS1 antigen for early diagnosis of dengue virus infection. 
The Southeast Asian journal of tropical medicine and public health, 42(3), pp.562–9. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/21706934 [Accessed October 26, 2015]. 
Kaul, R. et al., 2003. Direct interaction with and activation of p53 by SMAR1 retards cell-cycle 
progression at G2/M phase and delays tumor growth in mice. International journal of cancer. 
Journal international du cancer, 103(5), pp.606–15. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12494467 [Accessed August 15, 2015]. 
Kaur, P. & Kaur, G., 2014. Transfusion support in patients with dengue fever. International journal of 
 248 
 
applied & basic medical research, 4(Suppl 1), pp.S8–S12. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4181139&tool=pmcentrez&rendert
ype=abstract [Accessed October 28, 2015]. 
Kawai, T. & Akira, S., 2008. Toll-like receptor and RIG-I-like receptor signaling. Annals of the New 
York Academy of Sciences, 1143, pp.1–20. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19076341 [Accessed November 13, 2015]. 
Kazama, I., 2015. Physiological significance of delayed rectifier K(+) channels (Kv1.3) expressed in T 
lymphocytes and their pathological significance in chronic kidney disease. The journal of 
physiological sciences : JPS, 65(1), pp.25–35. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/25096892 [Accessed August 29, 2015]. 
Khadka, S. et al., 2011. A physical interaction network of dengue virus and human proteins. 
Molecular & cellular proteomics : MCP, 10(12), p.M111.012187. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3237087&tool=pmcentrez&rendert
ype=abstract [Accessed November 3, 2015]. 
Kim, J.-M. et al., 2004. Improved recombinant gene expression in CHO cells using matrix attachment 
regions. Journal of Biotechnology, 107(2), pp.95–105. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168165603002670 [Accessed October 30, 
2015]. 
Kingsolver, M.B., Huang, Z. & Hardy, R.W., 2013. Insect antiviral innate immunity: pathways, 
effectors, and connections. Journal of molecular biology, 425(24), pp.4921–36. Available at: 
http://www.sciencedirect.com/science/article/pii/S0022283613006323 [Accessed October 1, 
2015]. 
Klickstein, L.B., 2001. Production of a complete cDNA library. Current protocols in molecular biology 
/ edited by Frederick M. Ausubel ... [et al.], Chapter 5, p.Unit5.8A. 
Knaus, H.-G. et al., 1995. [125I]Margatoxin, an Extraordinarily High Affinity Ligand for Voltage-Gated 
Potassium Channels in Mammalian Brain. Biochemistry, 34(41), pp.13627–13634. Available at: 
http://dx.doi.org/10.1021/bi00041a043 [Accessed August 27, 2015]. 
Koni, P.A. et al., 2003. Compensatory anion currents in Kv1.3 channel-deficient thymocytes. The 
Journal of biological chemistry, 278(41), pp.39443–51. Available at: 
http://www.jbc.org/content/278/41/39443.long [Accessed August 29, 2015]. 
Kotak, S., Busso, C. & Gönczy, P., 2014. NuMA interacts with phosphoinositides and links the mitotic 
spindle with the plasma membrane. The EMBO journal, 33(16), pp.1815–30. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4195763&tool=pmcentrez&rendert
ype=abstract [Accessed November 23, 2015]. 
Kow, C.Y., Koon, L.L. & Yin, P.F., 2001. Detection of Dengue Viruses in Field Caught Male Aedes 
aegypti and Aedes albopictus (Diptera: Culicidae) in Singapore by Type-Specific PCR. Journal of 
Medical Entomology, 38(4), pp.475–479. Available at: http://dx.doi.org/10.1603/0022-2585-
38.4.475 [Accessed October 23, 2015]. 
Kreusch, A. et al., 1998. Crystal structure of the tetramerization domain of the Shaker potassium 
channel. Nature, 392(6679), pp.945–8. Available at: http://dx.doi.org/10.1038/31978 [Accessed 
August 31, 2015]. 
Krishnan, M.N. et al., 2008. RNA interference screen for human genes associated with West Nile virus 
infection. Nature, 455(7210), pp.242–5. Available at: http://dx.doi.org/10.1038/nature07207 
[Accessed August 4, 2015]. 
Kuadkitkan, A. et al., 2010. Identification and characterization of prohibitin as a receptor protein 
mediating DENV-2 entry into insect cells. Virology, 406(1), pp.149–161. Available at: 
http://dx.doi.org/10.1016/j.virol.2010.07.015. 
Kuhn, R.J. et al., 2002. Structure of dengue virus: implications for flavivirus organization, 
maturation, and fusion. Cell, 108(5), pp.717–25. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4152842&tool=pmcentrez&rendert
ype=abstract [Accessed October 19, 2015]. 
 249 
 
Kulkarni, A. et al., 2004. HIV-1 integration sites are flanked by potential MARs that alone can act as 
promoters. Biochemical and biophysical research communications, 322(2), pp.672–7. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/15325282 [Accessed November 10, 2015]. 
Kumar, A., Zhang, J. & Yu, F.-S.X., 2006. Toll-like receptor 3 agonist poly(I:C)-induced antiviral 
response in human corneal epithelial cells. Immunology, 117(1), pp.11–21. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1782193&tool=pmcentrez&rendert
ype=abstract [Accessed August 6, 2015]. 
Kummerer, B.M. & Rice, C.M., 2002. Mutations in the Yellow Fever Virus Nonstructural Protein NS2A 
Selectively Block Production of Infectious Particles. Journal of Virology, 76(10), pp.4773–4784. 
Available at: http://jvi.asm.org/content/76/10/4773.long [Accessed October 27, 2015]. 
Kuno, G., Gómez, I. & Gubler, D.J., 1991. An ELISA procedure for the diagnosis of dengue infections. 
Journal of virological methods, 33(1-2), pp.101–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/1939502 [Accessed October 28, 2015]. 
Kurane, I. et al., 1991a. Activation of T lymphocytes in dengue virus infections. High levels of soluble 
interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of 
children with dengue. The Journal of clinical investigation, 88(5), pp.1473–80. Available at: 
http://www.jci.org/articles/view/115457 [Accessed August 31, 2015]. 
Kurane, I. et al., 1991b. Activation of T lymphocytes in dengue virus infections. High levels of soluble 
interleukin 2 receptor, soluble CD4, soluble CD8, interleukin 2, and interferon-gamma in sera of 
children with dengue. The Journal of clinical investigation, 88(5), pp.1473–80. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=295652&tool=pmcentrez&renderty
pe=abstract [Accessed October 27, 2015]. 
Lahiri, M., Fisher, D. & Tambyah, P.A., 2008. Dengue mortality: reassessing the risks in transition 
countries. Transactions of the Royal Society of Tropical Medicine and Hygiene, 102(10), 
pp.1011–6. Available at: http://trstmh.oxfordjournals.org/content/102/10/1011.short 
[Accessed November 18, 2015]. 
Lai, C.-Y. et al., 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course 
of infection are predominantly cross-reactive and recognize epitopes containing highly 
conserved residues at the fusion loop of domain II. Journal of virology, 82(13), pp.6631–43. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2447043&tool=pmcentrez&rendert
ype=abstract [Accessed October 7, 2015]. 
Lanciotti, R.S. et al., 1992. Rapid detection and typing of dengue viruses from clinical samples by 
using reverse transcriptase-polymerase chain reaction. Journal of clinical microbiology, 30(3), 
pp.545–51. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=265106&tool=pmcentrez&renderty
pe=abstract [Accessed October 28, 2015]. 
Landy, A. (1989) Dynamic, Structural, and Regulatory Aspects of Lambda Site-specific Recombination. 
Ann. Rev. Biochem. 58, 913-949 [Accessed July 7, 2015]. 
Lang, J., 2012. Development of Sanofi Pasteur tetravalent dengue vaccine. Revista do Instituto de 
Medicina Tropical de São Paulo, 54, pp.15–17. Available at: 
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0036-
46652012000700007&lng=en&nrm=iso&tlng=en [Accessed November 21, 2015]. 
Laurent-Rolle, M. et al., 2014. The interferon signaling antagonist function of yellow fever virus NS5 
protein is activated by type I interferon. Cell host & microbe, 16(3), pp.314–27. Available at: 
http://www.sciencedirect.com/science/article/pii/S1931312814002947 [Accessed November 4, 
2015]. 
Lee, M.S. et al., 2013. Negative regulation of type I IFN expression by OASL1 permits chronic viral 
infection and CD8+ T-cell exhaustion. PLoS pathogens, 9(7), p.e1003478. Available at: 
http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1003478 [Accessed 
June 11, 2015]. 
Lee, Y.-R. et al., 2008. Autophagic machinery activated by dengue virus enhances virus replication. 
 250 
 
Virology, 374(2), pp.240–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18353420 
[Accessed October 28, 2015]. 
Lemaitre, B. et al., 1995. A recessive mutation, immune deficiency (imd), defines two distinct 
control pathways in the Drosophila host defense. Proceedings of the National Academy of 
Sciences of the United States of America, 92(21), pp.9465–9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=40822&tool=pmcentrez&rendertyp
e=abstract [Accessed September 4, 2015]. 
Lemaitre, B. et al., 1996. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the 
potent antifungal response in Drosophila adults. Cell, 86(6), pp.973–83. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8808632 [Accessed January 16, 2015]. 
Leung, J.Y. et al., 2008. Role of nonstructural protein NS2A in flavivirus assembly. Journal of 
virology, 82(10), pp.4731–41. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2346727&tool=pmcentrez&rendert
ype=abstract [Accessed August 14, 2015]. 
Levitan, I. & Barrantes, F., 2012. Cholesterol Regulation of Ion Channels and Receptors, John Wiley & 
Sons. Available at: https://books.google.com/books?id=T4Zr3CfwBwYC&pgis=1 [Accessed August 
27, 2015]. 
Lewis, R.S. & Cahalan, M.D., 1995. Potassium and calcium channels in lymphocytes. Annual review of 
immunology, 13, pp.623–53. Available at: http://www.ncbi.nlm.nih.gov/pubmed/7612237 
[Accessed September 1, 2015]. 
Li, K. et al., 2005. Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta 
production in hepatocytes. The Journal of biological chemistry, 280(17), pp.16739–47. Available 
at: http://www.jbc.org/content/280/17/16739.full [Accessed August 15, 2015]. 
Li, S., 2004. A Map of the Interactome Network of the Metazoan C. elegans. Science, 303(5657), 
pp.540–543. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1698949&tool=pmcentrez&rendert
ype=abstract [Accessed October 2, 2015]. 
Li, Y. et al., 2013. Human apolipoprotein A-I is associated with dengue virus and enhances virus 
infection through SR-BI. PloS one, 8(7), p.e70390. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070390 [Accessed April 7, 
2016]. 
Libraty, D.H. et al., 2002. High Circulating Levels of the Dengue Virus Nonstructural Protein NS1 Early 
in Dengue Illness Correlate with the Development of Dengue Hemorrhagic Fever. The Journal of 
Infectious Diseases, 186(8), pp.1165–1168. Available at: 
http://jid.oxfordjournals.org/content/186/8/1165.long [Accessed October 17, 2015]. 
Lima, M. da R.Q. et al., 2010. Comparison of three commercially available dengue NS1 antigen 
capture assays for acute diagnosis of dengue in Brazil. PLoS neglected tropical diseases, 4(7), 
p.e738. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2897844&tool=pmcentrez&rendert
ype=abstract [Accessed October 28, 2015]. 
Lin, C.S., 1993. Voltage-gated potassium channels regulate calcium-dependent pathways involved in 
human T lymphocyte activation. Journal of Experimental Medicine, 177(3), pp.637–645. 
Available at: 
http://jem.rupress.org/content/177/3/637.abstract?ijkey=7ac43e3fb467e86ad7b5c8e8ee36d2a4
f7a990b1&keytype2=tf_ipsecsha [Accessed August 31, 2015]. 
Lin, M.-H. et al., 2014. Membrane undulation induced by NS4A of Dengue virus: a molecular dynamics 
simulation study. Journal of biomolecular structure & dynamics, 32(10), pp.1552–62. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/23964591 [Accessed October 27, 2015]. 
Lindenbach, B.D. & Rice, C.M., 1999. Genetic Interaction of Flavivirus Nonstructural Proteins NS1 and 
NS4A as a Determinant of Replicase Function. J. Virol., 73(6), pp.4611–4621. Available at: 
http://jvi.asm.org/content/73/6/4611.abstract [Accessed October 26, 2015]. 
 251 
 
Lindenbach, B.D. & Rice, C.M., 2003. Molecular biology of flaviviruses. Advances in virus research, 
59, pp.23–61. Available at: http://www.ncbi.nlm.nih.gov/pubmed/14696326 [Accessed 
September 7, 2015]. 
Linnen, J.M. et al., 2008. Dengue viremia in blood donors from Honduras, Brazil, and Australia. 
Transfusion, 48(7), pp.1355–62. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18503610 
[Accessed October 25, 2015]. 
Linthicum, K.J. et al., 1996. Dengue 3 virus distribution in the mosquito Aedes aegyptl: an 
immunocytochemical study. Medical and Veterinary Entomology, 10(1), pp.87–92. Available at: 
http://doi.wiley.com/10.1111/j.1365-2915.1996.tb00086.x [Accessed October 22, 2015]. 
Lisova, O. et al., 2007. Mapping to completeness and transplantation of a group-specific, 
discontinuous, neutralizing epitope in the envelope protein of dengue virus. The Journal of 
general virology, 88(Pt 9), pp.2387–97. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.83028-0 [Accessed 
November 2, 2015]. 
Liu, J. et al., 2012. A synthetic double-stranded RNA, poly I:C, induces a rapid apoptosis of human 
CD34(+) cells. Experimental hematology, 40(4), pp.330–41. Available at: 
http://www.exphem.org/article/S0301472X11005947/fulltext [Accessed August 13, 2015]. 
Liu, J. et al., 2013. HIV-1 Tat protein increases microglial outward K(+) current and resultant 
neurotoxic activity. PloS one, 8(5), p.e64904. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0064904 [Accessed 
September 1, 2015]. 
Liu, J. et al., 2012. Involvement of Kv1.3 and p38 MAPK signaling in HIV-1 glycoprotein 120-induced 
microglia neurotoxicity. Cell death & disease, 3, p.e254. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3270274&tool=pmcentrez&rendert
ype=abstract [Accessed September 1, 2015]. 
Liu, S. et al., 2013. MAVS recruits multiple ubiquitin E3 ligases to activate antiviral signaling 
cascades. eLife, 2, p.e00785. Available at: http://elifesciences.org/content/2/e00785.abstract 
[Accessed November 19, 2015]. 
Liu, W.J. et al., 2006. A single amino acid substitution in the West Nile virus nonstructural protein 
NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence 
in mice. Journal of virology, 80(5), pp.2396–404. Available at: 
http://jvi.asm.org/content/80/5/2396.long [Accessed July 7, 2015]. 
Liu, W.J. et al., 2004. Analysis of adaptive mutations in Kunjin virus replicon RNA reveals a novel role 
for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven 
transcription. Journal of virology, 78(22), pp.12225–35. Available at: 
http://jvi.asm.org/content/78/22/12225.long [Accessed October 27, 2015]. 
Ma, H. et al., 1987. Plasmid construction by homologous recombination in yeast. Gene, 58(2-3), 
pp.201–16. Available at: http://www.ncbi.nlm.nih.gov/pubmed/2828185 [Accessed November 7, 
2015]. 
Ma, L. et al., 2004. Solution structure of dengue virus capsid protein reveals another fold. 
Proceedings of the National Academy of Sciences of the United States of America, 101(10), 
pp.3414–9. Available at: http://www.pnas.org/content/101/10/3414.abstract [Accessed 
October 19, 2015]. 
Macharia, R.W., Ombura, F.L. & Aroko, E.O., 2015. Insects’ RNA Profiling Reveals Absence of “Hidden 
Break” in 28S Ribosomal RNA Molecule of Onion Thrips, Thrips tabaci. Journal of Nucleic Acids, 
2015. Available at: https://doaj.org/article/c99b90cd973c45b081bfcdec6d639601 [Accessed 
September 27, 2015]. 
Mackenzie, J., Jones, M. & Young, P., 1996. Immunolocalization of the Dengue Virus Nonstructural 
Glycoprotein NS1 Suggests a Role in Viral RNA Replication. Virology, 220(1), pp.232–240. 
Available at: http://www.sciencedirect.com/science/article/pii/S0042682296903074 [Accessed 
September 28, 2015]. 
 252 
 
Mackenzie, J.M. et al., 1998. Subcellular localization and some biochemical properties of the 
flavivirus Kunjin nonstructural proteins NS2A and NS4A. Virology, 245(2), pp.203–15. Available 
at: http://www.sciencedirect.com/science/article/pii/S0042682298991565 [Accessed August 
14, 2015]. 
Macpherson, I. & Stoker, M., 1962. Polyoma transformation of hamster cell clones—an investigation of 
genetic factors affecting cell competence. Virology, 16(2), pp.147–151. Available at: 
http://www.sciencedirect.com/science/article/pii/0042682262902908 [Accessed July 30, 2015]. 
Mairiang, D. et al., 2013. Identification of new protein interactions between dengue fever virus and 
its hosts, human and mosquito. PloS one, 8(1), p.e53535. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0053535 [Accessed August 7, 
2015]. 
Malavige, G.N. & Ogg, G.S., 2013. T cell responses in dengue viral infections. Journal of clinical 
virology : the official publication of the Pan American Society for Clinical Virology, 58(4), 
pp.605–11. Available at: 
http://www.journalofclinicalvirology.com/article/S138665321300471X/fulltext [Accessed 
November 2, 2015]. 
Malonia, S.K. et al., 2014. Chromatin remodeling protein SMAR1 regulates NF-κB dependent 
Interleukin-8 transcription in breast cancer. The international journal of biochemistry & cell 
biology, 55, pp.220–6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25239884 [Accessed 
November 13, 2015]. 
Malonia, S.K. et al., 2011. Gene regulation by SMAR1: Role in cellular homeostasis and cancer. 
Biochimica et Biophysica Acta - Reviews on Cancer, 1815(1), pp.1–12. Available at: 
http://www.sciencedirect.com/science/article/pii/S0304419X10000600 [Accessed June 30, 
2015]. 
Mankouri, J. et al., 2009. Suppression of a pro-apoptotic K+ channel as a mechanism for hepatitis C 
virus persistence. Proceedings of the National Academy of Sciences of the United States of 
America, 106(37), pp.15903–8. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2747216&tool=pmcentrez&rendert
ype=abstract [Accessed September 1, 2015]. 
Mao, Y. et al., 2000. SUMO-1 conjugation to topoisomerase I: A possible repair response to 
topoisomerase-mediated DNA damage. Proceedings of the National Academy of Sciences of the 
United States of America, 97(8), pp.4046–51. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=18143&tool=pmcentrez&rendertyp
e=abstract [Accessed November 3, 2015]. 
Martins, V.E.P. et al., 2012. Occurrence of natural vertical transmission of dengue-2 and dengue-3 
viruses in Aedes aegypti and Aedes albopictus in Fortaleza, Ceará, Brazil. PloS one, 7(7), 
p.e41386. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0041386 [Accessed October 
23, 2015]. 
Massé, N. et al., 2010. Dengue virus replicons: production of an interserotypic chimera and cell lines 
from different species, and establishment of a cell-based fluorescent assay to screen inhibitors, 
validated by the evaluation of ribavirin’s activity. Antiviral research, 86(3), pp.296–305. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/20307577 [Accessed November 6, 2015]. 
Mathew, A. & Rothman, A.L., 2008. Understanding the contribution of cellular immunity to dengue 
disease pathogenesis. Immunological reviews, 225, pp.300–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18837790 [Accessed November 2, 2015]. 
Matsumoto, M. & Seya, T., 2008. TLR3: interferon induction by double-stranded RNA including 
poly(I:C). Advanced drug delivery reviews, 60(7), pp.805–12. Available at: 
http://www.sciencedirect.com/science/article/pii/S0169409X07003833 [Accessed May 18, 
2015]. 
Matter, N., Herrlich, P. & König, H., 2002. Signal-dependent regulation of splicing via phosphorylation 
of Sam68. Nature, 420(6916), pp.691–5. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12478298 [Accessed November 3, 2015]. 
 253 
 
Matz, M. V, 2002. Amplification of representative cDNA samples from microscopic amounts of 
invertebrate tissue to search for new genes. Methods in molecular biology (Clifton, N.J.), 183, 
pp.3–18. Available at: http://www.ncbi.nlm.nih.gov/pubmed/12136765 [Accessed September 
29, 2015]. 
Mayhew, G.F. et al., 2007. Construction and characterization of an expressed sequenced tag library 
for the mosquito vector Armigeres subalbatus. BMC genomics, 8(1), p.462. Available at: 
http://www.biomedcentral.com/1471-2164/8/462 [Accessed September 5, 2015]. 
Mazzon, M. et al., 2009. Dengue virus NS5 inhibits interferon-alpha signaling by blocking signal 
transducer and activator of transcription 2 phosphorylation. The Journal of infectious diseases, 
200(8), pp.1261–70. Available at: http://jid.oxfordjournals.org/content/200/8/1261.full 
[Accessed August 15, 2015]. 
McCloskey, C. et al., 2010. Kv1.3 is the exclusive voltage-gated K+ channel of platelets and 
megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count. The Journal 
of physiology, 588(Pt 9), pp.1399–406. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2876798&tool=pmcentrez&rendert
ype=abstract [Accessed August 29, 2015]. 
McFarlane, M. et al., 2014. Characterization of Aedes aegypti innate-immune pathways that limit 
Chikungunya virus replication. PLoS neglected tropical diseases, 8(7), p.e2994. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002994 [Accessed 
September 9, 2015]. 
McLean, J.E. et al., 2011. Flavivirus NS4A-induced autophagy protects cells against death and 
enhances virus replication. The Journal of biological chemistry, 286(25), pp.22147–59. Available 
at: http://www.jbc.org/content/286/25/22147 [Accessed September 9, 2015]. 
McMeniman, C.J. et al., 2009. Stable introduction of a life-shortening Wolbachia infection into the 
mosquito Aedes aegypti. Science (New York, N.Y.), 323(5910), pp.141–4. Available at: 
http://www.sciencemag.org/content/323/5910/141.abstract [Accessed June 17, 2015]. 
van Meerloo, J., Kaspers, G.J.L. & Cloos, J., 2011. Cell sensitivity assays: the MTT assay. Methods in 
molecular biology (Clifton, N.J.), 731, pp.237–45. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/21516412 [Accessed June 11, 2015]. 
Meertens, L. et al., 2012. The TIM and TAM families of phosphatidylserine receptors mediate dengue 
virus entry. Cell host & microbe, 12(4), pp.544–57. Available at: 
http://www.sciencedirect.com/science/article/pii/S1931312812003046 [Accessed August 17, 
2015]. 
Mendoza, M.Y. et al., 2002. A putative receptor for dengue virus in mosquito tissues: Localization of a 
45-KDA glycoprotein. American Journal of Tropical Medicine and Hygiene, 67(1), pp.76–84. 
von Mering, C. et al., 2002. Comparative assessment of large-scale data sets of protein-protein 
interactions. Nature, 417(6887), pp.399–403. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12000970 [Accessed November 6, 2015]. 
Messina, J.P. et al., 2014. Global spread of dengue virus types: mapping the 70 year history. Trends 
in microbiology, 22(3), pp.138–46. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3946041&tool=pmcentrez&rendert
ype=abstract [Accessed July 14, 2014]. 
Mia, M.S. et al., 2013. Trends of dengue infections in Malaysia, 2000-2010. Asian Pacific journal of 
tropical medicine, 6(6), pp.462–6. Available at: 
http://www.sciencedirect.com/science/article/pii/S1995764513600759 [Accessed October 27, 
2015]. 
Michels, M. et al., 2014. Platelet function alterations in dengue are associated with plasma leakage. 
Thrombosis and haemostasis, 112(2), pp.352–62. Available at: 
http://th.schattauer.de/en/contents/archive/issue/1895/manuscript/21012.html [Accessed 
August 31, 2015]. 
Miller, C., 2000. An overview of the potassium channel family. Genome biology, 1(4), p.REVIEWS0004. 
 254 
 
Available at: http://europepmc.org/articles/PMC138870/?report=abstract [Accessed August 31, 
2015]. 
Miller, J.L. et al., 2008. The mannose receptor mediates dengue virus infection of macrophages. PLoS 
pathogens, 4(2), p.e17. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2233670&tool=pmcentrez&rendert
ype=abstract [Accessed October 26, 2015]. 
Miller, M.B. & Tang, Y.-W., 2009. Basic Concepts of Microarrays and Potential Applications in Clinical 
Microbiology. Clinical Microbiology Reviews, 22(4), pp.611–633. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2772365&tool=pmcentrez&rendert
ype=abstract [Accessed April 15, 2015]. 
Miller, S. et al., 2007. The non-structural protein 4A of dengue virus is an integral membrane protein 
inducing membrane alterations in a 2K-regulated manner. The Journal of biological chemistry, 
282(12), pp.8873–82. Available at: http://www.jbc.org/content/282/12/8873.abstract 
[Accessed October 24, 2015]. 
Miller, S., Sparacio, S. & Bartenschlager, R., 2006. Subcellular localization and membrane topology of 
the Dengue virus type 2 Non-structural protein 4B. The Journal of biological chemistry, 281(13), 
pp.8854–63. Available at: http://www.jbc.org/content/281/13/8854 [Accessed October 27, 
2015]. 
Modis, Y. et al., 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proceedings 
of the National Academy of Sciences of the United States of America, 100(12), pp.6986–91. 
Available at: http://www.pnas.org/content/100/12/6986.full [Accessed October 20, 2015]. 
Modis, Y. et al., 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature, 
427(6972), pp.313–9. Available at: http://dx.doi.org/10.1038/nature02165 [Accessed October 
20, 2015]. 
Modis, Y. et al., 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 
envelope glycoprotein. Journal of virology, 79(2), pp.1223–31. Available at: 
http://jvi.asm.org/content/79/2/1223.short [Accessed October 20, 2015]. 
Mohammed, H. et al., 2008. Dengue virus in blood donations, Puerto Rico, 2005. Transfusion, 48(7), 
pp.1348–54. Available at: http://www.ncbi.nlm.nih.gov/pubmed/18503611 [Accessed October 
25, 2015]. 
Morrison, J., Aguirre, S. & Fernandez-Sesma, A., 2012. Innate Immunity Evasion by Dengue Virus. 
Viruses, 4(12), pp.397–413. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3347034&tool=pmcentrez&rendert
ype=abstract [Accessed April 6, 2015]. 
Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays. Journal of Immunological Methods, 65(1-2), pp.55–63. 
Available at: http://www.sciencedirect.com/science/article/pii/0022175983903034 [Accessed 
August 21, 2014]. 
Mounier, N. et al., 1992. Insect muscle actins differ distinctly from invertebrate and vertebrate 
cytoplasmic actins. Journal of Molecular Evolution, 34(5), pp.406–415. Available at: 
http://link.springer.com/10.1007/BF00162997 [Accessed November 5, 2015]. 
Mukhopadhyay, S., Kuhn, R.J. & Rossmann, M.G., 2005. A structural perspective of the flavivirus life 
cycle. Nature Reviews Microbiology, 3(1), pp.13–22. Available at: 
http://www.nature.com/nrmicro/journal/v3/n1/full/nrmicro1067.html#B2 [Accessed October 
20, 2015]. 
Müller, P. et al., 2005. Identification of JAK/STAT signalling components by genome-wide RNA 
interference. Nature, 436(7052), pp.871–5. Available at: 
http://dx.doi.org/10.1038/nature03869 [Accessed July 31, 2015]. 
Müller, S. & Dejean, A., 1999. Viral immediate-early proteins abrogate the modification by SUMO-1 of 
PML and Sp100 proteins, correlating with nuclear body disruption. Journal of virology, 73(6), 
pp.5137–43. Available at: 
 255 
 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=112559&tool=pmcentrez&renderty
pe=abstract [Accessed November 3, 2015]. 
Mungrue, K., 2014. The laboratory diagnosis of dengue virus infection, a review. Advance Laboratory 
Medicine International, 4(1), pp.1–8. Available at: http://www.scopemed.org/?mno=48483 
[Accessed May 31, 2015]. 
Muñoz-Jordan, J.L. et al., 2003. Inhibition of interferon signaling by dengue virus. Proceedings of the 
National Academy of Sciences of the United States of America, 100(24), pp.14333–8. Available 
at: http://www.pnas.org/content/100/24/14333.full [Accessed August 14, 2015]. 
Muñoz-Jordán, J.L. et al., 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of 
flaviviruses. Journal of virology, 79(13), pp.8004–13. Available at: 
http://jvi.asm.org/content/79/13/8004.long [Accessed August 15, 2015]. 
Muñoz-Jordán, J.L., 2010. Subversion of interferon by dengue virus. Current topics in microbiology 
and immunology, 338, pp.35–44. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19802576 
[Accessed August 15, 2015]. 
Mustafa, M.S. et al., 2014. Discovery of fifth serotype of dengue virus (DENV-5): A new public health 
dilemma in dengue control. Medical Journal Armed Forces India, 71(1), pp.67–70. Available at: 
http://www.sciencedirect.com/science/article/pii/S0377123714001725 [Accessed January 11, 
2015]. 
Muylaert, I.R. et al., 1996. Mutagenesis of the N-linked glycosylation sites of the yellow fever virus 
NS1 protein: effects on virus replication and mouse neurovirulence. Virology, 222(1), pp.159–68. 
Available at: http://www.sciencedirect.com/science/article/pii/S0042682296904067 [Accessed 
October 26, 2015]. 
Nam, D.K. et al., 2002. Oligo(dT) primer generates a high frequency of truncated cDNAs through 
internal poly(A) priming during reverse transcription. Proceedings of the National Academy of 
Sciences of the United States of America, 99(9), pp.6152–6. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=122918&tool=pmcentrez&renderty
pe=abstract [Accessed November 7, 2015]. 
Nam, V. et al., 2012. Community-based control of Aedes aegypti by using Mesocyclops in southern 
Vietnam. The American Journal of Tropical Medicine and Hygiene, 86(5), pp.850–9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3335693&tool=pmcentrez&rendert
ype=abstract [Accessed October 28, 2015]. 
Nam, V.S. et al., 2000. National progress in dengue vector control in Vietnam: survey for Mesocyclops 
(Copepoda), Micronecta (Corixidae), and fish as biological control agents. The American journal 
of tropical medicine and hygiene, 62(1), pp.5–10. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/10761718 [Accessed October 28, 2015]. 
Nasirudeen, A.M.A. et al., 2011. RIG-I, MDA5 and TLR3 Synergistically Play an Important Role in 
Restriction of Dengue Virus Infection E. Harris, ed. PLoS Neglected Tropical Diseases, 5(1), 
p.e926. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0000926 [Accessed November 
19, 2015]. 
Nayak, V. et al., 2009. Crystal structure of dengue virus type 1 envelope protein in the postfusion 
conformation and its implications for membrane fusion. Journal of virology, 83(9), pp.4338–44. 
Available at: http://jvi.asm.org/content/83/9/4338 [Accessed October 21, 2015]. 
Nene, V. et al., 2007. Genome sequence of Aedes aegypti, a major arbovirus vector. Science (New 
York, N.Y.), 316(5832), pp.1718–23. Available at: 
http://www.sciencemag.org/content/316/5832/1718.abstract [Accessed November 6, 2015]. 
Netsawang, J. et al., 2010. Nuclear localization of dengue virus capsid protein is required for DAXX 
interaction and apoptosis. Virus research, 147(2), pp.275–83. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168170209004134 [Accessed October 27, 
2015]. 
Nicolaou, S.A. et al., 2009. Localization of Kv1.3 channels in the immunological synapse modulates 
 256 
 
the calcium response to antigen stimulation in T lymphocytes. Journal of immunology 
(Baltimore, Md. : 1950), 183(10), pp.6296–302. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2783516&tool=pmcentrez&rendert
ype=abstract [Accessed August 27, 2015]. 
Noisakran, S. et al., 2008. Identification of human hnRNP C1/C2 as a dengue virus NS1-interacting 
protein. Biochemical and biophysical research communications, 372(1), pp.67–72. Available at: 
http://www.sciencedirect.com/science/article/pii/S0006291X08008589 [Accessed October 24, 
2015]. 
Noisakran, S. et al., 2012. Infection of bone marrow cells by dengue virus in vivo. Experimental 
hematology, 40(3), pp.250–259.e4. Available at: 
http://www.sciencedirect.com/science/article/pii/S0301472X11005935 [Accessed August 31, 
2015]. 
Nojima, T. et al., 2009. Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing. 
Nucleic acids research, 37(19), pp.6515–27. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2770646&tool=pmcentrez&rendert
ype=abstract [Accessed November 23, 2015]. 
Normile, D., 2013. Tropical medicine. Surprising new dengue virus throws a spanner in disease control 
efforts. Science (New York, N.Y.), 342(6157), p.415. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24159024 [Accessed November 19, 2015]. 
O’Neill, L.A.J. & Bowie, A.G., 2010. Sensing and signaling in antiviral innate immunity. Current 
biology : CB, 20(7), pp.R328–33. Available at: 
http://www.sciencedirect.com/science/article/pii/S0960982210000874 [Accessed November 
11, 2015]. 
Ohara, O. & Temple, G., 2001. Directional cDNA library construction assisted by the in vitro 
recombination reaction. Nucleic acids research, 29(4), p.E22. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=29629&tool=pmcentrez&rendertyp
e=abstract [Accessed November 4, 2015]. 
Oldenburg, K.R. et al., 1997. Recombination-mediated PCR-directed plasmid construction in vivo in 
yeast. Nucleic acids research, 25(2), pp.451–2. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=146432&tool=pmcentrez&renderty
pe=abstract [Accessed November 5, 2015]. 
Oliphant, T. et al., 2006. Antibody recognition and neutralization determinants on domains I and II of 
West Nile Virus envelope protein. Journal of virology, 80(24), pp.12149–59. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1676294&tool=pmcentrez&rendert
ype=abstract [Accessed November 2, 2015]. 
Osorio, J.E. et al., 2011. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent 
vaccine for protection against dengue fever. Vaccine, 29(42), pp.7251–60. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4592106&tool=pmcentrez&rendert
ype=abstract [Accessed November 21, 2015]. 
Osorio, J.E. et al., 2014. Safety and immunogenicity of a recombinant live attenuated tetravalent 
dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-
controlled, phase 1 study. The Lancet Infectious Diseases, 14(9), pp.830–838. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4648257&tool=pmcentrez&rendert
ype=abstract [Accessed October 6, 2015]. 
Otsuki, K. et al., 1979. Studies on avian infectious bronchitis virus (IBV). III. Interferon induction by 
and sensitivity to interferon of IBV. Archives of virology, 60(3-4), pp.249–55. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/228636 [Accessed September 25, 2015]. 
Pahl, H.L., 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene, 
18(49), pp.6853–66. Available at: 
http://www.nature.com/onc/journal/v18/n49/full/1203239a.html [Accessed November 13, 
2015]. 
Pando-Robles, V. et al., 2014. Quantitative proteomic analysis of Huh-7 cells infected with Dengue 
 257 
 
virus by label-free LC-MS. Journal of proteomics, 111, pp.16–29. Available at: 
http://www.sciencedirect.com/science/article/pii/S1874391914003443 [Accessed November 6, 
2015]. 
Panyasrivanit, M. et al., 2009. Co-localization of constituents of the dengue virus translation and 
replication machinery with amphisomes. The Journal of general virology, 90(Pt 2), pp.448–56. 
Available at: http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.005355-
0;jsessionid=3sncfmf4d8g3j.x-sgm-live-02#tab2 [Accessed April 9, 2016]. 
Panyi, G. et al., 2003. Colocalization and nonrandom distribution of Kv1.3 potassium channels and 
CD3 molecules in the plasma membrane of human T lymphocytes. Proceedings of the National 
Academy of Sciences of the United States of America, 100(5), pp.2592–7. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=151385&tool=pmcentrez&renderty
pe=abstract [Accessed August 27, 2015]. 
Panyi, G. et al., 2004. Kv1.3 potassium channels are localized in the immunological synapse formed 
between cytotoxic and target cells. Proceedings of the National Academy of Sciences of the 
United States of America, 101(5), pp.1285–90. Available at: 
http://www.pnas.org/content/101/5/1285.full [Accessed August 29, 2015]. 
Patel, V.J. et al., 2009. A comparison of labeling and label-free mass spectrometry-based proteomics 
approaches. Journal of proteome research, 8(7), pp.3752–9. Available at: 
http://pubs.acs.org/doi/abs/10.1021/pr900080y [Accessed April 12, 2016]. 
Patramool, S. et al., 2011. Proteomic analysis of an Aedes albopictus cell line infected with Dengue 
serotypes 1 and 3 viruses. Parasites & Vectors, 4(1), p.138. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3151224&tool=pmcentrez&rendert
ype=abstract [Accessed September 30, 2015]. 
Pattanakitsakul, S.-N. et al., 2007. Proteomic analysis of host responses in HepG2 cells during dengue 
virus infection. Journal of proteome research, 6(12), pp.4592–600. Available at: 
http://dx.doi.org/10.1021/pr070366b [Accessed November 22, 2015]. 
Peeling, R.W. et al., 2010. Evaluation of diagnostic tests: dengue. Nature Reviews Microbiology, 
8(12), pp.S30–S37. Available at: 
http://www.nature.com/nrmicro/journal/v8/n12_supp/full/nrmicro2459.html#top [Accessed 
October 19, 2015]. 
Peleg, J., 1968. Growth of arboviruses in monolayers from subcultured mosquito embryo cells. 
Virology, 35(4), pp.617–619. Available at: 
http://www.sciencedirect.com/science/article/pii/0042682268902936 [Accessed July 30, 2015]. 
Peng, X. et al., 2009. Virus-host interactions: from systems biology to translational research. Current 
opinion in microbiology, 12(4), pp.432–8. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2742299&tool=pmcentrez&rendert
ype=abstract [Accessed November 19, 2015]. 
Perich, M.J. et al., 2000. Behavior of Resting Aedes aegypti (Culicidae: Diptera) and Its Relation to 
Ultra-low Volume Adulticide Efficacy in Panama City, Panama. Journal of Medical Entomology, 
37(4), pp.541–546. Available at: http://jme.oxfordjournals.org/content/37/4/541.abstract 
[Accessed October 22, 2015]. 
Petersen, K. et al., 2002. Matrix attachment regions (MARs) enhance transformation frequencies and 
reduce variance of transgene expression in barley. Plant molecular biology, 49(1), pp.45–58. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/12008898 [Accessed October 30, 2015]. 
Pherez, F.M., 2007. Factors affecting the emergence and prevalence of vector borne infections (VBI) 
and the role of vertical transmission (VT). Journal of vector borne diseases, 44(3), pp.157–63. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/17896618 [Accessed October 23, 2015]. 
Phuc, H.K. et al., 2007. Late-acting dominant lethal genetic systems and mosquito control. BMC 
biology, 5(1), p.11. Available at: http://www.biomedcentral.com/1741-7007/5/11 [Accessed 
September 28, 2015]. 
Platanias, L.C., 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature 
 258 
 
reviews. Immunology, 5(5), pp.375–86. Available at: http://dx.doi.org/10.1038/nri1604 
[Accessed December 8, 2014]. 
Pokidysheva, E. et al., 2006. Cryo-EM reconstruction of dengue virus in complex with the 
carbohydrate recognition domain of DC-SIGN. Cell, 124(3), pp.485–93. Available at: 
http://www.sciencedirect.com/science/article/pii/S0092867406000079 [Accessed November 
14, 2015]. 
Pongs, O. et al., 1988. Shaker encodes a family of putative potassium channel proteins in the nervous 
system of Drosophila. The EMBO journal, 7(4), pp.1087–96. Available at: 
http://europepmc.org/articles/PMC454441/?report=abstract [Accessed August 31, 2015]. 
Pouliot, S. et al., 2010. Maternal dengue and pregnancy outcomes: a systematic review. Obstetrical & 
gynecological survey, 65(2), pp.107–18. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20100360 [Accessed October 25, 2015]. 
Preußat, K. et al., 2003. Expression of voltage-gated potassium channels Kv1.3 and Kv1.5 in human 
gliomas. Neuroscience Letters, 346(1-2), pp.33–36. Available at: 
http://www.sciencedirect.com/science/article/pii/S0304394003005627 [Accessed August 29, 
2015]. 
Pryor, M.J. et al., 2004. Histidine 39 in the dengue virus type 2 M protein has an important role in 
virus assembly. Journal of General Virology, 85(12), pp.3627–3636. 
Pryor, M.J. & Wright, P.J., 1994. Glycosylation mutants of dengue virus NS1 protein. The Journal of 
general virology, 75 ( Pt 5)(5), pp.1183–7. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/0022-1317-75-5-1183 
[Accessed October 26, 2015]. 
Punzel, M. et al., 2014. Dengue virus transmission by blood stem cell donor after travel to Sri Lanka; 
Germany, 2013. Emerging infectious diseases, 20(8), pp.1366–9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4111198&tool=pmcentrez&rendert
ype=abstract [Accessed October 25, 2015]. 
Ramanathan, M.P. et al., 2006. Host cell killing by the West Nile Virus NS2B-NS3 proteolytic complex: 
NS3 alone is sufficient to recruit caspase-8-based apoptotic pathway. Virology, 345(1), pp.56–72. 
Available at: http://www.sciencedirect.com/science/article/pii/S0042682205005258 [Accessed 
October 29, 2015]. 
Rampalli, S. et al., 2005. Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of 
the SIN3/histone deacetylase 1 complex. Molecular and cellular biology, 25(19), pp.8415–29. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1265755&tool=pmcentrez&rendert
ype=abstract [Accessed August 15, 2015]. 
Redman, P.T. et al., 2007. Apoptotic surge of potassium currents is mediated by p38 phosphorylation 
of Kv2.1. Proceedings of the National Academy of Sciences of the United States of America, 
104(9), pp.3568–73. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1805571&tool=pmcentrez&rendert
ype=abstract [Accessed September 1, 2015]. 
Reggiori, F. et al., 2010. Coronaviruses Hijack the LC3-I-positive EDEMosomes, ER-derived vesicles 
exporting short-lived ERAD regulators, for replication. Cell host & microbe, 7(6), pp.500–8. 
Available at: http://www.sciencedirect.com/science/article/pii/S1931312810001769 [Accessed 
March 23, 2016]. 
Reikine, S., Nguyen, J.B. & Modis, Y., 2014. Pattern Recognition and Signaling Mechanisms of RIG-I 
and MDA5. Frontiers in immunology, 5, p.342. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4107945&tool=pmcentrez&rendert
ype=abstract [Accessed November 19, 2015]. 
Reimer, T. et al., 2008. poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I 
IFN and TNF responses in human macrophages. Journal of leukocyte biology, 83(5), pp.1249–57. 
Available at: http://www.jleukbio.org/content/83/5/1249.long [Accessed July 1, 2015]. 
 259 
 
Reyes-Del Valle, J. et al., 2005. Heat shock protein 90 and heat shock protein 70 are components of 
dengue virus receptor complex in human cells. Journal of virology, 79(8), pp.4557–67. Available 
at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1069525&tool=pmcentrez&rendert
ype=abstract [Accessed November 14, 2015]. 
Robert Putnak, J. et al., 2005. An evaluation of dengue type-2 inactivated, recombinant subunit, and 
live-attenuated vaccine candidates in the rhesus macaque model. Vaccine, 23(35), pp.4442–
4452. Available at: http://www.sciencedirect.com/science/article/pii/S0264410X0500441X 
[Accessed November 2, 2015]. 
Rodríguez, M.M., Bisset, J.A. & Fernández, D., 2007. Levels of insecticide resistance and resistance 
mechanisms in Aedes aegypti from some Latin American countries. Journal of the American 
Mosquito Control Association, 23(4), pp.420–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18240518 [Accessed October 28, 2015]. 
Rodriguez-Madoz, J.R. et al., 2010. Inhibition of the type I interferon response in human dendritic 
cells by dengue virus infection requires a catalytically active NS2B3 complex. Journal of 
virology, 84(19), pp.9760–74. Available at: http://jvi.asm.org/content/84/19/9760.long 
[Accessed August 16, 2015]. 
Roosendaal, J. et al., 2006. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a 
major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. 
Journal of virology, 80(9), pp.4623–32. Available at: http://jvi.asm.org/content/80/9/4623 
[Accessed October 27, 2015]. 
Rutschmann, S., Kilinc, A. & Ferrandon, D., 2002. Cutting Edge: The Toll Pathway Is Required for 
Resistance to Gram-Positive Bacterial Infections in Drosophila. The Journal of Immunology, 
168(4), pp.1542–1546. Available at: http://www.jimmunol.org/content/168/4/1542.full 
[Accessed October 1, 2015]. 
Sabin, L.R., Hanna, S.L. & Cherry, S., 2010. Innate antiviral immunity in Drosophila. Current Opinion 
in Immunology, 22(1), pp.4–9. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2831143&tool=pmcentrez&rendert
ype=abstract [Accessed October 1, 2015]. 
Salazar, C. et al., 2007. A cytoskeletal actin gene in the mosquito Anopheles gambiae. Insect 
Molecular Biology, 3(1), pp.1–13. Available at: http://doi.wiley.com/10.1111/j.1365-
2583.1994.tb00145.x [Accessed November 5, 2015]. 
Salazar, M.I. et al., 2007. Dengue virus type 2: replication and tropisms in orally infected Aedes 
aegypti mosquitoes. BMC microbiology, 7(1), p.9. Available at: 
http://www.biomedcentral.com/1471-2180/7/9 [Accessed September 29, 2015]. 
Salinas, M. et al., 1997. New Modulatory   Subunits for Mammalian ShabK+ Channels. Journal of 
Biological Chemistry, 272(39), pp.24371–24379. Available at: 
http://europepmc.org/abstract/MED/9305895 [Accessed August 28, 2015]. 
Samsa, M.M. et al., 2009. Dengue virus capsid protein usurps lipid droplets for viral particle 
formation. PLoS pathogens, 5(10), p.e1000632. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2760139&tool=pmcentrez&rendert
ype=abstract [Accessed April 23, 2015]. 
Sánchez-Vargas, I. et al., 2009. Dengue virus type 2 infections of Aedes aegypti are modulated by the 
mosquito’s RNA interference pathway. PLoS pathogens, 5(2), p.e1000299. Available at: 
http://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1000299 [Accessed 
September 29, 2015]. 
Sands, S.B., 1989. Charybdotoxin blocks voltage-gated K+ channels in human and murine T 
lymphocytes. The Journal of General Physiology, 93(6), pp.1061–1074. Available at: 
http://jgp.rupress.org/content/93/6/1061 [Accessed August 31, 2015]. 
Sasaki, T. et al., 2013. Dengue virus neutralization and antibody-dependent enhancement activities 
of human monoclonal antibodies derived from dengue patients at acute phase of secondary 
infection. Antiviral research, 98(3), pp.423–31. Available at: 
 260 
 
http://www.sciencedirect.com/science/article/pii/S0166354213000727 [Accessed October 28, 
2015]. 
Schexneider, K.I. & Reedy, E.A., 2005. Thrombocytopenia in dengue fever. Current hematology 
reports, 4(2), pp.145–8. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15720964 
[Accessed August 31, 2015]. 
Schlake, T. et al., 1994. Gene expression within a chromatin domain: the role of core histone 
hyperacetylation. Biochemistry, 33(14), pp.4197–206. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8155635 [Accessed October 30, 2015]. 
Schmitz, A. et al., 2005. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the 
suppression of effector memory T cells in autoimmune diseases. Molecular pharmacology, 68(5), 
pp.1254–70. Available at: http://molpharm.aspetjournals.org/content/68/5/1254.abstract 
[Accessed September 3, 2015]. 
Scott, J.C. et al., 2010. Comparison of Dengue Virus Type 2-Specific Small RNAs from RNA 
Interference-Competent and –Incompetent Mosquito Cells S. L. O’Neill, ed. PLoS Neglected 
Tropical Diseases, 4(10), p.e848. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2964303&tool=pmcentrez&rendert
ype=abstract [Accessed October 5, 2015]. 
Seo, J.S. et al., 2014. Cell cycle-dependent SUMO-1 conjugation to nuclear mitotic apparatus protein 
(NuMA). Biochemical and biophysical research communications, 443(1), pp.259–65. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/24309115 [Accessed November 23, 2015]. 
Sessions, O.M. et al., 2009. Discovery of insect and human dengue virus host factors. Nature, 
458(7241), pp.1047–50. Available at: http://dx.doi.org/10.1038/nature07967 [Accessed April 17, 
2015]. 
Shafee, N. & AbuBakar, S., 2003. Dengue virus type 2 NS3 protease and NS2B-NS3 protease precursor 
induce apoptosis. The Journal of general virology, 84(Pt 8), pp.2191–5. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.19022-0#tab2 
[Accessed October 27, 2015]. 
Shagin, D.A. et al., 2002. A novel method for SNP detection using a new duplex-specific nuclease 
from crab hepatopancreas. Genome research, 12(12), pp.1935–42. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=187582&tool=pmcentrez&renderty
pe=abstract [Accessed November 6, 2015]. 
Shcheglov, A. et al., 2007. Normalization of cDNA libraries A. A. Buzdin & S. A. Lukyanov, eds., 
Dordrecht: Springer Netherlands. Available at: 
http://www.springerlink.com/index/10.1007/978-1-4020-6040-3 [Accessed October 3, 2015]. 
Shepard, D.S. et al., 2011. Economic impact of dengue illness in the Americas. The American journal 
of tropical medicine and hygiene, 84(2), pp.200–7. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3029168&tool=pmcentrez&rendert
ype=abstract [Accessed November 4, 2015]. 
Shepard, D.S., Undurraga, E.A. & Halasa, Y.A., 2013. Economic and disease burden of dengue in 
Southeast Asia. PLoS neglected tropical diseases, 7(2), p.e2055. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002055 [Accessed February 
17, 2015]. 
Shera, K.A., Shera, C.A. & McDougall, J.K., 2001. Small tumor virus genomes are integrated near 
nuclear matrix attachment regions in transformed cells. Journal of virology, 75(24), pp.12339–
46. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=116130&tool=pmcentrez&renderty
pe=abstract [Accessed November 10, 2015]. 
Shi, P.-Y., 2014. Flavivirus NS5 Prevents the InSTATement of IFN. Cell host & microbe, 16(3), pp.269–
71. Available at: http://www.sciencedirect.com/science/article/pii/S1931312814003035 
[Accessed November 3, 2015]. 
Shu, P.Y. et al., 2000. Dengue NS1-specific antibody responses: isotype distribution and serotyping in 
 261 
 
patients with Dengue fever and Dengue hemorrhagic fever. Journal of medical virology, 62(2), 
pp.224–32. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11002252 [Accessed November 
2, 2015]. 
Silva, E.M. et al., 2013. Mapping the interactions of dengue virus NS1 protein with human liver 
proteins using a yeast two-hybrid system: identification of C1q as an interacting partner. PloS 
one, 8(3), p.e57514. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3597719&tool=pmcentrez&rendert
ype=abstract [Accessed June 19, 2015]. 
Sim, S. & Dimopoulos, G., 2010a. Dengue virus inhibits immune responses in Aedes aegypti cells. PloS 
one, 5(5), p.e10678. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0010678 [Accessed 
September 14, 2015]. 
Sim, S. & Dimopoulos, G., 2010b. Dengue virus inhibits immune responses in Aedes aegypti cells. PloS 
one, 5(5), p.e10678. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2872661&tool=pmcentrez&rendert
ype=abstract [Accessed September 14, 2015]. 
Sim, S., Jupatanakul, N. & Dimopoulos, G., 2014. Mosquito Immunity against Arboviruses. Viruses, 
6(11), pp.4479–4504. Available at: http://www.mdpi.com/1999-4915/6/11/4479/. 
Singh, K. et al., 2007. p53 target gene SMAR1 is dysregulated in breast cancer: its role in cancer cell 
migration and invasion. PloS one, 2(7), p.e660. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1924604&tool=pmcentrez&rendert
ype=abstract. 
Singh, K. et al., 2009. Tumor suppressor SMAR1 represses IkappaBalpha expression and inhibits p65 
transactivation through matrix attachment regions. The Journal of biological chemistry, 284(2), 
pp.1267–78. Available at: http://www.jbc.org/content/284/2/1267.long [Accessed July 7, 
2015]. 
Singh, M.P. et al., 2010. NS1 antigen as an early diagnostic marker in dengue: report from India. 
Diagnostic microbiology and infectious disease, 68(1), pp.50–4. Available at: 
http://www.sciencedirect.com/science/article/pii/S0732889310001276 [Accessed October 26, 
2015]. 
Singh, S. et al., 2010. SMAR1 regulates free radical stress through modulation of AKR1a4 enzyme 
activity. The international journal of biochemistry & cell biology, 42(7), pp.1105–14. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/20097305 [Accessed November 12, 2015]. 
Sinha, S. et al., 2012. Chromatin remodelling protein SMAR1 inhibits p53 dependent transactivation 
by regulating acetyl transferase p300. The international journal of biochemistry & cell biology, 
44(1), pp.46–52. Available at: 
http://www.sciencedirect.com/science/article/pii/S1357272511002937 [Accessed August 15, 
2015]. 
Sinha, S. et al., 2010. Coordinated regulation of p53 apoptotic targets BAX and PUMA by SMAR1 
through an identical MAR element. The EMBO journal, 29(4), pp.830–42. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2829167&tool=pmcentrez&rendert
ype=abstract [Accessed November 12, 2015]. 
Siu, R.W.C. et al., 2011. Antiviral RNA interference responses induced by Semliki Forest virus 
infection of mosquito cells: characterization, origin, and frequency-dependent functions of 
virus-derived small interfering RNAs. Journal of virology, 85(6), pp.2907–17. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3067965&tool=pmcentrez&rendert
ype=abstract [Accessed September 30, 2015]. 
Sobhanifar, S., 2003. Yeast two hybrid assay: A fishing tale. BioTeach Journal, 1(Figure 3), pp.81–88. 
Available at: 
http://scholar.google.com/scholar?hl=en&btnG=Search&q=intitle:Yeast+Two+Hybrid+Assay+:+A+
Fishing+Tale#0. 
Sokolov, Y., 1997. Purification, Visualization, and Biophysical Characterization of Kv1.3 Tetramers. 
 262 
 
Journal of Biological Chemistry, 272(4), pp.2389–2395. Available at: 
http://www.jbc.org/content/272/4/2389.long [Accessed August 25, 2015]. 
Souza-Neto, J.A., Sim, S. & Dimopoulos, G., 2009. An evolutionary conserved function of the JAK-
STAT pathway in anti-dengue defense. Proceedings of the National Academy of Sciences of the 
United States of America, 106(42), pp.17841–6. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2764916&tool=pmcentrez&rendert
ype=abstract [Accessed August 24, 2015]. 
Spiker, S. & Thompson, W.F., 1996. Nuclear Matrix Attachment Regions and Transgene Expression in 
Plants. Plant physiology, 110(1), pp.15–21. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=157689&tool=pmcentrez&renderty
pe=abstract [Accessed October 30, 2015]. 
Sreenath, K. et al., 2010. Nuclear matrix protein SMAR1 represses HIV-1 LTR mediated transcription 
through chromatin remodeling. Virology, 400(1), pp.76–85. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/20153010 [Accessed November 3, 2015]. 
Sriburi, R. et al., 2004. XBP1: a link between the unfolded protein response, lipid biosynthesis, and 
biogenesis of the endoplasmic reticulum. The Journal of cell biology, 167(1), pp.35–41. 
Available at: http://jcb.rupress.org/content/167/1/35.long [Accessed November 20, 2015]. 
Stadler, K. et al., 1997. Proteolytic activation of tick-borne encephalitis virus by furin. Journal of 
virology, 71(11), pp.8475–81. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=192310&tool=pmcentrez&renderty
pe=abstract [Accessed October 20, 2015]. 
Szabò, I. et al., 2005. A novel potassium channel in lymphocyte mitochondria. The Journal of 
biological chemistry, 280(13), pp.12790–8. Available at: 
http://www.jbc.org/content/280/13/12790.long#F1 [Accessed August 30, 2015]. 
Tahoun, A. et al., 2011. Comparative analysis of EspF variants in inhibition of Escherichia coli 
phagocytosis by macrophages and inhibition of E. Coli translocation through human- and bovine-
derived M cells. Infection and Immunity, 79(11), pp.4716–4729. 
Taimen, P. et al., 2004. NuMA and nuclear lamins are cleaved during viral infection--inhibition of 
caspase activity prevents cleavage and rescues HeLa cells from measles virus-induced but not 
from rhinovirus 1B-induced cell death. Virology, 320(1), pp.85–98. Available at: 
http://www.sciencedirect.com/science/article/pii/S0042682203008651 [Accessed June 15, 
2015]. 
Tambyah, P.A. et al., 2008. Dengue hemorrhagic fever transmitted by blood transfusion. The New 
England journal of medicine, 359(14), pp.1526–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/18832256 [Accessed October 25, 2015]. 
Tan, F.L.-S. et al., 2005. Dengue haemorrhagic fever after living donor renal transplantation. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association, 20(2), pp.447–8. Available at: 
http://ndt.oxfordjournals.org/content/20/2/447.long [Accessed October 25, 2015]. 
Tanabe, M. et al., 2003. Mechanism of up-regulation of human Toll-like receptor 3 secondary to 
infection of measles virus-attenuated strains. Biochemical and Biophysical Research 
Communications, 311(1), pp.39–48. Available at: 
http://www.sciencedirect.com/science/article/pii/S0006291X03019600 [Accessed November 
12, 2015]. 
Tassaneetrithep, B. et al., 2003. DC-SIGN (CD209) mediates dengue virus infection of human dendritic 
cells. The Journal of experimental medicine, 197(7), pp.823–9. Available at: 
http://jem.rupress.org/content/197/7/823.long [Accessed August 27, 2015]. 
Tauszig, S. et al., 2000. Toll-related receptors and the control of antimicrobial peptide expression in 
Drosophila. Proceedings of the National Academy of Sciences of the United States of America, 
97(19), pp.10520–5. Available at: http://www.pnas.org/content/97/19/10520 [Accessed July 8, 
2015]. 
 263 
 
Tavalai, N. & Stamminger, T., 2009. Interplay between Herpesvirus Infection and Host Defense by 
PML Nuclear Bodies. Viruses, 1(3), pp.1240–64. Available at: http://www.mdpi.com/1999-
4915/1/3/1240/htm [Accessed November 23, 2015]. 
Taylor, M.P. & Kirkegaard, K., 2007. Modification of cellular autophagy protein LC3 by poliovirus. 
Journal of virology, 81(22), pp.12543–53. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2169029&tool=pmcentrez&rendert
ype=abstract [Accessed April 9, 2016]. 
Teixeira, M.G. et al., 2013. Epidemiological Trends of Dengue Disease in Brazil (2000–2010): A 
Systematic Literature Search and Analysis T. R. Unnasch, ed. PLoS Neglected Tropical Diseases, 
7(12), p.e2520. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0002520 [Accessed October 
4, 2015]. 
Tergaonkar, V., 2006. NFκB pathway: A good signaling paradigm and therapeutic target. The 
International Journal of Biochemistry & Cell Biology, 38(10), pp.1647–1653. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/16766221 [Accessed September 21, 2015]. 
Thaithumyanon, P. et al., 1994. Dengue infection complicated by severe hemorrhage and vertical 
transmission in a parturient woman. Clinical infectious diseases : an official publication of the 
Infectious Diseases Society of America, 18(2), pp.248–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/8161636 [Accessed October 2, 2015]. 
Tham, H.-W. et al., 2014. CPB1 of Aedes aegypti interacts with DENV2 E protein and regulates 
intracellular viral accumulation and release from midgut cells. Viruses, 6(12), pp.5028–46. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4276941&tool=pmcentrez&rendert
ype=abstract [Accessed September 29, 2015]. 
Thomas, P. & Smart, T.G., 2005. HEK293 cell line: a vehicle for the expression of recombinant 
proteins. Journal of pharmacological and toxicological methods, 51(3), pp.187–200. Available 
at: http://www.ncbi.nlm.nih.gov/pubmed/15862464 [Accessed July 9, 2014]. 
Thompson, B.S. et al., 2009. A therapeutic antibody against west nile virus neutralizes infection by 
blocking fusion within endosomes. PLoS pathogens, 5(5), p.e1000453. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2679195&tool=pmcentrez&rendert
ype=abstract [Accessed November 2, 2015]. 
Thongrungkiat, S. et al., 2011. Prospective field study of transovarial dengue-virus transmission by 
two different forms of Aedes aegypti in an urban area of Bangkok, Thailand. Journal of vector 
ecology : journal of the Society for Vector Ecology, 36(1), pp.147–52. Available at: 
http://www.bioone.org/doi/abs/10.1111/j.1948-7134.2011.00151.x [Accessed October 23, 
2015]. 
Tsai, Y.-T. et al., 2009. Human TLR3 recognizes dengue virus and modulates viral replication in vitro. 
Cellular Microbiology, 11(4), pp.604–15. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19134117 [Accessed October 9, 2015]. 
Tu, Y.-C. et al., 2012. Blocking double-stranded RNA-activated protein kinase PKR by Japanese 
encephalitis virus nonstructural protein 2A. Journal of virology, 86(19), pp.10347–58. Available 
at: http://jvi.asm.org/content/86/19/10347.long [Accessed August 15, 2015]. 
Uetz, P. et al., 2000. A comprehensive analysis of protein-protein interactions in Saccharomyces 
cerevisiae. Nature, 403(6770), pp.623–7. Available at: http://dx.doi.org/10.1038/35001009 
[Accessed August 7, 2015]. 
Umareddy, I. et al., 2007. Dengue virus serotype infection specifies the activation of the unfolded 
protein response. Virology journal, 4, p.91. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2045667&tool=pmcentrez&rendert
ype=abstract [Accessed November 20, 2015]. 
Vicente, R. et al., 2006. Association of Kv1.5 and Kv1.3 contributes to the major voltage-dependent 
K+ channel in macrophages. The Journal of biological chemistry, 281(49), pp.37675–85. 
Available at: http://www.jbc.org/content/281/49/37675.long [Accessed August 31, 2015]. 
 264 
 
Wallis, T.P. et al., 2004. Determination of the disulfide bond arrangement of dengue virus NS1 
protein. The Journal of biological chemistry, 279(20), pp.20729–41. Available at: 
http://www.jbc.org/content/279/20/20729.long [Accessed October 26, 2015]. 
Wang, E. et al., 2000. Evolutionary Relationships of Endemic/Epidemic and Sylvatic Dengue Viruses. 
Journal of Virology, 74(7), pp.3227–3234. Available at: http://jvi.asm.org/content/74/7/3227 
[Accessed October 17, 2015]. 
Wang, T.-Y. et al., 2010. A mini review of MAR-binding proteins. Molecular biology reports, 37(7), 
pp.3553–60. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20174991 [Accessed July 27, 
2015]. 
Wang, Y., Tong, X. & Ye, X., 2012. Ndfip1 negatively regulates RIG-I-dependent immune signaling by 
enhancing E3 ligase Smurf1-mediated MAVS degradation. Journal of immunology (Baltimore, 
Md. : 1950), 189(11), pp.5304–13. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23087404 [Accessed November 3, 2015]. 
Wasinpiyamongkol, L. et al., 2012. Protein expression in the salivary glands of dengue-infected Aedes 
aegypti mosquitoes and blood-feeding success. The Southeast Asian journal of tropical medicine 
and public health, 43(6), pp.1346–57. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/23413697 [Accessed September 30, 2015]. 
Watanabe, T., Watanabe, S. & Kawaoka, Y., 2010. Cellular networks involved in the influenza virus 
life cycle. Cell host & microbe, 7(6), pp.427–39. Available at: 
http://www.sciencedirect.com/science/article/pii/S193131281000171X [Accessed May 27, 
2015]. 
Watson, A.A. et al., 2011. Structural flexibility of the macrophage dengue virus receptor CLEC5A: 
implications for ligand binding and signaling. The Journal of biological chemistry, 286(27), 
pp.24208–18. Available at: http://www.jbc.org/content/286/27/24208.full [Accessed April 7, 
2016]. 
Watterson, D., Kobe, B. & Young, P.R., 2012. Residues in domain III of the dengue virus envelope 
glycoprotein involved in cell-surface glycosaminoglycan binding. The Journal of general 
virology, 93(Pt 1), pp.72–82. Available at: 
http://jgv.microbiologyresearch.org/content/journal/jgv/10.1099/vir.0.037317-0#tab2 
[Accessed March 22, 2016]. 
Wellenreuther, R. et al., 2004. SMART amplification combined with cDNA size fractionation in order 
to obtain large full-length clones. BMC genomics, 5(1), p.36. Available at: 
/pmc/articles/PMC436056/?report=abstract [Accessed September 29, 2015]. 
Welsch, S. et al., 2009. Composition and three-dimensional architecture of the dengue virus 
replication and assembly sites. Cell host & microbe, 5(4), pp.365–75. Available at: 
http://www.cell.com/article/S1931312809000985/fulltext [Accessed May 15, 2015]. 
White, L.A., 1987. Susceptibility of Aedes albopictus C6/36 cells to viral infection. Journal of clinical 
microbiology, 25(7), pp.1221–4. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=269180&tool=pmcentrez&renderty
pe=abstract [Accessed September 14, 2015]. 
WHO, 2011. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue 
Haemorrhagic Fever. , pp.1–196. Available at: 
http://www.searo.who.int/entity/vector_borne_tropical_diseases/documents/SEAROTPS60/en/ 
[Accessed October 28, 2015]. 
WHO, 1997. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. 2nd edition. 
Geneva : World Health Organization. Available at: 
http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/ [Accessed 
August 31, 2015]. 
WHO, 2012. Global Strategy for dengue prevention and control, 2012–2020. WHO Press. Available at: 
http://www.who.int/denguecontrol/9789241504034/en/ [Accessed October 17, 2015]. 
Wilder-Smith, A. & Gubler, D.J., 2008. Geographic expansion of dengue: the impact of international 
 265 
 
travel. The Medical clinics of North America, 92(6), pp.1377–90. Available at: 
http://www.sciencedirect.com/science/article/pii/S0025712508000989 [Accessed September 
28, 2015]. 
Winnebeck, E.C., Millar, C.D. & Warman, G.R., 2010. Why does insect RNA look degraded? Journal of 
insect science (Online), 10, p.159. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3016993&tool=pmcentrez&rendert
ype=abstract [Accessed September 21, 2015]. 
Wise de Valdez, M.R. et al., 2011. Genetic elimination of dengue vector mosquitoes. Proceedings of 
the National Academy of Sciences of the United States of America, 108(12), pp.4772–5. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3064365&tool=pmcentrez&rendert
ype=abstract [Accessed October 25, 2015]. 
Wong, K. et al., 2012. Susceptibility and response of human blood monocyte subsets to primary 
dengue virus infection. PloS one, 7(5), p.e36435. Available at: 
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0036435 [Accessed October 1, 
2015]. 
Wong, S.S. et al., 2012. The dengue virus M protein localises to the endoplasmic reticulum and forms 
oligomers. FEBS letters, 586(7), pp.1032–7. Available at: 
http://www.sciencedirect.com/science/article/pii/S0014579312001718 [Accessed October 25, 
2015]. 
Wu, J. et al., 2013. Voltage-gated potassium channel Kv1.3 is highly expressed in human 
osteosarcoma and promotes osteosarcoma growth. International journal of molecular sciences, 
14(9), pp.19245–56. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3794831&tool=pmcentrez&rendert
ype=abstract [Accessed August 29, 2015]. 
Wu, S.J. et al., 2000. Comparison of two rapid diagnostic assays for detection of immunoglobulin M 
antibodies to dengue virus. Clinical and diagnostic laboratory immunology, 7(1), pp.106–10. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=95832&tool=pmcentrez&rendertyp
e=abstract [Accessed October 29, 2015]. 
Wulff, H. et al., 2004. K+ Channel Expression during B Cell Differentiation: Implications for 
Immunomodulation and Autoimmunity. The Journal of Immunology, 173(2), pp.776–786. 
Available at: http://www.jimmunol.org/content/173/2/776.full [Accessed August 31, 2015]. 
Wulff, H. et al., 2003. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target 
for MS. The Journal of clinical investigation, 111(11), pp.1703–13. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=156104&tool=pmcentrez&renderty
pe=abstract [Accessed November 17, 2015]. 
Xi, Z., Ramirez, J.L. & Dimopoulos, G., 2008. The Aedes aegypti toll pathway controls dengue virus 
infection. PLoS pathogens, 4(7), p.e1000098. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2435278&tool=pmcentrez&rendert
ype=abstract [Accessed May 12, 2015]. 
Xie, X. et al., 2013. Membrane topology and function of dengue virus NS2A protein. Journal of 
virology, 87(8), pp.4609–22. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3624351&tool=pmcentrez&rendert
ype=abstract [Accessed August 14, 2015]. 
Xie, X. et al., 2015. Two distinct sets of NS2A molecules are responsible for dengue virus RNA 
synthesis and virion assembly. Journal of virology, 89(2), pp.1298–313. Available at: 
http://jvi.asm.org/content/early/2014/11/06/JVI.02882-14 [Accessed October 24, 2015]. 
Xu, C. et al., 2011. HIV-1 gp120 enhances outward potassium current via CXCR4 and cAMP-dependent 
protein kinase A signaling in cultured rat microglia. Glia, 59(6), pp.997–1007. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3077451&tool=pmcentrez&rendert
ype=abstract [Accessed September 1, 2015]. 
 266 
 
Xu, J., 2003. The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body 
weight. Human Molecular Genetics, 12(5), pp.551–559. Available at: 
http://hmg.oxfordjournals.org/content/12/5/551.full [Accessed August 29, 2015]. 
Yamamoto, M. et al., 2003. Role of adaptor TRIF in the MyD88-independent toll-like receptor 
signaling pathway. Science (New York, N.Y.), 301(5633), pp.640–3. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/12855817 [Accessed September 22, 2015]. 
Yao, R. et al., 2001. Identification of a PDZ domain containing Golgi protein, GOPC, as an interaction 
partner of frizzled. Biochemical and biophysical research communications, 286(4), pp.771–8. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/11520064 [Accessed November 3, 2015]. 
Yao, X. et al., 1996. Molecular cloning of a glibenclamide-sensitive, voltage-gated potassium channel 
expressed in rabbit kidney. The Journal of clinical investigation, 97(11), pp.2525–33. Available 
at: http://www.jci.org/articles/view/118700 [Accessed August 30, 2015]. 
Yap, G., Sil, B.K. & Ng, L.-C., 2011. Use of saliva for early dengue diagnosis. PLoS neglected tropical 
diseases, 5(5), p.e1046. Available at: 
http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001046 [Accessed October 
28, 2015]. 
Yauch, L.E. et al., 2009. A protective role for dengue virus-specific CD8+ T cells. Journal of 
immunology (Baltimore, Md. : 1950), 182(8), pp.4865–73. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2674070&tool=pmcentrez&rendert
ype=abstract [Accessed October 20, 2015]. 
Yellen, G., 2002. The voltage-gated potassium channels and their relatives. Nature, 419(6902), 
pp.35–42. Available at: http://dx.doi.org/10.1038/nature00978 [Accessed July 12, 2015]. 
Yoneyama, M. et al., 1996. Autocrine amplification of type I interferon gene expression mediated by 
interferon stimulated gene factor 3 (ISGF3). Journal of biochemistry, 120(1), pp.160–9. 
Available at: http://www.ncbi.nlm.nih.gov/pubmed/8864859 [Accessed July 31, 2015]. 
Yoneyama, M. et al., 1998. Direct triggering of the type I interferon system by virus infection: 
activation of a transcription factor complex containing IRF-3 and CBP/p300. The EMBO journal, 
17(4), pp.1087–95. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1170457&tool=pmcentrez&rendert
ype=abstract [Accessed July 31, 2015]. 
Yong, Y.K. et al., 2007. Rapid detection and serotyping of dengue virus by multiplex RT-PCR and real-
time SYBR green RT-PCR. Singapore medical journal, 48(7), pp.662–8. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/17609830 [Accessed October 28, 2015]. 
Yu, C.-Y. et al., 2006. Flavivirus infection activates the XBP1 pathway of the unfolded protein 
response to cope with endoplasmic reticulum stress. Journal of virology, 80(23), pp.11868–80. 
Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1642612&tool=pmcentrez&rendert
ype=abstract [Accessed November 20, 2015]. 
Yu, I.-M. et al., 2008. Structure of the immature dengue virus at low pH primes proteolytic 
maturation. Science (New York, N.Y.), 319(5871), pp.1834–1837. 
Yu, S.P. & Kerchner, G.A., 1998. Endogenous voltage-gated potassium channels in human embryonic 
kidney (HEK293) cells. Journal of neuroscience research, 52(5), pp.612–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/9632317 [Accessed August 13, 2015]. 
Yusof, R., 2000. Purified NS2B/NS3 Serine Protease of Dengue Virus Type 2 Exhibits Cofactor NS2B 
Dependence for Cleavage of Substrates with Dibasic Amino Acids in Vitro. Journal of Biological 
Chemistry, 275(14), pp.9963–9969. Available at: http://www.jbc.org/content/275/14/9963.long 
[Accessed October 27, 2015]. 
Zahn-Zabal, M. et al., 2001. Development of stable cell lines for production or regulated expression 
using matrix attachment regions. Journal of Biotechnology, 87(1), pp.29–42. Available at: 
http://www.sciencedirect.com/science/article/pii/S0168165600004235 [Accessed October 30, 
2015]. 
 267 
 
Zambon, R.A. et al., 2005. The Toll pathway is important for an antiviral response in Drosophila. 
Proceedings of the National Academy of Sciences of the United States of America, 102(20), 
pp.7257–62. Available at: http://www.pnas.org/content/102/20/7257.long [Accessed October 
1, 2015]. 
Zhang, L. et al., 2009. Analysis of vaccinia virus-host protein-protein interactions: validations of yeast 
two-hybrid screenings. Journal of proteome research, 8(9), pp.4311–8. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2738428&tool=pmcentrez&rendert
ype=abstract [Accessed June 19, 2015]. 
Zhang, M. et al., 2013. Differential proteomics of Aedes albopictus salivary gland, midgut and C6/36 
cell induced by dengue virus infection. Virology, 444(1-2), pp.109–18. Available at: 
http://www.sciencedirect.com/science/article/pii/S0042682213003462 [Accessed September 
10, 2015]. 
Zhang, M. et al., 2012. TRAF-interacting protein (TRIP) negatively regulates IFN-β production and 
antiviral response by promoting proteasomal degradation of TANK-binding kinase 1. The Journal 
of experimental medicine, 209(10), pp.1703–11. Available at: 
http://jem.rupress.org/content/209/10/1703.figures-only [Accessed August 13, 2015]. 
Zhang, W. et al., 2003. Visualization of membrane protein domains by cryo-electron microscopy of 
dengue virus. Nature Structural Biology, 10(11), pp.907–912. Available at: 
http://dx.doi.org/10.1038/nsb990 [Accessed October 19, 2015]. 
Zhang, X. et al., 2013. Cryo-EM structure of the mature dengue virus at 3.5-Å resolution. Nature 
Structural & Molecular Biology, 20(1), pp.105–10. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3593067&tool=pmcentrez&rendert
ype=abstract [Accessed February 28, 2016]. 
Zhu, Y.Y. et al., 2001. Reverse transcriptase template switching: a SMART approach for full-length 
cDNA library construction. BioTechniques, 30(4), pp.892–7. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/11314272 [Accessed July 9, 2015]. 
Zong, R.T., Das, C. & Tucker, P.W., 2000. Regulation of matrix attachment region-dependent, 
lymphocyte-restricted transcription through differential localization within promyelocytic 
leukemia nuclear bodies. The EMBO journal, 19(15), pp.4123–33. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=306587&tool=pmcentrez&renderty
pe=abstract [Accessed November 1, 2015]. 
Żyżyńska-Granica, B. & Koziak, K., 2012. Identification of suitable reference genes for real-time PCR 
analysis of statin-treated human umbilical vein endothelial cells. PloS one, 7(12), p.e51547. 
Available at: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0051547 
[Accessed July 10, 2015]. 
 
